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Abstract 
The purpose of this research is to determine the information to be collected for aseptic 
dispensing in NHS hospitals, and its use for management and business purposes in 
relation to capacity, demand, performance and efficiency. 
Mixed methodologies were adopted on an exploratory basis. Qualitative methods 
included: regular expert input; workshops; out-turn questionnaires; Affinity Analysis; 
surveys; and structured interviews. Quantitative methods included: activity data surveys; 
targeted surveys; and Delphi methods. 
The research systematised the collection and collation of the required data and 
determined novel ways of analysing and manipulating it to aid decision-making. These 
were used to evaluate the impact of major capital investment and variations in practices 
between different parts of the country. 
A benchmarking approach should be applied in utilising the data and statistical indicators. 
Nomenclature issues can influence data quality. Therefore clear, unambiguous guidance 
was developed for data collection. Existing pharmaceutical information systems will be the 
main sources of the data for the foreseeable future. 
The research focused on the North West of England, with successful application in the 
West Midlands. Its transferability to non-NHS and foreign hospitals is inferred, as long as 
similar operational arrangements apply. 
The research enables: the measurement of progress towards implementing the 
Breckenridge (1996) recommendations; the evaluation of performance for aseptic 
production and usage to inform capacity planning; and the presentation of the degree of 
collaboration between hospitals. 
The research addresses the absence of set data for an important hospital support service, 
and applies relevant lessons from other fields and industries. It enables a systematic 
approach to capacity planning and performance evaluation, at a time when the 
contribution of the service to support clinical governance is being fully recognised. 
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Chapter 1 Introduction 
1.0 Introductory Overview 
The research covered by this thesis relates to the question of what information can and 
should be collected in relation to the production and preparation of aseptic products, 
primarily in National Health Service (NHS) hospitals in the United Kingdom (UK), and how 
it should be used for management and business purposes. The main focus of the work is 
in the North West of England. 
Aseptic preparation involves sterile products being administered to patients by injection or 
irrigation, with the products being prepared in a hospital pharmacy or assembled in the 
clinical area, usually by a nurse. There is national guidance and legislation, in terms of 
production in pharmacies and clinical governance. It is likely that hundreds of thousands 
of such products are administered each day across the country. It is recommended that 
aseptic preparation should preferably be undertaken in pharmacies (Breckenridge, 1976) 
but hospitals do not have data that will confirm what the balance of aseptic preparation is 
between pharmacies and clinical areas. 
This lack of set data relating to the production and usage of aseptic products prompted 
the research relating to this thesis, at a time when improvements and a more business- 
like approach were required for these services. 
However, any data and analyses need to fit in with both the managerial and professional 
vocabulary. Therefore a research question that needed to be examined was how collected 
data should be used to support management discussions concerning key concepts such 
as "capacity", "workload" and "collaboration", in respect of business processes relating to 
aseptic production and preparation. 
A further issue to be encompassed within the research was that of nomenclature. Different 
professions sometimes use the same words to mean different things, and sometimes they 
use different words to mean the same thing. With the range of professions involved in 
aseptic production and preparation this could have potential implications for the quality of 
any such data, when consistency and accuracy of interpretation are required. 
Consequently, nomenclature needed to be included in the research. 
Chapter 1 therefore sets the scene, with Section 1.1 providing the main reasons and 
background for the research. Sections 1.2-1.6 describe: where Pharmacy sits within 
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hospital services, and how aseptic dispensing sits within a pharmacy; how aseptic 
dispensing, preparation and technique are defined, and the influence of legislation; and 
the different types of production facilities. Section 1.7 then outlines the national approach 
to managing the associated risks from the 1970s up to 1997. 
The year 1997 represents something of a landmark in the approach and attitudes towards 
aseptic preparation, particularly in the North West. Therefore, before moving on to a more 
regional focus, Sections 1.8 and 1.9 outline the National situation in respect of both 
pharmacy and mainstream information systems, given their potential as the sources of 
required data. 
Section 1.10 describes the history of aseptic dispensing work in the North West, from its 
initial response to national directives to the identification of the need to evaluate the 
impact of major capital investment. Section 1.11 places the North West in the national 
context, primarily in relation to clinical governance and modernising medicines 
management. The importance of clinical governance and managing clinical risk is central 
to why aseptic production and usage should be measured and monitored. Sections 1.12 
and 1.13 then place these pharmacy-related initiatives within the context of the overall 
governmental approach to improving performance within the NHS, including the use of 
benchmarking. 
It was important for the research to look outside the NHS, to see if there are lessons to be 
learned. Therefore Sections 1.14-1.16 consider the commercial pharmaceutical sector 
and private hospitals within the UK, before looking at the international picture. 
The chapter then concludes by summarising the need for information and data to support 
the development and management of aseptic production and preparation in the NHS 
(Section 1.17), before describing the specific aim and objectives covered by this thesis 
(Section 1.18). Section 1.19 sets out a framework, which is used to present the research 
findings, breaking them down into 18 components, with the purpose of each and the 
researcher's role/contribution outlined. The framework is integral to Chapters 3,4 and 5, 
ensuring correspondence for each component across them, e. g. Sections 3.8,4.8 and 5.8 
respectively detail the methodology, methods and results for Nomenclature. 
Finally a flowchart is provided in Section 1.20 outlining the links between the various steps 
in the research process. 
It should be noted that the author of this thesis is also known as the researcher 
throughout. 
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1.1 Research background 
1.1.1 Reason for research 
This thesis relates to aseptic dispensing and preparation, primarily in NHS hospitals in the 
UK. The activity is extremely common in acute clinical care within hospitals, and involves 
risks according to a range of factors (e. g. complexity and risk of preparation error, and 
chemical stability/shelf life) which point to whether preparation should take place within a 
pharmacy rather than in a clinical area (NHS Executive North West, 1997). Therefore the 
management of these risks is very important to support clinical governance. However, 
data has not been routinely collected in respect of aseptic production and usage. 
Consequently there has not been the development of measures and indicators to enable 
pharmacists, managers and other professionals to manage, plan, deliver and evaluate 
these services. 
The modernisation of the NHS has driven improvements in care and support services, 
with a range of central and local initiatives to specifically improve aseptic dispensing and 
preparation. Yet without accepted relevant data, and agreed ways of utilising such data, it 
is not possible to evaluate the degree to which the aims and objectives of any initiatives 
have been met. 
The research, to which this thesis refers, addresses this deficiency, by establishing: what 
data can and should be collected in respect of aseptic production and usage; how such 
data can be manipulated to provide statistical measures that are meaningful and useful to 
pharmacists, managers and others; and whether the findings can be successfully applied 
to actual initiatives, so as to evaluate their efficacy. 
1.1.2 Researcher's personal research interests 
The researcher has long been interested in examining how commonplace or specialised 
subjects/concepts might be measured or expressed statistically (see Section 11.1 for a list 
of publications not relating to this research). This research is an example of this: what is 
meant by terms used every day (in the NHS), such as "workload", "capacity", and 
"collaboration", and how are they best measured for practical usage? The nature of such 
terms is that they are concepts that are open to interpretation, but which are used all the 
time for business and management purposes. Indeed, they will be interpreted differently in 
different arenas, and can evolve over time. 
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Because there are no absolute measures for the concepts, research approaches 
necessarily involve the (quantitative) development and use of proxy measures, integrated 
with testing the (qualitative) acceptability for their use to professionals, managers and 
others working within the field. Consequently, an iterative mixed methodological process 
is essential, as methods are continually refined/ upgraded in the light of developments in 
practice and data, and the constituency's responses to results. In each and all cases the 
research problem dictated the approach applied, taking into account any constraints (see 
Section 3.0.6). 
1.1.3 Background information 
To consider the research approach, methods and results it is first necessary to have 
background information of: 
Aseptic dispensing and preparation, and where they feature in the overall role of 
pharmacy; 
The environments of aseptic dispensing and preparation, and the associated risks; 
How aseptic dispensing and preparation are organised and the rules that apply to them; 
and 
The history of aseptic dispensing and preparation development in the NHS, and 
associated dynamics, together with an appreciation of the situation in the private sector 
and abroad. 
It is also important to appreciate the role of information in connection with aseptic 
dispensing and preparation, and how this compares and relates to developments in 
information systems, data and performance measurement in the NHS, and the wider 
public sector. Suitable allowance will also need to be made (as far as possible) for 
changes in pharmaceutical services and information systems, as NHS modernisation 
unfolds (DoH, 2000d; Secretary of State for Health, 2002; NHS Executive, 1998). 
This context is necessary in order to set out the aims and objectives of the research, and 
the reasons for pursuing them. 
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1.2 Hospital Pharmacy Departments 
A full hospital pharmacy service has been described as providing patient-focused 
medicines management, in accordance with statutory requirements and the Code of 
Ethics of the Royal Pharmaceutical Society of Great Britain (Healthcare Commission, 
2005). This service should also actively support education and research throughout the 
Trust (ibid). Figure 1.1 below provides an outline. 
The main departments and functions relating to aseptic dispensing and preparation come 
under Preparative Unit Services, although nearly all other functions can have an important 
bearing, e. g. drug purchasing and supply. All aseptic preparation facilities should be 
commissioned by quality control and then monitored at regular intervals (Beaney, 2006). 
"Asepsis" is defined as: 
The state of being free of living pathogenic micro-organisms. 
The process of removing pathogenic micro-organisms or protecting against 
infection by such organisms. 
(Medical-dictionary. thefreedictionarycom, 2006) 
Therefore, the word "aseptic" refers to working in a sterile environment, free from 
contaminating germs or bacteria, and using sterile techniques and instruments 
(Drugdevelopment-technology. com, 2006). Accordingly, aseptic dispensing is defined as 
the activity of supplying a sterile product in its appropriate form, using aseptic technique, 
to the patient pursuant to a doctor's prescription (DoH, 2003a). 
However, aseptic dispensing and preparation represent only one of the two main 
components of Preparative Unit Services. The other is classical/traditional manufacturing, 
which was not covered by this research. Classical manufacturing consists of terminally 
sterilised manufacture and non-sterile manufacture (ibid). 
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Figure 1.1 Healthcare Commission Description of Pharmacy Services 
CLINICAL SERVICES 
0 Designated Clinical Pharmacista- 
O Monitor drug therapy for 
ul, lxopiatauess safely and 
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1.3 Aseptic Dispensing and Preparation 
From the perspective of the Medicines Act 1968 (Medicines Act, 1968), aseptic dispensing 
should be seen as two separate but linked activities (Farwell, 1995). The first activity is 
dispensing, which is the supply or issue of a finished product to the patient or to the 
person responsible for its administration. The second activity is preparation, which is the 
manipulation of the product leading to this final presentation (ibid). 
In order to achieve sterility, the facilities and performance requirements of aseptic 
preparation are necessarily very strict. The performance criteria of a facility should be 
established prior to building (Beaney, 2006), and adherence to the design specification 
should involve installation, operational and performance qualifications (British Standards 
Institute, 1999; Beaney, 2003). 
With regard to performance requirements, all aseptic operations should be performed in a 
workstation sited within a controlled workspace environment conforming to EU Guide 
grade A (Medicines and Healthcare products Regulatory Agency, 2003). This may be 
provided by: 
9A Laminar Flow Cabinet: situated in a clean room that is dedicated to aseptic 
preparation, with the room environment complying with EU Guide grade B. 
"A Pharmaceutical Isolator: sited in a dedicated room used for the isolator and its 
ancillary equipment and related activities, with the room environment complying 
with EU Guide grade D. 
(ibid) 
There are many specific design and performance requirements that need to be adhered to 
in aseptic preparation facilities. These include: Clean rooms have associated changing 
rooms, designed as airlocks and used to provide separation of the different stages of 
change, thereby minimising microbial and particulate contamination of protective clothing 
(Beaney, 2006); Support rooms from which materials can be passed onto and out of the 
clean room through a hatch(es), with the doors of the hatch(es) interlocked (ibid); Ideally, 
clean air devices should run continuously; Pressure differentials across inlet high 
efficiency particulate air (HEPA) filters in cabinets, isolators and clean rooms, and 
between rooms of different classifications should be constantly indicated; All rooms and 
equipment used for preparation activities should be cleaned regularly and frequently in 
accordance with written procedure; All equipment should be operated in accordance with 
written operating instructions; Major equipment, including air-handling systems, should be 
subject to a suitable planned preventative maintenance schedule (ibid). 
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Such requirements must be met to ensure the quality of the aseptic products, irrespective 
of the volumes prepared, as long as safety is not jeopardised (see Section 11.38). 
Therefore creating and maintaining an aseptic environment represents a substantial fixed 
cost. 
There is no standard design of an aseptic preparation unit, with variations across the 
country, to a greater or lesser extent (NHS Executive North West, 2001). Consequently 
there will always be limitations placed on any "standard solutions" recommended by any 
party. 
Radiopharmaceuticals were initially included in the research, but subsequently excluded 
because they involve special units and have very specific requirements, different from 
other aseptic products (see Section 6.5). They have short shelf lives (generally less than 
24 hours) that have been the subject of some controversy within pharmaceutical circles 
(Beaney, 2006), and especially since guidance questioned end-user dispensing in other 
departments by non-pharmacy staff (NHS Pharmaceutical Quality Assurance Committee, 
2004). 
1.4 Medicines Act 1968 
The Medicines Act 1968 (Medicines Act, 1968) was introduced to regulate the 
manufacture, distribution and importation of medicinal products. This required the 
manufacture, wholesaling, importation and marketing of medicines to be controlled 
through a licensing system operated by the Department of Health's (DoH) Medicines 
Control Agency (MCA). The objectives of the licensing provisions were to provide 
assurance on the safety, quality and efficacy of medicines via a system of product 
licenses (PL) and manufacturing licenses (ML). 
Section 7 of the Act authorises the holder of a PL to: Sell, supply or export the product; 
Procure the manufacture or assembly of the product; and, Import the product. (Note: 
European Directives refer to marketing authorisations (MA) in preference to PLs; As a 
product approval, the two terms can be considered interchangeable). 
Section 8 of the Act covers manufacturing licenses. Anybody who wishes to manufacture 
or assemble a medicinal product must hold a ML. Manufacture includes any process 
performed in the course of making the product. Assembly is the filling or labelling of the 
primary container. A ML covers the manufacture of broad classes or compounds (e. g. 
tablets, eye drops, ointments, etc. ). A ML is only granted after an inspection of the 
premises has been made in the light of accepted criteria for good manufacturing practice. 
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The Act necessarily provided for some exemptions, given the practicalities of delivering 
healthcare at the time, and subsequently: 
Section 9 enables Doctors and Dentists to be exempted from the licensing requirements 
of sections 7&8 (ML & PL), in the following circumstances: Products prepared to their 
prescription for administration to a particular patient of theirs; Products manufactured to 
their own prescription or that of another practitioner for a particular patient; When 
procuring the manufacture of stocks of products up to a maximum limit of 5 litres of fluid 
and 2.5 kg of solids; and, Products imported for administration to a particular patient. 
Section 10 enables Pharmacists to be exempted from the licensing requirements of 
sections 7&8 (ML & PL), in the following circumstances: Preparing or dispensing a 
medicinal product in a hospital or health centre by or under the supervision of a 
pharmacist in accordance with a doctor's prescription; Assembling a medicinal product in 
a hospital or health centre by or under the supervision of a pharmacist; Preparing a stock 
of medicinal product in a hospital or health centre by or under the supervision of a 
pharmacist with a view to dispensing them. 
Section 11 states that a registered Nurse or a certified Midwife does not require a 
manufacturer's licence in order to assemble medicinal products in the course of his/her 
profession. 
A ML generally authorises manufacture or assembly of a product only if the licence holder 
also holds a PL in respect of that product or is manufacturing on behalf of the PL holder. 
Products may, however, be manufactured as part of a "specials dispensing service" 
(Specials) in response to special orders received from hospitals, retail pharmacists, 
wholesalers etc. A person providing these services is granted a ML (Specials) Licence 
that authorises the manufacture of medicinal products without a product licence. 
1.5 Licensed and Unlicensed Units 
There are essentially two types of manufacturing units within hospitals, licensed and 
unlicensed. These are described as follows: 
9 
1.5.1 Licensed Manufacturing Units 
These units possess a ML (Specials) Licence under the provision of the Medicines Act 
(Medicines Act, 1968). A license is granted by the Medicines Control Agency (MCA) (now 
the Medicines and Healthcare products Regulatory Agency - MHRA) following an 
inspection of facilities, operating procedures, documentation and quality control 
procedures within a unit. A unit has to be audited against the Rules Governing the 
Manufacture of Medicinal products in the European Community (Commission of the 
European Communities, 1992). 
This is normally seen as the most appropriate option for larger units that wish to provide a 
comprehensive local service and/or services to other hospitals. 
1.5.2 Unlicensed Manufacturing Units 
Unlicensed units do not hold a manufacturing licence. Preparation of medicines in 
anticipation of a prescription is exempted from the licensing requirements by virtue of 
conditions given in section 10 of the Act. MCA guidelines on the application of the 
Medicines Act to NHS hospitals advise that the units can undertake aseptic preparation 
providing set criteria are met (MCA, 1992). Activities should always be in accordance with 
the latest defined NHS guidelines (Medicines Act, 1968; Farwell, 1995; NHS Executive 
North West, 1997). For example, the conditions specified by MCA in 1992 were extended 
to cover preparation for dispensing directly to individual patients by Farwell (1995). 
Preparation activities meeting the set criteria will nonetheless require an acceptable level 
of quality assurance together with regular external audit by quality assurance staff 
(Beaney, 2006). 
Table 1.1 describes the main differences between licensed and unlicensed manufacturing 
units. It should be emphasised that the required standards for the facilities, operational 
procedures and documentation are the same for both licensed and unlicensed units. 
Notwithstanding the above standards that aseptic units are required to meet, it is 
important to appreciate that the lack of consistency in the design of aseptic units across 
the country (NHS Executive North West, 2001), has always presented a major constraint 
when attempts have been made to make valid comparisons (Gandy and Beaumont, 
2003a). This reflects many factors: whether a unit was "added on" to an existing hospital 
(which may be very old or modern), with associated space and functionality constraints, or 
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was an integral component of comprehensively designed building; the approach to 
hospital planning design prevailing at the time a unit was built; and, the local emphasis 
placed on aseptic services, which would influence the aseptic production size and 
capacity. 
Table 1.1 Comparisons of Key Issues Relating to Licensed Units & 
Those Operating Under Section 10 Exemptions of the Medicines Act 1968 
SECTION 10 EXEMPT UNITS LICENSED UNITS 
Mainly in response to a prescription No formal request documentation required 
but can make in anticipation of 
demand 
Some small batch preparation may Batch preparation is usual practice 
occur 
Operates under Pharmacists' Operates with "Key Personnel" defined in 
supervision license 
Output restricted by MCA guidance Output regulated, but not usually restricted 
by MCA 
Shelf life restricted to a maximum of Shelf life defined by validation work, 
7 days normally well in excess of "Section 10" 
restrictions 
Often a mixture of dedicated and Primarily dedicated, specialist staff 
rotational staff 
Needs high numbers of pharmacists Skill mix allows for increased utilisation of 
and technicians support staff grades 
Relatively high capital costs Relatively high capital costs 
High product costs Relatively low product costs in spite of extra 
license and inspection fees 
Internal audit system and inspection Internal audit, external audit and inspection 
by Regional Quality Assurance by MCA 
specialists 
(NHS Executive North West, 1997) 
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1.6 Aseptic Practice and Technique 
"Aseptic Technique" refers to the manipulation of sterile products by personnel so as not 
to introduce microbial and/or particulate contamination (DoH, 2003a). 
Aseptic technique is the effort taken to keep the patient as free from hospital micro- 
organisms as possible (Crow, 1989). It is a method used to prevent contamination of 
wounds and other susceptible sites by organisms that could cause infection. This can be 
achieved by ensuring that only sterile equipment and fluids are used during invasive 
medical and nursing procedures. 
1.7 Managing Risk Associated With Ward-based Aseptic Practice and 
Techniques: National picture 1970s -1997 
The first major published recognition of problems with aseptic practices and techniques in 
hospitals was in the 1970s, with the publication of the Breckenridge report (Breckenridge, 
1976). The situation at that time was one where: there was a general lack of information 
regarding stability and compatibility of drugs in intravenous fluids; where pharmacists 
were rarely involved in advising doctors and nurses about these issues; nurses were in a 
"wasteland" due to poor training; labels showing that a drug had been added were often 
not attached to fluid bags; and, it was common practice, for example, to add drugs to 
inappropriate fluids (Graham, 2005). 
The report recommended that drug-infusion mixtures ideally should be prepared in 
pharmacy-run facilities and not in wards, advice that was subsequently recommended by 
the British National Formulary. If this was not possible, the report went on to suggest that 
pharmacists should be at the forefront in giving advice about the addition of drugs to fluids 
in clinical areas, and should be heavily involved in training and educating doctors and 
nurses in this area of clinical practice (Breckenridge, 1976). 
Given the huge number of such preparations in NHS hospitals, such a major change (ibid) 
could not hope to be implemented straightaway, and required an ongoing process. 
Consequently products were often prepared on an individual basis. In addition, the 
subsequent growth in chemotherapy, parental nutrition, nuclear medicine, etc expanded 
the range of special injections that, due to their complexity or hazards, had to be handled 
away from patients in special environments (Chief Pharmacist, 1994). Therefore, the 
focus of many national pharmacy initiatives since Breckenridge (1976) has been to 
increase patient safety by improvements in the preparation and usage of aseptic products, 
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primarily by risk management. The basic tenet is that it is preferable for aseptic 
preparation to be undertaken in pharmacies rather than in clinical areas, particularly for 
"high risk" products (Farwell, 1995; Chief Medical Officer and Chief Pharmacist, 1996; 
NPSA, 2006). Consequently data requirements have focused on audit and compliance. 
Unfortunately, the early 1990s saw a number of fatal incidents. One involved the deaths of 
two children in April 1994 at the Royal Manchester Children's Hospital following their 
injection of products that had been kept in proximity to a radiator (Anon, 1994), which 
resulted in the DoH undertaking a critical review of local practices for aseptic production. 
In addition, the Chief Pharmacist in 1994, highlighted the significant growth in the aseptic 
preparation of medicines in facilities managed by pharmacists. This was often done using 
Section 10 exemptions from full licensing available to pharmacists under the Medicines 
Act 1968. The evidence suggested that the standards of practice utilised did not always 
reach the levels of good practice recommended. This was seen as having the potential of 
increasing the significant risk regarding patient safety (Chief Pharmacist, 1994). 
As a consequence, the Chief Pharmacist issued the Farwell report (Farwell, 1995) which 
described best practice and policies, and consolidating much of the guidance and 
requirements from Breckenridge (1976) and the Medicines Act 1968. 
Moreover, the Secretary of State in 1996 asked the MCA to investigate standards of 
aseptic preparation in unlicensed NHS pharmacies in the UK (Chief Medical Officer and 
Chief Pharmacist, 1996). The survey involved a 10 per cent sample of all unlicensed 
aseptic dispensing units (i. e. 26), with advance notification of visits given. Widespread 
deficiencies were reported, and the MCA concluded that standards and guidelines were 
not being consistently met (ibicn. Most of their concerns related to facilities, equipment and 
quality assurance. In over 60 per cent of the sample there were "significant failings" 
(against the standards required), although one in six of the units were considered to have 
standards comparable to those in licensed units (ibicf). 
This prompted the DoH to issue EL(96)95, which focused on the need for any unlicensed 
aseptic dispensing carried out within a Trust pharmacy to comply with published 
standards, and compelling all hospital Trusts to undertake an internal audit of all such 
facilities (ibid). The associated audit questionnaire enabled the evaluation of current 
practice, aiming at whether facilities, processes and resources met required standards, 
with proposed action to address any shortfalls. The deadline for completion was March 
1997. 
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Importantly, the audit questionnaire did not collect data regarding levels of activity either in 
aseptic dispensing units or clinical areas. The whole exercise took place without any 
background data on the size and balance of aseptic dispensing and preparation taking 
place in these environments. Consequently, it was not possible for the DoH, or anyone, to 
have any appreciation of the relative volumes involved and the degree to which the 
Breckenridge (1976) recommendation to shift the balance of preparation away from 
clinical areas to pharmacies had been put into effect. Arguably this reflected a significant 
gap in knowledge. 
1.8 Information & Information Technology 
1.8.1 NHS Information Systems & Electronic Prescribing 
The NHS has a relatively poor track-record in respect of investment and application of 
Information Management & Technology (IM&T) (NHS Executive, 1998). The publication of 
Information for Health (ibid) highlighted both existing shortcomings and future investment 
strategy. This resulted in a multi-billion pounds investment programme to improve IM&T 
systems and services across the NHS with a target that 4 per cent of total NHS spend 
should be on information technology by 2008 (Wanless, 2002), more than doubling the 
percentage at the time. 
The Government intended IM&T investment to be at the heart of its overall modernisation 
programme for the NHS (Audit Commission, 2001). Electronic prescribing systems (EPS) 
(sometimes referred to as e-prescribing)2 were a priority for reducing medical errors 
(Goundrey-Smith, 2004; HSJ, 2002), and pharmacy automation in respect of dispensing 
was a key factor in re-engineering hospital pharmacy services for a modern working 
environment (Audit Commission, 2001). 
EPS reduce medicine errors significantly by providing timely, legible information (Wyatt 
and Walton, 1995; Schiff and Rucker, 1998; CFH, 2006b). This reduces transcription 
errors (a major source of medicine errors) and the loss of prescription sheets (Audit 
Commission, 2001). Therefore computer technology is not an optional extra but a 
fundamental part of the modernisation agenda for a range of changes, including clinical 
governance and pharmacy (DoH, 2000d; NHS Wales, 2001), creating the opportunity to 
release scarce pharmacy resources into direct patient care. Therefore the priority for 
pharmaceutical services within the Information for Health strategy was EPS. All Trusts 
would be expected to achieve the goal of having a Level 3 Electronic Patient Record by 
the target date of 2005 (NHS Executive, 1998). 
2 EPS is not Electronic Prescription Service 
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There were perceived problems at the outset of the national investment programme for 
EPS in 2002, in terms of slippage on procurement, and the impact on local support and 
actions of having a centralised approach to delivery (HSJ, 2002; Hoeksma, 2002; Bolton, 
2002). Procurement and implementation should take place over the period 2008 - 2010 
(CFH, 2006b). 
1.8.2 EPS and Data on Aseptic Preparation 
The focus of EPS is on clinical specialties, and improving clinical governance, and they do 
not include aseptic products/preparation per se although some such activity might be 
inferred (CFH, 2006b). (This situation was subject to review with the production of the 
formal functional specification (CFH, 2007a)). 
Existing pharmaceutical information systems relating to aseptic dispensing support the 
operation of pharmacies (e. g. to produce labels), rather than generate detailed data for 
analysis (Gandy and Beaumont, 2003a). There are four main systems that have been 
established since the 1990s (ibid). 
This situation in respect of limited relevant data being electronically available from NHS 
systems placed constraints on research methods. (A confirmatory check on progress was 
required towards the conclusion of the research, see Section 11.57). 
1.9 Mainstream NHS Information & Data 
The main measurements of hospital activity have traditionally focused on what is done by 
the medical profession, with the production of minimum datasets for patients attributed to 
whichever consultant is responsible for a patient for a given period of time. The Korner 
review of NHS data was undertaken in the mid-1980s (DHSS, 1984). Prior to this a 
patient's whole stay would be attributed to the consultant and specialty responsible 
immediately prior to discharge. This meant that specialties that were involved in the early 
stages of patients' stays did not get sufficient credit for their contribution, and arguably 
those that were involved in the latter stages got undue credit. The solution recommended 
by Korner was to break down the overall patient's spell into each episode under the care 
of a different consultant and specialty, where internal transfers were involved (ibid). This 
resulted in the creation of (inpatient) Finished Consultant Episodes (FCEs). These FCEs 
could be combined in different analytical ways to best answer a query. FCEs were used 
as the main activity currency in the early days of the "internal market" in the early 1990s. 
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However, it was suspected that some Trusts were more imaginative than others in how 
they recorded internal transfers: with increases in the number of FCEs being greater than 
the increases in the number of patient spells, resulting in apparent increases in patient 
throughput and apparent decreases in costs per case. FCEs are retained as a currency 
but these criticisms meant that First Finished Consultant Episodes (FFCEs) are now more 
generally used, because they are essentially the same as spells, i. e. a patient is only 
counted once. 
The level of demand for aseptic products will naturally reflect the number and the related 
casemix of patients treated in a hospital, together with any local policies regarding aseptic 
preparation (Gandy et al, 2003; Gandy, 2005; Gandy and Beaumont, 2006; Hardy and 
Mellor, 2007). Therefore any analysis of aseptic preparation and usage for a hospital over 
a period of time, particularly where any movement in aseptic preparation between clinical 
areas and pharmacies is being investigated, should appropriately take into account 
changes in (inpatient) activity and casemix. FFCEs and FCEs in their different forms (e. g. 
inpatients, outpatients, A&E) are in practice the only readily available activity data for NHS 
hospitals. Therefore, along with their associated occupied bed-days, they are the main 
data used for quantifying changes in patient activity volumes and casemix over a period of 
time. Consequently FCEs, FFCEs/Spells and Occupied Bed-days are the only realistic 
data that can currently be used as proxy measures for hospitals' volumes and casemix 
(ibid). 
1.10 North West Initiatives in respect of Aseptic Dispensing 1997 - 2005 
1.10.1 EL(96)95 & Original North West Survey 
When the DoH issued EL(96)95 (Chief Medical Officer and Chief Pharmacist, 1996), the 
Regional Pharmacist for NHS Executive North West commissioned the researcher to 
collate and analyse the local internal audit responses. In addition to the audit a survey 
was also commissioned which focused on all aseptic dispensing and preparation across 
the North West, in order to provide information on the types and volumes of aseptic 
products, characteristics of aseptic dispensing units, and expiry periods (Gandy et al, 
1998a). This was because of concern at the lack of data for the production and usage of 
aseptic products (See Section 1.7) and to establish whether the amount of aseptic 
preparation taking place in clinical areas was sufficiently large as to suggest that the 
commercial sector might be interested in meeting requirements. 
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The results of the audit and the survey (ibid) demonstrated the diversity of services and 
facilities across the North West and raised a number of concerns. A particular concern 
was the range and volume of products being prepared in wards and clinical areas rather 
than in licensed and unlicensed aseptic facilities. At least 65 per cent were prepared in 
this way (ibici). (This figure was subsequently updated to 79 per cent (Gandy et al, 2003; 
Gandy, 2005)). 
1.10.2 North West Working Party of Chief Executives and Chief Pharmacists 
The North West survey also found that many units were considerably under-utilised 
(Gandy et al, 1998a). Given the financial constraints of that period this could be ill 
afforded. In the circumstances, the Trust Chief Executives in the North West set up a 
working party to identify best practice/guidelines, and look wider than just the use of the 
aseptic facilities themselves (NHS Executive North West, 1997; Gandy et al, 1998b; 
Gandy et al, 1998c). (The researcher acted as the project manager for the working party 
and chief author and editor of its report). 
The working party report (NHS Executive North West, 1997) was circulated throughout the 
North West, with copies sent to the Chief Pharmacist at the DoH who circulated it 
throughout the UK as an example of "best practice". The report (ibid) sought to identify 
best practice and the actions necessary for Trusts to collaborate and develop local 
solutions that, importantly, would have local ownership (NHS Executive North West, 1997; 
Gandy et al, 1998b; Gandy et al, 1998c). It did not provide a blueprint for how future 
aseptic services should be organised in the North West. 
Two factors emerged from the working party as being key to the approach: the need for 
local provision to provide a flexible, responsive service; and that a pharmaceutical aseptic 
unit should not necessarily be expected to deliver all the needs of a Trust (ibicf). 
Collaboration between Trusts was seen as key for the regionwide organisation of future 
aseptic services to operate successfully, and to maintain high standards on a cost- 
effective basis. It could also provide the infrastructure to facilitate staff training, skills 
assessment, manpower development and quality assurance (ibid). This begged the 
research question of how "collaboration" might be measured, which is an important 
component of this thesis. 
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1.10.3 Outcomes from North West Working Party Report 
As a result of the working party report (ibid), Trusts in the North West were invited by NHS 
Executive North West to determine the most efficient, collaborative solutions locally, 
allowing for future trends in standards and demand. One obvious parameter for 
collaboration was geography, given that Trusts had historically worked on a geographical 
basis (Gandy et al, 1998b; Gandy et al, 1998c). 
There was unanimity amongst the working party members that a significant increase in 
pharmaceutical aseptic dispensing was required to effect any real shift in the balance 
between pharmacies and clinical areas. Given the balance at the time, even allowing for 
data constraints (Gandy et al, 1998a), it was not be realistic to look to completely 
eliminate aseptic preparation in clinical areas, within existing resources and the prevailing 
culture, because it would have meant almost trebling pharmaceutical production from 1.1 
million to 3.0 million per annum. To eliminate aseptic preparation in clinical areas would 
require a total review of current practices in clinical areas and would necessitate an 
extensive period of consultation, the outcome of which would be uncertain; whereas there 
were no objections from Trust Chief Executives to shifting the balance of aseptic 
preparation further towards pharmacies, particularly to appropriately deal with risk. 
To generate momentum and facilitate the working party recommendations (NHS 
Executive North West, 1997), the NHS Executive North West provided £3 million capital 
funds to support capital developments in aseptic dispensing units across the North West 
that would markedly increase production capacity and enable collaborative arrangements. 
The underpinning assumption made by NHS Executive North West was that the resultant 
increase in production capacity across the region would enable a broadly equivalent 
reduction in the number of aseptic preparations taking place in clinical areas (Gandy et al, 
1998b; Gandy et al, 1998c). 
A competitive process was followed, with various Trusts in the North West presenting 
business cases and proposals for capital schemes in their aseptic dispensing units 
(supported by partner Trusts where appropriate). The process incorporated a "market 
management" component where production projections and usage projections from all 
Trusts were balanced (by the researcher) to ensure that there would be sufficient demand 
for any additional products (Beaumont, 1999). This allowed Trusts to provide 
new/improved data resulting in a revised total of 3.8 million aseptic preparations in clinical 
areas per annum across the North West (Gandy et al, 2003). 
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The NHS Executive North West approved eight schemes, of various sizes, from all the 
proposals submitted by Trusts. However, before awarding capital funds, Chief Executives 
of purchasing Trusts were required to commit to buying the numbers of aseptic products 
they had specified during the process for a minimum of two years, from the Trusts that 
received capital funding. This was to guarantee that there were customers for the 
additional production volumes, and avoid the danger of the schemes producing products 
that no-one wished to purchase (Gandy and Beaumont, 2006). 
The potential contribution of the commercial sector was taken into account, although the 
limited availability of commercial aseptically prepared products at that time, was 
recognised (Gandy et al, 1998a). 
1.10.4 Evaluation of Capital & Collaboration Programme 
In addition to the above outcomes, the working party highlighted many issues relating to 
the lack of data regarding aseptic preparation (NHS Executive North West, 1997) these 
included, for example, the validation processes; physico-chemical stability data; 
environmental monitoring data in uncontrolled environments. A key concern was the lack 
of consistently defined and collected data for aseptic preparation in clinical areas (Gandy 
et al, 1998a). Data was required by pharmacists and managers that was relevant to the 
development of a definition of what constitutes the "capacity" of an aseptic dispensing unit 
(Gandy and Beaumont, 2003b). This would involve some form of time weighting for each 
type of product, given that different types of products take different amounts of preparation 
time. 
Good (project) management requires initiatives to be monitored and evaluated, to 
determine the degree to which the aims and objectives have been realised. The NHS 
Executive North West needed to evaluate the £3 million Capital & Collaboration 
Programme (C&CP) (Beaumont, 1999) in respect of changes in: (weighted) workload; 
capacity and the use of facilities; collaboration between Trusts; the balance between 
pharmacies and clinical areas; etc. As the only available robust relevant data involved 
simple counts of the numbers of the different aseptic products dispensed by pharmacies, 
these requirements represented a large gap in knowledge. The NHS Executive North 
West endorsed the need for research into how aseptic production and usage should be 
measured. 
The opportunity for the research covered by this thesis was born from these 
circumstances. However, it should be emphasised that this placed its own constraint on 
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the research because of its set deliverables. Consequently it was necessary for the 
research to establish the limits of usefulness and acceptability for relevant constituencies, 
and transferability to demonstrate its general efficacy. 
1.11 Clinical Governance and Medicines Modernisation: National Picture 1997 to 
date 
1.11.1 Emphasis on Clinical Governance 
The DoH emphasised the importance of clinical governance with the publication of "The 
New NHS: Modern Dependable" (DoH, 1997) and subsequent guidance (DoH, 1998a; 
DoH, 1999a). Hospitals were required to develop comprehensive risk management 
strategies to ensure the safety and well-being of patients and staff. The continuing 
practice of preparing pharmaceutical products in clinical areas rather than in 
pharmaceutical aseptic facilities was readily perceived as a key risk, and therefore the 
North West report (NHS Executive North West, 1997) was very timely. Should problems 
occur in the preparation and administration of such products that lead to a major hazard 
for a patient, or even death, then the hospital concerned, and its staff, were open to 
litigation/prosecution and confidence in services would be damaged (Gandy et al, 1998b). 
1.11.2 Medicines Expenditure & Trends 
At the beginning of this decade, the NHS spent £1.5b on medicines per annum, which 
was 4.6 per cent of total costs, and pharmacy staff cost c. £270m (Audit Commission, 
2002). Not surprisingly, pharmaceutical services and medicines management have been a 
continuing focus for a range of central initiatives, either specifically, or as part of more 
general guidance and directives from central government. 
More specifically to this thesis, the DoH introduced the Controls Assurance Framework in 
1999, which included a section devoted to reducing risk involved in the use of medicines 
(DoH, 1999b). The Controls Assurance Standards for Medicines Management (CASfMM) 
acknowledged that aseptic dispensing was an increasing and demanding activity for 
pharmacy services (NHS Executive, 1999), and that some NHS manufacturing capacity 
was needed to prepare medicines that were not commercially available. The CASfMM 
argued that Trusts should always consider whether collaboration with other trusts for the 
provision of common aseptically prepared items and manufacturing was a viable 
alternative to individual trusts investing in these services. An advantage of such 
collaboration was the possible release of pharmacy staff and capital for investment in 
other activities (Audit Commission, 2001). 
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1.11.3 Medicines Management 
In 2000/01 the DoH required hospitals in England to assess their services against the 
DoH's Medicines Management Framework, highlighting priority action areas (DoH, 
2001b). In addition, the Audit Commission encouraged the collection of baseline data 
regarding medicines management arrangements, to enable local auditors to work with 
hospitals, and chief pharmacists in particular, to improve services (Audit Commission, 
2001). This baseline data involved indicators dealing with cost, uptake of processes, 
staffing and intensity of workload, and staff deployment, on a benchmarking basis. 
Performance was interpreted on a benchmarking basis, e. g. whether organisations were 
placed in the top or bottom quartile. Reference was made to the policy aim to minimise the 
administration of IV antibiotics on wards, compared to oral, because of higher costs and 
clinical risks (Audit Commission, 2002). Pharmacy staff were related to Trust activity using 
FCEs as the main indicator for activity. However, this examined all pharmacy activity, 
without separating out aseptic dispensing. The important point was highlighted that the 
local context could potentially provide reasons why values of indicators cannot be 
interpreted on their own (ibid), which is directly relevant to the question of how 
(benchmarking) analyses developed within this research should best be utilised. 
In addition pharmacists were expected to apply more general modernisation guidance to 
medicines management, such as the "10 high impact changes for service improvement 
and delivery" (DoH, 2004b; Cooke, 2005). 
1.11.4 Risk Assessment 
In 1999, the DoH undertook a risk assessment survey of all 125 hospital pharmacy units 
in England holding a manufacturing licence. The questionnaire covered: workforce, 
facilities, products and capacity. The drivers for the exercise at the time were: unplanned 
closures of NHS Units (MHRA intervention) due to lack of investment; the role of 
production facilities in supporting supply chain/managing product shortages; and, the 
ageing facilities/poor local investment strategies (see Section 11.2 Reference 10). 
The results of the risk assessment survey indicated that the current manufacturing service 
was uncoordinated, with no system of peer review of prescribing habits, and a duplication 
of effort across some units. Shortages of products arose which potentially put patients at 
risk, and the costs of products were variable (see Section 11.2 Reference 7). The results 
raised concerns regarding the continued viability of NHS manufacturing units and led the 
Government to commission a multi-disciplinary Advisory Group to undertake a UK-wide 
risk assessment of NHS pharmaceutical manufacturing. 
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1.11.5 National Investment for Pharmaceutical Modemisation 
As a result of the Advisory Group's findings (DoH Advisory Group, 2002), in 2002, 
Ministers made available £4m capital to begin the process of modernising hospital 
manufacturing services, with a multi-disciplinary Implementation Board formed to lead the 
process in England. The following year, the DoH announced £42m capital was to be 
utilized (available across 2004/05 and 2005/06), to help deliver a cohesive, financially 
robust traditional NHS manufacturing service to provide medicines tailored to the specific 
needs of individual patients in circumstances where these needs cannot be met by the 
use of licensed medicines (DoH, 2003a). The processing of the bids was dealt with 
through four regional groups. 
These capital initiatives meant that pharmaceutical manufacturing units within Trusts were 
faced with several options. These included to become a lead unit within the modernised 
hospital manufacturing service, a strategic support unit within the modernised service, or 
to opt out from the developing arrangements (e. g. local aseptics provision). A logical 
consequence of modernisation is the requirement to rationalise the products prepared, 
based upon: standardisation; clinical desirability; technical assessment; and 
determining appropriate presentations (e. g. 'ready to use' v 'ready to 
administer' (ampoule/vial v syringe)) (see Section 11.2 Reference 10). There was 
a likelihood that "high risk" preparations would need to move to preparation in 
pharmacies (see Section 11.2 Reference 7), which was reaffirmed by Hardy and Mellor 
(2007). 
Partnership working between the NHS and the commercial sector was emphasised where 
there was an advantage to the NHS and a clear benefit to patients (DoH, 2003a). The 
Association of Commercial Specials Manufacturers, working collaboratively with the 
Implementation Board, prepared general principles of working with the NHS which 
covered a variety of issues including business models, risk management and intellectual 
property rights. As is stated above in Section 1.10.3, the commercial sector's contribution 
to the NHS was limited in respect of aseptic dispensing (Gandy et al, 1998a), partly due to 
its need be able to produce standard products in sufficient quantities to be economically 
viable. The wide range of requirements of the NHS and the limited shelf lives of products, 
for example those used in the treatment of children (Aston University Business 
Partnership Unit, 2004) had militated against significant expansion of the commercial 
sector's contribution in the past. 
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In the event, just under 30 per cent of the total capital funds were allocated to aseptic 
dispensing schemes, but the figure varied considerably across the four regions of 
England: in the North it was less than 10 per cent (partly because of the past investment 
in the North West); in London it was just under 50 per cent; in the South of England (exc. 
London) it was broadly 67 per cent; but in Central it was zero (see Section 11.2 Reference 
10). 
However, no methodology has been established to fully evaluate whether the approved 
schemes will have met their stated goals (see Section 11.2 Reference 12). 
1.11.6 Monitoring Progress 
Building on the Audit Commission work (Audit Commission, 2001,2002), the Acute 
Hospital Portfolio Medicines Management reviews in 2005/06 (Healthcare Commission, 
2005), generated a benchmarking data set to inform on a hospital's progress against set 
Medicines Management initiatives. This enabled Trusts to compare their performance with 
one another. They could also re-use the tools involved to measure their progress over 
time. 
The core questionnaire for the review broke down into nine sections (with an average of 
ten questions in each section) about different aspects of medicines management, 
including pharmacy staff and skill mix, and medicines management structures and 
strategies. Despite a wide range of questions, there was nothing that quantifies what was 
happening in terms of full aseptic production and usage. Indeed, there is reference to the 
fact that aseptic preparations are not all recorded in pharmacy systems (ibid), and that this 
has led to known problems with data completeness in relation to cancer medicines (ibis). 
1.11.7 Other Related Initiatives 
In addition to the above national programmes there have been other significant regionally 
based initiatives in recent years. These include a one-year project to develop a risk 
assessment tool for extemporaneous preparations, taking into account clinical risk, 
technical risk, a risk assessment of the current list of preparations, and the identification of 
the most risky products (see Section 11.2 Reference 9), and a two-year risk assessment 
of parenteral product preparation across North of England (Hardy and Mellor, 2007). The 
goals of the latter were to: Review the frequency, site of preparation and level of 
pharmacy control for recognised high-risk items; Collate information on a range of 
high/medium risk products to allow prioritisation for pharmacy preparation; Review current 
output of parenteral products from licensed and unlicensed units and compare with 
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information collated above; To identify and prioritise for pharmacy preparation those 
high/medium risk products which are not currently prepared in either licensed or 
unlicensed units. 
The National Patient Safety Agency (NPSA) carried out a consultation exercise on 
proposals to carry out risk assessments of clinical area preparation activities throughout 
the NHS (NPSA, 2006), with a view to prioritizing the transfer of high-risk products to 
pharmacies. The NPSA subsequently issued a bulletin on injectable medicines (NPSA, 
2007). 
All these point to increased emphasis on moving aseptic preparation from clinical areas to 
pharmacies. 
1.11.8 Continuing Evolution of Services 
It is concluded from the above that the medicines and pharmaceutical services are fully 
recognised as priorities by the Government, not only in terms of their contribution to 
clinical governance and patient care, but also in terms of ensuring that the services and 
processes themselves are fit for purpose and cost effective. However, the sheer size of 
medicines consumption and the complexity of the associated requirements mean that a 
great amount of time and effort will be required to achieve the identified goals universally. 
For example, it has been pointed out that a lack of stability and compatibility data is a 
considerable barrier to preparing products that are ready-to-administer in pharmacy- 
managed aseptic units (Graham, 2005). Therefore, at least in the short term, practical 
strategies will involve targeting pharmacy production efforts towards "high risk products" 
(Beaney, 2005a; Hardy and Mellor, 2007). 
The thrust and many details of the national and regional initiatives described above are 
consistent with the recommendations from work undertaken within the North West in the 
late 1990s, in respect of aseptic preparation (NHS Executive North West, 1997; Gandy et 
al, 1998a; Gandy et al, 1998b; Gandy et al, 1998c). Advice from the commercial sector is 
that the North West has always been seen as being clearly ahead of the rest of the 
country in respect of its aseptic dispensing services (see Section 11.2 Reference 5). 
When Professor Breckenridge looked at progress to 2005 in addressing the issues raised 
in his report (Breckenridge, 1976), he noted that significant proportions of products were 
still prepared in wards and theatres, including those that are "high risk" because, for 
example, they include complicated dose calculations. However, the role of pharmacists 
had increased dramatically (Graham, 2005). Nevertheless, despite the importance of the 
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Breckenridge (1976) recommendations, hospitals' annual health check does not require 
data relating to aseptic dispensing and usage to be collected (Healthcare Commission, 
2005). This suggests the timeliness of the research. 
Aseptic production and preparation is clearly still evolving at the time that this thesis is 
submitted. Consequently it was important to ensure that the results of the research were 
suitably robust so as to maintain their validity for the foreseeable future. 
1.12 Governmental Approach to Improving Performance In Healthcare since 1997 
In 1989, the then Conservative Government introduced a market environment and 
competition into the NHS (Propper et al, 2003) where hospitals became sellers or 
"providers" of services, and health authorities (and some General Practitioners) acted as 
buyers or "purchasers". In 1997, the new Labour Government maintained this split of 
responsibilities but rejected the market management mechanisms of its predecessors 
(Laurance, 1997; Baggott, 1998; Webster, 1998; Paton, 1999). Market competition was 
replaced with a performance management regime relying on benchmarking standards 
(DoH, 1997). Improvements in performance and standards were to be achieved by 
sharing information and transparently comparing performance (ibid). Partnership would 
replace competition (ibid). 
The new approach to performance management involved relative performance evaluation 
through key indicator benchmarking that ranked organisations in comparative league 
tables. As a result, hospitals competed in respect of comparative positioning through 
benchmarking on indicators, rather than in a market (Northcott and Llewellyn, 2005). 
The Government reinforced its approach with a strategy of denouncing "failing" hospitals, 
which was a useful device for engaging public pressure against those Trusts with bad 
results (Trosa, 1997). 
The next drive to identify best practice by Government was the establishment of 
Foundation NHS Trusts, which was available to three star Trusts (in 2003) (DoH, 2002a). 
The hope was that the freedoms Foundation NHS Trusts received would provide an 
incentive to others to improve (DoH, 2002b), although the King's Fund (2003) commented 
that being a top rated Trust does not guarantee innovation and responsive management. 
Foundation NHS Trusts were to remain subject to the annual performance rating. 
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The star ratings approach (DoH, 2002b, 2002d) was planned to end in 2005, and has 
since been replaced by a system developed by the Healthcare Commission (2006,2007) 
that awards organisations one of five grades for overall performance, by focusing on an 
"annual healthcheck" which includes 472 "prompts" The emphasis is placed on every 
organisation declaring annually, in a statement checked by local partner organisations, 
whether it is compliant with standards. Evidence would be required, and there is the 
opportunity for unannounced "spot checks" (ibid). It is described as involving targets plus 
standards, and is a fundamentally different process to star ratings, with more co-operation 
between the Healthcare Commission and local partners (HSJ, 2004b). 
In summary, the Government has been able to point to benchmarking as a new, 
collaborative tool for improving health processes and outcomes, while at the same time 
using it to reinforce standards, ensure centralised accountability and curtail provider 
power. Therefore, benchmarking has been a useful political instrument for driving 
performance, but as long as performance indicators are employed for political purposes, 
the more desirable attributes of benchmarking will be difficult to achieve. 
1.13 Examples of Relevant Change Influences and Processes 
Given the previous section, it is important to have an outline appreciation of some of the 
change processes that can impact on health and hospital services. The Prime Minister 
made no apologies for many reforms being driven from the centre (DoH, 2004), and whilst 
Local Delivery Plans, and similar, allow locally identified priorities, these are often 
subordinate to the achievement of national goals. This is partly due to the NHS Executive 
and Department of Health being organised in such a way that different parts/departments 
focus on specific areas, which leads to guidance being issued with its own (national) 
priorities and objectives. Examples are Payments by Results - Finance (DoH, 2007b), 
Connecting for Health - IM&T (CFH, 2007c), Agenda for Change - Human Resources 
(DoH, 2007a), and National Service Frameworks for categories of services such as 
Children, Young People & Maternity Services (DoH, 2003b) or specific conditions such as 
Cancer (DoH, 2000b) and Heart Disease (DoH, 2000c). 
Therefore, NHS organisations deal with such parallel pressures by balancing them within 
their own local circumstances and resources. As a consequence of the fact that the nature 
and organisation of NHS services can vary due to historical and geographical reasons, 
collaboration between NHS organisations is essential to achieve results, and is a 
prerequisite (sometimes prescribed) for achieving results. 
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Payments by Results (DoH, 2007b) presents an overarching constraint, because it 
dictates that each Trust is paid a flat national tariff to for a given type of care. The national 
tariff is in effect the average national cost for a type of care, calculated from the reference 
cost returns from each Trust across the country. This means that the cost of a treatment 
for commissioners will be the same wherever the patient is treated, be it within the NHS or 
in the independent sector. This is a way of opening up the market for the Government, 
and driving change. The rationale is that Trusts will have to become more efficient and 
improve quality to compete, and the reality of only receiving a set tariff will drive necessary 
changes. 
Consequently the pressure for Trusts to review all of their services (including pharmacy) 
will be greatly influenced by the degree to which their total actual costs vary from what 
they are paid through tariff, and other income. Many will be considered to be already 
covered by the tariff, while others have specific allocations earmarked. Getting allocated 
funds to be fully spent on the target service(s) is not always straightforward (British 
Council, 2003). 
One process used by the NHS to drive forward change in respect of new or priority 
initiatives is to allocate "targeted investment", where a given national sum of money is 
invested in specific priority services. Whilst this is nothing new, there has been particular 
emphasis to enable modernisation (and the modernising hospital manufacturing monies is 
that relevant to pharmacy (DoH, 2003a)). Such a funding mechanism has clear attractions 
as it enables Government to publicly state that it is making a particular service/client group 
a priority and is prepared to invest substantial resources accordingly. It also ensures that 
the money is invested in the specified area and that there is greater central control. 
However, a requirement for initiatives to be fully evaluated is not always specified. 
If "targeted investment" money were spread evenly across the country then the amount 
available for each organisation is usually very limited and insufficient to support many of 
the individual schemes submitted. Consequently a competitive situation is created 
whereby only a selection of the bids will be approved. Few (relevant) organisations will 
want to be seen not to make a bid for such funding, which means that the effort put in to 
develop the rejected proposals will have been wasted, with the associated local 
disappointment. One effect can be that "targeted investment" influences organisations to 
be reactive, rather than proactive, and "chase the money", rather than developing a 
holistic approach locally, with locally set targets and priorities, such as that required by the 
European Foundation for Quality Management's (2007) Excellence model and Total 
Quality Management (Stark, 2007). Also, whilst collaborative/joint bids from organisations 
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would clearly be welcomed, and would probably be consequently given a high rating, the 
time involved, and logistical and competitive pressures can militate against their 
production, which in turn can mean that collaborative opportunities can be missed. 
It can be seen that moving forward with modernisation and service improvement in the 
NHS is complex, and that medicines modernisation (DoH, 2003a) faces particular 
challenges because of the fact that pharmacy is primarily a support department, seeking 
to meet the requirements of a wide range of hospital services which will each be subject to 
their own, potentially divergent, pressures and trends. To manage this properly it is self- 
evident that pharmacists, managers and other professionals should require sound data on 
what pharmacies produce and how this is utilised by the various services. 
1.14 Commercial Pharmaceutical Sector in respect of Aseptic Products 
The commercial sector is a comparatively small player in the overall picture of aseptic 
production in the NHS. Gandy et al (1 998a) identified that it accounted for only 2 per cent 
of all aseptic products used in the North West of England. This masked the fact that it 
accounted for 40 per cent of cytotoxics and 5 per cent of Total Parenteral Nutritions 
(TPNs), and 0.04 per cent of all other aseptic products combined (ibid). 
There are significant constraints in NHS pharmacy data in general, and aseptic dispensing 
in particular (Jackson and Walker, 1998; National Prescribing Centre, 1998; Jackson, 
1999; Gandy et al 1998a). By comparison, the commercial sector regularly collects and 
utilises aseptic production data, as this is a clear necessity to enable it to achieve its 
business objectives. Data is generally collected on: product types manufactured; volumes 
of products; cabinet types and functions; and staff levels (see Section 11.2 Reference 6). 
Clearly, the commercial sector does operate on a different basis than the NHS 
(companies need to make profits and returns on investment for their shareholders), and 
therefore the management of risk is very important (So, 2005). 
The commercial sector prefers to focus on a limited range of products that can be mass- 
produced, preferably utilising as much automation as possible. Nevertheless, many 
processes are the same in principle, and it follows that the NHS can learn some lessons 
from it in respect of information (see Section 11.2 Reference 6). 
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To be able to justify any significant future engagement with the commercial sector it is 
essential that hospitals have some appreciation of the current and future demand for 
aseptic products in order to support the business case. This requires data and as has 
been demonstrated, there is insufficient data routinely collected to reflect either aseptic 
production within a hospital's aseptic dispensing unit or what is prepared in clinical areas 
(Gandy et al, 1998a). 
(It should be noted that the commercial sector itself sees the North West as clearly ahead 
of the rest of the country in respect of aseptic dispensing services (see Section 11.2 
Reference 6; NHS Executive North West, 2001) suggesting that undertaking the research 
primarily within the region, and utilising local references, could hardly have involved a 
more advantageous environment). 
1.15 Aseptic Preparation in Private Hospitals 
In terms of numbers of beds, private hospitals in the UK are general small and treat 
elective cases. Such cases can require aseptic preparations that are deemed to be of a 
sufficiently low risk that they can be undertaken in clinical areas. (More critical cases 
make greater use of aseptic preparations). Nevertheless, all private hospitals must meet 
accreditation standards for registration purposes, which cover policies and procedures for 
the control of infection (See Section 11.58). 
They have pharmacies for classical dispensing, but because of their size they do not 
normally have aseptic dispensing units. Aseptic preparation takes place in clinical areas, 
with related fluids often bought in bulk. The control of the calculations for a drug mix 
remains with the pharmacist. Any requirement for pharmacy preparation is normally 
covered by contractual arrangements with the pharmacies of neighbouring NHS hospitals. 
(This situation was reflected in telephone enquiries to BUPA and Nuffield Hospitals). 
It is inferred that private hospitals are not central to the research and can therefore be 
excluded. 
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1.16 International Picture 
The literature review outlines the international picture in respect of how aseptic 
preparation is undertaken relative to pharmacies (See Section 2.3). There are many 
variations between countries with the UK being more advanced than other countries in 
Europe in respect of centralised additives intravenous services (CIVAS). 
1.17 Need for Information and Data to Support Aseptic Dispensing and 
Preparation in the NHS 
Pharmaceutical services, being a support service, are often "below the radar" for senior 
management in hospitals - unless something goes wrong (Anon, 1994). Therefore, whilst 
Trusts ought to routinely review and invest in these services, such priority has not always 
been forthcoming, with one of the reasons arguably being ignorance. The lack of routine 
data to demonstrate the use and production of aseptic products, and a means of linking 
these with the casemix of patients treated, leaves financial budgets as the only readily 
available related data, leading to a likely focus on the "bottom line" and "balancing the 
books". There is also the vicious circle that means that: the information systems are not in 
place to provide the data to demonstrate the important role, contribution and potential of 
aseptic services and products; and because there is not the data to demonstrate the role, 
contribution and potential of aseptic services and products, there is not the case for 
improving information systems in this area to provide such data. 
Therefore there is a clear need for the consistent, acceptable collection and usage of 
quality data in respect of aseptic dispensing and preparation in the NHS. This is so that 
this critically important area can be planned, managed and operated in such a way that its 
services can be optimised in their own right, and so that their contribution to clinical care 
and governance can be maximised within hospitals both individually and collectively. 
This research is aimed at meeting this requirement by establishing: a realistic, robust 
specification of what data can and should be collected; how such data can be best used 
and manipulated to meet services' needs; and whether such data and analyses can meet 
such needs. 
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1.18 Aim & Objectives of Research 
The aim of the research is to identify the types of data and ways of measuring aseptic 
preparation and production required to evaluate changes in activity and performance over 
time. 
The research will address the following questions: 
" How should activity relating to aseptic preparation in hospital pharmacies and 
clinical areas be counted, collated and analysed? 
" Can existing information systems readily provide such data? 
" What statistical indicators can be developed to support collaboration and capacity 
planning for (NHS) aseptic production, and to evaluate related initiatives? 
" How can such data and statistical indicators be best utilised? 
The objectives of the research are: 
" To establish sound, practical methods of collecting data which meet the needs of 
services; 
" To establish (proxy) statistical indicators that relate to the concepts of 
"collaboration", "capacity" and "workload"; 
" To provide analyses of the data collected to hospital trusts to support them with 
collaborative arrangements and capacity planning; 
" To evaluate the changes engendered by capital investment programmes. 
1.19 Presentation of Research 
Table 1.2 details the constituent components of the research, confirming the contribution 
of the researcher for each. This structure has been replicated within Chapters 3,4 and 5 
of this thesis to aid the reader. For example, Section 3.8,4.8 and 5.8 respectively detail 
the methodology, methods and results for Nomenclature. 
It also links the components to the research phases quoted in the original rd9r application 
to register for a PhD. 
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1.20 Linking the Steps in the Research Process 
Figure 1.2 outlines the steps required to achieve the stated research goals. Section 4.0 
describes the ongoing validation process applied throughout the research. 
Figure 1.2 Flowchart Outlining Steps in Research Process 
What information is required on aseptic preparation and 
production? 
What data needs to be collected? 
Is it feasible to collect the data? 
What are the nomenclature issues that could impact on 
data quality? 
Collect baseline data. 
Evaluate efficacy of data and collection methods. 
I 
IF 
Make agreed changes to Interpret "collaboration" in Determine time weightings 
data and collection context of aseptic to apply to data. 
methods. preparation. 
Develop statistical 
Collect five Quarters data. Construct proxy statistical indicators relating to 
indicators. "caoacitv" and "workload" 
Evaluate efficacy of indicators when applied to data. 
Evaluate impact of Capital & Collaboration Programme, 
(and individual schemes) 
using data*, time weightings and statistical indicators. 
Validate research findings to establish: 
" If they can show changes over time; 
" If they are transferable to other parts of UK; 
" If they can be used for computer modelling 
purposes to support capacity planning; 
" If they can be applied for all capacity planning 
purposes in aseptic dispensing production? 
" If current developments in NHS information 
systems mean that the data collection methods 
might be overtaken; 
" How it should be used and interpreted to 
support evaluation and capacity planning 
Given delays in C&CP 2003/04 data was collected and used for final evaluation 
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Chapter 2 Literature Review 
2.0 Introductory Overview 
Having outlined the scope of the research in Chapter 1 it was essential that the Literature 
Review adequately covered the wide range of subjects relating to the components 
described in Section 1.19. 
A strategic, systematic approach was required (see Section 2.1) which would cover both 
pharmaceutical and non-pharmaceutical references and databases, and take advantage 
of professional forums on the Internet. This built upon the professional advice and 
literature search techniques and results from earlier work (NHS Executive North West, 
2001). 
Sections 2.2 and 2.3 provide overviews of relevant literature relating to aseptic 
preparation and clinical governance within the UK and internationally, respectively. They 
include examples of problems, such as medication errors, that have required the various 
initiatives described to take place, and which arguably justify the requirement for research, 
as is covered by this thesis. Section 2.3 also describes where the UK sits within the 
international spectrum of pharmaceutical organisational arrangements. 
The subsequent three main sections review literature with specific focus on three of the 
key research questions: Nomenclature (2.4), Collaboration (2.5) and Capacity and 
Workload Measurement (2.6). The latter two particularly examine the question of data and 
measurement. Section 2.7 therefore examines the situation in respect of the availability of 
data relating to pharmacies and aseptic preparation. 
Section 2.8 (Computerised Capacity Planning Software) effectively links Sections 2.6 and 
2.7, but within a modelling context. Section 2.9 then examines capacity modelling and its 
relation to skills availability, and the development of pharmacy skills within the NHS. 
Sections 2.10 examines what NHS data is available on overall patient activity, as not all 
patient treatment involves aseptic preparation, and therefore activity relating to the 
research needs to be considered within a total NHS context. Section 2.11 then looks at 
how the UK Government has approached the question of performance management since 
the Labour Party was elected in 1997, with particular reference to its use of 
benchmarking. This is necessary to reflect the managerial culture within the NHS that 
applied during the course of the research. 
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2.1 Strategic Approaches to Literature Review 
2.1.1 Background 
From the outset the literature review needed to be set into some context of what were the 
likely issues that might arise during the course of the research, and where published 
literature would be beneficial. Given the potentially wide range of issues that could be 
interpreted as being relevant it was necessary initially to try and identify priority topics for 
the literature search. Set out below is a summary of the thinking applied to this question at 
the time, which helped shape the approach adopted. 
The thrust of Breckenridge (1976) and Farwell (1995) was to move aseptic preparation 
from clinical areas to pharmacies, but it would be desirable to first clarify the issues and 
circumstances that brought about their recommendations. Therefore an appreciation of 
aseptic technique, best practice and clinical governance was required. 
A central concern was what data can and should be collected to reflect aseptic production 
and preparation, and how this might relate to clinical practice. Literature was therefore 
required about pharmacies, pharmaceutical systems and aseptic preparation, together 
with any related information systems and data. Data quality was very important, and not 
specific to just pharmacy, often relying on how consistently and accurately definitions and 
nomenclature are interpreted. 
As different types of product involve different production times, it was necessary to 
establish how production activity data could translate into aseptic unit workload. Evidence 
of the relationship between the different stages of the aseptic production process and 
available data needed to be taken into account, as did the potential impact on production 
of the availability of key equipment such as cabinets, and the licensing status of a unit. 
Certain key words, regularly used by pharmacists and managers in respect of aseptic 
production, are conceptual by nature. These include capacity, collaboration, and 
workload. It was therefore necessary to evaluate their interpretation within the 
pharmaceutical and non-pharmaceutical literature, and examine how such words were 
interpreted statistically. 
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Even if relevant data and derived metrics are identified, they must be made available to 
pharmacists and managers in ways meaningful to them. Therefore it was necessary to 
evaluate how appropriate comparisons can be best effected, and whether they can be 
used for modelling purposes, having regard for the characteristics of aseptic dispensing 
units. A particular focus was required on benchmarking, given the emphasis placed on 
benchmarking by the Government in its efforts to improve public sector performance. 
Finally, published influences concerning how the availability and skill mix of pharmacists 
and aseptic unit staff might impact on production were required. 
2.1.2 Literature Searches 
Standard methods of accessing Internet and NHSnet websites, and the LJMU library, 
were applied for keywords viz. Admixture, Aseptic Dispensing, Intravenous, Management, 
Parenteral, Statistics, Workload, and Work Study, were employed. These reflected 
professional advice used in earlier work (NHS Executive North West, 2001). 
Combinations were used, as follows: - 
aseptic& dispensing& workload; aseptic& preparation& workload; aseptic& dispensing& 
statistics; admixture& workload; admixture& work study; parenteral& dispensing& 
workload; aseptic& dispensing& management& quantification; intravenous& dispensing& 
work study. 
(Because of the limited results from "aseptic dispensing" the alternative of "aseptic 
preparation" was also used. Also, "quantification" was tried) 
2.1.3 Scope of literature review 
It should be emphasised that the results from these literature searches were very limited, 
and therefore the sole use of search terms was considered to be limited. Therefore, a 
literature review was undertaken to explore the wide range of publications relating to 
pharmacy to establish those of direct relevance, and where health and business metrics 
and information systems could be applied to the research. Journals/websites were 
identified during the earliest stages of the research and were broadly categorised in terms 
of their relevance to the research, as follows: Directly Relevant, Partly Relevant and 
No/Minimal Relevance. Section 11.3 lists those that were deemed as "No Relevance". 
As the NHS is subject to governmental direction, many official sources were included, and 
these reflect the evolution of services in general and pharmacy in particular. 
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Gandy et al (1998a) broke ground in determining aseptic production and usage data 
across a significant number of hospitals. Analyses showed large volumes of aseptic 
products "made up on ward", but this was an understatement as some Trusts recorded 
"data not available" (ibid). Concerns were expressed that existing information systems did 
not necessarily provide such data and at the lack of activity currencies (ibid). The 
subsequent North West risk management work was the first serious attempt to develop 
detailed guidelines for locations for aseptic preparation by product type (NHS Executive 
North West, 1997; Gandy et al, 1998b; Gandy et al, 1998c). 
Coincidently, the election of the Labour Party into Government in 1997 marked a change 
in the approach to how the NHS and other public services were managed (see Section 
1.12). 
Therefore, a timeframe was set for directly relevant (UK) literature. The review is 
pragmatic and includes direct professional knowledge and advice. Those 
journals/websites that were of relevance to the research were first thoroughly searched for 
appropriate publications back to the mid-1990s, with specific references to earlier 
publications obtained. Subsequently, published literature was surveyed regularly, 
generally quarterly given the publication cycle of many journals, with repeated use of 
keywords (see Section 2.1.2). 
Advantage was taken of available opportunities that influenced the choice of methods: 
building upon existing relationships between the researcher and lead pharmacists in the 
North West, which included seeking direct views and advice; direct approaches to national 
initiatives and bodies; and, direct approaches for relevant lead experts and advisors in the 
UK and elsewhere, including Professor Breckenridge himself. The involvement with North 
West pharmacists also meant access to current initiatives and a great deal of 
unpublished, but relevant work, which is included in the Appendices where appropriate. 
Some research related to the researcher's consultancy commissions. 
2.1.4 Available Pharmaceutical Literature Sources 
Pharm-line® (2007) is a well-established database for medicines management, pharmacy 
practice and prescribing, which started in 1978. It comprises more than 200,000 abstracts 
from major English language pharmaceutical and medical journals. All of the 27 journals 
covered were accessed electronically, with searches undertaken of each. 
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Journals/websites that were categorised as Directly Relevant to the research were: 
" The American Journal of Health-System Pharmacy3 
" Canadian Journal of Hospital Pharmacy; 
" European Journal of Hospital Pharmacy; 
" The Hospital Pharmacist; 
" The Hospital Pharmacists Group Newsletter; 
" Journal of Pharmacy Practice and Research (Australia); 
" The Pharmaceutical Aseptic Services Group website; 
" The Pharmaceutical Journal; 
" The Pharmacy Management Journal; 
The Pharmaceutical Journal and the Hospital Pharmacist are co-publications of the 
Pharmaceutical Society. The latter was established by the Royal Pharmaceutical Society 
of Great Britain for the publication of articles, reviews, reports and papers about any 
aspect of hospital pharmacy, and was found to be the most relevant of all journals, given 
the relative number of papers referenced. 
Journals/websites that were categorised as Partly Relevant (with the area of research 
shown in brackets) were: 
" American Medical Informatics Association (clinical decision making and 
electronic prescribing); 
" Healthcare Pharmacy (electronic prescribing); 
" Hospital Pharmacy (USA) (medication error); 
" International Journal of Pharmacy Practice (USA) (prescription errors and 
decision support); 
" Journal of American Pharmacists Association (pharmacists' work activities and 
electronic prescribing) 
" Journal of Pharmacy Technology (USA) (pharmaceutical preparation 
mathematics and pharmacy skill-mix); 
" Prescribing & Medicines Management (medicines management); 
Official Governmental/NHS publications and guidance relating to pharmacy were clear 
sources to be referenced. 
3 AJH-SPharm covers a wide range: Website searched on admixture and other relevant key words, with some 
links to "similar articles in PubMed" used. PubMed is www oubmed. Qov, which is a service of the (American) 
National Library of Medicine and the National Institute of Health. 
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Pharmweb is a premier internationally-used website with a variety of forums for 
professionals to liaise with one another. This was interrogated using a structured key 
question (see Section 11.4 for details). 
2.1.5 Non-Pharmaceutical Literature Sources 
Non-pharmaceutical journals and publications reviewed were: 
" Benchmarking: an International Journal 
" British Journal of Healthcare Computing & Information Management 
" British Journal of Health Care Management 
" Health Service Journal (HSJ) 
" Health Management 
" Journal of the American Medical Association 
" Private Hospital Healthcare Europe 
As for Pharmacy relevant Official Governmental/NHS publications and guidance were 
included. 
'Performance Measurement and Metrics' appeared relevant but its focus is library & 
information services. Similarly 'The Analyst' (published by the Royal Society of Chemistry) 
did not yield relevant references. 
The Cochrane Library (2007) is an important source of reliable evidence about the effects 
of health care, dealing with clinical effectiveness, but this is not the focus of the research. 
2.2 Aseptic Technique, Best Practice and Clinical Governance 
Despite the recommendations to move aseptic preparation from clinical areas to 
pharmacies (Breckenridge, 1976; Farwell, 1995) problems continued to be observed in 
the clinical areas, with the outcome being death in the worst cases (Anon, 1994). 
Patients have a right to be protected from preventable infection and nurses have a duty to 
safeguard the well-being of their patients (Crow, 1989; King, 1998). An aseptic technique 
should be implemented during any invasive procedure that bypasses the body's natural 
defences, e. g. the skin and mucous membranes, or when handling equipment such as 
intravenous cannulae and urinary catheters that have been used during these procedures. 
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Whilst it is difficult to maintain sterility, it is important to prevent contamination of sterile 
equipment. Poor aseptic techniques can lead to contamination. A 22 per cent syringe 
contamination rate has been observed for syringes prepared by intensive care unit 
nurses, compared to a1 per cent rate for the syringes prepared by pharmaceutical 
technicians (Van Grafhorst et al, 2002). A study to establish nurses' actions whilst carrying 
out aseptic techniques suggested that not all nurses followed the same actions and that 
the rationale for the practice of aseptic techniques is not always research based (Bree- 
Williams and Waterman, 1996). Similar discrepancies were found amongst medical staff 
(Sellors et al, 2002). Nurses can feel uncertain about how to undertake an aseptic 
technique (Hallett, 2000). Unfortunately some routine infection control practices cannot be 
rigorously studied for ethical or logistical reasons, for example wearing versus not wearing 
gloves (Mangram et al, 1999). 
Briggs et al (1996) suggest assessment of the individual patient's circumstances before 
each procedure: predicting and planning for potential problems can maintain asepsis. 
The DoH (2000a) found that annually 10,000 hospital patients have serious adverse 
reactions to medicines, and one-fifth of clinical negligence litigation stemmed from hospital 
medication errors (ibid). Medication errors alone cost the NHS about £500 million a year in 
additional days spent in hospital (Audit Commission, 2001; DoH, 2001a). The upward 
trend in medication errors in the UK, similar to that in other countries, is probably due to 
the increasing pace of work in hospitals and greater toxicity of modern medicines. 
Consequently, Trusts were set a target to reduce serious medication errors by 40 per cent 
by 2005 (DoH, 2001 a). 
Medication errors account for 7 per cent of patients safety incidents reported by hospital, 
mental health and ambulance Trusts in 2004 (National Audit Office, 2005), and whilst 
these will not all relate to aseptic preparation a good proportion will. Day-to-day pressures 
can lead to acknowledged best practice being ignored (loft, 2001), and it is believed that 
significant numbers of incidents still go unreported, particularly cases involving medicine 
errors or those "leading to serious harm" (National Audit Office, 2005). The continued 
blame culture in Trusts is a main reasons why staff are reluctant to report patient safety 
incidents (ibid). Nurses are perceived as the most common source of error, particularly 
where drugs are administered: fear of disciplinary action and admitting to a "silly" mistake 
stops them reporting errors if no ill effects on a patient (Audit Commission, 2002). 
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Medicines management is a very significant part of Trusts' clinical governance 
responsibilities (Audit Commission, 2001). It is central to the quality of healthcare, 
underpinning many specific objectives set out in The NHS Plan (DoH, 2000d). As 
hospitals do not always manage medicines to best effect, "A Spoonful of Sugar" (Audit 
Commission, 2001) addressed the main strategic challenges and issues, suggesting ways 
to meet and overcome potential obstacles and barriers, and improve the effectiveness of 
medicines' management. 
The NHS Executive North West working party (1997) described "Best practice" in respect 
of aseptic dispensing as: 
"All sterile medicinal products should be supplied by the pharmaceutical 
department to the practitioner in a form ready to administer and fit for their 
intended purpose". 
It set guidance on standards, expiry periods and policies, to enable Trusts to ensure that 
the risk associated with aseptic preparation, and the protocols followed, were fully 
evaluated and acceptable (ibid). These included a matrix specifying where each main 
types of aseptic products should (not) be prepared (ibid). The options were: 
" Pharmacy: Wards not acceptable even if pharmacy closed/not available; 
" Pharmacy: Ward preparation is acceptable only if pharmacy closed/not available; 
" Specialist clinic areas, e. g. ICU, operating theatres, maternity, coronary care 
areas, and in suitable designated aseptic facilities; 
" All wards/departments. 
Hardy and Mellor (2007) established current practice in 42 (82 per cent) of the 51 local 
secondary care acute in the North of England and calculated that the annual total aseptic 
preparation of high-risk drugs in clinical areas was 1,227,325. The largest group were 
Potassium solutions, which were of particular concern, with 108,197. 
Farwell (1995) made implicit reference for best use to be made of available facilities and 
resources, whilst having appropriate regard to safety: 
0 Processes should be organised to make best use of facilities and equipment (Para 
6.5) (ibid); 
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" Facilities for aseptic dispensing should be designed, constructed and operated in a 
manner appropriate to the activities undertaken and with respect to the equipment 
installed so that, by segregation and process control, maximum protection can be 
afforded to the product and, where necessary, the operator (Para 8.1) (ibid); 
" Planned preventative maintenance programmes should exist, covering all key 
equipment, to standards agreed with the responsible pharmacist (ibid); 
"A comprehensive quality assurance programme set up by the responsible 
pharmacist in conjunction with the Quality Controller is essential for all aseptic 
preparation activities. Individual product quality is generally not tested as would be 
the case in batch produced materials and therefore confidence that the patient will 
receive a medicine of suitable content, strength and purity is dependent on the 
controls built into the processes, the assessment of the raw materials and 
packaging components and the performance of staff and equipment (Para 15.1) 
(ibid); 
" Quality assurance activity should particularly concentrate on those aspects of 
product manipulation and processing at which the integrity of the system is at 
greatest risk (Para 15.2) (ibid); 
The four central pillars of modernisation of the NHS manufacturing service are (DoH, 
2003a; Hardy and Mellor, 2007): 
" Clinical governance: the application of clinical governance principles to the 
prescribing, manufacture, supply and administration of unlicensed medicines. 
" Capital investment: to maintain and modernise the current NHS manufacturing 
capacity and to assist in planning for future service needs; Investment should be 
linked to change. 
" National co-ordination: creating a cohesive national service that has robust 
communication networks and is responsive to changing patient need and to 
changes within the wider manufacturing industry. 
" Working with Industry partners: so that good practice principles on ways in which 
the NHS and colleagues in the commercial sector should work in partnership can 
be agreed and promulgated. 
In order of priority the NHS Manufacturing Service deliver traditional manufacturing and 
aseptic preparation, including cancer chemotherapy. Improvements in cancer 
chemotherapy services were required to support the implementation of the original 
Calman Cancer Plan that envisaged a significant expansion of oncology services (DoH, 
2000b). 
42 
2.3 International and Regional Practices concerning Aseptic Preparation 
The European Association of Hospital Pharmacists (2001) surveyed pharmacies in the 16 
countries it covered in 2000. The response rate was 27 per cent (similar to its previous 
survey in 1995), with the UK's rate being 17 per cent. Public hospitals (i. e. owned by the 
government) accounted for 84 per cent of responses, with this being exclusively the case 
in the UK, Denmark, Slovakia & Greece, and almost the case in France, Slovenia & 
Sweden. Key points relevant to the research were: 
" The survey showed that the UK is exceptional in its pharmacists visiting patient 
care areas at least once a day, with pharmacists spending at least 50 per cent of 
their time there. (This relates to all pharmacists not just those involved in the area 
covered by this thesis). 
" More than 50 per cent of EU hospital pharmacies do not provide any additive 
services to the wards, and when it is, it mostly concerns cytotoxics, then TPNs. 
Even then the UK ranked 6t' highest for the percentage of hospitals preparing 
cytotoxics, and 4`h highest for TPN. 
" There are hospitals in every EU country that do not provide any IV services. In 
some cases they are irrelevant (e. g. psychiatric hospitals), but Greece, Hungary, 
Finland, Slovakia & Slovenia such hospitals accounted for over 80 per cent. 
" The UK appeared to be in "pole position" amongst EU countries for preparing 
nearly all IV admixture products for almost all patient care areas and special units 
within hospitals. 
The survey results suggest that the UK arrangements for the preparation of aseptic 
products are at one end of the European spectrum in terms of decentralised 
pharmaceutical practice and the range/coverage of aseptic services. The lack of progress 
in developing CIVAS elsewhere in Europe was highlighted by Griffiths (2002). 
The survey was repeated in 2005 covering 28 countries - EU member states plus 
Switzerland, Norway and Croatia (Results in press4: see Miharija-Gala (2007)). 
In the United States most Total Parenteral Nutrition (TPN) and IV products are prepared in 
hospital pharmacies and predominantly the practice is moving to the preparation in clean 
rooms within pharmacy facilities for IVs, TPNs and of course cytotoxics (Rattinger, 2007). 
° The results of the EAHP 2005 survey were to be reported at the EAHP Congress at Bordeaux in late March 
2007 although there is no indication when the full results will be published. 
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The management of local hospitals in the Middle East by Western companies, through 
contracts, has led to the adoption of "Western practice" for quality assurance (Saeed, 
1995), which in terms of aseptic preparation means that the focus is on pharmacies, with 
products provided ready for injection. However, this is not always the case, with variations 
according to the type, size and locality of hospitals, with pharmacies often not undertaking 
aseptic dispensing (Al-Salti, 2001; Section 11.58). Also, over time the circumstances and 
practices at hospitals can alter according to managerial arrangements. At present, 
practice is generally moving forward towards CIVAS solutions, to support stringent control 
of infection policies (see Section 11.58). 
It is noted that the World Health Organisation initiated a quality assurance programme as 
being a requirement for accreditation of hospitals worldwide (Saeed, 1995; Yousef et al, 
1996; AI-Assaf, 1999), although the actual application is unclear (AI-Salti, 2001). However, 
these did not stipulate set arrangements and policies in respect of aseptic preparation. 
None of the sources outlined above yielded pointers to how aseptic preparation is 
quantified and measured in the countries concerned. 
Beaney (2006) highlights that although there is a general acceptance amongst 
pharmacists that variations exist in pharmacy and aseptic dispensing facilities and 
services across the UK, this has not been confirmed through, for example, a specific 
survey. For example, in the North East of England more Radiopharmaceuticals are 
delivered by Nuclear Medicine departments, compared to pharmacies, than elsewhere in 
the country (ibid). The DoH survey completed in 1997 required an audit of aseptic 
dispensing units against published standards but did not ask for details of the services 
provided (Chief Medical Officer and Chief Pharmacist, 1996). 
2.4 Nomenclature for Aseptic Preparation 
As stated in Section 2.1.1, the consistency and accuracy with which nomenclature is 
interpreted can impact on data quality, and therefore it was important to establish how this 
might relate to aseptic preparation. For illustration, dictionary definitions differ for one key 
word - "Parenteral". For example, Mosby's Medical and Allied Health Dictionary states: 
"Not in or through the digestive system" (Glanze et al, 1986), whilst On-line Medical 
Dictionary gives "Not through the alimentary canal but rather by injection through some 
other route, as subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, 
intrasternal, intravenous etc. " (On-line Medical Dictionary, 1997). 
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The literature review sought references for the different uses of nomenclature, but found 
that the greater the number of sources referenced, the more complex matters became. 
Nomenclature in different publications reflects the professional background involved. No 
attempt was found in the literature to assimilate nomenclature across professional 
boundaries. This is not surprising given that any such venture would undoubtedly fail to 
achieve universal consensus; trying to establish consistent use of all nomenclature within 
any single profession across a country would be difficult in view of the inevitable variations 
in local custom and practice. 
There can be differences in the use of nomenclature across countries. An American 
pharmaceutical company found that the use of specific terminology is different in the US 
compared to the UK (see Section 11.2 Reference 4). This had led to confusion, and still 
could not be ignored when people communicated across the Atlantic. Examples were: 
batch production; CIVAS; dispensing; multidose therapy; and patient specific. 
Studies have referred to the problems associated with achieving clarity in the use of terms 
within health services (Advanced Life Support Group, 1995; Anderson, 1999; Brown, 
1998; Gandy et al, 1998d). 
Actually defining nomenclature can be problematical within different clinical contexts: 
Brown (1998) describes the use of terminology in "truth telling", stating that when truth is 
concealed or withheld, it may not be a lie so much as the suppression of information 
(which may be considered harmful to the patient); Anderson (1999) outlines the merits of 
generic versus branded prescribing, firstly in ensuring the patient actually receives what 
the prescriber intends, and secondly, that the patient clearly understands what their 
medicine is. 
The Association of Accident & Emergency Consultants argued for national standards in 
the use of nomenclature within documentation supporting critical systems and processes 
relevant to Major Incident Plans (MIPs) (Advanced Life Support Group, 1995). Hospital 
emergency services each had their own form of MIP, developed in ad-hoc ways to reflect 
local circumstances and needs. There was no real consistency in the use of nomenclature 
within MIPs, with nomenclature differing, not only between hospitals, but also between 
emergency services likely to find themselves engaged in the operational management of 
the same major incidents. Questions such as "What is 'Major Incident Standby'? " and 
"How is a 'Major Incident' defined? " are examples. As a result, the handbook for Major 
Incident Medical Management and Support (ibid) was produced and MIPs were 
subsequently much more focused, and interrelated the plans of all local and regional 
45 
emergency services and agencies. Nomenclature relating to the key critical elements of 
the process was made clear (ibid). 
Gandy et al (1998d) discussed nomenclature problems associated with integrated care 
pathways, care packages and care profiles and how they were often used 
interchangeably. In the absence of established, referenced definitions for these terms they 
defined their use of the nomenclature in respect of their study relating to cancer services. 
Cancer services provide a good example of how nomenclature needs to be clear. The 
term "palliative care" was used very broadly in the past, which resulted in the published 
guidance (NHS Executive, 1996) to distinguish between "palliative interventions" and 
"specialist palliative care". Corcoran and Gandy (1997) discussed how these terms 
translated into data. 
Nomenclature for staff can be loose or ambiguous. An example is "practitioner" which is 
commonly applied to nurses and operating department staff. Operating department 
practitioners do not have exemption under sections 9& 11 of the Medicines Act (MCA, 
1992) to prepare/manipulate medicines. As a result, Trusts seeking to integrate nursing 
and operating department policies for the administration of medicines found that they 
cannot make generic use of the term "practitioner" and had to be very specific throughout 
because to do otherwise could have serious results. 
Similarly, the term °clinician" is commonly inferred to apply a medical practitioner, when it 
is now more widely understood to relate to all types of clinical professional - medical, 
nursing and other health care professions. This is still a cause of significant general 
confusion, particularly with the public. 
Whilst on the surface it may not seem to matter if there are differences in use of 
nomenclature between professional groups, it can be seen from the above that it can be 
very important for inter-professional work, and work between the same profession in 
different organisations. There are clear benefits from appropriate, consistent use of 
nomenclature for staff moving between hospitals and between services, as there should 
be no requirement to re-familiarise themselves in the fundamentals of nomenclature within 
such documents as MIPs (Advanced Life Support Group, 1995). 
For the purposes of data analysis, consistent nomenclature is of fundamental importance 
for processes and activity to be measured objectively. The increasing use of audit to 
compare services and organisations raises yet another level of complexity. Many 
questionnaires designed to elicit comparative data are flawed as they fail to define terms, 
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which have different meanings in different organisations or parts of the organisation. 
Results might be used in constructing league tables or for the application of corrective 
action. 
Inevitably nomenclature and definitions evolve with language and knowledge. Sometimes 
this may be driven by the development of technology - computer terminology often takes 
everyday language and applies it to a new piece of hardware or software, rather than 
invent a new word that would mean nothing to the user. Also the definition of "death", both 
medically and legally, has reflected experience and developments in medical science 
(Glanze et al, 1986; Fontana Dictionary of Modern Thought, 1988; Fortean Times, 2000). 
What should be noted is that people will take words and terms, and interpret or abuse 
them for their own purposes, as was illustrated in the novel "1984" (Orwell, 1954). 
Consequently, whatever steps are rightly taken to address any problems associated with 
nomenclature, there will never be a final "right" answer. It is more important to appreciate 
the dynamics of nomenclature and language and always check that nomenclature is being 
used clearly and consistently within whatever context applies. 
2.5 Metrics Surrounding Collaboration 
2.5.1 Collaboration in Healthcare 
As increased collaboration between pharmacies and Trusts was an objective of the 
C&CP, its evaluation should include whether collaboration had actually increased. In turn 
this raised the question "How can collaboration be measured? " to confirm it has taken 
place and its impact. But there is a danger that "collaboration" is interpreted in different 
ways. Three (relevant) definitions are: 
" "When two or more people work together to create or achieve the same thing" 
(Cambridge Dictionaries Online) 
" "The act of working together with another person or group to achieve something, 
especially in science or art" (Longman Web Dictionary) 
" Work jointly on an activity or project (Oxford Concise English Dictionary). 
The interpretation of the North West working party is reflected in the key recommendation 
that Trusts should "liaise with each other to consider all models of collaboration to allow 
the development of aseptic services across a geographical area" (NHS Executive North 
West, 1997). This was an imperative for bids for the subsequent C&CP (Beaumont 1999), 
as the capital and revenue investment required would be prohibitive if a totally 
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comprehensive aseptic preparation service was provided within each Trust. The working 
party argued that Trusts should not acquire equipment for specialist preparations if it will 
be under-utilised, and therefore a Trust should not necessarily expect to meet all of its 
needs locally (NHS Executive North West, 1997). 
Local aseptic units need to provide ready-to-use aseptic preparations that cannot be 
provided in the appropriate form, and at the appropriate time by outside sources. These 
normally involve preparations with short shelf lives, particularly complex preparations, and 
any special requirements of the Trust (ibid). However, the range of products involved may 
be comparatively limited, and the volumes could be very large, and likely to increase 
should the desired shift in aseptic preparation from clinical areas to pharmacies take place 
(ibid). By comparison, there are considerable numbers of products for which demand from 
an individual Trust may be small, but which could benefit from efficient production 
processes were the volumes to be large enough. Such volumes could be created if Trusts 
collaborate (ibid). 
No region-wide arrangements would deliver an appropriate solution for all such products 
due to logistics, although some specialist work may be appropriately centralised e. g. BCG. 
Therefore the degree to which the production of a particular aseptic preparation can and 
should be centralised was important, and the working party outlined three different 
models: 
" Hub and Spoke: where a central facility is developed (optimising the use of 
resources for processing a range of items) whilst local facilities focus on those that 
necessitate local preparation. The central facility would be appropriately licensed; 
" Co-operative: where a limited number of Trusts (with particular links of geography 
or specialist services) look to balance the workload between themselves. 
Processes would be optimised for selected items with each Trust focusing on an 
agreed range in such a way that they complement one another. One or all of the 
facilities could be licensed. 
" Network: where it is accepted that local facilities are required, but the aim is to 
ensure that best use is made of all those available. For example, quality facilities 
that are comparatively under-utilised may be licensed for set items and serve the 
Trusts within the network for those items, through complementary arrangements. 
The aim would be to make maximum use of local facilities, thereby negating the 
need for a very large central facility and minimising the need for new capital 
investment. (ibid) 
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Examples of collaboration for NHS pharmacies involve links with the commercial sector, 
such as in the North West, where Christie Hospital, in Manchester, began a partnership 
relationship with Baxter Healthcare in the early 1990s (O'Connor, 2005; So, 2005). The 
partnership was reaffirmed with the signing of a 10-year repeat contract in 2005 (ibid, 
ibid. Baxter prepares 90 per cent of the chemotherapy drugs at Christie - 70,000 per 
annum, with more than 80 per cent being pre-ordered (ibid, ibid). Whilst other companies 
also prepare chemotherapy drugs for the NHS, Baxter is unusual in that it has three 
significant joint ventures with the NHS (the others being at Oxford Radcliffe Hospital and 
Mount Vernon Hospital in London) (O'Connor, 2005). 
The measurement of collaboration is through the commercial Baxter-Christie contract, 
with inbuilt key performance indicators for monitoring purposes. These include: turnaround 
time for drug requests; the percentage of pre-ordered drugs; amount of wastage (ibis). 
There is also an annual financial review (ibid). The requirements of the contract itself 
make such data collection an imperative. The contract is based on risks that are 
acceptable to both sides, with the main risks for the private sector being: building facilities; 
installing adequate equipment to cater for current and future prescribing patterns; 
maintaining appropriate staffing levels and expertise; and meeting any changes in 
regulatory requirements (So, 2005). To manage such risk future income must balance risk 
and return (ibid). On average an 8- 10 year contract allows enough time for sufficient 
income streams for a new build to be commercially viable and ensure value for money for 
the NHS (ibid). 
The success of such joint ventures is likely to encourage similar initiatives, and the 
Government highlighted that where the extra capacity to improve the delivery of care is 
not available within the NHS, healthcare providers from the private sector should be 
considered (ibid). Breen (2004) states that the NHS as a customer already works with a 
plethora of suppliers and expects quality service at the right price, on time and fulfilled 
deliveries, with a need to monitor supplier performance and work with suppliers to develop 
their performance, particularly to develop the pharmaceutical supply chain. Such a 
contract-based model would not apply for NHS organisations collaborating with one 
another, because the NHS organisations operate with one another through service level 
agreements, that are not enforceable in law. They only hold contracts with non-NHS 
organisations (although this may change as Foundation Trusts mature). 
In the NHS and public sector, collaboration is generally interpreted as organisations 
working jointly, or in partnership (Pollard and Noble, 2005; Summerton, 2004), sometimes 
through formal arrangements, such as 'virtual' care trusts between health and social 
services for specific care groups (Martin, 2004), and sometimes with vehicles such as 
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local area agreements (Shannon, 2005). Similarly collaboration can take place across 
organisations, on a professional basis, with clinical networks (Edwards, 2002; Smith, 
2003). "Collaboratives" are also set up to enable NHS organisations to learn from one 
another and improve quality by disseminating best practice (Harvey, 2005; Cancer 
Services Collaborative, 2007). 
2.5.2 Measuring Collaboration 
Many references relate to collaboration and measurement, but few actually deal with 
measuring collaboration per se. Instead, they look at "collaboration to develop measures", 
"measuring the outcomes from successful collaboration" and "evaluating social/interactive 
aspects of collaboration". 
Arbor (2001) and Bietz et al (2001) sought to evaluate the social underpinnings of 
collaboration, and discussed measures of collaborative success, but in an 
academic/research environment, i. e. it is aimed at people (researchers) working together. 
"Collaboratory" (sic) was defined as a: 
"network-based facility and organizational entity that spans distance, supports rich 
and recurring human interaction orientated to a common research area, fosters 
contact between researchers who are both known and unknown to each other, and 
provides access to data sources, artefacts and tools required to accomplish 
research tasks". 
(ibid) 
Illustrative measures that may reflect success, both in terms of process and product 
included: frequency and impact of publications; satisfaction of collaborators; level of 
interpersonal trust; degree of mutually consistent work practices; and level of public 
interest. Organisational and community consequences of collaboratory use were: 
expanded access; structural transformation; and increased production. Success measures 
for the latter included increased rates of publication (ibid). 
Arbor (2001) and Bietz et al (2001) were unable to develop a universal measure of 
success for collaboratories (sic), but developed a framework, eliciting a number of 
possible measures of success, and pinpointing open issues and problems. This proposed 
a 3-dimensional framework, with any measures used to gauge success varying on each of 
three axes: 
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" Dimension 1- Stakeholders (technologists, domain, users, scientists, 
sponsors/funders, corporations) 
" Dimension 2- Level of analysis (individuals, groups, organizations, fields, social 
policy) 
" Dimension 3- Time (short-term vs. long-term measures of success) (ibid) 
South Carolina Commission On Higher Education (2004) looked at "Institutional co- 
operation and collaboration", which involves the sharing and use of technology, programs, 
equipment, supplies, and source matter experts within the institution and with other 
institutions and with the business community. Benchmarking demonstrates effectiveness 
using compliance/performance data collected every 3 years. Institutional performance 
involved two indicators: 4A - Sharing and use of Technology, Programs, Equipment, 
Supplies and Source Matter within the Institution, with Other Institutions and with the 
Business Community; and 4B - Cooperation and Collaboration with Private Industry. 
The Trillennium Corporation (2004) runs specific courses on how to profit from 
collaboration. This measures the gains and benefits of collaboration: measure the return 
on investment from substantial improvements in the ability to quickly solve 
multidisciplinary, cross-functional, and inter-divisional problems, and benchmarking. 
De Jong and Jackson (2000) examined the measurement of inter-professional 
collaboration, through testing the reliability of the Mater Attitude Measure, which relates to 
understanding and implementing behaviour change in professionals. De Jong at al (1990) 
had previously aimed to develop and research the reliability and validity of a generic 
instrument to measure attitudes of health professionals towards integration, filling the void 
in validated instruments available for this purpose. Its methods involved the conceptual 
framework of Fishbein and Ajzen (1975), The Theory of Reasoned Action, which links 
attitudes, beliefs, intentions and behaviours. Its results from a series of focus groups, 
surveys and interviews with professionals elicited three categories of data: patient 
outcomes; resources (human, financial); and professional relationships. 
The British Educational Communications and Technology Agency (Becta) (2006) set out 
collaborative criteria in respect of its Information and Communications Technology (ICT) in 
Practice Awards for 2006. The impact of their ICT collaboration was measured by: 
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0 providing evidence of impact on practitioners' continuous professional 
development 
" providing evidence of impact on practitioners' confidence and competence levels 
with I CT 
0 providing evidence of impact on learners' standards. 
How collaboration has maintained high quality standards was demonstrated by: 
" using training and/or support materials that promote effective collaboration using 
ICT 
" modelling high quality teaching with practitioners 
" demonstrating how the collaboration is tailored to individual needs and learning 
styles 
" providing evidence that the partners value the collaboration 
" providing evidence of how feedback is used to inform development of the 
collaboration. 
Gariba (2003), indicated that development co-operation generally, and evaluation in 
particular are coming under considerable stress, as evidence is increasingly demanded 
with the increased competition for public resources in all countries. The functions of 
measurement, monitoring and evaluation were called to the task. He highlighted the need 
for accountability and set out five basic principles for co-operation in development 
evaluation. These included "Collaboration on what is measured or evaluated". As like 
many publications the aim is to collaborate on what to measure rather than to measure 
collaboration itself. 
Wand (2003) highlighted that internal collaboration is the key to improved innovation in 
research for pharmaceutical companies. The study suggested that to optimise Research 
and Development (R&D) investments and create more sustainable value, pharmaceutical 
companies should focus on improving internal collaboration across traditional boundaries 
within the organisation. Once collaboration becomes a corporate priority, pharmaceutical 
firms will want to measure collaboration benefits against corporate business objectives. 
Outcome (or production-orientated) metrics are essential for assessing quantifiable 
benefits (ibid). 
Collaboration is evaluated in the military environment. Noble and Kirzl (2003) examined 
objective metrics for the evaluation of collaborating teams. They identified that there are 
two principle goals: to quantify changes in team performance, in order to determine the 
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extent to which new technology, process, or organization improves team effectiveness; 
and, to explain the reasons for changes in effectiveness. The need for objective 
performance measures is stressed, highlighting that many evaluations are based on 
subjective measures exclusively. These have an important part to play, but should not be 
the sole basis for evaluation, because a person's self-assessment does not always align 
with performance. Objective measures help document a credible audit trail to explain the 
reasons for the performance impact. 
Noble (2002) also evaluated how collaboration and teamwork work from a cognitive 
perspective, with the goal of helping explain guidelines for effective collaboration 
processes and tool use. He indicated that collaboration and teamwork provide many 
benefits, but they also impose costs that can undermine a team if not managed well. Good 
teamwork maximises benefits while minimising costs (Evidence Based Research, 2001). 
There are three collaborative processes: Team set up and adjustment; Joint problem 
solving; and, Synchronize and act. Whilst then describing the various facets of 
collaboration and teamwork, there is no measure for "collaboration" itself. 
Noble and Letsky (2002) similarly examine cognitive-based metrics to evaluate 
collaborative effectiveness, looking at effective collaboration within culturally diverse 
multinational coalitions, which are essential in many military operations. They define 
collaboration as "the mental aspects of joint problem solving for the purpose of achieving 
a shared understanding, making a decision, or creating a product. " This emphasises the 
cognitive and problem solving aspects of collaboration, as opposed to other definitions 
that place greater emphasis on information sharing. For example, the Information 
Superiority Working Group (Alberts et al, 2001) defines collaboration as "actors actively 
sharing data, information, knowledge, perceptions, or concepts when they are working 
together toward a common purpose and how they might achieve that purpose efficiently or 
effectively. " 
2.5.3 Established metrics potentially applicable to Collaboration 
It is inferred that there are no readily available metrics in respect of collaboration that can 
be directly transferred to the research area. In the circumstances it is necessary to 
examine valid, alternative possibilities to how "collaboration" is interpreted. One possibility 
was to see the degree of "collaboration" between Trusts and pharmacies as the amount of 
interaction between them, with the flows of aseptic products potentially forming the 
currency. 
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Gandy (1979) addressed a problem relating to NHS patient flows and the interactions 
between health authorities, i. e. two authorities could have similar catchment populations 
as a net result of widely different patient flow patterns. Catchment population calculations 
were very important to resource allocation at the time (DHSS, 1976), with various 
approaches and formulae developed to reflect this essentially abstract concept (Gandy, 
1981a; Gandy, 1981b; Senn, 1981; Skidmore, 1981). The issues facing a health authority 
were very different if it treated all of its own patients, with minimal traffic of patients to and 
from neighbouring authorities, compared to a situation where there were very significant 
flows of patients into and out of the authority. Geography and traditional referral patterns 
were factors. The question was how to reflect such varying dynamics (Gandy, 1979). The 
solution was to create a diagram that plotted the percentage of residents that were treated 
in an authority against the percentage of patients treated within the authority who were 
residents (ibid). The nearer that an authority's co-ordinates were to the point (100,100) 
then the more independent that authority was of other authorities. Conversely, if 
neighbouring authorities were in the centre of the diagram then the greater their inter- 
dependence (ibis), or interaction with one another. 
The requirement for such a diagram (ibid) ceased in 1989, with the introduction of a 
market environment into the NHS (Propper et al, 2003) with hospitals becoming 
"providers" of services, and health authorities acting as "purchasers". This was because 
the health authorities effectively undertook both such functions previously: providing local 
hospital services for local patients, and sending local patients for treatments in hospitals in 
other health authorities, where this made sense; and therefore they interacted with one 
another. 
However, the diagrammatic approach was taken up by Public Health in Italy where it is 
referred to as the "Nomogramma di Gandy", and it continues to be generally used. It is 
incorporated in public health reports (3 references), publications (11), and books (1), as 
well as being taught on university Medical Statistics courses (2). See Section 11.5 for 
details of these specific references. 
2.6 Capacity and Workload Measurement 
2.6.1 Definitions 
Capacity and Workload are essentially two concepts open to interpretation. The Compact 
Oxford English Dictionary defines them, as follows: 
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Capacity: the maximum amount that something can contain or produce. 
htto: //www. askoxford. com/concise oed/capacity? view=uk 
(accessed 23/03/07,10.15am) 
Workload: the amount of work to be done by someone or something. 
http: //www. askoxford. com/concise oed/workload? view=uk 
(accessed 23/03/07,10.16am) 
2.6.2 Capacity Plans 
Capacity planning is a requirement in both licensed and unlicensed aseptic units (Beaney, 
2006)). Beaney (ibid) sets out a specimen format of a capacity plan. 
Capacity planning is described as a system used to assess: volumes and types of 
workload to be undertaken within given timeframes; resources (staff, facilities, equipment) 
necessary to meet these workloads; and, potential strategies when available resources 
are inadequate. It includes indirect activities such as ordering, stock control, and product 
testing, as well as direct production. It should also be considered at two levels: medium to 
long-term (6/12+ months); acute (daily/weekly) (Lillywhite, 2000). 
Capacity planning should ensure: response times are within agreed limits; quality and 
safety are not compromised; staff overtime is not excessive; staff do not suffer excessive 
pressure; and, error/defect rates do not increase (Beaney, 2006). 
The key variables on aseptic processes and procedures are: whether automated or 
manual procedures are involved; whether individual prescriptions or batch processes 
apply; the size of any batches; type of preparation; shelf life; and the facilities themselves 
(NHS Executive North West, 2001). 
Gandy et al (1998a) established that the types of (inter-related) additional resources that 
NHS units generally require to increase their capacity can include: increase in opening 
hours; increase in staff; increase in equipment; accommodation improvements; 
environmental monitoring. 
In the commercial sector the elements of capacity planning are: capacity model; forecast; 
scheduling; "control mechanisms", with flexibility built into any model (see Section 11.2 
Reference 6). 
55 
2.6.3 Influence of Cancer Services Developments 
Cassidy and Glynne-Jones (2005) highlighted the lack of NHS capacity to deliver cancer 
services, with the demand for drug treatment increasing over 10 years, and likely to 
continue. New treatments may not be deliverable because of capacity constraints, and 
some perverse incentives created by Payments by Results (DoH, 2007c) might mean 
hospitals do not implement capacity saving measures (Pharmaceutical Journal, 2005). 
Williamson (2006) describes how the continuing and accelerating rise in patient episodes 
for chemotherapy, created considerable pressure for pharmacies and demands for 
increased chemotherapy capacity. The local solution was to centralise services, with 
benefits in terms of collaboration, safety, increased efficiency in staff management and 
training, and increased production. The capacity planning model previously used enjoyed 
limited success in supporting business cases. Therefore other models were used (Low et 
al, 2003; Shield, 2004). 
Low et al (2003) translated workload projections into staff requirements. Shield (2004) 
evaluated the methods of Trudeau (1980) and Matanin (1984) in respect of preparation 
times for cytotoxics, and highlighted that Low et al (2003) did not differentiate staff grades 
or complexity of preparation. Furthermore, although capacity planning is a requirement for 
aseptic units (Beaney, 2006), it was not undertaken in many departments. Where they 
were written, the varying methods resulted in significant variations in plans (Shield 2004). 
No published work had linked variable time requirements for different types of 
chemotherapy with the grades of pharmacy staff involved (ibid). Consequently "uniform 
formula for calculating available capacity, (which) could then be used for staff bids" were 
developed (ibid). This broke down the process with assigned average times, attributed to 
staff type/grade. Allowance could be included for audit, training, etc. All the sites in the 
related surveys were unlicensed. 
The British Oncology Pharmacy Association (2001) linked staff shortages, capacity and 
patient safety, and emphasised the importance of getting staffing right. There were 
problems nationwide, but particularly in the South and London, with the two London Trusts 
with the worst vacancy levels reporting three chemotherapy associated Serious Untoward 
Incidents in two years (ibid). 
The Shield model (2004) was adopted by the Modernisation Agency as the basis for its 
draft capacity planning model, part of an overall redesign toolkit for chemotherapy 
services (NHS Modernisation Agency, 2005). 
56 
2.6.4 Capacity and Workload Measurement 
Measurement in aseptic preparation has focused on risk assessment (Beaney and 
Goode, 2003; Munro, 2003; Beaney et al, 2005), error rates (Bateman, 2003), and self- 
assessment in medicines management (Curtis, 2003; Chief Pharmacist, 2003; 
DHSSPSNI, 2005), rather than actually quantifying production. 
Publications explicitly related to capacity planning used formulae to calculate the required 
(additional) staff to achieve projected outputs (Low et al, 2003; Purkis, 1997; Shield, 
2004). Allowance was made for the time taken at each stage of preparation and the type 
of staff involved. Therefore, such capacity plans might be better thought of as staffing or 
resource planning (ibid; ibid, ibid). 
Milne (2003) observed that recording workload statistics in aseptic units has always been 
determined by datasets and methods of counting established at local level, making it 
difficult to compile accurate comparisons. It was important that methods of recording 
activity and workload statistics comply with nationally agreed criteria so that the volumes, 
types and complexities of work carried out in aseptic units can be benchmarked. Once a 
standardised method was agreed and implemented it would provide a foundation for 
establishing a national capacity planning model for aseptic facilities. Otherwise any 
capacity model can only be a rough estimate (ibid). 
To this end, Milne (ibicn recommended standard datasets, as follows: 
" Daily patient treatment episodes (one daily patient treatment episode defined as 
"one patient receiving one or more items in a 24 hour period which are part of the 
same treatment"); 
" Final containers prepared (e. g. syringe, infusion bag, disposable infusion device or 
reservoir pouch for an infusion device; more than one final container of the same 
drug may be dispensed to achieve the prescribed dose of a drug); 
" Complexities (five bands A-E, based on number of aseptic manipulations 
performed during preparation). 
NHS Pharmaceutical Production Committee (Lillywhite, 2000) suggested key quantitative 
indicators to assess whether available resources matched workload over a period of time: 
overtime worked; response/lead times; number "out of stocks"; error/defect rates; targets 
for "indirect" activities (percentage met); and numbers of complaints. It recommended 
benchmarking across hospitals to determine appropriate action (ibid). 
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In the commercial pharmaceutical sector data collected to support capacity planning 
includes product types manufactured, volumes of products, cabinet types & functions, and 
staff levels (see Section 11.2 Reference 6). Also, the industry has applied systematic 
mathematical programming for long-term, multi-site capacity planning under clinical trials 
uncertainty (Levis, 2004; Shah, 2004). 
In industry, sizing and capacity are important to operate in a competitive market to avoid 
wastage and preserve the survival of the enterprise. Dealing with capacity is not easy 
because of a lack of clarity in decisional processes, large numbers of variables, the high 
correlation among variables, and high levels of uncertainty (Matta and Semararo, 2005). 
Having a flexible capacity enlarges the spectrum of possible future scenarios because 
many alternative strategies are viable, thus making risk evaluation more difficult. Many 
advantages of manufacturing systems are not easy to quantify and therefore they are 
seldom evaluated properly. Strong interactions amongst components of advanced 
manufacturing systems make it necessary to carry out evaluations considering the system 
as a whole (ibid). 
"Manufacturing capacity" is defined as the set of human resources and equipments that a 
company can use to produce goods or services to sell in the market. Its dimensions are: 
type of manufacturing system (e. g. rigid/flexible, automated/manned); amount (quantity); 
and cost. The aim is to balance capacity with demand (ibid). 
Main outputs of a capacity planning problem are: a capacity plan and products to market. 
To obtain these requires mechanisms for: decision models and tools for quantitative 
evaluation and appropriate (process and system) databases. Outputs include: "aggregate 
long term capacity", which is the amount of production capacity required to produce the 
potential product mix at the established service level; and "service level" which is a 
definition of the minimum level of satisfaction of the market demand that is acceptable to 
achieve the strategic goals. "Product mix" is a key indication. To produce these outputs 
requires use of: mathematical programming, expert systems and process and systems 
database(s) (ibid). 
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2.6.5 Unit Time Equivalents 
In assessing workload volumes and complexity, assessment could be simplified if 
standard work units (reflecting 'activity' time) are assigned to each product category or 
task (Lillywhite, 2000). Acute planning should use a capacity planning matrix, with pre- 
determined strategies to address identified shortfalls and surpluses: deferring production, 
overtime, transfer work elsewhere, etc (ibid). Beaney (2006) recommends the adoption of 
standard preparation time values and staffing times, but these should be determined 
locally for each unit. Shield (2004) applied standard times for each process step. 
The commercial sector recognises the importance of defining a unit of currency for each 
product and service. This can involve either a full time and motion study or taking the 
simplest product as the basis for comparison (see Section 11.2 Reference 6). The former 
will determine standard minute values (SMVs), but to introduce these into the NHS would 
be impractical and arguably inappropriate because of the costs and the comparatively 
small volumes involved (NHS Executive North West, 2001). The latter approach involves 
agreeing unit time equivalents (UTEs), which act as a weighting system that can be 
applied to all products based on the most basic item. UTEs drive a clear understanding of 
current and future capacity (see Section 11.2 Reference 6). The key resources linked to 
this are numbers of cabinets and staff (ibid) 
The values of UTEs need continual review as practices evolve. For example, dose 
banding is a system whereby doses of intravenous cytotoxics are calculated on an 
individual basis and rounded up or down within an agreed band to predetermined 
standard doses. A range of ready-to-use chemotherapy syringes or infusions, 
manufactured in-house or purchased as "specials", may be used to administer the 
prescribed dose (Plumridge and Sewell, 2001, MacLean et al, 2003). Dose banding still 
requires staff time for quality control, dispensing & checking, but removing the need to 
aseptically prepare the syringes, releases staff time (Williamson, 2006). 
The above describes a situation where several principles are accepted within the NHS, 
but there has been no opportunity to define data, and metrics to interpret it, so that aseptic 
production and usage can be scrutinised and evaluated to support known objectives. The 
absence of agreed, consistent interpretations of concepts such as capacity and workload 
presents genuine constraints. 
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2.6.6 Measuring the Aseptic Dispensing Process and Facilities 
In seeking to establish standard production times for aseptic products in pharmacies the 
NHS Executive North West (2001) chose to consider the period from the start of the 
aseptic process (i. e. receipt of request/prescription/order) to the end (i. e. product approval 
by supervising pharmacist), breaking it down into five common elements, with checks 
required between each stage: 
" Assembly of components and documentation; 
" Transfer into a controlled work zone; 
" Manipulation and aseptic preparation of the products; 
" Checking and labelling; and 
" Product approval. 
Several other authors broke the overall process into detailed constituent parts, but these 
differ from one another (Andrews, 2006; Benson and Longshaw, 1981; Shield, 2004). 
Figure 2.1 presents comparisons. 
The NHS Executive North West (2001) identified that cabinets accounted for between 25 
per cent and 40 per cent of the total time, according to the products. The latter was 
consistent with Shield's (2004) calculations for cytotoxics. 
However, different units apply different methods of work and wide variations can occur 
even within the same unit in making similar products, e. g. one unit prepared 37 different 
types of syringes, where the number of ampoules required to make one syringe could be 
as many as 25. Also, the process time involved in making similar products can vary 
depending on the speed with which solutions mix (NHS Executive North West, 2001). 
Importantly, aseptic dispensing units are nearly all different from one another in facilities 
and design, a point confirmed by quality assurance specialists from across the country 
(ibicf). Even the size of a hatch can constrain the speed of production (Andrews, 2006). 
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The reason for such variability has been identified as lying 
"in the general nature of the published guidance which give broad requirements in 
terms of general standards that a facility must meet but little help in terms of how to 
achieve those standards. As a result there have been a number of occasions when 
pharmacies and other similarly regulated areas have either been badly designed or 
inadequately constructed such that they offer little or no advantage over the old and 
sometimes decrepit facilities they are replacing". 
GRC Mott MacDonald (2006) 
Such variability in facilities and how units operate means that logically each product in 
each unit needs to be individually timed and given it's own unique time, but this would 
involve a prolific amount of work. This serves to reinforce both the choice of UTEs as the 
means of weighting aseptically prepared products and the need for local knowledge. 
Industry often adopts a system based on informed opinion from qualified staff on how long 
a task should take (i. e. the values of UTEs) (see Section 11.2 Reference 6), where such a 
value is the same irrespective of production volume (ibid). Nevertheless, it is essential that 
there is clarity/agreement about what part(s) of the aseptic process any UTE covers. 
2.7 Information Systems & Data relating to Pharmacy and Aseptic Preparation 
2.7.1 EPS 
The contribution of information systems to clinical governance in respect of 
pharmaceuticals is widely recognised. Computerised systems containing rules to prevent 
incorrect or inappropriate prescribing reduce the incidence of errors and increase the 
appropriateness of medicine treatment (Evans et al, 1994; Johnston et al, 1994; Pestotnik 
et al, 1996; Bates et al, 1998; Evans et al, 1998; Raschke et al, 1998; Shojania et al, 
1998), although there are questions about the effectiveness of computer-aided 
prospective drug utilisation reviews (Chrischilles et al, 2002). Leape et al (1995) 
calculated that improved information systems could contribute to the prevention of 78 per 
cent of transcription errors leading to adverse medicine events. Using computers to 
generate worksheets and labels also helps efficiency within a pharmacy (Graham, 2005). 
EPS are a priority (NHS Executive, 1998). A national functional specification was 
developed over 2006/07, with a view to procurement and implementation during 2008 - 
2010 (CFH, 2000a; CFH, 2006b; CFH, 2007a). Its focus is clinical specialties, and it does 
not include aseptic products/preparation per se although some such activity might be 
inferred (CFH, 2006a). 
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A prototype (basic) specification was constructed for Trusts to use in 2002 (Walker, 2002). 
This described aseptic products such as cytotoxics, TPNs and CIVAS as "specialist 
functions" (ibid). Only one IM&T supplier (JAC) appeared to make significant progress 
with the development of electronic prescribing by 2004; the inference was that this was 
due to its specialist pharmacy knowledge, gleaned through its role as market leader in 
pharmacy systems (Goundrey-Smith, 2004). 
Pharmacy Stock Control is outside the scope of the (formal) specification, and its 
specification/software development "is a considerable time off", with links between them 
and EPS still to be specified (CFH, 2006a). Data on whether a patient had his/her drug 
delivered by prefilled syringe that had been made up on the ward or in pharmacy may be 
a requirement for a future generation of EPS, but at this stage it is not a primary focus for 
system development (ibid). 
Notwithstanding the above, there is a question as to the degree to which EPS would be 
able to provide comprehensive, unambiguous data around aseptic products and 
preparation, because of a range of practical and process issues (Chief Pharmacist Wirral 
Hospitals NHS Trust, 1998). For patient care the data in EPS is vertically organised, and it 
can be difficult to get information that goes across systems (ibkn, which means that a 
likely approach to investigating aseptic production and preparation would involve the 
transfer of identified data into a data warehouse for subsequent analysis (ibicf). 
From the perspective of actually implementing EPS, few hospitals have considerable 
experience of such systems (e. g. Wirral Hospitals NHS Trust has operated a system since 
before 1995), and most NHS hospitals made little progress by 2004 (Goundrey-Smith, 
2004). Some hospitals introduced EPS within a single well-defined clinical specialty, or on 
a pilot basis (not always successfully), yet there is significant difference between this and 
implementing EPS throughout all clinical areas within a Trust, given the technical and 
training implications (ibid; Walker, 2002). 
2.7.2 Complexity of Pharmaceutical Data 
Even if EPS can provide data concerning (aseptic) medicines a patient receives, it cannot 
be automatically assumed that the data available will meet requirements. For example, 
the National Prescribing Centre's Hospital Prescribing Information Project (Jackson and 
Walker, 1998; National Prescribing Centre, 1998; Jackson, 1999) examined the 
practicability of achieving an effective national database on hospital drug usage, broadly 
equivalent to that collected by the Prescription Pricing Authority's Prescribing Analyses 
and Costs information system. It concluded that it was only feasible to record expenditure 
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rather than activity volumes for the identified purposes. The number of different measures 
and descriptions used for products was so great it presented major obstacles to the easy 
collection of data. Less than half of the hospitals involved had computer systems or 
configurations that met the minimum project criteria. Fitzpatrick (2001) subsequently 
reiterated that it was not possible to obtain data on drug volumes because of the lack of 
common drug identifiers and highlighted that reliance would have to be placed on manual 
acquisition of any data. Fitzpatrick also argued that medicines management should be 
studied by utilising outcome measurement (ibid). 
2.7.3 Information Systems relating to Aseptic Dispensing 
Evaluation of the four main information systems used specifically for aseptic dispensing 
established that Trusts can configure such systems differently to reflect local 
requirements. This gives potential for differences in product definition, coding systems, 
report formats and data export facilities, which means that any data collection needs to be 
at a suitably high level (e. g. product category) to ensure consistency and compatibility 
(NHS Executive North West, 2001) (See also Section 5.2). 
2.8 Computerised Capacity Planning Software 
Within industrial environments, material requirements planning (MRP) is a systematic 
method for determining the quantity and timing of dependent-demand items, but it is not 
sufficient to cope with balancing plant capacity with demand adequately, and therefore 
further development produced the so-called manufacturing resources planning system 
(MRP2) which consists of both material requirements planning and the capacity 
requirements planning functions (Wu, 1996). Capacity requirements planning (CRP) is 
the function of determining the capacity requirements needed to carry out production 
plans. MRP systems assume that capacity is available when needed unless told 
otherwise. CRP on the other hand takes material requirements from the MRP system and 
converts them into standard hours of load of labour and machine on the various 
workstations. By utilising the management information system, CRP attempts to develop 
loading plans that are in good balance with plant capacities. Thus CRP is an iterative 
process that first simulates loads on the workstations and then feeds back the necessary 
information to suggest changes if the plans are not feasible (ibid; OMNI 2005). 
Consequently the development of capacity plans often involves the use of software 
models relating to MRP2 (Thacker, 2006a; Thacker, 2006b; Business Performance 
Improvement Consultancy, 2006; OMNI, 2005; McGuffie-Brunton, 1998). These deal with 
both aggregate/long term and detailed/short-term levels (Thacker, 2006b) and plan for the 
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utilisation of labour, materials, equipment and facilities. Flexible manufacturing systems 
allow for the specific mix of pieceparts to be produced in a given period (Parrish, 1993). 
Aggregate plans for production are translated into the individual steps necessary to realise 
those plans, with data generated to develop capacity plans (OMNI, 2005). 
Computer modelling can determine the step points in production so that decisions can be 
made to optimise resources and outputs, taking into account the two main types of 
capacity constraint: 
" Hard ceiling: where it is extremely difficult to add or remove capacity e. g. 
expensive plant or equipment working at full capacity, or a scarce skill. A change 
here would impute a step change in the fixed costs of the operation and 
consequently demand a compensating increase in mean and aggregate outputs. 
" Soft ceiling: where it is relatively easy to flex capacity by overtime, sub contracting, 
etc. 
(Thacker, 2006a) 
Increased sophistication of capacity plans and capacity planning procedures can be 
reflected by an increased need for computer power (OMNI, 2005). MRP2 software has 
become extremely complex both in terms of functionality and visual presentation, making 
it impractical to write detailed requirements specifications, or invitations to tender 
(Business Performance Improvement Consultancy, 2006). Therefore, there is a reliance 
on purchasing available software packages, which can run the risks of software problems, 
or "bugs", and inadequate support from the software vendor. It is essential to have a clear 
understanding and vision of what is to be achieved through using the software (ibid). Even 
then the success rate of MRP2 implementation can be poor, with consequences in time 
and cost (Thacker, 2006b). 
Importantly, aseptic dispensing units are one part of a whole hospital pharmacy 
department. There will normally be interaction between the units and the rest of the 
department in the deployment of staff. Therefore, to be meaningful and effective, the 
whole of a pharmacy ought to be modelled and not just the aseptic preparation unit. Beer 
(1996) explores the utility and feasibility of modelling in depth. 
The full cost of introducing capacity planning software is not inconsiderable, and the 
variation across the NHS in units and pharmacies (see Section 2.6.6) suggests that each 
Trust would need its own locally customised application. It is unlikely that the consequent 
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aggregate costs to the NHS would be countenanced, given the comparative marginal 
benefits that could be anticipated. 
2.9 Aseptic Skill Mix Issues, Skills Management & Quality 
2.9.1 Skills Development in the NHS 
Skill mix and role diversification were introduced into the hospital pharmacy sector nearly 
two decades ago, in response to developments in clinical pharmacy and a shortage of 
pharmacists (Samuels and Hassell, 2004). Pressures on the recruitment of pharmacists 
and changes in university courses' structures emphasised the need to look at skill mix and 
link this to the amount of aseptic preparation that was produced on a licensed basis (NHS 
Executive North West, 1997; Gandy et al, 1998b; Gandy et at, 1998c) Therefore, whilst 
pharmacies in the NHS have not specifically adopted a skills-based quality management 
approach to their services, these pressures and modernisation initiatives mean that great 
emphasis has been placed on the development and application of competencies (Royal 
Pharmaceutical Society of Great Britain 2003a, 2003b, 2004; Samuels and Hassell, 2004; 
British Pharmaceutical Conference, 2004; McRobbie et al, 2005; McGuire, 2005; Cattell et 
al, 2005) 
For example, the NHS Knowledge and Skills Framework is a key element of Agenda for 
Change (Foster, 2004) which will have lasting implications, and provides the opportunity 
to redefine the NHS pharmacy career and explore multidisciplinary working and re- 
engineer service deliverables (Cattell et al, 2005). 
Skill mix has been the subject of review (DoH, 2002c; Samuels and Hassell, 2004; British 
Pharmaceutical Conference, 2004) although there are concerns that proposals might 
weaken the medicines safety net (Pharmaceutical Journal, 2002). In essence reviews 
seek to attribute tasks and responsibilities to the most appropriate personnel, taking into 
account all staff, including pharmacists, pharmacy technicians and pharmacy support 
workers. In Denmark, the role of pharmacy technicians have extended into 
"pharmaconomists", taking responsibility for many tasks traditionally associated with 
pharmacists, without their supervision (Samuels and Hassell, 2004). 
Skill mix is seldom clearly defined and, as a result, the concept is poorly understood, 
which makes it difficult for pharmacists to engage with skill mix debates in any meaningful 
way (ibid). Skill mix cam be defined as the "balance between trained and untrained, 
qualified and unqualified and supervisory and operative staff within a service area as well 
as between staff groups" (ibicf). 
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Yet the progress could be undermined by the variety of methods applied to evaluate the 
competence of pharmacists in clinical practice (McRobbie et al, 2005). There is a lack of 
standardised performance criteria, and a lack of clarity of some roles. The concern is that 
the plethora of "competencies" being produced have no objective data to support them, 
and without a rigorous approach, the resulting competencies will not meet their aims. 
There needs to be a competence-based practitioner development framework (ibis). 
2.9.2 Skills Management and Quality 
Quality improvement has long been a priority across all sectors, and whilst there may 
have been successes in (industrial) manufacturing, the service sector has proved more 
difficult. This is because quality is generally interpreted as conformance to specification, or 
fitness for purpose or use, thereby equating quality with standardisation. As a 
consequence, quality levels are perceived as the inverse measure of deviation from a 
specification. Also, there is often no tangible product resulting in the service sector 
(Beckford, 2002). 
The established industrial model of quality control involves a documented, procedure- 
based management approach. The complexities and variability of service provision in the 
service sector mean that quality improvement cannot be successfully modelled in this way 
(ibid). 
The most successful approaches in the service environment are based on the premise 
that professions rely for service quality on the professionalism and judgement of the 
individual employee or partner. To maintain professional service quality such systems 
require explicit recognition of the nature of professionalism, and robustness in practice. 
Therefore, the only way to solve the problem of quality in the service sector is to employ 
trained, educated staff and grant them the freedom necessary to do the job. This requires 
an effective and manageable quality management system based on the development and 
recording of the skill base (ibid). 
Using skills to assure quality is not a new idea. Section 6 of the ISO 9001: 2000 standard 
deals with the effective management of skills, highlighting that to provide quality personnel 
it is necessary to both use competent staff and also support competence (International 
Organization for Standardization IS09000,2000). Nevertheless, good skills-based quality 
management explicitly uses skills as the basis of quality, with the organisational 
processes captured at a high, less detailed level. Therefore task and procedure 
descriptions are minimized or even done away with in many situations (Beckford, 2002). 
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A skills-based quality management system assures the quality of outputs through the 
determination of the abilities and competence needed to deliver the service, and then 
ensuring that only operators whose skills match those needed for a particular process are 
permitted to work on it (ibid). 
It should always be remembered that services are delivered by people, and therefore 
process control is essentially the control of the behaviour of the people providing the 
service. Appropriate behaviour is assured by ensuring that the provider of the service has 
the skills, knowledge and competence deemed necessary to the provision of the service 
(ibid). 
Services are also delivered to people, who vary, which is why complexities of service 
provision arise. The potential range of resultant situations is a key reason for the failure of 
the traditional process engineering approach to quality management (ibid). For example, 
doctors and nurses when determining their requirements for aseptic products will not only 
reflect evolving clinical practice and requirements, but also the potentially widely varying 
case-mix of patients that enter a hospital (ibid). 
It is not possible to model all possible situations in advance, and therefore it is not 
possible to specify all activities and solutions in advance. It is not, then, possible to chart 
the process fully in advance (ibid). 
People are extremely good at dealing with complexity, but when they are skilled, educated 
or trained for the task at hand. By defining the skills necessary to the fulfilment of the task: 
The complexity of the procedural system necessary for its control is reduced, process 
definition is transformed into a statement of professional competence. 
The level of managerial and supervisory intervention is reduced; tasks become owned by 
the front-line provider. 
Organizations need to match the body of skills held by their personnel and the set of skills 
needed to deliver the service (identified through role analysis). It is relatively simple to 
construct a relational database to carry out this task and to extend its utility to the creation 
of personal development plans, pre-selection for internal promotions and the generation of 
job specifications for recruitment purposes (ibid). Computer software packages do exist to 
maintain and manage skill sets, once defined (Integra Management Systems©, 2006; 
VSSkiIlsManager©, 2006; VSDentist©, 2006). 
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The adoption of a skills-based quality management system would have a clear impact on 
any large organization, such as a hospital, as well as specific key services such as 
pharmacy. A particular challenge is to ensure that the skills match is in place all of the 
time. There are implications for training, recruitment, promotion and retention policies - 
but it is the key to consistent service quality. Strategic human resource development, as a 
sub-set of the wider strategic function, forms the link between current and future 
performance by managing the skills base of the organization (Beckford, 2002). 
2.10 NHS Data related to Patient Activity 
Gandy et at (1998a) identified the issues surrounding the acquisition of data on aseptic 
preparation in clinical areas, but even if it were readily available it would clearly be 
necessary to set it in the context of patient activity. Yet routinely available patient data has 
its own constraints. For example, minimum datasets' data only demonstrate (to a 
reasonable degree) what a medical consultant has done - they give no record of the 
contribution of all the other professions, such as nurses, therapists and pharmacists. The 
latter are effectively treated as overheads both in terms of activity and finances, and how 
overheads are dealt with in individual hospitals can vary considerably (see Section 
11.11.2 Reference 11). Even where other medical consultants contribute to the care of a 
patient, in assisting the responsible consultant or even where there is joint care (such as 
for palliative care), this contribution is not recorded (Corcoran and Gandy, 1997). 
Cox and Marriott (2002) highlighted the problems of linking medication-related deaths 
from adverse drug reactions and medication errors, with minimum datasets that use 
International Classification of Diseases (ICD) codes for patients' diagnoses, and how the 
media interpreted such analyses by the Audit Commission (2001). 
Minimum datasets indicate the specialty but not the ward of a patient, and some 
specialties share wards (CFH, 2007b). This needs to be borne in mind if any cross- 
references are attempted with pharmaceutical data, so as to ensure consistency. If 
pharmacy data were to involve wards, then individual hospitals would need to use full data 
from their patient administration systems. 
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2.11 Governmental Approach to Performance Management and Benchmarking 
since 1997 
A key aim of the 1999 NHS Performance Assessment Framework (PAF) was to increase 
the scope of benchmarking across all dimensions of performance, including efficiency and 
service quality. This benchmarking focus supported "culture change" to help the NHS to 
move from "acceptable to best practice" (DoH, 1999c). 
The stated aim of the benchmarking approach was the identification, understanding, 
dissemination and implementation of best practice (Northcott and Llewellyn, 2005), 
although competitive league tables and performance standards are at odds with central 
notions of process improvement and learning outcomes (Kouzmin et al, 1999; Holloway et 
al, 1999; Hinton et al, 2000). 
Benchmarking's appeal in the context of health sector performance improvement is its 
avoidance of any need to pre-determine what best practice might comprise (Northcott and 
Llewellyn, 2003). Although the identification of best practice is recognised as problematic 
in benchmarking literature (Kouzmin et al, 1999), it is particularly complex in the public 
health sector (Northcott and Llewellyn, 2003). It is argued that benchmarking through 
league tables obfuscates this problem and then creates the paradox that the application of 
performance measurement becomes critical in defining performance itself (Ball et at, 
2000). 
The first NHS benchmarking indicators used by the Labour government related to costs 
(DoH, 1998). The subsequent PAF applied a balanced-scorecard approach to 
performance management across six key areas for continuous development in healthcare 
delivery (Kouzmin et al, 1999). The NHS Plan emphasised the importance of comparative 
performance measurement, whilst highlighting the historic lack of standards and the deficit 
of clear incentives (or levers) to improve performance (DoH, 2000d). In order to address 
this the NHS Executive introduced "rating systems" based on stars", ranging from three 
star (for the highest level of performance) to zero star (for the poorest level of 
performance) (Wait and Nolte, 2005). Acute hospitals were judged on 45 criteria including 
length of time patients wait for operations, and cleanliness. (Other types of Trusts had 
different criteria relevant to their services) (Northcott and Llewellyn, 2005). Through this 
means, the Government sought to enable delegated authority within healthcare whilst 
ensuring that such devolved powers did not result in high variability in terms of results 
(ibid). However, relative rankings rather than any clear standard of acceptable 
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performance say little of the scale and significance of performance variations between 
categories (Northcott and Llewellyn, 2003). 
Responses from within the NHS to the Government's strategy of denouncing 'failing" 
hospitals were mixed (Trosa, 1997), and there was widespread criticism (Seddon 2003, 
2004; Edwards, 2004; HSJ, 2004a; BBC Online, 2003). Variations were often interpreted 
as artefacts of fundamental incomparability between benchmarking organisations 
(Bullivant, 1996), and hospital managers would seek to justify, rather than modify, their 
position on indicator league tables (Northcott and Llewellyn, 2003; Jones, 2002). It 
appeared that providers responded to identified variations in performance either by 
seeking to discredit the ratings system in its entirety or by arguing that their less than 
highly rated performance was justified by factors that the rating scheme did not fully take 
into account (Northcott and Llewellyn, 2005). An unintended consequence is that 
managers are drawn to focus on the management of reported performance, at the 
expense of the management of performance itself (Ball et al, 2000). This highlights the 
importance of indicators being acceptable, or accepted as valid, by the organisations to 
which they are applied. 
NHS also sought other, arguably "softer", measures to enable improved performance. The 
Modernisation Agency actively promoted good practice and innovations, and trained 
facilitators to help deliver local change (NHS Modernisation Agency, 2007a). It was set up 
in 2001 and ceased in 2005 when it was superceded by the NHS Institute for Innovation 
and Improvement (NHS Modernisation Agency, 2007b). Linked to this was the concept of 
"beacon" NHS Trusts, where selected exemplars of best practice in specific areas of 
health care service and innovation were publicised on a special NHS website (now 
defunct). There were 371 such beacon sites covered (Northcott and Llewellyn, 2005) but 
the scheme ceased in 2003 (NHS Beacons, 2004). The Healthcare Commission 
introduced the annual healthcheck in 2005 (Healthcare Commission, 2005). 
The DoH established the Information Centre in April 2005 to centralise the collection and 
dissemination of information across the NHS. It recognised the need to develop 
information products and services, which would encourage senior, strategic NHS staff to 
make effective use of information. On the basis of negotiations through 2005, and 
Ministerial approval, the formation of a joint venture company 'Dr Foster Intelligence' was 
announced by the Secretary of State for Health in February 2006 (National Audit Office, 
2007). Dr Foster has developed products, many of which are of a benchmarking nature, 
such as guides comparing services and standards in NHS and private hospitals 
throughout the UK answering: Who will treat me? How long will I have to wait? Which 
facilities and services are available - and when? How well does the hospital follow 
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guidelines / meet targets? (Dr Foster, 2007). It has also redeveloped the Key Indicators 
Graphical System, relating to Local Authorities' PAF (ibid). In December 2005, Dr Foster 
was identified as one of the top ten fastest growing companies in Britain in the Sunday 
Times Virgin Atlantic Fast Track 100 league table (Dr Foster, 2005), which suggests that 
the organisation will play a major role in future NHS benchmarking. However, a search of 
its website yielded no reference to aseptic dispensing (Dr Foster, 2007). 
The NHS Benchmarking Club, founded in 1996, presents a voluntary opportunity to 
enable the sharing of ideas and information on processes. One of its aims is to "promote 
the use of benchmarking as a means of securing improvement and recognition that 
managerial effectiveness must support clinical effectiveness" (Northcott and Llewellyn, 
2005). It is essentially a networking forum (NHS Benchmarking Club, 2006). At June 2006 
there were 90 members of which 80 were English Primary Care Trusts (PCTs) (or their 
Welsh and Scottish equivalents), four Strategic Health Authorities (SHAs), and 6 were 
classed as "Other organisations". Of the latter only two were acute hospitals, i. e. acute 
Trusts have not joined the club, and therefore the Club's contribution to improving 
services in acute hospitals is questionable (ibid). The impact of mergers of PCTs and 
SHAs in 2006, can only be conjectured, but it is reasonable to infer that there will be a 
significant reduction in the number of members. 
Acute hospitals do exchange benchmarking information on a voluntary basis (Llewellyn 
and Northcott, 2002), often via a private sector benchmarking agency (Northcott and 
Llewellyn, 2005). Results from such sources are usually private and anonymised, and it is 
inferred that they are used to inform Trusts of their own current position compared to 
similar organisations (ibid). This serves to reflect how important confidentiality can be in 
benchmarking, with this being a precondition of the original North West aseptic dispensing 
survey (Gandy et al, 1998a). 
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2.12 Gaps in Literature 
The above sections point to gaps in the literature about what data should be collected in 
respect of aseptic dispensing and usage, not only in the UK but across the world. The 
varying emphasis on pharmaceutical aseptic dispensing is one reason, and the UK 
appears to be amongst the most advanced in centralising services. 
Similarly no established metrics and statistical indicators used to describe "capacity", 
"workload" and "collaboration" were identified in the literature in a hospital aseptic 
production context, although there is a great deal of literature that would suggest that 
benchmarking is the most appropriate means of utilising such metrics to evaluate and 
monitor performance once determined. 
The consultancy work of the researcher initiated information and data to be collected in 
respect of aseptic preparation and production, to address the fact that none was available 
for pharmacists and managers to make important decisions about how the related 
services should be planned and developed. 
It is apparent from all available literature that timely information is critical to the 
management of aseptic services. The identification and collation of such information is 
usually based on reactive, non-systemised responses from NHS management. 
The literature surrounding the appropriate information for this type of decision-making is 
usually linked loosely to commissioned consultancy work for the NHS. The increased 
emphasis on nationwide initiatives that has taken place, as opposed to local initiatives, 
means that there is a need for such information to be systematised consistently across the 
NHS, which in turn requires publication so that it can be embedded in operational and 
planning processes. 
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Chapter 3 Methodology 
3.0 Introduction 
3.0.1 Philosophical Approach to Methodology 
Students differ greatly in the way they learn (Kolb, 1984; McCarthy, 1990). Therefore, in 
an attempt to rationalise identity, professional standpoint and ideology in relation to the 
research, this researcher examined his strategic approach to learning. Kolb (1984) linked 
theory to practice and developed a 'cycle' to describe these phenomena. The Kolb cycle 
infers that learning processes undergo transitions involving Concrete Experience 
(feelings), Reflective Observation (watching), Abstract Conceptualisation (thinking) and 
Active Experimentation (doing). In utilising this model to evaluate the researcher's learning 
style it was anticipated that this would point to the preferred research style. 
Honey and Mumford (1992) developed a learning styles inventory. This researcher was 
subjected to a styles assessment, administered at Liverpool John Moores University: the 
scoring and the test determined a learning style of "converger". Thus this researcher, 
according to the adaptation of Kolb's Learning Styles inventory, combines Active 
Experimentation (AE) and Abstract Conceptualisation (AC) attributes as a preferred style. 
The AE mode of learning has a tendency to be experience based and test things in 
practice. The AC mode relates "knowledge about" something, which is theoretical, and 
perhaps comprehensive. The combination of CE and RO placed this researcher into a 
quadrant of the model titled "converger". 
Convergent knowledge brings to bear a number of facts or principles on a single topic: 
problems have "right" and "wrong" answers (Hudson, 1967). Convergent learners tended 
to be more highly valued (in school) because most assessment approaches focus on 
convergent skills (ibid). 
An evaluation of the researcher's research style (undertaken at the same time) indicated 
the researcher is a positivist. Anecdotally, it is unusual for a positivist to have a learning 
style of a "converger". The difference between positivists who are "accommodators" and 
those who are "convergers" is that the former relate to 'concrete experience' and the latter 
relate to 'abstract conceptualisation'. 
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3.0.2 Overview of Methodological Approach 
The methodological approach was shaped by the original proposals for research funding 
(NHS Executive North West, 2001) which required specific details, including costs, plans 
and project management arrangements. The researcher was the lead applicant, with a 
specific role in relation to the information aspects. The research was effectively submitted 
for and on behalf of the professional pharmacist and managerial communities within the 
North West. Therefore the relationship between the researcher and the subjects of the 
research (i. e. the professionals) was necessarily close and inter-related, and this 
consequently constrains the paradigms and methodologies. The involvement of experts 
was also predetermined (see Section 3.0.4). 
The research undertaken for this thesis is one of iterative exploration: seeking to establish 
information requirements and data availability; evaluating how concepts might be 
measured/interpreted using the data and derived statistical indicators; testing whether the 
data can be collected and used in ways that meet the information requirements; improving 
methods and indicators until it is considered that potential has been maximised or specific 
boundaries reached; and so on. As Alexander (1964) indicates it is not a case of "get it 
right first time" but as an evolutionary process of adaptation and learning. 
Box (1996) argues that the domination of Statistics by Mathematics rather than by 
Science has greatly reduced the value and the status of the subject, with the 
mathematical "theorem - proof paradigm" supplanting the "iterative learning paradigm" of 
scientific method; a misunderstanding affecting university teaching, research, the granting 
of tenure to faculty and the distributions of grants by funding agencies. 
What the research for this thesis does not attempt to do at any point is to test a given 
hypothesis, because there was no substantive hypothesis to test. Therefore Popper's 
(1981) falsification of theory has no relevance, and the relationship with particular 
paradigms is influenced accordingly. 
3.0.3 Relationship to Paradigms 
The paradigm relating to any research is very important. A paradigm may be viewed as a 
set of basic beliefs (or metaphysics) that deals with ultimates or first principles. It 
represents a worldview that defines, for its holder, the nature of the "world", the 
individual's place in it, and the range of possible relationships to that world and its parts 
(Guba and Lincoln, 1994). A paradigm is based on ontological, epistemological and 
methodological assumptions (ibid). Examples of major paradigms are given in Table 3.1. 
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Guba (1990) describes: Ontology as addressing what is the nature of knowledge or 
reality; Epistemology as addressing what is the relationship between the researcher and 
the knowledge; and Methodology as addressing how the inquirer should go about finding 
out knowledge. 
In relation to the research for this thesis, the ontological question (Guba and Lincoln, 
1994) is that the nature of reality is that of professional (mainly pharmaceutical) practice, 
primarily within the UK. 
The epistemological question (ibid) is that the researcher (as the knower/would-be 
knower) necessarily works closely with professionals and managers. This was because of 
the technical nature of many issues and the fact that the research was essentially for 
them. The researcher's role was clear and explicit. 
Table 3.1 Basic Beliefs (Metaphysics) of Alternative Inquiry Paradigms 
(Guba and Lincoln, 1994, p 109) 
Item Positivism Postpositivism Critical Theory et Constructivism 
at 
Ontology Real "reality" Critical realism - Historical realism Relativism - 
but "real" reality but - virtual reality local and 
apprehendable only imperfectly shaped by social, specific 
and probabilistically political, cultural, constructed 
apprehendable economic, ethnic, realities 
and gender 
values; 
crystallised over 
time 
Epistemology Dualist/ Modified Transaction/ Transaction/ 
objectivist; dualist/objectivist; subjectivist; subjectivist; 
findings true critical value-mediated created findings 
tradition/community findings 
; findings probably 
true 
Methodology Experimental/ Modified Dialogic/ Hermeneutical/ 
manipulative; experimental/ dialectical dialectical 
Verification of manipulative; 
hypotheses; critical multiplism; 
chiefly falsification of 
quantitative hypotheses; may 
methods include qualitative 
methods 
Therefore, analyses of the four alternative paradigms in Table 3.1 in relation to the 
research serve to exclude three of them: 
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" Positivism assumes that the investigator and the investigated "object(s)" are 
independent entities, and that questions/hypotheses are stated in propositional form 
and subjected to empirical test to verify them. None of these apply to the research. 
" Critical Theory has ontology of historical realism, which does not apply to the research 
area. Although there are links between investigator and investigated "object(s)" the 
approach prevented any values of the former influencing inquiries, and so the value 
mediation of its epistemology is not relevant. Dialogic and dialectical methods are also 
not relevant because there is no transforming ignorance and misapprehensions into 
informed consciousness. 
" Constructivism has a relativist ontology where realities apprehendable in the form of 
multiple, intangible mental constructions, socially and experientially based, local and 
specific in nature, and dependent for their form and content on the individual persons 
or groups holding the constructions. The epistemology links the investigator and 
investigated object so that "findings" are literally created as the investigation proceeds. 
Neither of these apply to the research given the practical NHS environment and 
processes involved. 
This leaves Postpositivism: for the epistemology dualism is largely abandoned as not 
possible to maintain, but objectivity remains a "regulatory ideal"; special emphasis is 
placed on external "guardians" of objectivity such as critical traditions and the critical 
community (ibid), with this being maintained within the research by the existence of an 
expert panel of professional peers, and similar. (They also addressed the danger of the 
researcher's "subjectivity" (Deetz, 1992,1996)). The research methodology involves 
discovery as an element in inquiry, and emic viewpoints are solicited throughout to assist 
in determining the meanings and purposes that people ascribe to their actions. These 
aims are accomplished largely through the increased utilisation of qualitative techniques. 
All apply to the research approach. 
Given the research's use of statistics within an "iterative learning paradigm" rather than a 
"theorem - proof paradigm" (Box, 1996), it follows that both quantitative and qualitative 
methodologies need to be applied as required, according to the existing research 
requirements, i. e. a mixed methodological approach is essential. 
A mixed methodological approach is in line with Guba and Lincoln's (1994) inference that 
methodological questions are secondary to the choice of research paradigm. They 
suggest: 
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'From our perspective, both qualitative and quantitative methods maybe used 
appropriately with any research paradigm' 
(Guba and Lincoln, 1994 p 105) 
They go on to question why quantitative methodologies are privileged over the insights "of 
creative and divergent thinkers" suggesting how qualitative inputs can readdress the 
balance. 
The appropriateness of such an approach within the NHS is reflected in Hill-Bailey's 
(1997) suggestion that post modern healthcare researchers (i. e. nurses) readily mix the 
quantitative experimental model, and natural inquiry qualitative perspectives in their 
design, knowledge existing in both areas with the resultant need for a mixed methodology. 
Polft and Hungler (1995) defined the concept of triangulation as: "The use of multiple 
methods or perspectives to collect and interpret data about some phenomenon to 
converge an accurate representation of reality". Certainly the use of a variety of data 
sources, or a mixed methodology would be an example of the process of triangulation. 
Both Playle (1995) and Duffy (1985) recognised the importance of multi-faceted data 
collection methods, suggesting that such an approach "minimises distortion" and provides 
assurance that the data is representative of the phenomenon being studied, thereby 
adding rigour to the design. 
Alvesson and Deetz (2000) make reference to the characteristics of an ethnography, 
which is a method, but for some "it is even a paradigm". This uses both quantitative and 
qualitative methods, and commonly involves the researcher establishing close contact 
with one or a few key informants who then guide the researcher and help him or her with 
crucial information. It is defined as a study of an exploratory nature, working with 
unstructured data and being case orientated and interested in meanings. Alvesson and 
Deetz (ibid) think that the term serves best if reserved for studies involving a longer period 
of field-work in which the researcher tries to get close to the community (organisation, 
group) being studied, relies on their accounts as well as on observation of a rich variety of 
naturally occurring events (plus other material, for example documents or material 
artefacts) and has an interest in cultural issues. 
Whilst ethnography is generally used in relation to anthropology and related subjects, it is 
interesting that the research covered by this thesis exhibits several of the characteristics 
described, particularly in respect of mixing methods, the relationship between researcher 
and the subjects of the research, the exploratory approach, working with unstructured 
data, and timescales. 
ýs 
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3.0.4 Use of Expert Input 
Expert input was a "given" for the research from the outset given its origins and nature 
(see Section 3.0.2) and offered many opportunities without which the value of the 
research would have been limited. 
The relevance of expert input to new systems or where insufficient information is 
available, was emphasised by Matta and Semeraro (2005). 
"Analytical models are based on assumptions that characteristic parameters are 
either deterministic (static allocation) or probabilistic (queuing network/simulation). 
They are valid when historical datasets are available to describe the way the 
parameters are distributed, but they become less and less significant when it 
comes to developing a new system or when no or insufficient information is 
available on an existing system. In the latter case, experts on the system 
analysed are asked to provide useful indications concerning the variables 
involved". 
(Matta and Semeraro, 2005, p234-5) 
Guba and Lincoln (1994) illustrate the inherent complexity in an inquiry a researcher may 
undertake, in the eticlemic dilemma. The etic perspective (outsider view of a cultural 
group) is brought to bear on an inquiry. This etic perspective, which may be hypotheses to 
be tested, may have little or no meaning within the emic perspective (the way members of 
a cultural group view themselves, an insider view). Guba and Lincoln (1994) suggest that 
qualitative data are useful for revealing and "uncovering" emic views. The qualitative 
researcher is likely to have a very different relationship with informants and data than that 
of quantitative researcher. This relationship is likely characterised by a researcher 
immersed in the subjective condition or state of his/her sample, with a flexible approach to 
data collection. 
The research necessarily balanced the etic and emic perspectives, given that it required 
the respective skills and knowledge of the researcher and the professionals to come 
together to form a whole. Each had limited knowledge of the others' field(s) but knew that 
their requirements, disciplines and practices had to be respected and suitably 
accommodated if the research was to be successful. This required ongoing dialogue and 
interaction, the simplest means of achieving this was by the creation and maintenance of 
an expert panel (managed through a series of structured, regular and ad hoc meetings, 
together with reports circulated for comment). 
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Not only did this provide a means of triangulating the findings of the research to establish 
rigour, but it had a number of advantages: 
" Consistency over the period of the research. 
" Ready advice on variations between different geographical zones and types of 
hospitals. 
" Enabling pre-notification to fellow professionals of what was to be covered in any 
local interviews, to clarify expectations. 
" The minimisation of what Guba and Lincoln (1994) refer to as "context stripping", 
where precise quantitative approaches focus on selected variables necessarily 
"strip" other variables that exist on the context that could alter findings. 
" The researcher could provide personal opinions and engage in "real" conversation, 
thereby making interviews more honest, morally sound and reliable (Fontana and 
Frey, 1994). 
" Minimising inconsistencies from interviews and identifying (potential) anomalies in 
data and analyses. 
" Validating interview results. 
" Validating whether the research was on course to achieve its aims and objectives. 
" Enabling triangulation with the wider professional community, as appropriate. 
In a similar way appropriate use was made of relevant experts providing direct advice on 
an ad hoc basis, particularly where there were no published references or it was 
necessary to be as "up-to-date" as possible. These do not represent academic references 
and have therefore been separately referenced in Section 11.2 as Expert Inputs 
Statements. 
3.0.5 Qualitative and Quantitative Approaches 
Given the mixed methodological approach care was exercised in which specific qualitative 
and quantitative methods were applied. 
3.0.5.1 Questionnaires 
The principles outlined by Polfit and Hungler (1995) as the main strengths of using 
questionnaires as a design in research were applicable to the research: 
" The ability to administer to groups 
" Distribution in clinical settings is often inexpensive, efficient, and usually results in 
high yield 
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"A large geographically spread sample can be obtained 
" Greater anonymity can enable candid response 
" The lack of an interviewer creates a lack of interviewer bias 
(see Polit and Hungler 1995 p289) 
Polit and Hungler (1995) and Parahoo (1997) identify problems with self-report 
questionnaires, such as a respondent wishing to present a favourable image of him or 
herself, and their design being formulated on the basis of a researcher's own experience, 
as opposed to formulation based on the literature or an evidence base. Yet the use of self- 
report questionnaires in the research is limited to anonymous out-turn questionnaires 
evaluating the outcomes of workshops. All other questionnaires involve factual data (e. g. 
number of products, times, type of computer software). Therefore the problems of self- 
report data are not relevant. In practice, all questionnaires and survey designs were 
initially piloted with professionals and endorsed by the expert panel. 
The out-turn questionnaires largely involved closed questions, which readily yields data to 
compare respondents, and quick and easy analysis through the use of pre-coded 
responses (Parahoo, 1997). As there was limited time for the questionnaires to be 
completed at the end of a workshop this type of design was suitably expeditious (Polft and 
Hungler, 1995). 
3.0.5.2 Qualitative Interviews 
Qualitative interviews (i. e. unstructured and semi-structured, as opposed to "talking 
questionnaires") are relatively loosely structured and open to what the interviewee feels is 
relevant and important to talk about, within the remit of the research questions. 
Interviewees are less constrained by the researcher's pre-understanding and preferred 
language (Alvesson and Deetz, 2000). The researcher may get perspectives, information 
and ideas that he or she has not thought of before. Such an approach was regularly 
applied to obtain "richer" accounts (ibid), given the need to coalesce the researcher's 
perspective, expertise and knowledge with those of the (professional) interviewee, their 
positions often being complementary to one another. 
Getting close personal links between the researcher and the respondents - who are then 
seen as 'participants' may minimise potential problems of saying what the researcher was 
thought to want to hear (ibid) (although there is always a possibility of a Hawthorne effect 
(Olson et al, 2004)). Responses were peer-reviewed by the expert panel. 
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3.0.5.3 Developing Definitions of Concepts 
Alvesson and Deetz (2000) highlight the problems caused by trying to establish a 
common definition of a particular concept. The diversity of interpretation and the 
associated variables means that a coherent definition with universal aspirations may say 
relatively little in terms of the richness and complexity of the quite varied phenomena it 
supposedly refers to. The impossibility of fixing a concept is partly related to the ways in 
which words are informed by the root metaphors for the phenomenon being studied. 
Researchers, like other people, structure worlds metaphorically (Alvesson, 1993; Brown, 
1977; Morgan, 1980,1986). Words get their meaning through the metaphorical context in 
which they are employed. This means that words work in an imaginative and associative 
rather than analytically clear-cut manner (Alvesson and Deetz, 2000). Adding the fact that 
words can have different meanings in different cultures (see Chapter 11.2 Reference 4), 
there is a strong case for a move to a more local/ emergent approach (ibis/). 
In addition, there is a danger that the reader (or in the case of the research, the 
professional community) "knows" in advance what the concepts are and can separate 
them from 'culture' and 'strategy' due to commonsensical cultural conventions. This can 
result in prejudices, biases and taken-for-granted assumptions that can lock the research 
into closed, conservative and uncreative modes of thinking. (ibid). 
To address the above the research used workshops to explore and debate the concepts 
and related issues, using Affinity Analyses (Brassard, 1996) and dissemination to ensure 
that the potential problems did not arise, although nomenclature was fully recognised as a 
key issue (see Section 3.8). This approach being driven by participants, or jointly by 
participants and researchers, with allowance for cultural and institutional context and 
meaning creation patterns is seen as preferable to one that is one-sidedly, indeed 
authoritarianly, decided upon by the researcher (Alvesson and Deetz, 2000). Nowhere in 
the research was there any aspiration to develop a "grand theory", with all the 
connotations that that might involve (ibis). 
3.0.5.4 Delphi Techniques 
Delphi techniques are methods for obtaining forecasts from independent experts over two 
or more rounds. Experts are asked to predict quantities. After each round, an 
administrator provides an anonymous summary of the experts' forecasts and their 
reasons for them. When experts' forecasts have changed little between rounds, the 
process is stopped and the final round forecasts are combined by averaging. Delphi is 
based on well-researched principles and provides forecasts that are more accurate than 
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those from unstructured groups (Rowe and Wright 1999, Rowe and Wright, 2001). They 
are used where there is little or limited knowledge (Linstone and Turoff, 1975; Linstone, 
1984; Surowiecki, 2004), a situation which applied in the research. They are increasingly 
being used in healthcare to obtain professional consensus and information (Medix, 2007). 
Their advantages include: inexpensive; free of social pressure, personality influence and 
individual dominance; reliable; allows sharing of information and reasoning among 
participants. Disadvantages include: the selected group of people may not be 
representative; tendency to eliminate extreme positions; requires adequate time and 
participant commitment (Michigan State University Extension, 1994). 
3.0.6 Constraints 
Because the research involved such a large constituency as the North West of England, 
this placed constraints on what methods could be pursued, irrespective of the 
methodological options. These included: 
Organisation: The research needed to allow for and operate within existing NHS 
and pharmaceutical organisational structures, and their associated 
communications and working arrangements. In respect of aseptic 
dispensing, the aseptic managers and pharmacists in the North 
West Region (co)operate through three geographical zones, viz. 
Cheshire & Merseyside, Greater Manchester, and Lancashire, each 
with their own group and zonal co-ordinator. 
Practicality: Pharmacists, and other NHS professionals, are very busy and 
making time to provide contributions to the research would always 
be in competition with other priority demands; hence how realistic 
methods were in their demands on professionals' time was a major 
consideration. 
Precedent: Where pharmacists had successfully utilised a specific method 
previously, there was an implicit assumption that this should be 
used again. This particularly applied to the decision relating to 
surveys for activity data, which had the precedent of the researcher 
having undertaken the original survey of activity in aseptic 
dispensing units and clinical areas (Gandy et al, 1998a). 
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Terms of Reference: For some components of the work associated with the research the 
researcher's role was one of commissioned consultant. Therefore 
the methods to be applied were (sometimes) predetermined, and 
strict deadlines were usually applied. 
3.1 Data to Collect 
The first research question was what data should be collected? This is inherently both 
qualitative and quantitative. 
The expert panel interpreted this as what information is required by pharmacists, nurses, 
doctors and managers, in respect of their respective related roles. Varying interests within 
professions needed to be accommodated, e. g. Chief Pharmacists, Purchasing 
Pharmacists, Aseptic Managers. Therefore the range of information needs had to be 
determined. The options were: 
1. Survey personnel with questionnaire for proposals/suggestions about their needs, 
and the data required to meet them; analyse results; make recommendations. 
2. The researcher to draw lessons from literature; disseminate proposals; seek views 
through questionnaire about needs, and the data required to meet them; analyse 
results; make recommendations. 
3. Structured interviews with all relevant players to achieve goals. 
4. Gather key players from relevant professions and disciplines to debate 
requirements, evaluate literature, and make recommendations. 
Whichever options were to be applied the resulting outcomes/recommendations would 
need to be validated. 
The surveys in options one and two require piloting to ensure efficacy, and involve two 
stages: the first to determine agreed "needs" and the second to determine the data 
required to meet them. Undertaking such a process involves a considerable amount of 
time, which was not available within the commissioned plan timetable and resources. 
Professional ownership of the research and its findings is essential, and both options one 
and two would not allow interaction between key players and professions. Surveys can 
suffer from poor response rates, unless there is ownership. 
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Option three was not realistic given the number of Trusts and professions to be involved. 
The creation of the expert panel negated the need, with key players inputting quality 
advice. 
Option four was chosen (as a workshop) because it: creates ownership by involving key 
players; enables interactions between them, allowing consensual recommendations; 
makes best use of time. It also allowed for a collective evaluation of the lessons from the 
"original survey" (Gandy et al, 1998a), which had important local influence. 
To determine "information needs" the expert panel chose Affinity Analysis (Brassard, 
1996) as a robust, qualitative research and development method that yields significant 
findings: it involves all participants, establishes links between different needs, and 
prioritises them. Its advantages are that it is inclusive and non-directive, with no 
constraints, enabling the rapid identification of issues of relevance to the question asked. 
Its disadvantages are that it is usually time-limited and it can be mentally tiring, leading to 
passivity in some participants. The process needs validation to ensure full participation 
takes place. 
The NHS can be insular and ignore approaches applied in other sectors. Therefore the 
private sector was invited to present how it quantifies production activity. Baxter's was 
approached as the main private producer in the North West, whose people were well 
known to members of the expert panel. 
Given the objective to weight aseptic production, particular attention would be paid to the 
private sector approaches: 
1. Consensus categorisation of product type, allocating weighting according to complexity 
("unit time equivalents " (UTEs)); and 
2. Consensus categorisation of product type with measured time standards allocated to 
each group ("standard minute values" (SMVs)) 
The workshop should (qualitatively) evaluate these, in the context of their 
applicability/transferability to the NHS, through discussion and debate of the advantages and 
disadvantages, and the associated practicalities. 
The Affinity Analysis results would need triangulation. The clock diagram analysis stage 
would give a whole hospital overview, but aseptic preparation requirements vary between 
different hospital services. Therefore syndicate groups should focus on predetermined 
clinical areas, applying multidisciplinary expertise to validate the results in relation to each 
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clinical area, thereby establishing the degree of consistency of the identified information 
needs, together with any priorities. There should be sufficient groups to cover all types of 
main areas, whilst balancing the numbers and mix of the workshop attendees. 
To address the gap in knowledge about the types of aseptic products used in different 
hospital services, the opportunity could be taken to ask the syndicate groups about the 
degree of usage of the most common aseptic products in their hospital service. 
There were two basic options for managing the syndicate groups: unstructured 
discussion; and, a predetermined structure targeted at the workshop objectives. The 
expert panel chose the latter because of the time constraints, and because it was 
necessary to score the identified information requirements. It was anticipated that this 
would provide the best outcomes. 
The efficacy of the workshop needed validation to assure its findings. The options were for 
a structured out-turn questionnaire of participants and an (unstructured) evaluation by 
expert panel members at its subsequent meeting. The panel agreed that combining both 
would triangulate the outcomes, with the survey results being available to the panel at its 
meeting. 
The expert panel then needed to translate the findings into firm proposals for the next 
stage of the research. 
3.2 Information Systems Data Audit 
Identifying data requirements becomes largely academic if it is not feasible to (readily) 
collect/acquire such data. Pharmacists on the expert panel advised that existing 
(pharmaceutical) information systems could produce data similar to that identified by the 
workshop, but it was essential to confirm that the systems could actually deliver the 
research data. 
It was necessary to identify the (commercial) systems used across North West hospitals 
so that they could be tested against the required data, together with how they were used. 
With no central database holding such information, the most straightforward approach 
was to survey all units to establish the systems used, together with relevant details 
(quantitative). Alternatives made little sense to pursue. Trusts will have acquired their 
systems at different times. Therefore any survey needed to establish the systems' place in 
local information strategies. 
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Using the survey results, the expert panel identified a representative sample of units to 
audit, because details for a particular system should be the same wherever used. The 
sample covered all systems, geographical zones and types of hospitals (specialist and 
non-specialist). All identified Trusts were approached to agree to participate. 
The expert panel prepared a draft specification for the data audit, but it needed validation, 
which could only be achieved by an exploratory, pilot visit to an aseptic unit to establish 
the data and systems information available for one main system (qualitative and 
quantitative). 
Options for the main exercise were: (a) to visit each of the sample units, undertake 
interviews and scrutinise systems outputs and documentation; and (b) to pursue a 
"desktop" approach whereby operational manuals, print-outs and other relevant 
documentation from units were provided and reviewed (backed up by a questionnaire, 
telephone calls and correspondence to deal with queries). 
Both options involved a mix of qualitative and quantitative methods. The expert panel 
decided that whilst visits could be made to each unit, this would add little to what could be 
achieved by option (b) and would involve more time (which was at a premium). The 
reasoning was that systems are defined by their documentation and their standard print- 
outs, and interviewing local pharmacists on site about these would not add value. 
Where automatically generated data did not appear to fully meet identified requirements, 
local pharmacists were asked how data shortfalls could be addressed (qualitative). 
With developments in electronic prescribing systems (EPS), it was important to ascertain 
whether they might provide the required data within the foreseeable future. Three national 
sites piloted EPS and therefore a (qualitative) semi-structured interview with one of their 
chief pharmacists was appropriate, with further action taken if the expert panel considered 
it necessary. 
With pieces of the research moving in parallel with one another, the opportunity presented 
to collate preliminary (qualitative) ideas and outline proposals for the collection of the main 
research data, using lessons from the initial workshop and the Data Audit pilot visits. 
These were presented for validation to the expert panel, and adapted in line with advice 
given, before presentation to a Data Audit workshop5 as potential next steps in the 
5 For practical reasons, including timing, the Data Audit workshop's scope was broadened to cover issues 
relating to Nomenclature (see Section 3.8), as they were identified in the initial workshop, and could potentially 
impact on data. 
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research; the workshop itself acting as further validation. The expert panel considered this 
expeditious, as the alternative would involve developing proposals after the workshop, 
thereby requiring a further workshop (or other means) to validate them. Getting 
professionals together from across the North West for a third workshop on a similar theme 
would have been difficult. 
Again, the efficacy of the workshop required validation, with an out-turn questionnaire and 
the full expert panel considering the outcomes. A "participants evaluation" was deemed 
unnecessary because the workshop was not to 'brainstorm' ideas and views (which 
requires confirmation that everyone contributed); its focus was validating the Data Audit 
work's findings and confirming the way forward. 
Opportunities for placing findings on a website and inviting comments were not really 
viable at that point in time, and were arguably not as desirable as a workshop, because of 
the lack of direct interaction between professionals. 
3.3 Baseline Survey 
Having confirmed the identified data should be capable of being collected by survey, it is 
necessary to: test/confirm data can be collected, and is of suitable quality; and, to use the 
collected data as the research baseline. 
The two main (quantitative) options to collect the data were: 
1. To request preset analyses from local aseptic/pharmacy information systems, and 
collate them. However, Section 3.2 determined that this was not feasible because 
not all systems provide such preset analyses; it was impractical to request the 
software companies to develop these because of negotiation time, with no 
guarantee about the outcome, and the likelihood of financial charges. 
2. To collect the data through a survey. This was supported by the expert panel and 
the discussions at the workshops, and replicated the approach of the original 
survey (Gandy et al, 1998a) i. e. it was proven to be acceptable and practical. 
A full year's data was required to have validity as a baseline, and avoid seasonal 
variations. All reasonable means of ensuring data quality should be applied, e. g. figures 
that should correspond do correspond, column and row totals are correct. 
The expert panel (qualitatively) translated outputs from the first and second workshops 
with care, to establish the main survey design principles and ensure guidelines were clear 
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and complete. The better this was done the better the completion of the survey forms 
should be, so as to help maximise data quality. 
To minimise potential errors/mistakes, the (draft) design and associated guidelines 
required (qualitative) validation. The ideal option was to pilot the design and guidelines - 
with actual data recorded - and receive advice on whether: what was required was clear; 
the data was obtainable; and, any necessary changes were required. The expert panel 
would then evaluate comments and agree any amendments, before final (qualitative) 
checks prior to distribution. 
The main alternative was for the expert panel and selected aseptic managers to consider 
the design and guidelines and give the same advice, but without actually providing data 
(as with a pilot), using their knowledge of local systems. This is not as thorough as a pilot, 
but the expert panel pharmacists were satisfied with the draft design and guidelines, and 
felt that a pilot would not add (significantly) to such consideration. It was acknowledged 
that a pilot would involve several weeks to arrange, undertake and feed back, and time 
was critical. In the circumstances the alternative course of action was agreed. 
The survey was developed on the basis of three complementary forms (see Section 11.24 
for details of each): 
Form one dealt with the production of aseptic products within a pharmacy, with an 
indication of the customers involved (the categories were mutually exclusive and covered 
the full range of possibilities): 
" Individual patients (within Trust) 
" Use as Ward Stock (within Trust) 
" Use in Other NHS Trusts 
" Use by Non-NHS Users 
Form two dealt with the usage of aseptic products, with an indication from where they 
were sourced (the categories were mutually exclusive and covered the full range of 
possibilities): 
" Within Trust 
" Other NHS Trust Licensed Unit 
" Other NHS Trust Unlicensed Unit 
" Commercial 
" Other 
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Form three required one figure for each product category: the number of commercially 
acquired licensed products used in Trust without further manipulation in a pharmacy 
aseptic unit prior to administration to a patient. These products were excluded from Forms 
one and two to avoid any double counting. 
The mutually exclusive list of product categories included in the baseline survey, on each 
of the three forms, is set out below. The expert view was that these represented distinct, 
recognisable categories, which would be homogeneous within each category in terms of 
the amount of pharmaceutical aseptic preparation time and effort that would be required: 
" Cardioplegia Solutions 
" Cytotoxics - Infusions 
" Cytotoxics - Syringes 
" Cytotoxics - Devices 
" Epidural Injections 
" Eye Drops/ Eye Irrigations 
" Irrigations (exc. ophthalmic) 
" Minibag Plus 
" Minibag/ Infusion 
" Injection Devices (inc. Elastomeric Infusor) 
" Prefilled Syringe 
" TPN - Adult: Compounded 
" TPN - Adult: Simple Additions 
" TPN - Neonatal/ Paediatric 
" Radiopharmaceuticals 
" Other 
All acute hospital Trusts in the North West needed to be included, given that the C&CP 
covered the whole of the region. One option for survey distribution was to send it to all 
North West Trusts and ensure complete coverage. The alternative was to target Trusts 
using aseptic products in the original survey (ibid) and check directly that other Trusts had 
not changed in the interim. The former had disadvantages: Trusts that did not use or 
produce aseptic products could complain about time being wasted, and some would 
probably not reply; causing difficulties in determining whether non-respondents were not 
relevant or late responding. The latter course was chosen, because it was the most 
reliable option, and only added a little to the researcher's time and effort. 
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The survey guidance allowed Trusts flexibility on the number of sets of forms completed to 
allow for local circumstances: separate hospitals, with their own aseptic units, could be 
considered in their own right if the Trusts wished, to allow for NHS reorganisation where 
sometimes geographically disparate hospitals are part of the same Trust, even though 
they operate independently of one another for many operational purposes, e. g. 
Morecambe Bay Hospitals NHS Trust covered separate hospitals at Barrow, Kendal and 
Lancaster, each of which has had aseptic dispensing units. 
Trusts/sites were allocated confidential survey numbers to identify themselves in the 
results analyses, and retain anonymity. This was partly to help maximise the response 
and partly in recognition that Trusts were autonomous organisations within the NHS and 
"commercial confidentiality" could apply. (Some Trusts were in competition with one 
another for certain of the services). 
However, to enable the expert panel to qualitatively validate the data and analyses using 
local knowledge members had to have the full list of Trust/site codes. 
To ensure expeditious analysis, all data was held in a central database. 
3.4 Baseline Survey Evaluation 
A key research question was whether the baseline survey design was optimal, or could 
improvements be applied? No matter how good the prior testing, some changes would 
inevitably be required. Therefore the baseline survey was effectively a first step towards 
achieving the objective of determining 'definitive' recommendations. 
Accordingly, it was essential to (qualitatively) evaluate the baseline survey's efficacy and 
incorporate any necessary changes into the design for subsequent surveys, maintaining 
appropriate consistency to enable valid comparisons between results. 
To ensure the efficacy of any evaluation it had to be assumed that there would be 
problems and criticisms, and ensure they would all be identified and notified to the 
researcher and the expert panel. 
The evaluation covered the questions: 
(a) Were the survey forms and guidelines clear and unambiguous, so that 
pharmacists and aseptic managers could understand what was required and 
recorded? 
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(b) Could this data be acquired from local information systems? 
(c) Was the data collected "fit for purpose" in the context of the research? 
To address (a) there had to be (qualitative) opportunities/channels for the pharmaceutical 
constituency to record any problems and suggest improvements. The simplest means was 
to highlight that notifying problems/suggestions was welcomed. This involved either direct 
communication or face-to-face discussion (with the researcher attending zonal meetings 
of aseptic managers, or meeting local zonal co-ordinators). Both opportunities were made 
clear in survey correspondence, and stressed to the lead zonal co-ordinators for 
dissemination. 
As (b) was also a local issue, such problems and issues were to be notified through the 
same (qualitative) opportunities as (a). In addition, the researcher validated submitted 
survey forms, discussing anomalous data with the hospital concerned, ascertaining 
whether simple errors or the design and/or guidelines were involved. 
It was essential for data audit purposes to record all different types of queries and issues 
as they arose, because the data held on the database would have all such queries 
already addressed. A simple (qualitative) log was all that was required. 
Clearly, responses through (a) & (b) could not be accepted automatically, and had to be 
(qualitatively) evaluated themselves to determine whether they would justify amendments 
to the survey design and/or guidelines. There were only two options. The first was for the 
expert panel (in line with its role) to receive the feedback, together with potential 
responses, to undertake its evaluation, before then disseminating to the pharmaceutical 
community. The second was to simply collate the feedback - without the expert panel's 
comments - throughout the pharmaceutical community for its own comments, and for 
these in turn to be collated and considered by the expert panel. The latter was dismissed 
as impractical: pharmacists would expect to see the expert panel's views/comments on 
the feedback as part of any dissemination, together with having sight of the results and 
comments in respect of (c); and it would take considerable time and process. 
Evaluation (c) could only be (qualitatively) performed on the survey's completion and 
analysis. The main means would be for the expert panel to give critical (qualitative) 
consideration of whether the data and analyses were of appropriate quality and relevance 
to support the research objectives, whilst taking into account the feedback from (a) & (b). 
The expert panel would then propose changes in design and guidelines for subsequent 
surveys, disseminating the reasons for changes and responses to the feedback received, 
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along with the baseline survey results and commentary, to North West pharmacists and 
aseptic managers. 
This process was an additional means of (qualitative) validation, as it gave the first 
opportunity within the research for individual Trusts to benchmark themselves against 
each other, and the opportunity was both implicitly and explicitly open for them to review 
and revise their data if they thought, having made comparisons, that they had submitted 
(significantly) incorrect data. 
One important part of the evaluation was to ensure that references to product types were 
consistent throughout the research, to avoid confusion and misunderstanding. Lists of 
product types were quoted by the Regional working party (NHS Executive North West, 
1997) the baseline survey and the work-study exercise (see Section 3.10). It was not 
essential for the lists to be identical, because they had different purposes, but it was 
essential that the relationships between the lists were clear and understood. The 
straightforward method was to map the lists with one another and (qualitatively) scrutinise 
it for inconsistencies. 
3.5 Quarterly Surveys 
With the expert panel having agreed the survey design and guidelines for future data 
collection, it was necessary to determine the approach to evaluating the impact of the 
C&CP. The baseline data described the pre-programme situation, so data was required to 
describe the post-programme situation - the differences informing the (quantitative and 
qualitative) evaluation. Therefore it was necessary to determine: when and how such data 
should be collected; ensure that the data was consistent over the period, so that 
comparisons were legitimate; and that the data could be used to describe trends in 
activity. 
The methodological arguments for collecting the data were exactly the same as for the 
baseline survey, and therefore the conclusions as to the approach were the same. This 
was reinforced by the fact that the pharmacists expected a survey approach, its having 
been adopted for the baseline data (and original survey (Gandy et al, 1998a)). 
An important question was for what period(s) should data be collected to effect 
comparisons (bearing in mind that Trusts and partner organisations would wish to see the 
results as soon as possible)? It was envisaged that all capital schemes would complete 
within 15 months of the programme starting. 
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The main options were to take a full year that began after the end of the programme, 
thereby having clear pre and post programme sets of data, or to take a series of monthly, 
quarterly or 6-monthly surveys that ran from the start of the programme through to, and 
beyond its completion. (The first period within the latter option would start immediately 
after the end of the baseline financial year). 
To wait a whole year after the last scheme's completion before collecting data, would 
mean the results not being available until 15-18 months after the programme finished, 
allowing for data collection and analysis, which would likely be unacceptable to Trust 
managers and pharmacists. It would not lend itself to trend analyses, as there would only 
be two sets of data. 
Six-monthly surveys would not neatly cover a 15-month period, and 15 monthly surveys 
would triple the amount of data collection and validation, for limited advantage over five 
quarterly surveys. Five quarterly surveys would allow pre and post programme 
comparisons and trend analyses. The efficacy of the latter would present further means of 
validating the value and robustness of the data and any associated measures. Therefore 
the expert panel endorsed the collection of five quarters' data beginning immediately after 
the end of the baseline year. 
It was expected that units with capital schemes would have data for whole quarters before 
and after their start and completion. Where this was not the case (because a scheme 
completed in the last quarter) it would be reasonable to ask for projections of being fully 
operational, post-scheme, and make appropriate allowance with the data. (NB Resource 
constraints relating to the commission meant that it was not possible to go beyond five 
quarters). 
Given baseline data was for a full year, some appropriate adjustment would be required to 
provide equitable comparisons with quarterly data. The simplest method was to divide the 
annual figures by four, which is what was done to calculate a "baseline quarterly 
equivalent". 
To encourage and enable reliable data collection by aseptic managers the quarterly 
surveys were designed to be user-friendly. Suitably designed computer disks were 
suggested to enable pharmacists to enter data routinely daily/weekly/monthly with totals 
automatically generated. This would give the potential for data to be emailed directly for 
transfer to the database. The most practical software to use was Excel, as it was sufficient 
to deal with requirements, and it was the spreadsheet software which Trust staff were 
most familiar with. The expert panel supported the proposal. 
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As with the baseline survey, the quarterly survey design and guidelines were 
(qualitatively) tested prior to issue to ensure they worked. The most practical option was 
for the draft data entry software to be piloted with the three Chief Pharmacists on the 
expert panel, as they readily volunteered. 
3.6 Quarterly Surveys Evaluation 
As for the baseline survey, the efficacy of the revised quarterly survey design and 
guidelines required (qualitative) evaluation, including the electronic means of data 
submission. The basic methodological principles were the same as for the baseline 
survey. Therefore great use was made of the established communication channels with 
pharmacists and managers. 
In addition a (qualitative) evaluation of whether the quarterly surveys' data was consistent 
and comparable with the baseline survey was required. This was essential for measuring 
changes from the baseline, trend analyses and the impact of the C&CP. Appropriate 
allowance would need to be made where data had been removed following the evaluation 
of the baseline survey. 
The expert panel determined that the best means of pursuing such evaluations was to 
undertake the analyses and then (qualitatively and quantitatively) scrutinise them for 
consistency over time, with any (significant) activity changes being matched against 
known plans/circumstances. Any perceived problems and issues were checked with the 
unit concerned, with either the local pharmacist's explanation recorded or correction to the 
data. The researcher gave preliminary scrutiny, followed by the expert panel. 
Disseminating the results throughout the North West pharmaceutical and managerial 
networks further supported such validation (by offering the opportunity to provide 
feedback). 
3.7 Data Available in Clinical Areas 
Given the clinical governance objective to move the balance of aseptic preparation away 
from clinical areas to pharmaceutical aseptic units, can data be collected about aseptic 
preparation in clinical areas, which is of sufficient quality and robustness, for the purposes 
of the research? Pharmaceutical information systems show stock allocation, but do not 
record how stock is assembled and administered to patients (see Section 3.2). 
Consequently data on aseptic preparation within pharmacies and clinical areas is not 
strictly comparable. This is clearly important when considering activity volumes that may 
move from clinical areas to pharmacies. 
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The options for researching what data can be collected for clinical areas, and its 
robustness were essentially: a questionnaire survey; structured interviews; unstructured 
interviews; or a combination of these. Each would contain quantitative and qualitative 
aspects, to gain factual data and subjective opinions. The main participants would be 
nurses. 
There are many different types of clinical areas in any one hospital (e. g. adult medical 
wards; adult surgical wards; children's wards; critical care; theatres) that will have different 
usage of aseptic products. This means that the methods would need to ensure 
representative coverage. 
Given the numbers of hospitals across the North West it was recognised that custom and 
practice might vary between different geographical areas, reflecting that different hospitals 
across the country exhibit different local practices (Zavery et al, 2005; Hardy and Mellor, 
2007), together with historical reasons, such as relationships to different medical and 
nursing schools. 
Therefore it was important to attach meaning to the systems and processes involved in a 
given hospital, which cannot really be achieved by questionnaire (alone), and hence some 
form of interpretivism was essential. Structured interviews were clearly preferable to 
unstructured interviews, given that the requirement to glean information on target issues, 
and the latter could not guarantee that they would all be sufficiently and appropriately 
covered. 
It was impossible to have structured interviews with staff in all clinical areas of all the 
hospitals in the North West. This means that the methods would need to ensure 
representative coverage. 
To ensure that the structured interviews had been planned properly, a pilot visit was made 
to one major hospital to test the efficacy of the questions and the programme. 
Data from the interviews needed to be triangulated. As a workshop approach had been 
determined to validate the information systems data audit (see Section 3.2), the expert 
panel decided the same logic applied for the clinical areas data audit. Covering both at the 
same workshop would add value because it set the findings of these complimentary 
exercises alongside one another - one focused on production and the other focused on 
usage 
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3.8 Nomenclature 
As highlighted in Section 1.0, nomenclature is of fundamental importance in healthcare, 
as different professionals interpret different terms in different ways. This has implications 
for measurement, clinical governance, risk management and any comparative studies 
where clear definitions are not predetermined. 
The issue arose at the initial workshop when pharmacists' and nurses' use of words in 
different ways created some confusion. Therefore, to ensure that the collection and 
interpretation of data were as consistent as possible, it was necessary to establish and 
evaluate the differences in use and understanding of nomenclature in systems, processes 
and practice within and between clinical groups. 
The aim was therefore to determine for the purposes of the research covered by this 
thesis: 
" Agreed definitions for key terms that could be applied consistently in the research, 
so as to ensure robustness of interpretation and data quality; and 
" The full range of (alternative) words that can be applied for particular terms so as 
to appreciate the risk of the variable use of nomenclature in clinical areas. 
The nature of the issue required an interpretive approach, as the personal views and 
experience of professionals were involved. The method options were essentially: a 
questionnaire survey; structured interviews; unstructured interviews. These were the 
same as those for investigating the data available in clinical areas (see Section 3.7). 
Similarly, the issue of different types of clinical areas utilising aseptic products was 
important, as nomenclature might vary between them. Including nomenclature as part of 
the structured interview visits dealing with the data available in clinical areas, made sense 
in terms of time and resources. 
The next question was what structure should be applied? Time was a constraint for both 
interviewers and staff, and to simply ask staff what words they used, without any prior 
preparation, would involve much time and not guarantee the outcome. Therefore to 
address (1) above, the expert panel considered it best to prepare draft definitions of key 
terms for local staff to (qualitatively) scrutinise and either endorse or suggest 
amendments/improvements. The expert panel would then receive responses and 
qualitatively evaluate them with a view to a "final decision". To ask local staff to propose 
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their own definitions was considered wasteful of time and effort, as there would be 
inevitable variations, which would then in turn have to be evaluated and reconciled. 
To address (2) above, the panel applied a broadly similar approach for the same reasons. 
It determined a list of key terms and phrases, and then set out the most commonly used 
(alternative) words, so as to prompt responses from staff. Staff were asked to confirm 
whether they had heard of all the words on the list, to ensure that none were 
inappropriate. They were also invited to add new words to the list. In this way the goal of 
establishing a complete list of alternative words for each listed term should be achieved. 
The number of alternative words identified would provide some representation of the 
relative risk that different nomenclature could be used in clinical areas. However, it would 
be impossible to establish the frequency with which the termstwords were used in local 
everyday conversations without recording them and then analysing them, which would not 
have been acceptable. 
The process of interviewing followed that described for Data Audit in Clinical Areas (see 
Section 3.7). Details of the lists sent to Trusts as part of the planned agenda are provided 
in Section 11.19. 
3.9 Collaboration 
For collaboration, the literature review represented the first key stage, highlighting the 
different approaches to defining and measuring "collaboration" in a range of fields (see 
Section 2.5). The expert panel qualitatively considered these and debated their merits. 
None was a good fit for the aseptic dispensing situation. This meant that either 
established techniques, ostensibly unrelated to collaboration were somehow suitably 
translated for the purpose, or measures had to be developed from scratch. The former 
had to be exhausted first because the latter would be a last resort. 
The researcher had developed a graphical methodology for illustrating the inter- 
relationship between Health Districts (Gandy, 1979) which had been further developed in 
Italy as the Nomogramma Di Gandy (Franci and Belbusti, 1979; Zanetti and Montaguti, 
1983; Pavarin, 2001; See Section 11.5 for further references). Therefore the logistics 
underpinning it were understood and there was potential for it to be translated to the 
aseptic dispensing situation. 
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This could not be accepted at face value and therefore a brief was provided to the expert 
panel describing the background and what was involved, and how it might translate to 
aseptic dispensing, so that it could qualitatively consider whether it was worth taking 
things further. Such scrutiny was essential for any proposed method, to minimise any 
abortive quantitative work applying data to a model. 
Scrutiny included a check as to whether the identified research data (see Section 3.5) 
included data necessary for the model, and whether their application made sense in the 
aseptic context. Any model could not go further unless both applied. If necessary, a check 
could include whether some adaptation to a model might enhance the applicability for 
aseptic dispensing. 
Should a model pass this first check then it was necessary to further confirm its validity 
using data on a prototype basis. This quantitative application would need to qualitatively 
demonstrate patterns that could be usefully interpreted and give insight within the aseptic 
dispensing context, i. e. pharmacists and managers could see how they would inform their 
work and plans. The options (at the time) were to use actual baseline data or "dummy" 
data. The former was chosen as it was clearly preferable, and the timing coincided with 
the availability of the baseline survey data. Therefore its qualitative evaluation would 
include how well it sat alongside the baseline survey analyses. 
If a model passed the main evaluation, it would be necessary to validate whether it could 
be used to demonstrate trends over time. Such an evaluation would be made by 
qualitatively judging whether or not the model showed meaningful time patterns. This in 
turn required data to be available over time. Consequently relevant analyses could only be 
undertaken on completion of the quarterly analyses. 
The evaluation of any model was essentially twofold: first it had to be endorsed by the 
expert panel, and then it had to be accepted by the pharmaceutical community. This was 
not something to be done separately from the main dissemination routes prepared for the 
evaluation of the baseline and quarterly surveys, as the model needed to be considered 
alongside the survey results. Therefore its evaluation process was integral to those 
described in Sections 3.4 and 3.6. 
An experimental, iterative process was added to test if the use of a model could be 
expanded beyond what was initially envisaged, with similar evaluatory principles applied 
to those outlined above. 
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3.10 Work Study 
An important research objectives was to establish how to weight aseptic production 
activity to inform capacity planning and performance measurement. The means of 
applying weighting was debated at the initial workshop, with a qualitative analysis of the 
two main established approaches from industry, viz. UTEs and SMVs. (See Section 3.1). 
The clear consensus was for UTEs (see Section 6.1). 
The consequent research question was how to set values for the UTEs? There were two 
basic options: direct, empirical observation; and, estimates using professional advice. The 
former involved explicit quantitative methods, whilst the latter involved a qualitative 
approach to quantitative matters. The expert panel chose empirical observation because 
this should be more robust a method than relying on professional advice, and the results 
were likely to be more acceptable to pharmacists and managers alike. 
An advantage was that direct observation might yield pointers to efficiency improvements 
in the processes involved, which could in turn influence UTE values. In principle, it would 
be inappropriate to use weightings based solely on current practice, because they may 
include inefficiencies. Therefore empirical observation offered the possibility of both 
current UTE values and improved UTE values. 
To undertake empirical observation there were again options: the local Trust pharmacists 
themselves; pharmacists observing in aseptic units other than their own; and, an 
independent observer such as a work-study professional. 
The expert panel rejected the first option because pharmacists did not necessarily have 
the time and full range of skills required, and it would not be independent; the second was 
rejected by the expert panel because pharmacists did necessarily not have the time and 
full range of skills required. This left the third option, and so a work-study professional was 
commissioned, who thereby had the requisite skills and was independent. This implicitly 
involves direct observation, which required visits to aseptic units in hospitals. 
As with earlier components of the research, it would be impractical to visit all aseptic units 
in the North West. Therefore a sufficiently representative sample of units was agreed. 
To ensure research objectives were achieved, a specification for the work-study 
commission was drafted and then validated through a pilot visit to a main aseptic unit, 
where its completeness and practicality were examined. The key components of the 
specification are set out below (See Section 11.27 for full details): 
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A Projected 30 days consultancy, including writing up report; 
B The five common elements to the aseptic preparation of medicines in a 
pharmaceutical unit. Those to be covered, were: 
1 Assembly of components and documentation; 
2 Transfer into a controlled work zone; 
3 Manipulation and aseptic preparation of the products; 
4 Checking and labelling; and 
5 Product approval. 
(Checks were required to be made between each stage). 
C The variables to be taken into account, given their influence on processes and 
procedures were: 
" Whether there are Automated or Manual processes involved; 
" Whether there is Individual Prescription or Batch Processes, and 
where the latter applies, the Size of the Batches (e. g. 1- 100); 
" The Type of Preparation involved - the following to be targeted: 
Minibag Plus 
Minibag/Infusion 
Prefilled Syringes 
PCA Devices 
TPN 
(Eyedrops, Radiopharmacy and other products are excluded); 
" Shelf Life : this links with whether a Licence is involved; 
" Facilities 
D How the "Start" and "End" of any process was defined locally. 
E Each of the identified Trusts were to be visited, with a series of observations of the 
processes involved with the aseptic preparation of medicines that will cover all of 
the variables and types of preparation indicated above. There would need to be 
sufficient repeat observations to ensure the validity of the results. The following 
were to be incorporated: 
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" Definition of the processes undertaken and each of their constituent components; 
" Comparisons of the written processes/work programmes with those actually 
performed. Any variances should be noted and, where appropriate, quantified; 
" The duration of each of the constituent components should be measured and 
recorded; 
" As checks were required to be made between each of the key stages in the 
process, it will be necessary to quantify the associated delays/waiting times; 
" Classification of the processes in such a way that will enable analysis of the data 
to achieve the objectives of the research; 
" Classification of appropriate characteristics of staff involved in the processes; 
" The collection of basic information on the facilities and workload of the 
participating Trusts (see Questionnaire in Section 11.27.8). 
As with any commissioned piece of work it was necessary to monitor and manage the 
exercise, to ensure that it was on course. The researcher undertook this. 
Given the links to other aspects of the research, i. e. capacity and workload measurement, 
it was important to ensure that the (interim) findings of the work-study consultancy 
commission were consistent with what was required by them, as a qualitative validation 
that the commission had been specified correctly and would support the overall research 
aim. Given the plans for a workshop on Capacity and Workload (see Section 3.12) the 
expert panel decided that it made sense for the work-study professional to attend the 
workshop to present findings and contribute. 
In the event, the work-study exercise ran into significant practical problems, making it 
impossible to continue through to planned completion. A qualitative evaluation was 
required, and so a report was produced by the work-study professional for the 
consideration of the expert panel, which included available results, lessons learned and 
recommendations (see Section 11.28). 
Therefore the expert panel had to revise its methodological approach. It decided to apply 
the alternative approach initially rejected, viz. develop estimates using professional advice 
(see Section 3.11). 
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3.11 Unit Time Equivalents 
The previous section describes how the chosen methodology to determine LITE values 
was direct, empirical observation. Its failure to achieve objectives left the second of the 
two original options to be pursued, viz. estimates using professional advice. 
Seeking professional advice can be done in a number of ways: 
1. Face-to-face, qualitative interviews with all pharmacists (which would need to be 
structured rather than unstructured to achieve the tightly defined objectives); 
2. Circulate a questionnaire to all Trusts/units asking them to indicate the times taken to 
prepare different types of products. Analyses showing the mean values and 
distribution of the received data are then disseminated giving the opportunity for 
Trusts/units to confirm or revise their advice. The mean values from the final data form 
the basis of the UTEs. This approach would be qualitative, but could also include 
quantitative elements if pharmacists chose to actually time the production process; 
3. Use a group of (expert) pharmacists to make preliminary estimates for each type of 
product, and then circulate them (as a survey questionnaire) to aseptic managers for 
comment and (qualitative) endorsement, with the opportunity to suggest alternative 
UTE values where the preliminary estimates were considered to be wrong, or different 
to local times. 
(2) and (3) are iterative processes that test the consistency of expert advice. They 
embrace multiple perspectives and Delphi approaches (Linstone and Turoff, 1975; 
Linstone, 1984; Surowiecki, 2004) which can seek expert opinion, analyse it and feed the 
results back to the experts, with the opportunity for them to revise their original advice if 
they so wish, in light of the results. The revised data is then analysed to provide the final 
results. Approach (2) is closest to this, with (3) being a pragmatic adaptation. 
The expert panel qualitatively evaluated these options, determining that (1) was too 
impractical, given the number of units. The main difference between (2) and (3) was that 
the latter would use a specific group of pharmacists with acknowledged skills and 
experience as the "expert group", whereas the former used the whole pharmaceutical 
community itself as the "expert group". 
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The expert panel chose (3) ahead of (2), because it was more practical, and was likely to 
get a quicker and faster response; it is easier to consider a value and judge whether it is 
reasonable and applicable locally, compared with having to make local observations and 
estimates from scratch. The pharmacists on the expert panel also considered that it would 
curtail potentially extreme estimates being submitted. 
For the purposes of validation and ownership it would be necessary to take the analysed 
results and share them with senior pharmacists and aseptic managers across the North 
West (after the consideration and approval of the expert panel). This could be done by 
circulating the analytical report and then making a presentation for validation, via 
discussion, debate and comment. This was the methodology pursued with a view to 
establishing a single UTE value for each product type 
In the event, the North West pharmacists highlighted that there should not be one set of 
UTE values but two: one for licensed and one for unlicensed. This was accepted by the 
expert panel, which meant that a means of determining them was required. 
The view of the expert panel was that it would be unacceptable to repeat the whole 
process undertaken to determine the first UTE values (which would have been the ideal 
option). Time was a constraint and it considered that North West pharmacists were 
unlikely to be receptive to such an approach. The main alternative was to take the data 
and analyses from the survey and have them reviewed by the original "expert group" to 
(qualitatively) assign licensed and unlicensed values that were appropriately consistent 
with the data and analyses, and appropriately in balance with one another. The available 
data included responses from both licensed and unlicensed units and it was desirable to 
highlight any patterns that were relevant. Regression analyses were the clear option given 
the need to interpolate set/mean values, and upper and lower limits from a set of data. 
For the purposes of validation and ownership it would be necessary to again share the 
new LITE values with the North West pharmacists (after the consideration and approval of 
the expert panel). 
3.12 Concepts: Capacity and Workload 
It was necessary to determine how UTEs should relate to the concepts of "Capacity" and 
"Workload". 
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The literature search gave no immediately obvious, clear, specific definitions that could be 
applied. This meant that definitions within the context of the research were required. A 
qualitative methodology needed to be applied. The options were effectively the same as 
the four considered before the initial workshop (see Section 3.1) and the expert panel 
made the same choice for the same reasons: Draw together key players (in a workshop) 
to debate requirements, evaluate literature, identify and evaluate options, and make 
recommendations. 
The advantages were the same: it ensures ownership by involving key players; it enables 
interactions between them, which allows consensual recommendations to be made; it 
makes best use of time both in terms of the event itself, and it is speedy to arrange and 
complete. 
In addition, a workshop approach best allowed for the inclusion of an evaluation of the 
lessons from the work-study exercise and the results of the baseline survey. 
The expert panel agreed that the attendance at the workshop needed to be different from 
that at the first two workshops, because it focused very much on pharmacy issues. It 
would be important to aim for a full range of types of pharmacies to be represented, to 
triangulate the results. The only nurse to be invited was from the expert panel, which was 
for continuity purposes and to be able to identify where nurse-related issues might need to 
be highlighted. 
There was a need to draw out what "Capacity" and "Workload" might involve, and what 
the associated issues might be. As with the initial workshop, Affinity Analysis (Brassard, 
1996) was chosen (See Section 3.1), and for the same reasons, i. e. it is a robust, 
qualitative research and development method that can yield significant findings. Another 
reason for such an exercise was to ensure that the workshop did not start with 
preconceived ideas and views. This was a genuine danger given that the pharmacists 
invited had expertise and interest in the subjects considered, and they could therefore 
have strong views influenced by local experience. 
The expert panel decided not to validate the Affinity Analysis process for full participation 
from attendees, as in the initial workshop, because the number attending was smaller and 
focused on people who had a genuine interest. 
It was not possible to predict all options, points and issues that might arise about the 
concepts being discussed, but they would need to be fully explored and evaluated. 
Therefore it was planned that the workshop would use syndicate groups to develop ideas 
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and proposals, which were identified following collective discussion on the Affinity 
Analysis and any other preliminary presentations. The syndicate groups would work 
independently of one another, with discussion being unstructured (rather than structured) 
given the aforementioned uncertainty. Their feedback to the whole workshop would be 
qualitatively evaluated against each other, with overall conclusions and recommendations 
being derived. Such triangulation should ensure the validity of the outputs. 
A key objective was to validate whether the data identified for the baseline survey was 
sufficient to deal with "Capacity" and "Workload". This was one of the issues included in 
the discussions and the evaluation of the syndicate groups' findings. 
A validation of the efficacy of the workshop was required to assure its findings, and as for 
the first two workshops a structured out-turn questionnaire was agreed. 
In turn, the recommendations arising from the workshop needed to be validated. The 
expert panel would do this first, but sharing them with relevant staff from across the 
country would provide triangulation of the subjects and data. 
3.13 Statistical Indicators 
Given that no specific, singular definitions could be determined for "Capacity" and 
"Workload" (See Section 3.12), it was not possible to develop a single all-encompassing 
statistical indicator to describe each of them. The only alternative is to develop a range of 
statistical measures, which can inform pharmacists about key aspects of aseptic 
dispensing production, from which they can infer (relative) performance to inform (local) 
capacity planning. 
Such statistical indicators could only use the identified data. (The possibility of extending 
the range of collected data could not be ignored if during the process it became clear that 
a valid and valuable indicator could be created with additional data, and that data was 
agreed to be both robust and readily collectable; however, this would be treated as an 
exception). Any measures must be meaningful to pharmacists and managers, both 
conceptually and in their application i. e. by applying actual data across all aseptic units 
and Trusts. 
In circumstances where there is little or limited knowledge an iterative approach is 
required: qualitative views sought from relevant stakeholders; analyses undertaken of 
responses; with results fed back for validation; the views then revised if necessary, and 
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the cycle repeated until there is a consensus. No real alternatives are available to such a 
Delphi methodology (Linstone and Turoff (1975), Linstone (1984) Surowiecki (2004)). 
The qualitative options were to use the expert panel and/or the North West pharmacist 
community for triangulation. The approach could be to develop the statistical measures 
conceptually first and then apply data to the finally agreed measures, or to apply the 
available data to the statistical measures at each stage of their development, thereby 
enabling the stakeholders to see the associated results. The expert panel decided that the 
researcher should develop (draft) statistical measures, apply the data to them, and 
present the results to them as the initial stakeholder group. This was consistent with the 
researcher's skills and expertise and the expert panel's role. 
Once the expert panel was satisfied that the statistical measures were valid and usable, 
they would be disseminated to the North West pharmacist community for triangulation. 
The expert panel would receive any responses and further validate the statistical 
measures in their light, repeating the process as necessary to achieve the objective. 
As part of the validation process, established quantitative techniques such as sensitivity 
analyses would be applied to test the robustness of the statistical measures against 
variations in data and/or assumptions. 
3.14 Modelling 
Despite the conclusion that it is not possible to define a specific 'capacity' value, because 
aseptic units are very different from one another, and that a benchmarking approach be 
adopted so that pharmacists and managers can interpret and justify the scope for 
effecting local improvements (see Section 5.12), there will continue to be the desire to 
optimise levels of activity within given resources, with the most cost-effective solutions 
being sought. 
There might be variations in how this is applied: one Trust might seek to maintain (or even 
reduce) preparation and rationalise resources, whilst another might wish to switch as 
much aseptic preparation as it can afford, away from clinical areas into pharmacies. Yet 
the principle of cost-effectiveness (without compromising standards and safety) will 
remain. Therefore there will always be an interest in the scope to achieve this goal using 
sophisticated computer/statistical models. This makes it important to evaluate the 
potential for such modelling techniques to be applied within NHS aseptic units. 
There are essentially two main opportunities: 
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(a) To acquire relevant software models used in industrial environments for capacity 
planning, and evaluate their applicability for NHS aseptic dispensing units. 
(b) To evaluate the potential utilisation of proven capacity modelling techniques in the 
environment of NHS aseptic dispensing units. 
The software models in (a) usually relate to manufacturing resources planning (MRP2) 
(See Section 2.8), or similar systems. The main qualitative methods available for 
evaluation are: 
i. Obtain a copy of such software and try and introduce it to a NHS aseptic 
dispensing unit; and 
ii. Interview a senior pharmacist who has tried to introduce such software into a NHS 
aseptic dispensing unit, to establish the degree of success and any problems. 
In either approach there would need to be qualitative validation as to the general 
applicability of the findings. 
There are clear differences between the options in terms of time, effort and cost. Option (i) 
would first require a process to determine which of the available software models was 
"best" (however that might be measured). It would then require one or more chief 
pharmacists to agree to try and apply such software to their unit(s). Evaluation criteria and 
processes would need to be initiated, with the attempt to apply the software undertaken 
and findings recorded. The evaluation itself could then take place. The costs that would be 
involved would be considerable in terms of (senior) staff time, and the software itself 
would have to be bought. The total amount of time involved can be projected as at least 
six months. By comparison, Option (ii) involves minimal cost and could be undertaken 
quickly, if a suitable senior pharmacist is available. 
The expert panel chose (ii) because the arguments for it were overwhelming, and one of 
the chief pharmacists on the panel had actually attempted to apply MRP2 software to his 
unit, and was happy to be interviewed. In addition, there was concern that it would be 
difficult to recruit chief pharmacists to participate unless there were real incentives, and 
they would have to be persuaded that introducing the software had clear benefits. This 
presents something of a dilemma because it would not be possible to demonstrate clear 
benefits until after the software was introduced. The (financial and time) costs/risks 
associated with Option (i) were deemed unacceptable by the expert panel. 
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Question (b) required a different approach. Capacity modelling techniques had been 
successfully applied to other NHS services that might superficially be seen as similar to 
pharmacies, e. g. theatre & sterile supplies, radiological equipment (Gandy et al, 2006). 
Therefore it was necessary to first qualitatively examine whether the characteristics of, 
and processes associated with the aseptic dispensing were consistent with what was 
required to apply the techniques. 
Such an examination required "experts" in the related fields to qualitatively compare their 
knowledge in order to determine the degree to which the requirements for capacity 
modelling are fulfilled within aseptic dispensing environment. This is best done by a face- 
to-face interview, so as to enable questions to be immediately answered, and for issues to 
be discussed in depth. This "expert panel" approach (see Section 3.0.4) would establish 
the main points and issues, which would then require a critical review of published work, 
to confirm and expand upon them, with a view to determining a fully informed analysis. 
The research question, using the literature review and analyses, would then be further 
considered by the expert panel both for validation purposes, and to agree any findings. 
3.15 Acute Capacity Planning 
The focus of the research is to determine how the production and usage of aseptic 
products can be measured, in order to infer performance and inform capacity planning. 
Yet pharmacists and aseptic managers face capacity planning at two levels (Lillywhite, 
2000): 
" Medium to Long-term (6/12+ months); and 
" Acute (daily/weekly) 
The work-study professional highlighted the problems of acute capacity planning (see 
Section 11.28): the ongoing aseptic production cycles/patterns over a week need to be 
balanced with day-to-day demands on staff that can be predicted (e. g. training) or ad hoc 
(e. g. sickness). Hospitals often prepare week-end requirements in advance, for when 
aseptic dispensing units are closed. 
It is clear that the prime focus of the research relates to medium to long-term capacity 
planning. Nevertheless, it is necessary to determine how far the research can and cannot 
relate to acute capacity planning, to establish boundaries to the research and ensure 
clarity. Specific features of acute capacity planning include: 
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" Indirect activities such as ordering, stock control, and product testing, as well as 
direct production (ibid) i. e. tasks outside the measures identified by the research; 
"A need for standard preparation time values and staffing times to be determined 
locally for each unit (Beaney, 2006); 
" Local facilities design, given the lack of consistency (See Section 5.12) 
To attempt to encompass all such issues, utilising methodologies similar to those already 
applied, would involve significant additional research, because of the need to acquire 
considerable amounts of detailed data from each hospital that might participate: collecting 
daily data would be far more demanding than collecting annual or quarterly data, and 
collecting local standard time values for each stage of the overall aseptic process for each 
product type would require much greater effort than determining licensed and unlicensed 
UTEs (see Section 3.11). The amount of effort involved was anticipated by Syndicate 
Group B at the Capacity workshop (see Section 5.12) and rejected as not being practical, 
and because pharmacists would not be prepared to provide such amounts of data. Also, 
there would need to be a large number of participants to allow for variations in local 
circumstances, which would again add to the amount of effort. 
In the circumstances a literature review was undertaken to ascertain what might have 
been published. The main relevant initiative was the development of the capacity planning 
tool for chemotherapy that had been prompted by the NHS Modernisation Agency (2005) 
to enable the expansion of chemotherapy services, and was consulted on in early 2005 
(ibid). It used a published capacity planning model for chemotherapy (Shield, 2004), which 
applied standard times for each preparation step. The researcher critically reviewed the 
proposals and submitted a response as part of the consultation (See Section 11.45.2). 
The next stage of the national process was to commission the creation of a simulation tool 
to enable Trusts and Cancer Networks to plan what resources are required within their 
local chemotherapy and oncology networks. A. T. Kearney Management Consultancy 
developed the tool, entitled "C-Port" (Concentra, 2006), which was being rolled-out across 
the country when this research was concluding. 
Therefore it was necessary to establish whether C-Port could offer insights for the 
research. However, as chemotherapy represents a single and quite distinct strand of 
aseptic dispensing, with the cytotoxics cabinets generally dealing with all and only such 
products (See Section 5.17), there would need to be checks whether such a model might 
be transferable to general aseptic dispensing. The main option for doing this was to obtain 
the details of C-Port and to qualitatively interview key personnel at national and local level 
to get both perspectives. 
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Capacity planning is a requirement for aseptic dispensing units (Beaney, 2006) although 
there is no prescribed way of doing it. It was understood from contacts within the 
pharmaceutical community that individual aseptic dispensing units were developing local 
approaches to modelling acute capacity planning. Therefore direct contact was made with 
two that were known to have their own "in-house" methods, which were quite different 
from one another, and arguably represented different ends of the spectrum, so as to 
ensure reasonable balance. 
Whilst it may have been possible to consider other methods to establish local approaches 
to (modelling) acute capacity planning, such as a qualitative questionnaire survey, this 
would have involved considerable time and effort, which was not feasible at that stage of 
the research. Equally, it would be unreasonable to make such investment in an area that 
was not central to the research. Pharmacist advice was that a critical review of the two 
units' approaches should be sufficiently representative of the range of approaches 
available. 
A critical review would look to establish key commonalities and differences, determine 
lessons for the future of acute capacity planning, together with how they might relate to 
the research. Appropriate cross-reference would need to be made to the cytotoxics model. 
In order to test the validity of such a review it would first be necessary to ensure that the 
local pharmacists agreed with the analysis and findings. Following this it would be 
desirable to disseminate findings to a broader audience for further validation. The options 
would be to circulate the findings to key pharmacists (preferably their having been 
previously involved in the research, so as to readily appreciate the relevance) and/or to 
prepare a paper for publication. 
3.16 Transferability 
It was important to confirm the general applicability of the research findings in the wider 
NHS. The expert panel saw this point as being once the data requirements, survey 
methods and associated benchmarking analyses had been established (for the North 
West) (NHS Executive North West, 2001). 
Therefore, testing the transferability of the research findings and methods necessarily 
required the replication of the survey and analyses outside the North West. The degree of 
success would represent the results. 
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There were two options for undertaking a survey outside the North West. Either a whole 
Region (or Regions) is surveyed (i. e. all of the hospitals within the Region are included), 
or a disparate range of hospitals across different Regions is used. 
The problem with the latter option is how would the hospitals be chosen? It would be likely 
that only enthusiastic hospitals would volunteer to be involved, and this would be unlikely 
to be random: they would probably be larger hospitals with ambitious local agendas. It 
could also be difficult to recruit hospitals, given the associated logistics and the 
commitment that would be involved (see Section 6.16). 
By comparison, surveying another Region - if fully participating - would have the 
advantage of all sizes of units and varying interests, i. e. it would be arguably random 
within itself. Therefore it was concluded that the best methodology was to apply the 
research methods to another Region in the country. 
The opportunity to actually test the transferability of the research methods arose from an 
approach made to the researcher by chief pharmacists in the West Midlands Region. 
They specifically commissioned him to replicate the research methods locally, on a 
consultancy basis, given that they wanted information to enable them to plan services 
across the area. Therefore the expectation on the part of the commissioners was that a 
survey would be involved. (This also represented the most cost-effective approach in 
terms of consultancy time and costs). 
Whilst the successful application of the survey to the West Midlands would demonstrate 
transferability and general applicability, it also offered the potential to make comparisons 
between local results and those for the North West. This would indicate the value of the 
methods for making inter-Regional comparisons (or any comparisons between different 
groups of hospitals). The chief pharmacists in the West Midlands were keen to see such 
comparisons, so that their own results were not seen in isolation. The North West expert 
panel readily agreed to its data being used for such purposes. 
However, making inter-Regional comparisons raised the question of how to appropriately 
allow for the respective sizes of the Regions. The North West research and analyses had 
not had to deal with this. Therefore, it was necessary to identify suitable currencies for 
which data was available, and then make comparisons using them. A critical evaluation of 
the comparisons would then follow. 
The key question was what proportion of aseptic preparation was undertaken in 
pharmacies compared with clinical areas. The North West research had confirmed the 
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difficulty of collecting such data, and therefore it had not been collected for the West 
Midlands. This meant that the only option was to try and determine an appropriate proxy 
measure for comparative purposes. Taking available data, exploring the potential options 
for developing such proxy measures, and then evaluating them to see which has the most 
and sufficient value to meet requirements, would do this. 
3.17 Evaluation of Programme 
An objective of the research was to measure the impact of the C&CP when completed. 
This would serve two purposes: 
" To quantify the change in the production and usage of aseptic products prepared in 
pharmacies, across the North West; and 
9 To (qualitatively) validate the efficacy of the measures and methods developed by the 
research. 
The (significant) delays in some capital schemes had prevented a full evaluation, because 
this was not possible until the last scheme completed. 
The methodology was in effect predetermined by the earlier methodological decisions: a 
repeat of the (quantitative) survey design would be expected by the North West 
pharmaceutical and managerial constituency. Data needed to be collected for the most 
recent full year, post-programme activity (i. e. 2003/04). The baseline survey data already 
provided the pre-programme activity and performance levels. 
It was ascertained that since the last of the quarterly surveys, North West pharmacists 
had derived a single sheet survey format from the two survey forms determined by the 
research, and successfully used them to collect (local) ad hoc data. (The same guidance 
had applied). Qualitative pharmacist advice was that this single sheet format was likely to 
be better received for the survey. Therefore, before proceeding further, it was necessary 
for the researcher to validate that the revised format provided all of the data required to 
calculate all of the analyses and statistical indicators identified by the research. This 
required a qualitative and quantitative comparison of the two sets of survey forms. 
For similar validation purposes, the analytical methods identified through the research 
would need to be appropriately augmented by the techniques and lessons of the 
subsequent work/research. For example, by comparing the pre and post programme 
situation in the North West, rather than two different Regions (see Section 3.16). This 
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would be necessary to gauge the shift of aseptic preparation from clinical areas to 
pharmacies, and allow for changes in pharmacies, hospitals and organisations during the 
intervening period. 
Applying the methods to different years also offered the opportunity to quantitatively 
evaluate their robustness over time, and for demonstrating change per se, which would be 
an essential criterion to meet. 
The reorganisation of the North West Region into three separate and distinct Strategic 
Health Authorities (SHAs) during the period meant that an emphasis needed to be placed 
on how the methods could show quantitative and qualitative differences between different 
areas in terms of how local activity and performance had changed. This would go further 
than what had been achieved with the West Midlands exercise. 
The above could only be addressed by producing many different comparisons over time 
for the many activity data and performance measures broken down for each of the key 
characteristics: size of hospital; size of aseptic unit; geography; whether an aseptic unit 
was licensed or not; etc., and then qualitatively interpreting the value and/or significance 
of the results. 
The only data that would not be updated by the post programme survey concerned the 
UTE values. Therefore it was necessary to determine whether those used in the past were 
valid to apply to the most recent data. The two qualitative options for doing this were to 
repeat the original method or seek the views of senior pharmacists (mainly those who had 
been on the expert panel) as to whether they were still valid. The latter was right to pursue 
in the first instance, because if the professional advice was that the UTE values were still 
valid, i. e. there had been no changes, then the former was not required. This proved to be 
the case. (It was questionable whether the former would have been feasible within the 
timeframe). 
The original expert panel no longer existed, as such. Therefore the North West senior 
group of chief pharmacists filled this role, with the Regional Quality Controller acting as 
the main communications link and advisor to the researcher. The fact that this was not a 
multidisciplinary group did not present any problems because all of the focus of this stage 
of the research was on pharmacy matters. 
Specifically for those units that had received capital funds, it was necessary to 
quantitatively compare the changes in activity and performance with what had been 
planned in their business cases (Beaumont, 1999), not least for accountability purposes. 
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In the event, several of the units did not reach their targets. Therefore it was necessary to 
qualitatively determine why, and the most straightforward means was to contact them 
directly to ask the question through a telephone interview. To qualitatively validate the 
accuracy of the interviews, they were followed up by written confirmation of the stated 
reasons and circumstances, which were then agreed as correct. 
It followed that there was spare capacity in these units, and therefore it was desirable to 
quantitatively establish the potential impact of what would happen if all such spare 
capacity were utilised. This was so that pharmacists and managers could appreciate how 
much further they could go in shifting aseptic preparation away from clinical areas, using 
the capacity of existing aseptic facilities. 
The results from the repeat survey, including the changes over time, needed to be 
qualitatively validated and owned. The previous method had been to circulate them to all 
pharmacists for information and validation. This was therefore the natural choice, but 
there was an ad hoc opportunity for validation, presenting the results to a North West 
workshop of all pharmacies. 
3.18 New Information Systems 
Section 5.2 identifies that existing pharmacy information systems can provide the 
research data automatically, or at worst with further manual or other processing. Section 
5.7 shows that whilst there is data on stock issued to clinical areas, there is no readily 
available data on the numbers and types of aseptic preparations undertaken there, and 
hence some form of estimation is required (See Section 11.23). In both cases this 
involved the evaluation of contemporary information systems. In light of the significant 
investment in new information systems in the NHS, following the publication of Information 
For Health (NHS Executive, 1998), and the emphasis placed on EPS, the question has to 
be asked whether any new systems might yield new data that could transform the 
situation. 
To confirm the situation for the pharmacy information systems the options were to: repeat 
the survey of the North West (See Section 11.14); (qualitatively) survey a representative 
selection of Trusts; and (qualitatively) survey the systems suppliers. Initial contact was 
made with lead pharmacists for their views on the current situation. They confirmed that 
there was little or no change and therefore a repeat survey would probably be 
inappropriate. They also felt that suppliers were unlikely to respond in the context of the 
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research. Therefore a survey of representative Trusts was chosen as it was practical and 
did not preclude going back to one of the other options if the results so merited. 
Clearly, if EPS can provide quality data on the numbers and types of aseptic preparations 
undertaken in both pharmacies and clinical areas, then it could be possible to take a 
further step with the research. For example, the balance of aseptic preparation between 
pharmacies and clinical areas might be directly quantifiable, rather than having to rely on 
estimates, and establishing the number of aseptic products consumed by each specialty 
could enable capacity planning to (better) reflect changes in projected patient activity. 
Although the inference made as part of the research was that EPS will not provide such 
data in the foreseeable future (see Section 1.8) it is essential to confirm the latest situation 
in case of recent changes. 
Improvements in hospital systems in the NHS are being taken forward through the 
Connecting For Health initiative (CFH, 2007c). This involves the country being divided into 
five areas, each served by a Local Service Provider (LSP) commissioned to provide all 
relevant systems for hospitals in its area (CFH, 2007d). The systems commissioned 
include EPS. Therefore the only real option was to approach CFH and make direct 
enquires. 
It was also desirable to gain insights into any developments "on the ground" in hospitals 
where EPS were being used, in case of related local developments. The (qualitative) 
options were to undertake interviews with hospitals that had established experience of 
using EPS, or to send a structured questionnaire. Contact with CFH indicated that the 
number of such hospitals was limited, and the main candidates were the three national 
pilot sites (Burton, Winchester & Wirral). Using questionnaires was ruled out because 
insufficient time was available at the stage of the research. As the initial evaluation of EPS 
in a hospital environment had involved Wirral Hospital NHS Trust (See Section 3.2), a 
structured interview with lead personnel there would have the advantage of establishing 
any specific changes over time. Therefore the latter course of action was decided. 
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Chapter 4 Methods 
4.0 Validation 
4.0.1 Continual Validation 
Throughout the research the efficacy of the methods required validation. This was 
rigorously addressed by a variety of means: 
" The early period of research involved an expert panel, with the report (NHS Executive 
North West, 2001) peer-reviewed; 
" Subsequently the Chair of the original expert panel facilitated the North West Chief 
Pharmacists Group to fulfil this role; 
" Findings at key stages were presented to practising pharmacists across a region, as 
part of dissemination and to validate methods and recommendations; this involved a 
combination of circulating reports and presentations at meetings; 
" Papers were written for publication in peer reviewed journals and conferences. 
The use of experts and the continual engagement with professionals was particularly 
important to ensure the triangulation of many of the qualitative results. These validation 
methods were applied throughout, tailored to circumstances. 
4.0.2 Original Expert Panel 
The expert panel maintained an important qualitative function for the research: agreeing 
the efficacy of next steps (e. g. workshop arrangements, work study specification) and 
evaluating the resultant outcomes. The membership covered those professions with an 
interest and the three North West geographical zones, given how pharmacists organised 
themselves and the associated channels for communications. Any differences in 
circumstances, approach and experience across the North West needed to be highlighted 
immediately. The membership was as follows: 
" Director of Quality Control, North West Region (Chairman); 
" Head of Laboratories & Licensing, Medicines Control Agency. 
" Director/ Senior Pharmacist from each zone (3); 
" Primary Care Pharmaceutical Advisor; 
" Healthcare Information expert (also acting as project manager) (the researcher) 
" Senior Hospital Nurse 
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" Senior Hospital Doctor (Consultant Microbiologist) 
" Academic input from Liverpool Business School, Liverpool John Moores University 
(LJMU) 
Individual contributions were on a professional/advisory basis; the panel was not a 
representative forum. Members were provided with full briefing packs of relevant 
documentation and reports from the outset. 
There was regular communication and dissemination with Trusts and Health Authorities to 
ensure their engagement, and that the process was transparent. Dissemination included 
professional networks (by various panel members). Letters were written to the 
Pharmaceutical Journal and Microbiological publications to inform wider professional 
networks and enable interested partied to contribute should they wish. 
The research was project managed using standard project management techniques, such 
as Gantt charts, milestones (and milestone reports), and reports to the expert panel for 
guidance, advice and agreement on further action. 
The expert panel agreed the key words that should be used in the literature search. The 
researcher, as project manager, undertook the searches. 
4.1 Data to Collect 
A multidisciplinary workshop was arranged to establish the information required for the 
purposes of the research. Its specific aims and objectives were: 
" To review the lessons from the original survey (Gandy et al, 1998a); 
" Identify the information needed; 
" Identify relevant data and currencies; 
" Test these across a range of clinical scenarios; 
" Compare the situations in pharmacy and clinical areas; 
" Comment on how easy it is to collect such data; 
" Develop and agree recommendations; and 
" Ensure good practice in terms of research and development. 
Five members from the expert panel facilitated the workshop, with another five acting as a 
"control" group to objectively consider the findings. 
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The main thrust was qualitative. Therefore, the workshop was carefully structured to 
include appropriate, proven qualitative techniques, augmented by selected information. Its 
structure was: 
" Introduction and Aims & Objectives of Workshop 
" Affinity analysis (Brassard, 1996) to explore relevant information required within 
aseptic/pharmacy context 
" Prioritise requirements and determine provisional recommendations 
" Commercial Sector presentation on data collection and usage 
" Syndicate Groups to test and evaluate the findings from the Affinity analysis 
against predetermined clinical areas 
" Feedback from Syndicate Groups (suitably triangulated) 
" Main Conclusions and Recommendations 
The Affinity analysis used the question: "What information is required by professionals and 
managers in respect of aseptic preparation: how is it used, for what purposes, and what 
are the key issues? " (See Section 11.8) 
The commercial sector representatives presented how they approached relevant issues 
covered by the research, including how UTEs and SMVs relate to capacity. This was 
followed by questions and answers, and a (qualitative) debate about the relative merits of 
these measures for weighting aseptic production in a NHS context. A (qualitative) 
recommendation was then made. (A summary of the private sector presentation, the 
discussion and conclusions is provided in Section 11.10). 
To assure the Affinity analysis a (qualitative) process audit was applied to ensure all 
participants made meaningful contributions and the results were comprehensive and 
representative. Two of the five facilitators acted as process auditors: a Nurse and a 
Pharmacist. They used a structured audit form and specifically did not actively contribute 
to the exercise, as their role was to observe participants. It was essential that participants 
did not realise they were being observed, and therefore the auditors masked their real 
roles. The auditors recorded observations independently of one another, and handed in 
their completed forms at the end of the exercise. 
For the syndicate groups, the expert panel determined what it considered to be a 
sufficiently wide and representative selection of clinical areas from an acute hospital: 
General Medicine; Surgery/Theatres; Specialist Diagnosis Group - Cancer; and Specialist 
Clinical Area - Intensive Care Units (ICUs). The planned syndicate group membership 
dictated the overall attendance. Each had a chief pharmacist, a purchasing pharmacist, an 
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aseptic manager, a nurse and one "other", facilitated by expert panel members. The 
spread of pharmaceutical interests was necessary to ensure a full picture was obtained, 
particularly with regard to available information and data. The "others" enabled (indirectly) 
relevant interests and expertise to be included, such as Health Authority pharmaceutical 
advisors and Trust managers. 
Each syndicate group attached (qualitative) "importance scores" to the issues and items 
from the Affinity analysis for its clinical area. These scores ranged from 1= "No 
importance" to 5= "Very important". The groups determined views independently, so 
collating results informed the consistency of views across clinical areas. 
The syndicate groups then went through a predetermined list of questions, designed to 
establish key information about the clinical process in relation to the aseptic preparation of 
medicines, and how this might relate to information and data (qualitative). The list of 
questions was as follows: 
" What are the processes and key activities in the clinical area? 
" What are the activity categories and methods of counting? 
" How does clinical activity and counts relate to what is issued and counted to the 
clinical area by the pharmacy? 
" What determines production and assembly on wards? 
" What documents record the production and assembly of ward activity? 
" What further processing takes place of such records? 
" What other relevant data sources exist? 
" Consideration of any future developments that may require modifications to the 
above? 
A final question was to assign the same scores to a set list of (the most common) aseptic 
products, in relation to the clinical area (qualitative). These were: minibag plus; 
minibag/infusion; prefilled syringe; PCA devices; and TPN. This was to confirm the 
relevance of each product to each clinical area. Given that current practice may not be 
what is ideally required, the syndicate groups assigned scores for the 'Current' situation 
and the 'Ideal' situation, so as to address any constraints imposed by current 
circumstances and examine potential future dynamics. In the event the Surgery/Theatres 
group adapted this question by distinguishing between the importance of products in 
surgical wards and operating theatres (rather than 'current' and 'ideal'). 
Again, because groups answered questions independently, collating the results informed 
the degree of consistency in practices across clinical areas. 
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Syndicate groups' results were fed to the whole workshop, collated and final 
recommendations developed. 
The workshop was evaluated through Out-turn questioning (qualitative), which is standard 
practice for such events (see Section 11.11). The 26 questions were designed to 
ascertain views in a number of areas: 
" Was adequate information provided ahead of the workshop? (1 question) 
" The purpose of the project (3 questions) 
" The purpose of the workshop (8 questions) 
" Syndicate groups (4 questions) 
" R&D Capacity (5 questions) 
" The contribution of the Commercial Sector (2 questions) 
" Location, accommodation & facilities (3 questions) 
Responses were anonymous, but people were asked to indicate their profession, to 
enable comparisons between the different professionals' perceptions. There was always 
potential that (primarily) pharmacists and nurses would view matters differently from one 
another. 
Questions were kept as simple as possible, as they were answered at the end of a long c 
day. Each person tick an appropriate box against whether (s)he "Strongly Agreed", 
"Agreed", "Disagreed" or "Strongly Disagreed" with the statement/question, with an option 
to record "No View". 
Not all of the questions required "Strongly Agreed" or "Agreed" to be ticked for the 
interpretation to be deemed positive. Three questions (3g, 3h & 4b) were negatively 
structured questions, which would mean that "Strongly Disagreed" or "Disagreed" would 
represent a positive view. Also, two questions (5a & 6b) were neutral. 
The expert panel considered the outcome reports covering the different components of 
the workshop (see Sections 11.12 and 11.13), as a final validation of its outcomes and to 
made specific recommendations for the next stage. 
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4.2 Information Systems Data Audit 
4.2.1 Systems Survey 
A survey was undertaken of aseptic dispensing-related pharmaceutical information 
systems used in all North West Trusts (see Section 11.14). 
The questions were: 
1. Name of pharmaceutical information system 
2. Version of pharmaceutical information system 
3. Year current version acquired 
4. Are there up-to-date versions of the User Guide? 
5. Are there up-to-date versions of the System Documentation? 
6. Is system in place Year 2000 compliant? 
7. If not then will Trust replace ahead of Millennium? 
8. Is Trust pursuing acquisition of new pharmacy information system through 
procurement process? 
9. If "Yes" then in which year will it be in place? 
10. Is Trust actively pursuing electronic prescribing system through procurement 
process? 
11. If "Yes" then in which year will it be in place? 
12. If either 08 or Q 10 is "Yes" then is it part of a comprehensive IM&T procurement 
(for the Trust)? 
13. Hospitals (within Trust) that use pharmaceutical information system. 
The results were analysed and presented to the expert panel (see Section 11.15). 
4.2.2 Availability of Research Data 
They survey results were used to inform the selection of the hospitals/units to be included 
in the data audit exercise. Those chosen were: Aintree (JAC); Bolton (MDIS); Blackpool 
(MDIS); Burnley (Ascribe); Clatterbridge Centre for Oncology (CCO) (JAC); Manchester 
Children's (Ascribe); Mid Cheshire (HORIS); Stockport (Ascribe); and Wirral (JAC). CCO 
and Manchester Children's were included as specialist cancer and children's hospitals. 
A selection was made of the major aseptic products for which research data would be 
required, so as to assess the suitability and provision of data on the quantity by volume 
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produced. These were: minibag plus; minibag/infusion; prefilled syringes; PCA devices; 
and TPN; with scope for units to highlight other products of particular relevance locally. 
The tasks to be completed by the audit were: 
" Confirm system type and version 
" File content and structure 
" Documentation available 
" Assess relevance of data stored to target variables 
" Report generation and cycle times 
" Actual data storage and retrieval 
" Sample data quality and validation 
" Extent of data history 
" Major changes made to system & practice that may affect data history 
" Confirmation of nomenclature 
" Identify/ascertain any routine data quality processes 
The pilot visit was undertaken by the researcher to the Royal Preston Hospital using a 
structured template to explore the capabilities of the local system (MDIS) with regard to 
the target data and products. 
For the desktop work, computer manuals were obtained for the JAC (Aintree) and MDIS 
(Preston) systems and checked for functionality. Discussions and multiple system reports 
were obtained for the other two systems, Ascribe (Stockport) and HORIS (Mid Cheshire), 
to confirm their actual functionality. Discussions included the possible contributions of 
pharmaceutical information system data, such as clinical stock usage, to various models 
for measuring clinical aseptic activity. 
Telephone discussions took place with the remaining sample trusts that had not submitted 
'demonstrator system reports, supplemented with a structured questionnaire. The 
questionnaire included three factors: target product presentations; target data 
requirements; and evidence of difficulties and additional work required to meet the data 
requirements (see Section 11.16). 
The results generated were collated and presented to the expert panel for the purposes of 
preliminary validation. It was then important to validate the findings with personnel from 
across the North West, to confirm whether the identified data requirements were feasible 
to collect, and (if not) then check whether suitable amendments could be made to the 
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stated requirements so that appropriate, valid data is available and collectable for the 
purposes of the research. 
4.2.3 EPS 
In respect of EPS, one of three national pilot sites was local to the research (Wirral 
Hospitals NHS Trust), and therefore the opportunity was taken to undertake a (qualitative) 
structured interview with its chief pharmacist to establish (potential) relationships between 
such systems developments and research requirements (see Section 11.17). 
4.2.4 Outline Data Collection Proposals 
Following this visit the researcher developed preliminary ideas and outline proposals for 
how the main research data might be collected, taking on board the findings of the initial 
workshop and the lessons from the visit. These were first considered by the expert panel, 
and amended in the light of comments made. 
4.2.5 Validation Workshop 
The options available for validation were the same as the four identified for Section 4.1, 
and the analysis was the same, i. e. a workshop approach was adopted with syndicate 
groups to enable multi-professional input. Detailed discussion and debate was essential, 
something that could not really be achieved via the alternative options of questionnaire 
surveys and structured interviews. 
Therefore the results from both Data Audit exercises (see also Section 4.7) and the 
Nomenclature work (see Section 4.8) were fed into a multidisciplinary workshop. This 
offered the opportunity for the preliminary conclusions and recommendations to be tested 
out with professional colleagues prior to their submission to the expert panel. The aims 
and objectives were to: - 
" Receive the results of the Data Audit exercise 
" Validate the results and develop ideas 
" Further develop the Nomenclature issues 
" Develop proposals for the way forward 
" Ensure good practice in terms of research and development 
" Develop a survey design and approach 
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Invitations to participate in the workshop were issued to people involved in the initial 
workshop, to ensure continuity. It also avoided the need to repeat what the research was 
about. Moves were made to increase the number of nurses, following some concern about 
limited numbers. 
The structure involved presentations on the pharmacy information and clinical area 
elements of the Data Audit exercise, plus presentations on nomenclature issues and 
preliminary ideas/ proposals on how the main research data might be collected (to prompt 
discussion). There followed two multi-professional syndicate groups discussing each of 
the two elements of the Data Audit exercise in detail, together with the associated 
nomenclature issues. Comments from the syndicate groups were fed into a plenary 
session at the end of the workshop to debate and recommend the way forward. 
An out-turn questionnaire (qualitative), was completed, with the same approach and 
methods as that for the initial workshop (see Section 11.21). Questions were appropriately 
adapted to reflect the differences in coverage. The questionnaire for the Data Audit 
workshop had 26 questions designed to ascertain views in a number of areas: 
" Was adequate information provided ahead of the workshop? (1 question) 
" The purpose of the workshop (8 questions) 
" Syndicate Groups (3 questions) 
" R&D Capacity (6 questions) 
" Research progress (5 questions) 
" Location, accommodation & facilities (3 questions) 
The expert panel considered the outcome reports covering the different components of 
the workshop (see Sections 11.18 and 11.22), as a final validation of its outcomes and to 
made specific recommendations for the next stage. 
4.3 Baseline Survey 
As described in Section 4.2, the expert panel (qualitatively) developed preliminary 
ideas/proposals for how research data might be collected, which were debated at the Data 
Audit workshop. The resultant comments and advice were used by the expert panel to 
(qualitatively) agree definitive survey design principles and guidelines, from which the 
researcher prepared draft survey forms and guidelines. 
The forms and guidelines were (qualitatively) validated by the expert panel and lead 
aseptic managers from each zone, to confirm whether: it was clear what was required; the 
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data could be obtained from local systems; and, any changes were necessary. Advice 
was (qualitatively) fed to the next expert panel meeting, where minor amendments were 
agreed, and the survey design and guidance confirmed (see Section 11.24). 
Copies of the (paper) survey forms and guidance were distributed with a covering letter 
explaining the purpose, context and requirements of the survey. These were sent to all 
senior aseptic managers in the North West by the co-ordinators of the zonal aseptic 
managers groups; the expert group advised this as the most effective route. Six weeks 
were allowed for completion. 
Similar letters and copies of the forms and guidance were sent to all Trust Chief 
Executives and chief pharmacists in the North West, to ensure that Trust management 
was aware of, and supported the exercise. 
The original survey (Gandy et al, 1998a) confirmed that community, mental health and 
ambulance Trusts did not produce aseptic products and their usage was nil (or minimal). 
These Trusts were asked to confirm that this was still the case and that this situation was 
unlikely to change within the foreseeable future. If aseptic products were used or 
produced, a Trust would contact the researcher so that survey documentation could be 
sent. 
Data was to be collected for the last fully completed financial year. 
Completed returns were sent to the researcher for initial validation, which included: 
1. Activity totals in each row and column were the same as the sums of the activity 
recorded in the relevant cells; 
2. For each product category the total of the number of products produced for 
"Individual Patients" and "Use as Ward Stock" on Form one should be the same as 
the number recorded as the number for that product category on Form two which 
were sourced from "Within Trust"; 
3. Comparisons were made with the original survey (ibid) results for any major 
differences that might suggest an error; 
4. Logical checks, wherever possible: cancer centres are expected to produce/use 
cytotoxics. 
Where a query arose from validation, the researcher directly contacted the person who 
completed the form concerned to seek advice, with revised data being entered by 
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agreement. (The forms required the person who completed them to give their name and 
contact details for this purpose). 
When a form was validated and the data accepted the details were input to the database. 
(Checks were made to ensure that there had been no data input errors). 
Once all forms were returned, validated and entered on to the (Excel) database, a series 
of analyses were undertaken and incorporated into a draft results report to the expert 
panel. Allowing for the panel's suggested amendments, a copy of the analysis was then 
circulated to trusts for information (and comment). 
4.4 Baseline Survey Evaluation 
The timing of the survey forms and guidance distribution was such that all zonal aseptic 
managers groups met within the survey period. Therefore the researcher could attend any 
or all of these meetings and give advice/deal with queries, and there still to be time for the 
survey forms' completion. Alternatively the researcher met with the zonal co-ordinator for 
the same purpose. The choice was left to each zone. 
Any comments on survey design and guidance submitted directly to the researcher, were 
discussed with the correspondent to ensure complete understanding of the point(s) made. 
With no Trust Chief Executives on the expert panel (their commitments and 
responsibilities made this impossible) the researcher met with one of those from the 
regional working party (NHS Executive North West, 1997) who retained an interest, to 
further validate the research approach and methods. This involved a (qualitative) 
structured interview, with comments and advice fed to the expert panel (see Section 
11.32). 
During the early stages, some queries arose about where certain data should be 
recorded. For the small number where this was not clarified by reference to the guidelines, 
the researcher collated them and sought advice from the expert panel. As a result a small 
update on the guidance was issued (See Section 11.24.3). 
The researcher maintained a log of queries/issues that arose during data validation, and 
those from zonal meetings. When the survey completed, the researcher presented 
analyses of the queries/issues to the expert panel, with suggested actions for each (see 
Section 11.26). 
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The validation was a qualitative process undertaken by the expert panel. It was presented 
with a comprehensive analysis that covered: 
1. Copies of the survey forms and all guidance issued (inc. update) 
2. Analysis of the relationship between product types quoted by the Regional 
Working Party (ibic), the baseline survey and the work-study exercise (see Figure 
5.4.1). 
3. Detailed analysis of the different types of queries/issues that arose in respect of 
the survey forms. 
4. A summary of what were perceived as the key points: 
" The list of product categories needed reduction; 
" The future of Form three; 
" The inclusion/exclusion of terminally sterilised products. 
Expert panel members could add issues not covered by the researcher. In this way 
all actual and potential issues were evaluated. 
5. Potential future arrangements. 
The researcher undertook the comparisons described in (2) above by simply lining them 
up alongside one another and then mapping the relationships 
The analytical report on the baseline survey (see Section 11.25) itself acted as further 
qualitative evaluation of the survey design and guidance: did the analyses and 
comparative figures make sense, given the subjective experience of professionals "on the 
ground"? Perceived constraints and limitations with analyses could suggest improvements 
for the next stage of research, such as additional data. 
4.5 Quarterly Surveys 
The software disk and associated instructions were developed using Excel spreadsheet 
methods, with links established to readily populate the main database; file names were 
automatically generated to ensure each file was unique to a unit and period, minimising 
the possibility of data getting mixed up (see Section 11.39). 
Following the successful piloting, the software disks were distributed to all chief 
pharmacists at North West Trusts along with instructions and the guidelines (see Section 
11.39). Anonymity was maintained through continued use of the baseline confidentiality 
codes. Only participants in the baseline survey were included, as no other Trusts were 
relevant (see Section 4.3). Trust Chief Executives were copied into appropriate 
correspondence to keep them briefed. 
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Use of the software was not compulsory. If Trusts wanted to submit data by means other 
than email, then they could print off the forms from the software, complete them manually, 
and submit them for entry to the database. Data validation used the same methods as the 
baseline survey data (see Section 4.3). 
A full response could not be engineered from Trusts. Therefore, a "baseline quarterly 
equivalent" was calculated for trusts/units fully participating in the quarterly surveys by 
aggregating their baseline data and then dividing by four; including baseline data for non- 
respondents would skew analyses. Production and usage data for the three cytotoxics 
categories in the baseline data were added together. 
Once all received returns had been validated and analysed, a draft results report was 
presented to the expert panel. Emphasis was placed on trends over the five quarters. A 
copy of the report, incorporating the panel's suggested amendments, was circulated to 
trusts for information (and comment). 
4.6 Quarterly Surveys Evaluation 
The quarterly survey methods reflected the principles of the baseline survey, with design 
changes arising from its evaluation (see Section 4.4). Therefore few, if any, problems with 
design and guidance were anticipated. Nevertheless it was made clear that the researcher 
was readily accessible, keeping a log should issues arise. The survey was a standing 
agenda item for the various regular pharmacists' meetings. 
The opportunity was taken to update the pharmaceutical community about progress with 
the quarterly surveys when presentations were made to selected meetings, primarily 
about other components of the research. Feedback was always welcomed. 
By the end of the five quarterly surveys the focus of evaluation was more on how the 
quarterly surveys' data, in concert with relevant baseline survey data, could be used to 
support the calculation of the various statistical indicators. At that stage the efficacy of the 
quarterly survey design was something of a given. 
As for the baseline survey, the validation was a qualitative process undertaken by the 
expert panel, on similar lines to the process outlined in Section 4.4. 
The expert panel endorsed a report summarising the key analyses, with commentary, for 
circulation to Trusts for information and comment (see Section 11.40). 
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4.7 Data Available in Clinical Areas 
The expert panel agreed to a programme of hospital visits for structured interviews to 
investigate the question of available research data in clinical areas (plus nomenclature 
issues - see Section 4.8). 
Visits entailed investigating ward stocks, prescribing and associated processes, existing 
documentation and recording methods. To make best use of time on the day, an agenda, 
including the questions and issues to be covered, was sent for prior consideration by local 
staff (see Section 11.19). The main questions/ issues covered were: 
1. Stock processes. 
2. Review of documentation in association with: 
0 Methods of prescribing 
0 Recording of administration 
3. Ascertain which clinicians are involved within the process of assembly, 
preparation and administration. 
4. Alternative data collection methods. 
5. Approaches to the timing of data collection. 
In order to gauge the amount of recording that might be involved with data collection, the 
audited clinical areas were invited to randomly select an individual patient and establish 
the number of aseptic preparations administered over a 24-hour period. 
To assist in the fact finding within the clinical area, a conceptual model (Figure 4.1) was 
developed. 
130 
Figure 4.1: Conceptual Model of Stock Process Within Clinical Area 
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The questions and approach were piloted with two hospitals, prior to the arrangement of 
the programme of visits, with little or no amendments identified as being required. 
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The researcher drafted a programme of visits to nine hospitals, covering different types of 
hospitals and clinical areas, and covering the North West. Table 4.1 provides details. The 
expert panel agreed this as a sufficiently representative coverage. 
Table 4.1 Trusts and Clinical Areas covered in Data Audit of Clinical Areas 
ID 
Number 
Trust Clinical Area Visited 
8b Aintree Hospitals NHS Trust Theatre 
2b Bolton Hospitals NHS Trust Theatre 
7a Stockport Acute Services NHS Trust Theatre 
4a Wirral Hospitals NHS Trust Surgical - Colon rectal and 
general 
8a Aintree Hospitals NHS Trust Surgical 
5a Mid Cheshire Hospitals NHS Trust Surgical 
1b Burnley Health Care NHS Trust Paediatric Surgical 
la Burnley Health Care NHS Trust Paediatric Medicine 
6a Manchester Children's Hospitals NHS 
Trust 
Paediatric Medicine 
6b Manchester Children's Hospitals NHS 
Trust 
Paediatric ITU 
3a Blackpool Victoria Hospital NHS Trust ITU 
5b Mid Cheshire Hospitals NHS Trust ITU 
9a Clatterbridge Centre for Oncology NHS 
Trust 
Oncology - Radiotherapy 
9b Clatterbridge Centre for Oncology NHS 
Trust 
Oncology - Chemotherapy 
3b Blackpool Victoria Hospital NHS Trust Medicine and Haematology 
4b Wrral Hospitals NHS Trust Medicine - Stroke and 
haematology 
2a Bolton Hospitals NHS Trust Medicine - General 
7b Stockport Acute Services NHS Trust Medicine - Care of the Elderly 
Practicalities meant one site could be visited in one day, but it was possible to have two 
sets of structured interviews (morning and afternoon) allowing for travel, face-to-face 
discussions, visits to facilities, and note taking. Therefore, two different types of clinical 
areas were selected for each hospital, with a balance being struck between geography 
and clinical areas. The number of hospitals was considered sufficient. 
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The visits were all involved the lead nurse of the expert panel and a colleague with a 
nursing background. They transcribed interviews, subsequently confirming their content 
with the staff interviewed, so as to ensure accuracy. 
Data and notes from visits were collated and analysed, with conclusions/ 
recommendations fed into the Data Audit workshop along with those from the desktop 
exercise (see Section 4.2.5 for details of the whole workshop, which are not repeated 
here). Conclusions and recommendations were validated with professional colleagues 
prior to submission to the expert panel. 
The expert panel considered the outcome reports covering the different components of 
the workshop, as a final validation of its outcomes, and made specific recommendations 
for the next stage. 
The workshop identified an outstanding research question: How best to collect data on 
aseptic preparation in clinical areas? Whilst relevant, it was not central to the research. 
The expert panel deemed it sufficient to develop specification proposals for 
supplementary projects to this end (see Section 11.23). If funded, they could be pursued 
separately. 
4.8 Nomenclature 
The initial workshop established that nurses and pharmacists use nomenclature in 
different ways (see Section 3.8) and that the issue needed addressing to underpin the 
research. 
Structured interviews were arranged with nurses in clinical areas for data audit (see 
Section 4.7), and researching nomenclature required a similar approach. The expert panel 
pragmatically decided to incorporate nomenclature questions into the same visits and 
interviews (see Table 4.1 for programme of visits). The purpose was to explore local views 
and practices for comparison. 
The expert panel determined eight terms requiring explicit definition for the purposes of 
the research: 
Administration Ingredients 
Administration begins Parenteral 
Administration ends Preparation 
Assembly Product 
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The expert panel's lead nurse and lead clinician produced (draft) definitions of each term, 
which were validated first by the expert panel and secondly at the two pilot data audit site 
visits (see Section 4.7). Interviewed nurses were to be asked their views on their efficacy, 
with the opportunity to propose amendments/improvements. 
The expert panel also produced a list of words that might be used as alternatives to nine 
commonly used words/terms: 
Acquisition and Custody Ingredients 
Administration Preparation 
Container Product 
Dosage Route 
Equipment 
Hospital nurses were to add to the list based on local and personal experience; the aim 
being to establish as full a range as possible of alternative terms for each. 
To give nurses the opportunity fully respond in interviews and make best use of time, an 
agenda was sent in advance, with the above lists of words and (draft) definitions (see 
Section 11.19). 
The interviews' details were collated and validated at the Data Audit workshop, where 
syndicate groups critically examined the use of key terms (see Section 4.2.5). 
Recommendations were made to the expert panel taking into account comments and 
views from the workshop, and literature searches, so that a final list of terms and 
definitions could be agreed for consistent use for the purposes of the research. 
The interview programme focused on nurses in clinical areas, with no guaranteed input 
from local pharmacists. Pharmacists were not precluded from participating in interviews; 
the expert panel did not require their attendance primarily because of time constraints. 
The expert panel overcame this limitation by ensuring strong pharmaceutical input in the 
preparation of the lists planned for site visits, and in the final evaluation (the largest group 
on the expert panel were senior pharmacists). The involvement of a full range of 
pharmacists at the workshop also ensured that the inter-professional balance was 
appropriate. The workshop importantly set the nomenclature results alongside those for 
the data available in clinical areas, given their inter-relationship. 
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It was clear that the research could not address universal issues associated with 
nomenclature. All that could be done was ensure consistency within the research itself, 
and highlight issues for wider discussion and debate. 
4.9 Collaboration 
The availability of methods of measuring "collaboration" was tested through a literature 
search, with the (negative) results qualitatively evaluated by the expert panel for their 
applicability to aseptic dispensing (see Section 2.5). 
Next, an iterative approach was applied to establish whether methods not directly related 
to "collaboration" could be translated for the purposes of the research. This involved 
identifying a potential method and testing it; only moving on to further methods if the 
results were negative. There were two stages to testing: 
1. A qualitative appraisal of whether the method appeared to have potential, i. e. it 
could be applied conceptually to aseptic dispensing, and the data required was 
fully covered by the research data or the collection of any additional data was 
feasible; 
2. If the first stage was successful, research data was applied to the model to 
produce results, which were qualitatively evaluated by the expert panel as to 
whether they were both statistically and conceptually robust. If so endorsed, they 
were disseminated to the pharmaceutical community for consideration, and implicit 
validation, with responses invited. 
Adaptations to a method could be made in response to the evaluation, with the process 
repeated, until a method was confirmed as valid. 
The method subsequently used baseline and quarterly surveys data to test if it suitably 
reflected trends over time, applying the established evaluation processes. 
The later stages of the research enabled further exploration of the method's potential for: 
0 Comparing patterns of collaboration in different areas; 
" Comparing trends in collaboration between different areas; 
" Comparing how collaboration in respect of individual products had changed over 
time. 
135 
The researcher undertook this on an iterative basis, applying the above principles and 
processes. 
4.10 Work Study 
The researcher drafted a specification for a work-study professional to be commissioned. 
This was considered by the expert panel, amended in line with discussion and then 
approved (see Section 11.27). 
A professional with considerable experience of hospital work was recruited following 
established processes. The professional attended the pilot visit to a major Trust to validate 
the efficacy and practicalities of the specification. This allowed opportunity for questions to 
local pharmacists and aseptic staff, and confirmation of how particular tasks might be best 
approached. 
The expert panel prepared a representative list of aseptic units for the professional to visit, 
balancing a variety of factors, including geography, equipment, individual and batch 
preparation, types of units and products, and units that do and do not have licences. Units 
chosen were: 
" Burnley Health Care 
" Central Manchester Healthcare 
" Clatterbridge Centre for Oncology 
" Manchester Children's Hospitals (Pendlebury) 
" Morecambe Bay Hospitals (Lancaster) 
" Stockport Acute Services (Stepping Hill) 
" Wirral Hospitals (Arrowe Park) 
Chief Executives and chief pharmacists of the selected Trusts were asked to agree to the 
work-study professional visiting their aseptic unit to undertake interviews and 
observations. This was essential to reassure local staff that the exercise was for research 
purposes and that the results would not be used to amend local practices. Otherwise their 
willingness to accept the visits and fully contribute would be put in jeopardy. The letters 
enclosed a questionnaire asking for basic details about the local unit, so that the 
professional would have some appreciation of the unit and its work in advance (see 
Section 11.27.8). These included: 
" The availability of different types of cabinet (horizontal and vertical laminar flow 
cabinets, and isolators); 
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" Confirmation of which aseptic products were prepared locally, together with 
(approximate) annual figures; 
" Details of the ranges of batch sizes, where batch production took place; 
" An indication was requested of details of any automated filling equipment. 
The work-study professional began the programme of visits, but experienced difficulties 
that placed the overall exercise in jeopardy. Ways of addressing them were discussed 
with the researcher, but in the event they could not be overcome, and the termination of 
the commission was recommended. A report was written describing the work undertaken, 
the problems experienced and the efforts to address them, and any 
lessons/recommendations on the basis of the observations made. This report (see 
Section 11.28) was presented to the expert panel, which accepted the findings and 
recommendations. 
Prior to writing the report the work-study professional attended the Capacity and Workload 
workshop (see Section 4.12) and described the lessons learned to date. 
4.11 Unit Time Equivalents 
Having agreed that a group of (expert) pharmacists make preliminary estimates of UTEs 
for each type of product, the expert panel decided that this group should consist of the 
three lead chief pharmacists and the two Quality Controllers from within its membership. 
This ensured that practices from all three zones would be taken into account. The expert 
panel also determined that for the purposes of the research the UTE would cover the 
period of time from the receipt of instructions to the final check/booking off of the product. 
The work-study professional had recommended that it was reasonable to make estimates 
of UTEs by applying a standard unit value of one and a half minutes to the values from 
previous work done in Lancashire to relatively weight product types (primarily for cost 
purposes) (North West Aseptic Task Group, 1998). The expert panel endorsed this as a 
sensible starting point for the expert group of pharmacists. 
The researcher identified too many inconsistencies between the list of product types used 
in Lancashire and that developed for the research. Comparisons of the two lists were 
made, with consistent ("best estimate") values (qualitatively) estimated for the research 
product types by a chief pharmacist from the expert panel, with the degree of confidence 
clearly recorded (see Section 11.29). The researcher circulated these to other members of 
the expert group for consideration, together with chief pharmacists external to the North 
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West, in order to act as a form of validation. Responses were received from East Anglia 
and Yorkshire. 
In the event the preliminary UTE values were endorsed by the expert group of 
pharmacists, and then by the expert panel. 
In order to validate the preliminary UTE values with North West pharmacists, a 
(qualitative) questionnaire was prepared setting out the values for each product type and 
asked the person completing it to record (see Section 11.30): 
(a) A tick to confirm agreement that the proposed average time is reasonable; 
(b) Suggest an alternative average time if that proposed is not considered 
reasonable; 
(c) The shortest possible average time; and 
(d) The longest possible average time. 
The researcher drafted the questionnaire, which was validated by the pharmacists on the 
expert panel. (c) & (d) were to provide data on the range of average production times. The 
expert panel did not consider it appropriate to identify the potential longest and shortest 
production times per se, because UTEs themselves are viewed as statistical means, 
which can be applied to large volumes of activity, rather than single values. 
The researcher and Chair of the expert panel were to give a progress report to an Aseptic 
Managers Study Day planned for the near future. Given time constraints the expert panel 
took the opportunity to distribute the questionnaire to all aseptic managers, via the event 
organisers. The managers could complete it anonymously, or record their name and 
position. They were invited to hand in completed questionnaires to reception at the event, 
where the researcher quickly collated responses, so that feedback could be included 
within the progress report for triangulation purposes, with any wide variations being 
debated. 
Returned questionnaires were quickly analysed, to show the numbers that (dis)agreed 
with the proposed UTE values, and the variations quoted as alternative mean values. 
These were presented on an overhead projector, and debated. 
An important point raised was that the mean time of many product types would vary 
between licensed and unlicensed units, because the former include more batch work and 
the latter more individual work, which necessarily took longer. Therefore, it was agreed 
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that each product type needed two LITE values: one for licensed units and one for 
unlicensed units. 
Following the Study Day, thorough analysis of all completed questionnaires was 
undertaken, including late submissions. The expert group of pharmacists agreed there 
was sufficient consistency to determine final UTE values. 
To determine final values for the UTEs a meeting was held of the Chair, researcher and 
the three chief pharmacists on the expert panel. Ahead of the meeting the pharmacists 
were asked to independently determine their own views of the UTE values covering both 
licensed and unlicensed situations, together with the likely degree of variation. The 
researcher prepared a questionnaire to this end (see Section 11.31). In doing this they 
took into account the findings of the survey of aseptic managers, together with other 
responses received. Their respective views for each product type were compared and a 
consensus formed of the final UTE values. 
To determine the likely variation, minima and maxima values for the UTEs were set using 
regression analysis relating the mean times to minima and maxima indicated by the 
aseptic managers in the survey. Regression formulae were established (including if the 
line went through the origin). 
Differences between the values produced by the formulae, when the line did and did not 
pass through the origin were marginal for the higher values. For the lower values the 
differences could be inferred as due to where units were or were not licensed. Therefore 
the minima and maxima were set utilising whichever formula best reflected such 
circumstances. The values were rounded to the nearest whole number except for the 
lowest values. 
The expert panel (qualitatively) considered these UTEs (and their ranges) and endorsed 
them for use in the research, i. e. they were to be applied to the baseline and quarterly 
surveys data. They would be further validated when presented alongside the results by 
the North West pharmacists. The expert panel considered this preferable to circulating 
them again for comment, in isolation of such results. 
Note: The draft UTEs produced by the expert group were applied to the survey data 
before validation, in order to develop an understanding of how they could be used, and 
spreadsheet links effected; they were to be superseded with the finally agreed UTE 
values. 
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4.12 Concepts: Capacity and Workload 
The aims and objectives of the half-day Capacity and Workload workshop were to: - 
" Answer the question of what constitutes an optimal workload, or capacity, for an 
aseptic preparation unit; 
" Develop the concept and definition of "Capacity" for aseptic preparation; 
" Develop practical target workloads to allow for different circumstances; 
" Receive an update from the work-study exercise - key issues & pointers; 
" Consider how best to utilise survey data & what additional data might be required. 
Invitations to participate were accepted by fourteen people (in addition to the researcher, 
who was the main facilitator, and the work-study professional). These were not the same 
as those who had been involved in earlier workshops. 
Thirteen of the 14 were pharmacists, or worked in pharmaceutical departments. Four 
pharmacists were from the expert panel, and five were from a single Trust that had 
undertaken substantial work in the subject area. Pharmacists were invited who had 
specific expertise in respect of the situations for radiopharmacy, oncology, children and 
the commercial sector. No nurses attended (the Nurse from the expert panel was unable 
to attend). 
The thrust of the workshop was qualitative. Therefore, it was carefully structured to 
include appropriate, proven qualitative techniques, augmented by selected information. Its 
structure was: 
1. Introduction and Aims & Objectives of workshop 
2. Presentation of simple analyses from original survey (Gandy et al, 1998a) 
illustrating variations in intensity of use of North West aseptic dispensing units 
3. Presentation on lessons and findings from work-study exercise 
4. Presentation on lessons from known initiatives to improve throughput and 
efficiency in aseptic dispensing units 
5. Affinity analysis (Brassard, 1996) to explore what influences performance 
6. Syndicate groups to develop proposals around definitions and potential solutions 
7. Feedback from syndicate groups (suitably triangulated) 
8. Main conclusions and recommendations 
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(1) & (2) were delivered by the researcher, with the work-study professional presenting 
(3). The chief pharmacist from the Royal Preston Hospital (a member of the expert panel) 
presented (4). 
The Affinity analysis (Brassard, 1996) used the question: "What issues and practicalities 
influence the performance of work in a pharmaceutical aseptic dispensing unit? " (see 
Section 11.33). 
The workshop itself then determined that there should be two syndicate groups to develop 
proposals as to definitions for "capacity" and "target workload", with one group of six 
people and one of seven - it was agreed that having a third syndicate group (i. e. two 
groups of four and one of five) would be less effective. 
The groups worked completely independently of one another. Their results were then fed 
back to the whole workshop, collated and final recommendations developed (see Section 
11.34). 
An out-turn questionnaire (qualitative) was completed, with the same approach and 
methods as that for the two previous workshops (see Sections 11.11 and 11.21). 
Questions were appropriately adapted to reflect the differences in coverage, with 21 
questions designed to ascertain views in a number of areas (see Section 11.35): 
" Was adequate information provided ahead of the workshop? (1 question) 
" The purpose of the workshop (8 questions) 
" Syndicate Groups (3 questions) 
" R&D Capacity (3 questions) 
" Research progress (3 questions) 
" Location, accommodation & facilities (3 questions) 
The expert panel considered the outcome reports covering the different components of 
the workshop, and the out-turn survey (see Section 11.36), as a final validation of its 
outcomes. The respective merits of the approaches were (qualitatively) evaluated and 
specific recommendations made for the next stage (see Section 11.37). 
The opportunity was taken to validate the findings with Quality Control pharmacists from 
across the whole country, at an Audit Training Course in Birmingham. The researcher and 
Chair from the expert panel presented progress and key findings. They recorded the 
comments and views, with accuracy checked by the pharmacist who chaired the session 
(see Section 11.38). 
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4.13 Statistical Indicators 
The expert panel qualitatively evaluated the findings from the work-study exercise, the 
capacity/workload workshop, the Regional Quality Control Pharmacists, and available 
literature. Reference was made to the types of statistical indicators used in the 
commercial sector (see Section 4.1). 
Additional data requirements were confirmed: the numbers and types of cabinets in each 
aseptic dispensing unit. Such data was obtained from the Regional Quality Controllers, 
who kept records on them, and validated by circulating it to Trusts for confirmation or 
correction. The numbers of cabinets were "at a point in time" - rather than the average 
availability over a given period. Advice from the expert panel chief pharmacists was that 
the latter is too difficult to collect accurately. 
A series of prototype statistical indicators was identified, utilising the available data. In 
each case, the researcher sought initial preliminary views from the expert panel Chair for 
validation purposes. 
Licensed aseptic dispensing units had licensed UTEs applied to all of their activity, even 
though some products would inevitably be prepared on an unlicensed basis. The expert 
panel advised this, inferring that known constraints of existing information systems (See 
Section 4.2) would mean such a split of data was not feasible to collect on a 
comprehensive basis. 
Results were qualitatively validated by the expert panel as to how conceptually meaningful 
and useful they were to pharmacists and managers. Outlier figures were evaluated to 
determine how this had come about and whether this meant that an indicator was 
insufficiently robust. Sensitivity analyses were undertaken for relevant indicators to test 
their robustness, with results validated by the expert panel. (This involved a cyclical 
iterative process: analyse - present results - feedback - (re)analyse). 
When the expert panel considered statistical indicators as both valid and robust, the 
analyses and results from applying the indicators to the baseline and quarterly data were 
disseminated to North West pharmacists and aseptic managers to both inform them of 
relative performance and to validate the indicators. 
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4.14 Modelling 
4.14.1 Capacity Planning Software 
To evaluate the applicability of capacity planning software to NHS aseptic dispensing 
units, the following methods were applied: 
"A representative example of the software was chosen for scrutiny. This was MRP2 
software (McGuffie-Brunton, 1998). 
"A chief pharmacist on the expert panel, whose unit was the largest in the North 
West (and one of the largest in the country) in terms of annual numbers of 
products, had tried to introduce this software locally to improve efficiency. 
" The pharmacist collected files and notes from the exercise, and was interviewed 
by the researcher, who drafted a summary of the key points (see Section 11.42), 
which were subsequently endorsed by the pharmacist. 
" The expert panel evaluated the agreed summary and developed a consensus. 
4.14.2 Capacity Modelling 
To evaluate the applicability of capacity modelling to NHS aseptic dispensing units, the 
following methods were applied: 
" The researcher identified leading experts in the fields of capacity modelling and 
aseptic dispensing production: the Professor of Managerial Cybernetics at 
Liverpool John Moores University) and the Principal Pharmacist, Production and 
Aseptic Services Manager for Stockport Pharmaceuticals, Stepping Hill Hospital, 
Stockport, who was a past Chair of the NHS Pharmaceutical Production 
Committee. 
" The researcher facilitated a meeting between the two experts and himself, where 
the practicality and feasibility of applying capacity modelling techniques to aseptic 
dispensing production were fully explored. 
" The researcher recorded details of the meeting and shared them with the experts 
for validation and accuracy (see Section 11.43). 
" Given the findings, the researcher undertook a literature search and critically 
reviewed relevant publications in relation to the research question. 
" The researcher collated the experts' views and critical review to develop 
conclusions that the experts validated for dissemination (Gandy et al, 2006). 
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4.15 Acute Capacity Planning 
4.15.1 National Chemotherapy Simulation Model 
A literature review was undertaken, and in relation to the national chemotherapy capacity 
model, the researcher directly contacted the national manager responsible for the 
consultation process. The proposals were critically reviewed and comments submitted 
(see Section 11.45). 
Details of the subsequently developed simulation tool (C-Port) (see Section 3.15) were 
kindly provided by the national manager. (N. B. Access to the references can only be 
obtained via a password-protected website). These were critically reviewed from the 
research's perspective. A semi-structured telephone interview was undertaken with the 
national manager to: clarify points and issues in respect of relevant detail and how C-Port 
might be utilised; confirm C-Port's roll-out; and confirm the likely local effort required (see 
Section 11.46). The interview notes were confirmed as accurate. 
A structured interview was undertaken of the lead manager responsible for implementing 
C-Port for Clatterbridge Centre for Oncology and the Merseyside & Cheshire Cancer 
Network. This involved: an overview of C-Port and the associated training process; 
requirements to begin using the tool; and observations about how it would be utilised 
locally (see Section 11.47). Questions included: 
" What is C-Port and how does it work? 
" What are its purposes? 
" What are its main features, components and structures? 
" What are its outputs? 
" What is required of the user, particularly for inputs? 
" How is it being rolled-out? 
" How is it managed and operated? 
" What are the strengths and weaknesses? 
4.15.2 Local Acute Capacity Planning Models 
The researcher contacted lead pharmacists to enquire where particular progress had 
been made in the development of local acute capacity planning models. The advice gave 
two hospitals: North Manchester General Hospital and Leeds Teaching Hospitals. These 
appeared very different from one another, with the former using primarily manual methods 
and the latter developing computer-based spreadsheets. 
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The researcher contacted the respective lead pharmacy personnel responsible for the 
local approaches, and undertook semi-structured telephone interviews (see Sections 
11.48 and 11.49). Both leads readily provided details and advice. Neither were aware of 
any general approach, or software, that could be taken and used for local acute capacity 
planning: this was a reason why they had developed local solutions. Interview notes were 
confirmed as accurate. 
4.15.3 Analysis 
A preliminary critical review was undertaken to establish the key similarities and 
differences between the local models (and C-Port), and determine lessons for the 
research. 
A more detailed critical review is being undertaken, with the co-operation and 
collaboration of the lead personnel, to include: 
" Comparisons of the steps of the overall aseptic process covered by both local 
models and published work; 
" Comparisons and validation of any formulae applied; 
" Comparisons of the overall approach and the data required; 
" Comparisons of how the models are used locally. 
(Gandy, 2007 in progress) 
4.16 Transferability 
The fact that a consultancy commission was involved acted as a constraint on methods. 
Only one survey was commissioned, which was for the most recently completed full 
financial year (2000/01). (A series of quarterly surveys would have involved more data, 
more analyses and therefore more consultancy time and costs). 
The finally agreed survey forms and guidance were used (see Section 5.6)6, tailored for 
the West Midlands. Again, disks were provided for recording the data so that they could 
be emailed and efficiently entered in to the survey database, where data validation and 
checks were undertaken. Any queries were taken up directly with the hospitals concerned. 
The disks were circulated to pharmacists and aseptic managers with covering letters. 
8 Chief pharmacists in the West Midlands asked for additional data to be collected on the times that their 
aseptic dispensing units were open on average each day. This data was collected separately from the Trusts 
and used in certain analyses. The collection of this data was not required in the North West because of the 
concerns about its robustness for use in analyses (see Section 5.12). 
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The researcher linked with the West Midlands Regional Quality Controller as the local 
focal point for dealing with queries and issues concerning the commission. The Quality 
Controller and his staff gave support and advice to local pharmacists. 
All Trusts in the West Midlands were invited to send representatives to an initial workshop 
that served to launch the survey. The purpose of the workshop was to maximise data 
quality by ensuring all participants understood the nature of the survey and associated 
guidance. This involved appraising everyone of the North West research and its findings, 
before confirming the survey requirements, particularly in respect of guidance. All 
questions were answered/clarified. 
As for the North West, Trusts determined the basic local unit for data collection, allowing 
for geography and organisation structures. Each Trust/unit was allocated a confidential 
code, so as to maintain anonymity in the presentation of results. 
Data for the survey was submitted and validated. The Quality Controller provided the data 
in respect of the numbers of cabinets in each aseptic dispensing unit. The research 
analyses for activity, statistical indicators and UTEs (see Section 4.11) were applied to the 
submitted data to give local results for the West Midlands. 
To make comparisons between the two Regions' results, it was decided to use the North 
West baseline data because although the quarterly surveys' data was more up-to-date, 
they were incomplete for the Region. 
A search of national data published on the DoH's website identified the data available for 
all Trusts in both regions, that might be used as proxies for all Trusts' activity (of relevance 
to aseptic dispensing usage) as FCEs and admissions. (The advice of the respective 
Regional Quality Controllers was sought on these and other possible currencies before 
deciding to use these two). In addition population figures for each region were available. 
Consequently, the aseptic production figures for each region were translated into rates for 
each of: population; FCEs; and admissions; and comparisons made. 
As aseptic preparation activity in clinical areas was not collected as part of the 
commission, it was necessary to estimate whether the balance of aseptic preparation in 
clinical areas (compared to pharmacies) varied between the regions. This involved taking 
the results of work undertaken in the North West, in preparation for the C&CP, which gave 
locally accepted estimates of c. 3.8 million products aseptically prepared in clinical areas 
(Gandy et al, 2003). Combining this with pharmaceutical production meant 4.8 million 
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products were used in clinical areas annually. Dividing this number by the total of acute 
admissions in the North West gives a rate of usage of aseptic products per admission. 
Making the key assumption that this rate of usage should be similar for the West Midlands 
(or any other region), then enabled an estimate to be calculated of the total usage of 
aseptic products in the West Midlands. The percentage of such products supplied by 
pharmacies was then readily calculated, and comparisons made between the two regions. 
The consultancy report, including commentary and analyses, was first shared with the two 
Regional Quality Controllers to validate, to ensure no errors or inappropriate inferences 
were made, prior to the report being formally disseminated. In the event, only minor 
amendments were required. 
The report (see Section 11.50) was circulated to relevant personnel, with presentations 
made to chief pharmacists and to aseptic managers. The report was warmly welcomed 
and accepted as a basis for building future plans. 
The variations between the two regions' practices were suitably disseminated (ibid; 
Gandy, 2005). 
4.17 Evaluation of Programme 
Given the advice to the researcher to try and use the single survey form developed for ad 
hoc purposes to collect post programme data, it was essential to validate this form against 
the forms established by the research. 
To this end the researcher liaised with the Chair of the Greater Manchester Aseptic 
Managers Group, who also acted as the lead Chair across the three zonal groups. The 
Chair provided copies of the single form that had been completed by four local Trusts for 
2002/03 (see Section 11.51). The researcher compared the single survey form with the 
two forms from the previous research, to: 
" Identify differences in the data collected; 
" Confirm whether the analyses and statistical indicators identified by the research 
could still be produced; and 
" Advise on whether the differences would compromise the value and validity of any 
comparisons between the baseline data and the post-programme data, if the latter 
were collected using the single survey form. 
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The data categories to be recorded were: 
1. Prepared within pharmacy for use within own Trust (Production); 
2. Outsourced from other Trusts (Usage); 
3. Acquired from commercial sources (unlicensed products) (Usage); 
4. Prepared within pharmacy for other NHS Trusts and other users (Production) 
5. Prepared at ward level (best estimate) 
(It should be noted that data relating to (5) was not considered by the researcher to be 
part of the research, given the experience of the original survey (Gandy et al, 1998a); 
however, chief pharmacists had included it within their single survey form design, and had 
asked for its retention, on the basis that if sound data was provided then this would be 
useful). 
The conclusion was that with a number of small amendments, the 2002/03 single survey 
form could provide sufficient valid data to enable consistent comparisons with the baseline 
data and the associated main analyses and statistical indicators. The form included all of 
the product types that had been previously collected (see Section 11.39) except 
Cardioplegia Solutions. This was because the numbers were so low (709 across the North 
West in the baseline). Any such activity would need to be included under "Other", which 
would ensure that all products were still being covered. 
Accordingly the suitably revised single survey form was agreed with the Chair of the 
Greater Manchester Aseptic Managers Group and the Regional Quality Controller, and 
distributed by the former to all chief pharmacists/aseptic managers across the North West. 
Completed forms were to be submitted directly to the researcher. 
The researcher undertook data validation on the returns, and raised any queries with the 
persons who completed them directly. Data validation included ensuring: the survey forms 
were fully completed; any additions of figures had been correctly undertaken; and, there 
was sufficient consistency with the baseline data (and the planned expansion of 
production in the case of the units that received capital funds) to suggest that inadvertent 
errors had not been recorded. 
Several organisational changes had taken place since the baseline. In respect of Trusts, 
all of these involved mergers, and therefore baseline data for the constituent 
Trusts/hospitals was aggregated to ensure valid matches for the 2003/04 organisations. In 
terms of regional boundaries, whilst all of Cheshire & Merseyside SHA and Greater 
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Manchester SHA had been within the pre-existing North West Region, and therefore 
covered by the C&CP, Cumbria & Lancashire SHA covered Trusts from both Lancashire 
(North West Region) and Cumbria (Northern & Yorkshire Region). The decision was taken 
to only collect data from the Lancashire Trusts to be consistent with the baseline cohort of 
organisations, and because Cumbria had not been a part of the C&CP. 
Planned increases in production for aseptic dispensing units receiving capital funds were 
obtained by reference to the agreed business cases (Beaumont, 1999). 
The researcher questioned if the continued validity of the UTEs with the Regional Quality 
Controller, who raised it with colleagues on the (new) expert panel. They confirmed their 
validity. In addition up-to-date details of the licensing status and cabinet numbers were 
provided for aseptic dispensing units across the North West. 
Research analyses and statistical indicators were produced using the 2003/04 data, with 
aggregated baseline data used for organisations that had undergone mergers, so that 
comparisons were valid. As with previous research results, confidential codes were used 
to ensure appropriate anonymity. The same codes were used as previously, but with 
codes of the main site/Trust used where mergers occurred. 
Comparisons were made between the data, analyses and statistical indicators for the two 
years, to determine actual and relative values of any changes. Three categories of aseptic 
dispensing units were used for aggregating Trusts/units in respect of licensing status. 
They usefully delineated where changes occurred in licensing status, and also enabled 
clarity around which UTEs to apply to the different years' data. These were: 
" Units that were Licensed for both the baseline and 2003/04 surveys; 
" Units that were Unlicensed for the baseline survey and Licensed for 2003/04 
survey; 
" Units that were Unlicensed for both the baseline and 2003/04 surveys; 
Having two separate years' data also enabled an iterative approach to exploring the 
potential/validity of further analyses and indicators. Some had previously appeared to not 
have potential when considered for a single year, but taking two years' data showed there 
was comparative value. For example, the application of the collaboration diagram for 
product types (see Section 5.9). Also, fresh angles were suggested for some analyses: 
national developments in respect of chemotherapy activity (NHS Modernisation Agency, 
2005) suggested there would be merit in exploring the impact of separating out 
chemotherapy activity and dedicated chemotherapy cabinets from other activity and 
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cabinets to establish the impact on the overall analyses/indicator values. Their validity was 
evaluated by reference to the expert panel and the pharmacist community, as with the 
earlier stages of the research. 
The same methods applied to compare the North West and West Midlands in respect of 
the percentage of aseptic preparation performed in pharmacies and clinical areas (see 
Section 4.16), was used to estimate changes that had taken place over the period of the 
C&CP. This time, the number of beddays was added to the numbers of admissions and 
FCEs. Advice from the expert panel was that the use of aseptic products probably varied 
more in line with beddays than with either admissions or FCEs. 
Comparisons were made between the actual and planned increases in production for the 
aseptic dispensing units included in the C&CP. Where targets had not been met direct 
contact was made with the chief pharmacist or aseptic manager to establish why 
variations had occurred. The reasons were recorded, and validated by the person quoted. 
Projections were made of the potential impact for the overall balance of preparation 
between pharmacies and clinical areas if all of the unused spare capacity in the aseptic 
units that were part of the C&CP were to be utilised and replace aseptic preparation in 
clinical areas on a one-to-one basis. This was to set out how much further the balance 
could be further enhanced within existing capacity. 
A draft of the report presenting the findings was validated by first inviting the Regional 
Quality Controller to make comments and give advice. The finally agreed version (see 
Section 11.52) was given relevant circulation across the North West. 
The researcher also produced a specific report focusing in detail on the performance of 
the aseptic dispensing units included in the C&CP. This was kept separate and given 
restricted distribution, due to the sensitivity of the findings (see Section 11.53). 
A formal presentation was made to a workshop of North West pharmacists, with further 
validation through dissemination (Gandy and Beaumont, 2006). 
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4.18 New Information Systems 
A check was required to establish if new, better pharmacy information systems were 
available for aseptic dispensing units, or existing systems had improved. 
Contact was made with five chief pharmacists at sites where each system (see Section 
5.2) was in place, and (semi-structured) telephone interviews undertaken. Any changes in 
one system would apply across all its users. This meant that a full survey was not 
required. 
in respect of EPS, email contact was made with the Clinical Lead for ePrescribing at CFH 
in June 2006. A semi-structured telephone interview was undertaken aimed at whether 
new EPS would address research data requirements, and relevant timescales. It was 
noted that consultation was to begin on a draft functional specification for EPS in Summer 
2006 (CFH, 2006a) and that definitive comments could not be given until the process 
concluded. The researcher scrutinised the draft specification for relevant references to 
research data (ibid). 
The final functional specification for EPS was published in February 2007 and the Clinical 
Lead again contacted (CFH, 2007a). It was confirmed that consultation had not materially 
impacted on advice given in the interview. The researcher scrutinised the final 
specification for relevant references to research data (ibicf). 
A structured interview was arranged with the Lead Pharmacist IT responsible for the EPS 
at Wirral Hospitals NHS Trust to establish local and other developments. Comparisons 
were made with the earlier situation when the Data Audit took place (See Section 11.17) 
so that advice could be given on any changes since that time. 
151 
Chapter 5 Results 
5.1 Data to Collect 
The Affinity analysis exercise determined the main information requirements in respect of 
aseptic preparation are: Assess Demand, Activity, Human Resources, Risk, Service, Cost, 
Cost, Primary/ Community Care, Standards, and Information Management & Technology 
(IM&T) (see Section 11.8 for full results). 
Table 5.1.1 shows the collation of the syndicate groups' scores for how the Affinity 
analysis results related to different clinical areas: 
Table 5.1.1 Scores for Affinity analysis results as to relevance for clinical areas 
Syndicate Group/ 
Affinity Analysis Heading 
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Assess Demand 5 5 5 5 20 
Activity 5 5 4 2 16 
Human Resources 5 4/5 5 4 18/19 
Risk 5 5 5 5 20 
Service 5 4 4 5 18 
Cost 3 1 5 2 11 
Cost 1 4/5 3 1 9/10 
Primary/ Community Care 1 1 4 1* 7 
Standards 4 5 5 5 19 
IM&T 4 2/4 4 3 13/15 
* The minimum score of "1" was assigned although the group and heading do not 
relate to one another 
Table 5.1.2 shows the collation of the syndicate groups' scores for how common aseptic 
products relate to different clinical areas: 
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Table 5.1.2 Scores for common aseptic products as to relevance for clinical areas 
Aseptic Product/ ö W 
Syndicate Group*" n _ 
" 
"ý ` "ý v> z 
M IL V) (D 0.0 IL 1-- 
Sure 5 5 5 5 5 
Theatres 2 2 5 5 5 
Specialist Diagnosis 1 5 5 1 3 
Grou : Cancer - Current 
Specialist Diagnosis 2 5 5 3 3 
Grou : Cancer - Ideal 
Specialist Clinical Area: 2 5 3 4 4 
ICU - Current 
Specialist Clinical Area: 1 4 5 4 4 
ICU - Ideal 
Note: The Medicine syndicate group considered that local variations would be very high 
in the sense that neighbouring hospitals could have very different patterns for 
general medical activity. Therefore it did not complete this exercise. 
The data established as of most relevant to the research are: - 
" Product Presentation (e. g. minibag plus, prefilled syringes); 
" Ingredients (e. g. ampoules, vials); 
" Patient Type (e. g. child versus adult); 
" Administration (of product to patient) 
- Site 
- Route (e. g. intravenous, intramuscular) 
- Rate 
" Place of preparation Whether product was manufactured (licensed), 
prepared in local aseptic unit or prepared in a 
clinical area; 
" Assembly (by whom, e. g. nurse, pharmacist) 
The currencies that should be considered within the project were identified as: - 
0 Dose / Administration / Product (delivered to a patient) 
0 Ingredients 
One unanticipated result was that different professionals (nurses and pharmacists in this 
case) can use the same words for different things and different words for the same thing. 
Examples include: Administration, Assembly, Ingredients and (Product) Type. This could 
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have consequences for the recording, analysis and interpretation of data, making it very 
important, with the evaluation of Nomenclature being incorporated into the overall project 
(see Section 5.8 for Nomenclature results). 
The out-turn questionnaire survey results (see Section 11.12) were that the workshop was 
a success for how it was organised and its influence on participants. There was a strong 
positive response in respect of Research and Development capacity. 
5.2 Information Systems Data Audit 
A full response was received to the survey of pharmacy information systems, which 
showed there were four main computer information systems/packages used in aseptic 
dispensing departments. These are: Ascribe, JAC Pharmacy Systems, HORIS and MDIS 
(previously McDonnell Douglas Information Systems). Some hospitals had more than one 
of the systems. The number of units where each was used was: 
" Ascribe 13 
" HORIS 2 
" JAC 12 (Including one about to be installed) 
" MDIS 13 
(See Section 11.15 for full results) 
The Data Audit exercise established: 
(a) One feature of the packages is the latitude provided to the user to configure the 
system to reflect local views of situations. In the absence, and even in the 
presence, of wider standards this freedom can lead to differences in product 
definition, coding systems, report formats, data export facilities etc. 
(b) These difficulties only have a limited impact on the research if it quantifies activity 
on a broad product basis, and not at a detailed level. 
All the issues in (a) were evident to the National Prescribing Centre's Hospital Prescribing 
Information Project. It determined that it was impractical to try and collect data below a 
certain level of detail (Jackson and Walker, 1998; National Prescribing Centre, 1998; 
Jackson, 1999), so it concentrated on activity by economic/financial value rather than by 
volume, as was the original aim. Although the Data Audit focused on activity volumes, the 
principles involved were the same and conclusion (b) was drawn. 
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A full response to the audit questionnaire was received, with responses falling into two 
categories: 
" The computer system can provide all target data on the target products currently 
identified automatically 
" The computer system can provide base data relating to the target data and target 
products, but some manual or other processing would be required to meet the 
project data requirements 
For the latter, the additional collation work appeared achievable within the staff capacity of 
the aseptic dispensing unit, if sufficient notice of requirements was given. 
The systems were designed to support the aseptic production process (e. g. production of 
labels, batch numbers) rather than analysis of overall production. Such systems would not 
hold data on what aseptic preparation took place in clinical areas. 
The assessment of the impact of EPS, following the visit to Wirral Hospitals NHS Trust, 
was that they could have an impact on data availability, but their rate of adoption will not 
materially affect the achievement or outcome of the research. 
The workshop was evaluated as successful. It validated the main elements of the Data 
Audit exercise. The results included: 
"A survey of pharmacy-based aseptic activity is realistic, but needs to take into 
account the need for clear guidance notes to ensure consistent data; 
" Not all of the required survey information can be obtained from computerised 
pharmaceutical information systems; 
" An expanded range of product types should be used in the survey (to be 
consistent with the list in Table 9.1 of the North West report on maintaining asepsis 
during the preparation of pharmaceutical products (NHS Executive North West, 
1997). Some product types need to be divided into subcategories to reflect 
differentials in the amount of preparation (e. g. cytotoxics); 
" Clarification of how data might be used is needed to ensure any survey is 
sufficiently comprehensive (e. g. the recording of unaltered TPN bags). 
The out-turn questionnaires' results confirmed the workshop as a success (see Section 
11.22). The report on the Data Audit exercise was amended to take into account its 
findings, and submitted to the expert panel for consideration. Its recommendations were 
endorsed (see Section 11.18). 
155 
This presented the problem that to expand the list of product types would mean that the 
additional products had not been scrutinised as part of the Data Audit. This could not be 
ignored, otherwise the research methodology could be criticised, if the issue was not 
formally addressed. Two options available: (a) approach the Trusts again to ask for 
equivalent information for the extra products, and update the exercise and its results; and 
(b) make an informed judgement as to whether similar results would apply to these 
additional items (which were considered minor in terms of volume). 
The expert panel decided upon option (b) and determined that it was reasonable to expect 
the same results would have applied to the additional product types if they had been 
included in the Data Audit. In response to the workshop's advice, the expert panel decided 
that activity should be quantified by product presentation category, with specific 
breakdowns for cytotoxics, CIVAS products and TPN products, because the different 
types of presentations/manipulations make (substantially) different demands on resources 
in aseptic dispensing units. 
The expert panel also identified that some commercially acquired licensed products, such 
as TPN, can be used in clinical areas without having passed through the hospital's aseptic 
dispensing unit. This was considered a gap to be addressed, so that a full picture of the 
use and/or acquisition of aseptic products could be measured. Consequently, it was 
agreed that three types of data should be collected: 
1. Data about products prepared or manufactured in pharmacy aseptic preparation 
units 
2. Data about the source of aseptically prepared unlicensed products used in a Trust 
3. Data about the use of commercially acquired licensed products used in a Trust 
without further manipulation in a pharmacy aseptic unit before administration to a 
patient 
5.3 Baseline Survey 
All 37 trusts in the North West that produced or used aseptically prepared products 
participated in the survey. All other Trusts confirmed that they did not use them (or their 
use was minimal) and were excluded. 
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Of the Trusts that had not produced or used aseptic products in the original survey 
(Gandy et al, 1998a) all but two responded to the research letter in the affirmative and 
were therefore excluded. Two community Trusts said they did use aseptic products, but 
upon enquiry, both indicated that their volumes were very small and were provided by 
neighbouring Trusts' pharmacies. One was an ad hoc situation. Therefore it was agreed 
that they too would be excluded. 
Table 5.3.1 details the total volumes produced and used by each Trust/site, and Table 
5.3.2 provides details of total volumes produced and used by product type. Table 5.3.3 
summarises the relationship between size of unit and license state. Section 11.25 
provides full details of analyses. 
Key points include: 
" In broad terms, the situation in the baseline was similar to that in the original 
survey (Gandy et al, 1998a): the total number of products produced in North West 
aseptic dispensing units dipped from approximately 1.1 million to just under 1.0 
million, while the total number of products used increased from c. 1.0 million to c. 
1.1 million. 
" The most popular items produced were minibag plus, minibag/infusion and 
prefilled syringes, which together totalled 767,745 products and accounted for 78 
per cent of all the products produced. 
" The seven units that each produced over 50,000 products accounted for 57 per 
cent of all the products produced. The absence of any units having a workload in 
the range 9,000 to 18,000 products naturally divided units into "low" and "high" 
volume. 
" Seventeen of the aseptic units produced products for use outside the Trust. The 
total number of such products was 114,161 (12 per cent). 
" The total number of commercial unlicensed products used was 122,753 (11 per 
cent) - almost double that in the original survey (ibid). Cytotoxics accounted for 94 
per cent of such activity in the latter, but the number only increased by a little over 
3,000. The main increases were in other types of products, with over 20,000 
irrigations and prefilled syringes bought in. 
Note: Some data and analyses from the baseline survey were used in respect of other 
aspects of the research. These are shown in the appropriate section. 
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Table 5.3.1 Baseline Survey: Total volumes produced and used by each Trust/site 
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Code 
II 
m 1E 
- is 
a 
Mý to 
M 
i 
Ög 
s 
N 
z 
z 
ocd 
Zý 
NN Total 
? 
z 
I -a 
S 
Z 
Z 
C 
15 
ý 
a 
-W C 
"Rl 
º- 
Total 
111 19 794 375 I v4 1 I ü- 19 `1 71 v 
ttz 4 311 n 4 A] 11 4.71 _o, z1z 
- 
113 _ 4ä69 435 - 5 14 _04 1,705 
-1 
rn r+ 
114 3,642 32,506 10,783 1 4E , 
.1 143 4,239 71 411 ,;; 
115 55,206 - - 4,735 59,911 " 306 5 .In, 
116 - - - 12,580 - 290 
117 37,385 - - 2,190 39,575 -7,385 10 - - - 3? ri 
111 16,488 - - - 18,4,8 13,488 342 - 2,800 - 11 r. ;u 
120 8,389 6,389 8,389 4,492 - - 1:, ýý; sl 
121 3,730 - 3,730 3,130 100 1,300 65,000 
122 11,873 15,700 600 - 28,173 28,173 1,000 
123 3,561 - 2,561 3,561 2,803 26 443 - S" 
124 449 - - - 149 449 1,678 - 685 
125 1,1369 - - - 1, %'3 1,969 5,730 99 - - 1 
126 - - - - 1,695 4,720 - - r , 
41 
127 3,550 - - - 3`' -W i 3,550 2,703 - 4,850 - 11 
121 3,437 - - 3,4 37 3,437 - - - .I,, 
129 17,972 1,600 - 72 19,644 19,572 8,900 - 2,500 - iii 
130 530 - - - 7 520 7,520 3,470 10, yyu 
131 - - - - - 2,670 - - 2.671-1 
132 41-1,1055 - 726 40,? _83 40,055 207 - - - 41 :r. 
133 4,755 - - 4,755 4,755 2,612 - 11 - 
134 14,981 50,596 38,271 245 104,093 65,067 - - 510 
136 - - - - 236 156 - 
ý. 
136 6 512 - 2,948 - 71,460 68,512 292 - - 1.1 
137 88,105 5,646 4,743 98,494 93,751 107 93, rý, ti 
131 33,377 - - - 33,377 33,377 584 - 21,744 
139 64,814 - - - 64,814 r. ß_., 092 8,999 - 87 - 77,1'.. 
140 3,278 - 2,969 10,830 17,077 - - - 
141 3,719 - 8,719 119 1,066 - 126 
142 45,516 - 866 46,382 45,516 1,084 - 66 - 46 u. r 
143 6, `85 537 637 27 7,786 7,122 146 - 21,420 - 23,1.1.,, 
144 30 21,888 21,858 1,278 - - - 2I . r. 
145 7,190 51,623 4,455 11 63,279 58,813 4 - 141 
146 - - - - - - 
3,962 - - 
147 1.903 - - 18,903 18,903 1,162 - 31 - 10 i i'+r 
148 2,167 - - 2,167 2,167 1473 44 - - 3, i,,; 4 
149 - - - - - - 20 375 - 
150 791 - - 791 791 3,262 - 96 4 14 
151 15 286 1,800 - - 18,086 18,086 rn, 
152 9,686 41690 27,711 887 375 
Z, 7, 75 1,1t 
Total 661,283 208,133 94,360 19,801 983,577 869,506 102,732 6,666 111,153 1,101,151 
% of Total 61.2°0 21.2% 9.6% 2.0% 100.0% 79.0% 9.3% O. 6"ß 11.1' 0.0° 100.0". 
158 
rn 
Q) a 
U 
a 0 
.a a 
Co 
a 
ao U 
a 
O 
Co 
E 
Ö 
co 
Co 
N 
Q> 
cß 
m 
N 
M 
Lo 
Q) 
Fý 
=l C1 O L7 in -! 
6' 
i Cý ? 
Lr, 
O t7 
O 
6 
r 
fý 
ýLf Dý 
r.. _ 
) 
c; - 
iJ 
1 "J 
Cl 
V' 
r 
7 
. - 
ri Cr) O", r--- - - O 
C) Y7 CO V 4n OD O 
C LD `V O O 
i'J 1-14 N O 
le4ol 
) CD C1 CD CD O O C, Cti -i O 
d 
v 
ö O 
-_ : iayl0 
V 
rý . Llý C'J O n-l O CD I'-- M 
L rý M 
rJ Li CO CD (N CO C CO (=' - - 
Kl 
r i-V L(, CO ID Cl M r- o , f. 
,, i `) N M 'c7 N N 
ö : pasua3llu f _ý J N ' r 
gePPJauIuJo j 
, _1 C, 14 O O O m M O LO -7 w (T) LO CA -1 %ID 
sill 
cD 
pasuaw-lu f ö 
Jaulo 
O q, 'i (N M, O LO M Cr) if) N- Ll) "J N 
i- 00 V if tJ N 3 M 
Cl- 7: r LO - in ) o N O 
i i, N N 7 Cr l1 'J 
(V 
O 
M 
L1 7i 
Q) 
pasua a! I' Jotoo z 
-7 6) CO t tt Co !7 7 IiI to 
O CO 1 Cr) (N O") LO Ll'l OD O CJ - - 
O 
=J V 00 -t ' Cr) Lf) 6. C) , , ý 
ID ci ýt r- if) if) Cr) Lf IN rt I'' ' O 
rn . C co 
id ! N 
: tsnil uIi 
"- 6, LT, Lo uD u-) LD Lo r-- 
: 37. P- 
_ Ci ire co OÖ CA (, d L) O CO N ý v CO - r- r- O C) Lu , C) if) O C V CO (1 01 n-, Ll M o 
`- 
. - 
- N m ö c° IJ (N 
1e; ol 
Vý -r o LP CD 
N 
Cr) 
(J 
o o 
M 
LO 
CO C) 
OD 
V 
v 
CO 
Cr) r 
O 
I V CO Iýt M co p O 
:: leiol c: J 
1asflSHN-11ON 
O O r` CC) M r-_ rSr N v L O 
d I Cr) n_ in rn M CO in C) w 
v t Co Ln M N - -r r--- If' M 
- .. O) LO <t co IRP 
t0 
nö Ieiol isnli l9 
SHN 131110 
iý 
1 I 1J") 
CO C) M CD CO C) C) I- `J O M 
C- ý j LIC) U) CC) co (N Cr) rn ff) ; .a 
_ :3 ) OD 
if) CO 
Lf1 6, (7) 6? OD N G n- 
IPIOI rn l N 
N 
a- )PO IS pi 
o rV CO K O if7 t? CO ("V Cr) 471 in M 
C V if) t7 LT, (N r7 (-V rte- iI 00 o . LS O) S ýl CO OO LP m r- N 
z r- fq') . '7 r- L1 i lJ CS' L11 iý-i Cri 
iJ N 
Ielol SWOUled . C, co s, r .0 (n 
IenpiAupuI 
y O V 
0 fa . "D V 
. a y d ö ` y y o CL y 0. ä 
U) ` ö E q o w = ,= (D ` V (A 
= ö V 
xo - m m .ö 
d fl a> 
o IV 
L) 
4, Z Z Z s . - ö 6. 
_ _ 
d 
n a Ia. CL ö U w w 
Table 5.3.3 Relationship between Size of Production and License Status 
Total Products Produced* No. of Licensed Units No. of Unlicensed Units 
50,000 + 6 1 
25,000 - 50,000 3 3 
18,000 - 22,000 1 5 
9,000 - 18,000 0 0 
< 9,000 1 14 
5.4 Baseline Survey Evaluation 
There was a full response from Trusts for Forms one and two. Variable responses were 
received in respect of Form three (see below). 
Only one Trust submitted forms with absolutely no queries. Most others had small queries 
that were quickly addressed (see Table 5.4.1 for illustration of data validation analysis, 
and Section 11.26 for full summary overview) 
The mapping of product types used in the different exercises was showed that 
relationships were clear, and there were no conflicts to prejudice the research (see Figure 
5.4.1. 
Data about commercially-acquired licensed products (Form three) caused problems and 
necessitated updated guidance to be issued. The main problem with the guidance as 
originally written was that it opened the way for a wide range of products to be included 
which were superfluous to the research. Only 12 completed forms were received and 10 
of these included comments that suggested that there was limited confidence in the data. 
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5.5 Quarterly Surveys 
Table 5.5.1 shows the trends in production for participating Trusts over the five 
quarters, in comparison with the baseline. These were mixed with 13 increasing 
activity and eight reducing. The increase was 13 per cent over the five quarters, 
having peaked at 25 per cent after Quarter 3. This was largely due to Trust 152 
reducing production by 82 per cent; this was one of the Trusts having a C&CP capital 
scheme and the unit had to close to enable the scheme to proceed. 
Table 5.5.2 shows the trends in the total production of each product type, in 
comparison with the baseline. The picture of what happened in respect of the 
individual product types show: 
" Two of the most used products from the baseline survey - minibag plus and 
prefilled syringe - increased by around a third and a fifth respectively over the 
period, whilst the other most commonly used product (minibag/infusion) fell by 
about a quarter. This may represent some switch of usage between the products, 
with the aggregate for the three types of products increasing by only 12 per cent. 
" TPN usage fluctuated over the period, although the numbers for each category 
were not large. Those for adults with simple additions increased most (by over 
half in the last quarter), but neonates/paediatrics fell by around 20 per cent. 
" Cytotoxics usage per quarter was generally between 13,000 and 14,000, which 
was up by over 10 per cent from the baseline activity, with a peak in Quarter 3 of 
17,516. 
" The category "Other" was broadly consistent over each of the five Quarters, but 
this level was about four times that in the baseline. 
" The other products demonstrated the fluctuations that often arise from small 
numbers. 
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5.6 Quarterly Survey Evaluation 
Not all of the capital schemes completed within the planned timeframe. Therefore, it was 
not possible to use the five quarterly surveys' data to evaluate the whole capital 
programme. 
The expert panel's evaluation of the efficacy of the revised survey design and associated 
guidelines was that: 
" The quarterly survey design, guidance and processes represented a sound, 
practical method of collecting data on aseptic production and usage; 
" The quality of data was good; 
" The structured approach to data collection meant that, for the first time, there was 
a good picture of practice and activity in the aseptic units across the North West. 
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5.7 Data Available in Clinical Areas 
Table 5.7.1 summarises the types of documentation used in each Trust and clinical area 
covered. 
Tables 5.7.2 & 5.7.3 illustrate the variations in documentation amongst the participating 
Trusts. 
Table 5.7.4 shows the views of the nursing staff interviewed, as to the proportioning of 
shared responsibility of who carries out the preparation and administration of aseptic 
medicines. 
Table 5.7.5 provides details of the types of variables/ product types used in each of the 
audited clinical areas. 
Table 5.7.6 highlights that product types fall into two categories within the clinical area: 
" Category one implies that a currency of one unit dose may be used, as the product 
is recognised as being in its final product presentation state. 
" Products in Category two are those where more than one type of presentation can 
apply. If products are manufactured or pharmacy prepared, again a1 to 1 
relationship is implied. However, some product presentations may be 
interchangeable for the delivery of a particular drug dependent on the preferences 
of the individual clinician or local custom and practice. This would reflect the types 
of ingredients used. It would require individual assessment of the product as to the 
relationship, 1 to n, where n is the exact number of ingredients required to produce 
the final product. 
Table 5.7.7 provides an insight to the amount of recording that would be involved with a 
clinical survey. 
Table 5.7.8 summarises the responses to the alternative options for data collection, if 
continuous data collection did not take place. 
The other main results were the proposals for supplementary projects to address research 
questions identified through the process (see Section 11.23). 
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Table 5.7.2 In Patient Prescription Sheet 
(Also known as Wardex, medicine kardex/sheet, script, medicine chart etc. ) 
Trust Identification Number 
Specified Areas 1 2 3 5 6 7 8 9 
Prescribing Information (Instruction for 
use) 
I'l I-1 1"1 I'l 1,1 I'1 I'l III 
Patient Details H II I, /1 Ivi Iv1 IVI I, (1 II1 
Non administration coding H 11 l1 1'(1 1.1 1"1 
Drug Allergies/Sensitivity [V1 kI kl I. /I 1,, 1 1,1 I'1 II1 
Other Charts in use L Iý1 Iý1 
Once only (and pre anaesthetic) Ill [l IVI TIT -T, /-/I TT Ill Ill 
As required M [VI IVI I1 I'1 I, /1 1-1 1/1 
Regular 11 [I IVI II ICI M l, /l IVl 
Continuous infusion pumps [II 
Drugs prior to admission Iý1 
Medical Gases 11 
Variable dose and time IV1 I'1 
Fluids - (Regime for fluid replacement) I, (1 
PCA and S/C infusion Iý1 
Epidural [1 
Controlled drugs Iý1 
IV Additive administration 'Pharmacy 
Prepared' IV additive labels placement 
Nl 
Nurse Prescribing IJ lýl Iýl Iý1 
Pages found within document 6 4 2 6 6 6 4 4 
Note: Trust No. 4 was omitted from table as it uses a computerised system. 
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Table 5.7.3 Blood and Intravenous Fluid Chart 
(Also known Infusion Chart, Continuous Running Fluids, 24 Hr Fluids Chart etc. ) 
Required information (other than Trust Identification Number 
standard) 1 2 3 4 5 6 8 
Allergies / Sensitivities 1.1 
Affix Label or Enter Batch Number IV] I'll C1 [1 P1 P1 IT1 
Given and Witnessed Signature [? J fýl 1ý1 
Drip set changed I,, 1 
IV site changed ýý1 H 
Infusion Device Number HA 
Intragastric 1ý1 
Note: Trust No. 7 was omitted from table as the two documents are combined within the in 
patient prescription sheet. 
Table 5.7.4 Responsibility for preparation and administration of aseptic medicines 
Preparation & 
Administration 
Clinical Area Type Number of 
Trusts 
50/50 (Doctor / Nurse) 
80/20 (Anaesthetist / 
Nurse) 
Mainly nurses 
Paediatric 
Theatre 
Medical, Surgical, Oncology, 
Paediatric and Intensive Care 
1 
3 
8 
Note: All nursing staff undergo, (internal to individual NHS Trusts), training and 
assessment of the preparation and administration of aseptic medicines. 
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Table 5.7.6 Categories of Product Types 
Category One 
" TPN 
" Eye drops Single product administration, 
" Radiopharmaceuticals Supplied Ready for Administration 
" Cytotoxic within clinical area. 
" Minibag Plus 
Category Two Either single product administration, 
" Minibag/Infusion 
Ready for Administration 
" Prefilled syringes 
or 
Requiring preparation within clinical 
" PCA (devices) 
" Epidural 
area. 
May require the combining of more 
than one ingredient. 
Table 5.7.7 Random Count of Aseptic Preparations Administered 
Clinical Area Number of Administrations 
Theatre 4 
Chemotherapy 12 
Haematology 30 
Surgical 21 
Paediatric ITU 99 
Table 5.7.8 Local views of Frequency of Data Collection 
ID Beds Data ID Beds Data 
No Collection No Collection 
2a 27 Historical 7a 4 Theatres 1x4 or 2x2 1 1x4 
2b 7 Theatres 1x4 3b 18 Month 
3a 8 1x4 4a 24 Month 
5b 7 1x4 5a 28 Month 
9a 33 1x4 6a 24 Month 7 
1a 26 2x2 7b 19 Month 
1b 21 2x2 3 8a 23 Month 
4b 29 2x2 9b 28 Month 
8b 5 Theatres Historical 1 6b 6 
Unable 
2x2 
See Table 5.7.1 for details of the hospitals and clinical areas the ID numbers refer to. 
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5.8 Nomenclature 
Table 5.8.1 sets out the final definitions of key terms agreed for use within the project. Six 
of the definitions showed little or no variation from the original ones presented to local 
staff. Any changes recommended for these by the workshop involved simple refinements 
of detail. The definitions of Parenteral" and "Product" required most debate before 
conclusions were reached. 
Table 5.8.1 Definitions of terms agreed for use within research 
Administration 
Administration is the act of delivering the medicine in the right dose, in the right form, 
via the right route to the right patient at the right time according to both the patient's 
prescription sheet and the administration of medicines policy. 
Administration Begins 
Administration begins with preparing the patient which includes preparing the site / 
line of access for administration, checking the identification of the patient against the 
prescription sheet in accordance with the administration of medicines policy and 
within clinical guidelines for the correct use of equipment (e. g. infusion devices / 
syringe drivers / PCA devices) 
Administration Ends 
Administration ends either when the medicine has been delivered (given to the 
patient) in it's entirety and has been recorded; or can end before all of the prepared 
medicine has been given to the patient should any problem or unwanted effect occur 
(within either the patient or with any equipment used). In either event, the final act of 
administration is ensuring the comfort of the patient and recording that the medicine 
has or has not been given, stating reasons and initiating any necessary action in the 
latter case. 
Assembly 
Gathering together on a cleaned tray, trolley or appropriate work surface, all of the 
items of equipment and pharmaceutical agents required for the aseptic preparation 
and administration of a medicine to a patient, whatever the form, route, and method / 
technique of administration. 
Ingredients 
The collection of pharmaceutical agents, including diluents, infusion fluids and / or 
devices, required in order to achieve the final medicinal product, as defined on the 
patient's prescription sheet. Ingredients can vary according to the strength required. 
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Parenteral 
The administration of medicine(s) by injection. Parenteral methods are identified by a 
variety of routes including Intravenous, Intramuscular, Subcutaneous and 
Intradermal. Less common are: Intrathecal, Intrapleural, Intraperitoneal, Epidural, 
Intra-articular and Intraventricular. 
Preparation 
Preparation follows assembly. It is the procedure of using all of the assembled items 
in drawing up, mixing, combining or reconstituting the pharmaceutical agents, diluents 
and/ or infusion fluids into the right form, combination and strength according to the 
patient's prescription sheet, and via the correct delivery vehicle/ administration 
device. Preparation includes following clinical guidelines for the correct use of 
equipment. 
Product 
Is the whole or a constituent part of a medicine to be delivered to a patient. A product 
can be supplied in it's final form by the pharmacy department or can be supplied as 
individual (licensed) products which are drawn up / combined / reconstituted / mixed 
in the clinical area into the form required immediately prior to delivery to a patient. 
Table 5.8.2 summarises the numbers of words that were established as being used or 
interpreted in different ways, where alternatives were sought for commonly used words by 
professionals in clinical areas. For each term, the number of words included in the initial 
list is shown, together the numbers of words added by local staff during the visits. All of 
the words on the initial list were recognised by local staff, although particular ones may 
not have been generally used locally. It was not feasible to try and establish the relative 
frequency of usage of the different words, and no attempt to do this was made. 
Table 5.8.2 Numbers of words relating to specific terms 
Words relating to: No. of words 
on initial list 
No. of words added 
by hospitals visited 
Total words 
"Acquisition and Custody" 3 5 8 
"Administration" 14 4 18 
"Container" 9 3 12 
"Dosage" 5 4 9 
"Equipment" 12 5 17 
"Ingredients" 11 2 13 
"Preparation" 8 7 15 
"Product" 13 4 17 
"Route" 18 3 21 
Total 93 37 130 
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Table 5.8.3 provides details of the words relating to each term. The words shown in italics 
are those suggested by local staff, with the others being those on the initial list. 
Table 5.8.3 Words commonly used by professionals in clinical areas relating to specific 
terms 
Words relating to "Acquisition and Custody": 
Requisition Supply Issue Storing 
Order Stock Non-stock Storage 
Words relating to "Administration": 
Drug delivery Single nurse administ ration Manipulation 
Reconstitution Drug administration e rror Self administration 
Drug administration Untoward incident Route of Administration 
Single administration Sliding scale Clinical Incident 
Additive PCA Titrate 
Stat Bolus Infusion 
Words relating to "Container": 
Vial Package Ampoule Medicine container 
Syringe Prefilled syringe Minibag Minibag plus 
Bag Medication cassette Box Infusion device 
Words relating to "Dosage": 
Dosage units (mgs etc) Single dose International Units 
Stat dose Single administration Rate 
Amount given Titration Calculation 
Words relating to "Equipment" 
Giving set Gloves Drug Administration Set 
Infusion device PCA device Syringe driver 
Needles Syringes Dressing products I materials 
Apron Gauze swabs Alcohol swab 
Cannula Butterfly Pump 
Venflon Line 
Words relating to "Ingredients": 
Substance Particles Suspension Solution Treatment 
Solids Powder Diluent Additives 
Intravenous fluids Prescription Drugs Component parts Vehicle 
Words relating to "Preparation": 
Assembly Expiry date Batch Diluent 
Expiry time Compatibility Aseptic Mixing 
Preparation date Preparation time Prepared by Checked by 
Witnessed by Reconstitution Dilution 
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Words relating to " Product" 
Substance Stock I non-stock item Solution Treatment 
Powder Form Diluent Presentation 
Solids Generic Name Particles Drug 
Regime Infusion Bag Trade name 
Injection 
Words relating to "Route": 
Parenteral Intrapleural Epidural line 
Subcutaneous Intraperitoneal Pitcath 
Intravenous Intra-articular Infusion device 
Intradermal Central Line Syringe driver 
Intramuscular Arterial line PCA device 
Intrathecal Hickman Line Urinary Catheter into the bladder 
Long lines Porta Cath P. /. C. C. line 
5.9 Collaboration 
The reasons for testing the researcher's established graphical methodology for illustrating 
the inter-relationship between Health Districts (Gandy, 1979) are set out in Chapter 2. It 
allowed for measures of the volumes of patients treated within autonomous NHS 
organisations and the traffic between them, and described the degree of self-sufficiency. 
This passed the first test for methods not directly related to "collaboration" in that the 
Trusts could be seen as equivalent to Health Districts and volumes of aseptic products 
could be seen as equivalent to patients. The degree of self-sufficiency could be deemed a 
measure of "collaboration" because the greater the self-sufficiency of each organisation 
the less collaboration was in place. 
The first results were to define the collaboration measures in a similar way to those used 
between Health Districts, viz. 
Indicator A Percentage (of products) Locally Produced (that were used within Trust) 
= Number of Products Produced for Use within Trust x 100 
Total Products Produced 
Indicator B Percentage (of products) Locally Used (that were produced within Trust) 
= Number of Products Produced for Use within Trust x 100 
Total Products Used 
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It was confirmed that the data required to support the calculation of these indicators was 
all included in that that finally agreed to be collected. Details of the results for each Trust 
in tabular format are shown in Section 11.25. 
Figure 5.9.1 First Draft Collaboration Diagram By Trust Using Baseline Data 
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Figure 5.9.1 shows the results in the diagrammatic format: many Trusts were almost self 
sufficient in their production, with many not providing products for other Trusts, but 
receiving products in from others. The expert panel agreed that the diagram clearly 
demonstrated variations in the interactions between Trusts, which could be readily 
inferred as a measure of collaboration: the more Trusts gathered towards the (100 per 
cent, 100 per cent) point the more Trusts that were (virtually) self-sufficient, and the less 
collaboration was taking place. Therefore increased collaboration would be inferred from 
more Trusts moving away from the (100 per cent, 100 per cent) point. However, the panel 
felt uncomfortable with the measures themselves, in that they were quite difficult to 
describe and conceptualise. This was borne out from pharmacists' feedback. Accordingly 
consideration was given to whether the approach could be modified in some way that 
would be fully acceptable. 
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The process yielded measures that were effectively the inverse of those tried first, and 
used vocabulary that could be readily understood. Products that one Trust to another 
were described as being "exported" by the former Trust and "imported" by the latter. 
Therefore the second indicators tested were as follows: 
Indicator I Percentage of Products Used Locally that are Imported from outside a 
Trust = 
Number of Products Bought in by Trust from outside for Local Use x 100 
Total Products Used 
Indicator II Percentage of Products Produced Locally that are Exported from a Trust = 
Number of Products Produced by a Trust and Supplied to Other Trusts x 100 
Total Products Produced 
Figure 5.9.2 shows the revised version of the diagram using the same baseline data, with 
the analyses in tabular format shown in Section 11.25. 
The expert panel agreed that this version of the diagram again demonstrated variations in 
the interactions between Trusts, which could be readily inferred as a measure of 
collaboration. More importantly, it was able to be readily comprehended by pharmacists 
and managers, a view which was endorsed following dissemination. 
Key results included: 
" Aggregating the data across all Trusts indicated that there were a total of 231,651 
products sourced from outside the trust where the product was used (imported). 
" There were a total of 114,161 products produced within Trusts for use by outside 
parties (exported). 
" The difference between the two is largely attributable to the former including 
commercial unlicensed products, of which there were 122,753. 
(The data used for Figures 5.9.1 and 5.9.2 are provided in Section 11.25). 
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Figure 5.9.2 Import/ Export Collaboration Diagram By Trust Using Baseline Data 
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Application of the model to the quarterly data showed that the evolution of collaboration 
over time could be demonstrated in two different ways. The first is illustrated in Figure 
5.9.3, which is to apply the model to data for each point in time and then place the 
resultant diagrams alongside one another so that the eye can detect changes in the 
patterns. This is supplemented by the actual values of the two indicators for each point in 
time, which can be set in tables and trends quantified using traditional statistical 
techniques, e. g. percentage change from baseline. 
The second way is to calculate the aggregate values of the indicators and then apply them 
to a single diagram, with the sequence being highlighted by arrows linking the points in 
turn, as in Figure 5.9.4. Table 5.9.1 shows the data behind the values. 
The results relating to how the model compared patterns and trends in different areas, 
and for individual product types are shown in sections 5.16 and 5.17. 
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Figure 5.9.3: Import/ Export Collaboration Diagram for Baseline Quarterly 
Equivalent and each Quarterly Survey for Participating Trusts 
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5.10 Work Study 
The work-study professional visited six aseptic units: 
" Burnley General Hospital 
" Manchester Children's Hospital 
" Royal Preston Hospital 
" Stockport Acute Services (Stepping Hill) 
" Whiston Hospital 
" Wirral Hospitals (Arrowe Park) 
See Section 11.28 for full details of the results. The main recommendations were: the 
involvement of pharmacists in the different stages of the aseptic process varied between 
hospitals, and was often not optimal; units which manufacture for immediate patient needs 
and work a five day week should consider seven day working to reduce pressure on 
Thursdays and Fridays to meet patients' weekend requirements; ongoing aseptic 
production cycles/patterns over a week need to be balanced with day-to-day demands on 
staff that can be predicted (e. g. training) or ad hoc (e. g. sickness); grade mix of staff 
should be reviewed to reflect workload; daily data by staff grade and time should be 
collected by units for a minimum of two weeks to enable productivity to be reviewed; use 
and non use times for cabinets should be recorded; the true costs of products should be 
used for pricing products; activity weightings compiled by the Lancashire Aseptic 
Managers (North West Aseptic Task Group, 1998) should be used, together with a revised 
recording system. 
A key conclusion reached was that the establishment of accurate work measured times, 
which could be applied across a broad section of aseptic units, is not practical, because 
of: 
(a) The different methods of work between units. 
(b) The wide variations that occur even within the same unit in making similar 
products. For example, one unit visited prepare 37 different types of syringes, 
where the number of ampoules required to make one syringe can be as many as 
25. 
(c) The process time involved in making similar products can vary depending on the 
speed with which solutions mix. 
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In terms of when aseptic units were operational, the professional stated that "most units 
actually start to use their cabinets at about 9.30 a. m. and finish at about 3.30 p. m. with a 
stoppage of an hour or so for lunch". 
To illustrate the results of timings undertaken in respect of processes, the consultant 
provided examples for different product types. These are shown in Tables 5.10.1 -5.10.3 
below. On the basis of these and his other studies, the consultant considered that the in 
aggregate cabinet time accounted for approximately one third of the total aggregate 
activity time, varying between 25 per cent and 40 per cent for observed products. 
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Table 5.10.1 Selected Process Timings 
Minibag Plus (50 Ml; One Vial per Bag) - Batch of 50 
(Flucloxacillin Ig) 
ELEMENT 
No. 
ELEMENT DESCRIPTION BASIC 
MINUTES 
1 Receive Instructions 1.00 
2 Obtain Worksheets, Batch Nos., Complete Batch No. Book 3.00 
3 Obtain Tray, Tote Box, Vials & Minibags 4.00 
4 Spray Tray, Tote Box, Vials & Minibags 3.00 
5 Set up Computer and Print off 51 Labels 2.50 
6 Obtain Finger Plates & Labels, Attach & Complete Label 1.50 
7 Load Hatch (3 occasions); Unload Hatch (3 Occasions)* 6.00 
8 Gown Up (Suit, Hat, Gloves, Mask, Boots) 3.00 
9 Strip off Outer Wraps of Minibags 3.00 
10 Spray Minibags after Stripping 2.50 
11** Gown Up - Put on Additional Outer Garments 1.00 
12** Clean Cabinet using Spray & Wipes 2.00 
13** Finger Plates, Wipe and put into Cabinet 1.00 
14** Snip off Tops of Vials and Wipe 2.50 
15** Spray Minibags into Cabinet 2.00 
16** Assemble Minibags to Vials 3.00 
17** Clean Cabinet after Use 2.00 
18 Remove Protective Clothing 3.00 
19 Wipe Minibags Dry and Label 5.00 
20 Put into Plastic Bags and Seal, Aside 5.00 
21 Book off Computer 3.00 
TOTAL 59.00 for 50 
Personal Needs /Rest & Fatigue + General Allowances - ADD 
30 per cent 76.70 
Depending on layout of Aseptic Unit. In most Units this would be 8 
occasions in total. 
*` Element used in calculation of Cabinet Capacity 
Percentage of total Process time relating to Cabinets: 23 per cent 
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Table 5.10.2 Selected Process Timings 
Minibag Solution (50 Ml) - BATCH OF 20 (Ranitidine); Syringe used in 
Assembly 
ELEMENT 
No. 
ELEMENT DESCRIPTION BASIC 
MINUTES 
1 Receive Instructions 1.00 
2 Obtain Worksheets, Batch Nos., Complete Batch No. Book 3.00 
3 Obtain Tray, Tote Box, Vials & Minibags 4.00 
4 Spray Tray, Tote Box, Vials & Minibags 3.00 
5 Set up Computer and Print off 51 Labels 2.50 
6 Obtain Finger Plates & Labels, Attach & Complete Label 1.50 
7 Load Hatch (3 occasions); Unload Hatch (3 Occasions)* 6.00 
8 Gown Up (Suit, Hat, Gloves, Mask, Boots) 3.00 
9 Strip off Outer Wraps of Minibags 1.20 
10 Spray Minibags after Stripping 1.00 
11** Gown Up - Put on Additional Outer Garments 1.00 
12** Clean Cabinet using Spray & Wipes 2.00 
13** Finger Plates, Wipe and put into Cabinet 1.00 
14** ) Snap off Tops of Vials, Fill Syringe, Insert Syringe to Minibag, 
15** ) Complete Assembly and Aside 15.00 
16** ) 
17** Clean Cabinet after Use 2.00 
18 Remove Protective Clothing 3.00 
19 Wipe Minibags Dry and Label 5.00 
20 Put into Plastic Bags and Seal, Aside 2.00 
21 Book off Computer 1.00 
TOTAL 58.20 for 20 
Personal Needs /Rest & Fatigue + General Allowances - ADD 
30 per cent 75.70 
* Depending on layout of Aseptic Unit. In most Units this would be 8 
occasions in total. 
** Element used in calculation of Cabinet Capacity 
Percentage of total Process time relating to Cabinets: 36 per cent 
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Table 5.10.3 Selected Process Timings: 
TPN - Neonatal (Time for one TPN Neonatal) 
ELEMENT 
No. 
ELEMENT DESCRIPTION "ONE 
OFF" 
BASIC 
MINUTES 
BATCH 
OF 5 
BASIC 
MINUTES 
1 Receive Instructions 1.00 1.00 
2 Obtain Worksheets, Batch Nos., Complete Batch No. Book 0.40 2.00 
3 Obtain Tray, Vial, Minibag etc. (13 Items on Tray) (Est. ) 10.00 35.00 
4 Spray Tray to Hatch (3 Occasions, 2 Sprays each) 1.20 6.00 
5 Set up Computer, Enter Baby's Name, Amend & Print off 4.80 24.00 
Labels/Worksheet 
6 Obtain Finger Plates 1.50 1.50 
7 Load Hatch (1 occasion); Unload Hatch (3 Occasions) 0.20 0.60 3.00 
x3 
8 Gown Up (Fully Gowned) 5.00 5.00 
9 - - 
10 - - - 
11 - - - 
12** Clean Cabinet etc. 2.00 2.00 
13** Finger Plates to Cabinet 1.00 1.00 
14 - - - 
15 - - - 
16** Assemble in Cabinet (Inc. Wipe Cabinet between Ass. ) 11.60 58.00 
17** Clean Cabinet after Use 2.00 2.00 
18 Remove Protective Clothing 3.00 3.00 
19 - - - 
20 Put up Plastic Bag, put in TPN, Seal and Aside 0.40 2.00 
21 Book off Computer 0.40 2.00 
TOTAL 44.90 147.50 
Personal Needs /Rest & Fatigue + General Allowances - for 5 
ADD 30 per cent 58.40 191.80 
for 5 
TIME FOR ONE 58.40 38.40 
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In addition, there is work undertaken by a Pharmacist that not included in the 
above for 5 Neonatal TPNs. This is summarised as follows: 
(A) Calculate requirements for 5 babies = 11.00 minutes; 
(B) Check all parts of tray preparation before 2nd room = 22.00 minutes; 
(C) Check each tray after completion = 2.50 minutes per tray; 
(D) Balance residue of vials = 6.00 minutes. Average time for Tray = 10.30 
minutes 
** Element used in calculation of Cabinet Capacity 
Percentage of total Process time relating to Cabinets ("One-Off"): 37 per cent 
Percentage of total Process time relating to Cabinets ("Batch"): 43 per cent 
5.11 Unit Time Equivalents 
Table 5.11.1 provides summary details of the progression of the UTE values through the 
process described in Section 4.11. The finally agreed UTE values were ascribed the title 
of "Marker UTEs" by the expert panel, because they are for benchmarking purposes, and 
are not fixed performance targets (see Section 6.8 for discussion) 
Twenty questionnaires were received from aseptic managers across the North West, 
which represented a 69 per cent response. Eighteen of these were handed in at the 
Aseptic Managers Study Day (see Section 4.11). 
Table 5.11.2 provides a summary analysis of the responses. A full analysis is in Section 
11.30. 
The degree of agreement was substantial, with over half of the product categories getting 
an agreement level of at least 70 per cent. The remaining product categories had 
agreement levels of between 40 and 60 per cent. 
The aseptic managers advised that the differences highlighted by the survey seemed 
largely attributable to whether aseptic preparation was licensed or unlicensed. It was 
realised that the preliminary UTE values had actually been set for unlicensed production, 
and UTEs for licensed production had been inadvertently ignored. Therefore it was 
decided that each product should have two UTE values - one for where production is 
licensed and one for where it is not. 
187 
The finally agreed Marker UTEs for licensed and unlicensed units can be seen in Table 
5.11.1, together with the minima and maxima values set by using regression analysis. 
There were strong relationships for both: R2 values of 0.93 & 0.85 when the regression 
line was forced through the origin, and 0.94 & 0.88 respectively when the regression line 
was unforced (see Figures 5.11.1 - 5.11.4). 
When the mean UTE values had been finalised it was realised that the values for 
unlicensed products were broadly 50 per cent higher than the licensed equivalent. This 
was not predetermined, but the expert panel agreed that in retrospect it was a reasonable 
reflection of the difference between the circumstances. 
Table 5.11.1 Summary of Progression of UTE Values 
Preliminary Expert 
View Group 
considered View 
by Expert tested 
Group with Finally Agreed Finally Agreed 
Aseptic Marker UTE: Marker UTE: 
Managers Licensed Unlicensed 
Product Categories Mean Time Mean Mean Minima Mean Minima 
Used In Research (in Time Time (in & Time (in & 
minutes) (in minutes) Maxima minutes) Maxima 
minutes) 
Cardioplegia 15 15 10 7.5 & 15 12 & 23 
Solutions 15 
Cytotoxics 15 15 6 4.8 & 10 7.5 & 
10 15 
Epidural Injections 7.5 7.5 5 4&8 7.5 6& 12 
Eye Drops/Eye 7.5 7.5 5 4&8 7.5 6& 12 
Irrigations 
Irrigations (Exc. 7.5 7.5 5 4&8 7.5 6& 12 
Ophthalmic) 
Minibag Plus 1.5 1.5 1 0.8 &2 1.5 1.2 &7 
Minibag/Infusion 3 3 3 2.4 &3 5 4&8 
Injection Devices 12 12 12 9& 19 18 14 & 26 
Prefilled Syringes 6 6 6 4.8 & 10 7.5 & 
10 15 
TPN -Adult: 45 45 20 15 & 29 30 24 & 41 
Compounded 
TPN - Adult: 15 15 10 7.5 & 15 12 & 23 
Simple 15 
TPN - 45 45 30 24 & 41 45 36 & 60 
Neonatal/Paediatric 
Other* 7.5 7.5 5 4&8 7.5 6&12 
* It was appreciated that "Other" covered a wide range of products. The figure shown was 
thought to strike a balance across the types of products involved. 
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Table 5.11.2 Summary Results from Survey of North West Aseptic Managers as to their 
agreement with the Proposed Average Production TimeslUTEs 
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Cardio le la Solutions 15 19 1 95% 40 25 10 50 
Cytotoxics 15 14 6 70% 27 12 5 60 
Epidural Injections 7.5 15 5 75% 23 16 10 45 
Eye Drops/Eye Irrigations 7.5 14 6 70% 16 8 2.5 40 
Irrigations exc. Ophthalmic) 7.5 18 2 90% 21 14 5 40 
Miniba Plus 1.5 16 4 80% 15 14 0.5 35 
Miniba /Infusion 3 8 12 40% 14 11 3 45 
Infection Devices 12 11 9 55% 23 11 5 50 
Prefilled Syringes 6 9 11 45% 17 11 3 45 
TPN -Adult: Compounded 45 
12 8 60% 41 -5 17.5 90 
TPN -Adult: Simple 15 12 8 60% 31 16 5 90 
TPN - Neonatal/Paediatric 
45 10 10 50% 53 8 17.5 90 
Other 7.5 18 2 90% 20 13 20 60 
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Figure 5.11.1 Regression Chart: Relationship between Minimum & Mean 
Production Times (Unforced) 
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Figure 5.11.2 Regression Chart: Relationship between Maximum & Mean 
Production Times (Unforced) 
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Figure 5.11.3 Regression Chart: Relationship between Minimum & Mean 
Production Times (Forced) 
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Figure 5.11.4 Regression Chart: Relationship between Maximum & Mean 
Production Times (Forced) 
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5.12 Concepts: Capacity and Workload 
5.12.1 Workshop 
Affinity analysis determined that the issues and practicalities that influence performance In 
a pharmaceutical aseptic dispensing unit are: Down-time/Opening Times; Finance 
Arrangements; Facilities; Human Resources; Market; Measurement; Procedural Issues; 
Requirements Planning; Standards; and, Training (see Section 11.33 for full results). 
The key themes identified by the initial group discussion were: 
" Risk management is central to the overall issue. Major investment is required to 
minimise risk. 
" Volume is constrained by quality requirements. This is reflected by the fact that the 
MCA have always stated that productivity bonuses should not be allowed in 
aseptic preparation because of the need to ensure/maximise quality. 
" It would only be possible to (simply) use "cabinet capacity" in respect of workload if 
all aseptic preparation units were designed the same - but they aren'tl The 
introduction of an extra cabinet would not mean a proportional increase In the 
capacity of a unit, because there would need to be similar improvements to the 
overall infrastructure. Nevertheless, the Cabinet should be the starting point. 
" There is a need to cover for unpredictability in demand. Paediatrics is a classic 
example. Larger hospitals should be able to anticipate much of their demand and 
plan work patterns accordingly. 
" The key parameters are: Labour; Facilities; Equipment; and, Time. 
The themes were triangulated to define "Capacity" and "Target Workloads" with the 
syndicate groups adopting very different approaches. Group A adopted a "macro" (top- 
down) approach compared to Group B's "micro" (bottom-up) approach. Details of the 
findings of each are provided in Section 11.34, with key themes and issues summarised 
below. 
Group A identified the positive and negative factors that can increase and decrease 
workload; respective examples were numbers of cabinets and down time. Target workload 
should be the aggregated weighted production activity. The amount of batch production 
was influential. Calculations should only relate to when facilities are staffed, but collecting 
such data would be onerous and meet with resistance. 
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Group B determined that there are constraints in the process flows, particularly cabinets: 
the capacity of a unit is the maximum throughput of the cabinets. Target workload should 
be based on demand and not capacity. Allowance is required for non-production tasks 
such as training. 
5.12.2 Final Workshop Conclusions 
The two syndicate group approaches were complementary to one another, although this 
view was not unanimous. The main overall results are: 
" The research data could be used with Group A's approach although additional 
information would be necessary: Time a Unit was open, Numbers and Types of 
Equipment, and Unit Weightings for Products. 
" Group B's approach required more detailed information than the research data, 
which would be hard to collect, allowing for the fact that no two units are designed 
or resourced the same. 
" Staffing and staff mix are key (see Section 5.14) but even where existing 
information systems provide related data it is not necessarily of a quality or detail 
that would be directly helpful. Pharmacists are reluctant to keep providing more 
and more data, particularly if there is no practical feedback (and the potential 
"threat" of how figures might be (ab)used). 
" The only additional data required for the research is the number of cabinets (i. e. 
laminar air flow cabinets and pharmaceutical isolators), as it effectively describes 
the size of an aseptic dispensing unit. The number of cabinets is required rather 
than the number of associated workstations, because, in practice, in NHS aseptic 
units, only one operator would carry out aseptic manipulation in multiple- 
workstation cabinets at a time. 
" How any figures are used is clearly important. The research (at this point) 
envisaged a benchmarking approach to inform Trusts of their relative position to 
one another, and allow for their different circumstances. To try and specify exact 
workloads and capacities based on the comparatively limited data would be very 
difficult and probably counterproductive. 
The results of the out-turn questionnaire survey were that the workshop was a success 
from the perspective of how it was organised. There were mixed responses about whether 
the workshop and syndicate groups achieved their objectives (see Section 11.36). 
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5.12.3 Views of Expert Panel 
In response to the workshop's advice, the expert panel (upon triangulation) decided that: 
" No consensus could be reached about definitions for capacity and workload. The 
lack of consistency in aseptic unit design was a major constraint. Capacity was 
generally viewed as a measure of a unit's ability to maximise its workload. 
" Each unit or Trust should develop its own capacity plan. Although capacity plans 
should be developed locally, they should be open to external scrutiny, particularly 
where collaborative arrangements are in place. 
The expert panel also evaluated the relative merits of the approaches adopted by the 
syndicate groups and that described in the Work Study report (See Section 11.28) and 
concluded that: 
" Group A's approach is unlikely to be used more than as a theoretical background. 
" Group B's approach requires considerably more information that in the baseline 
survey, to take full account of all the factors (especially on staffing and staff mix) 
that influence capacity. Collecting such a large amount of information for all trusts 
would be difficult in terms of ensuring data quality and consistency. Even if the 
data could be collected, there would still be issues about how it should be used. 
Clarity about the benefits and use of additional data is essential to be able to justify 
requests for data from pharmacists. 
" The approach from the Work Study report was the most practical and acceptable 
choice for utilisation within the research, as its only additional data requirements 
are the number (and types) of cabinets in each aseptic dispensing unit, and 
whether any are used for specialist purposes. The former would be available 
centrally (with Regional Quality Controllers) and the latter represents a reasonable 
"one-off' request. 
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5.12.4 Validation by Regional Quality Control Pharmacists 
The presentation to the validation session at the Audit Training Course in Birmingham 
endorsed and added to the findings, which were all triangulated (see Section 11.38): 
" There is little or no consistency in the design (and some other factors) of aseptic 
units across the country. 
" The mix of units varies in different parts of the country: there are over 30 
Radiopharmacy units in Northern region but only four in the whole of Scotland. 
" There is no general clinical homogeneity across hospitals. 
" "Capacity" is the point beyond which production is "safe". 
" The period against which capacity is measured is key. Friday afternoons are 
particularly busy, compared to the rest of the week. If activity were to be measured 
across the whole of the week (or a longer period) then the "peak" periods would be 
submerged in the statistics, and the aggregate activity level may appear "safe". 
Such detail can only be dealt with locally. 
" The use of the term "capacity" is important: whilst the capacity for a single (half day) 
period from a safety perspective is X, then the capacity for the unit over a year could 
be argued as Xx 10 x 52. However, this is an academic figure because allowance 
should be made for training, leave, etc. Continued "flat out" performance would be 
unacceptable. 
" It would not be realistic to have a situation where production had achieved its capacity 
target for the day (ahead of the end of the day) with the staff then refusing to do any 
more even if there is time and the request is urgent. 
" There is a need to be clear and consistent about any calculations. 
" Each Trust should develop its own capacity plan. 
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5.13 Statistical Indicators 
5.13.1 Developed Indicators 
The statistical indicators that were developed focused on measuring the work actually 
done (which by definition is staffed) utilising available data, including the agreed Marker 
UTEs. The finally determined indicators followed the following stream of logic, based on a 
year's data: 
A Take the number of each of the products produced within the aseptic dispensing 
unit/trust for the period. 
B Weight the number of products by the associated Marker UTE value, allowing for 
whether or not a license is involved. 
C Aggregate the weighted numbers to give a total Aseptic Dispensing Unit Hours 
(ADUH). This represents the total (staffed) time involved in production. 
D Divide the total in (C) by 52 to establish the average total staffed time involved in 
production per week. This is called Aseptic Dispensing Unit Hours per Week 
(ADUHW), and it can be compared locally with the amount of time that a unit is 
normally open, which can vary considerably (Gandy et at (1998)* 1) . 
E The ADUHW is then divided by the number of cabinets in an aseptic unit to give 
Aseptic Dispensing Unit Hours per Week per Cabinet (ADUHWC), to allow for the 
simple assumption that a unit that has twice the number of cabinets as another 
unit should be able to produce twice as many products. 
F The work study exercise established that of the order of one third of the total 
process involves the cabinets, aggregating across all product types. Therefore 
dividing ADUHWC by three gives a reasonable estimate of the average number of 
Cabinet Hours per Week per Cabinet (CHWC), which gives a perspective of how 
intensively these important pieces of equipment are actually used. 
G Clearly the mix of types of products will vary between units and this will impact on 
the way the units operate. In order to gauge the balance between the products it is 
straightforward to divide the aggregate total production time (C) by the total 
number of products produced for the period. This gives The Average Weighted 
Time per Product (AWTP). 
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5.13.2 Calculating the Statistical Indicators Using Baseline Data 
To validate the statistical indicators, their values were calculated for each Trust/unit using 
the baseline data. The results are set out in Table 5.13.1. 
The results demonstrate the wide variation in the use made of the aseptic dispensing unit 
facilities: 
" ADUHW figures ranged from 7 hours to 114 for licensed units and from 2 hours to 
348 for unlicensed units. 
" The number of cabinets was a clear factor, as ADUHWC showed greater 
consistency, although variations were still marked: the indicator ranged from 7 
hours to 38 for licensed and from 1 hour to 69 for unlicensed. The unit with the 
highest figure for licensed units only produced TPNs (which have high Marker 
UTEs). The highest figures for unlicensed units were all for high volume units. 
" CHWC values showed only seven units appeared using each of their cabinets for 
more than two hours per day (with only one being licensed). This assumes that 
cabinet time is one third of the overall aseptic dispensing time. Work- study advice 
was that the range was from 25 per cent to 40 per cent according to the type of 
product prepared. Uplifting the percentage to 40 per cent across the board (i. e. a 
20 per cent increase in the figures shown in Table 5.13.1) would mean that only 
one more unit would meet this level. (It should be appreciated that the statistic is 
by definition an average over a week and that there are necessarily variations in 
the workload, with Thursdays and Fridays generally being highest in preparation 
for the week-end, which would point to the cabinets being used very sparingly at 
other times). 
" The values of AWTP varied between 1.7 and 20.7 minutes for licensed units, with 
a mean of 3.9. However, the higher figure related to the specialist TPN unit, and if 
this was ignored the upper limit was only 6.2 minutes, and the mean reduced to 
3.4. 
" For unlicensed units the AWTP varied between 3.5 and 25.5 minutes, with a mean 
of 9.2. 
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Table 5.13.1 Values of Statistical Indicators Using Baseline Survey Data 
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Sensitivity analyses were applied to the indicators to establish the effects of variations in 
the Marker UTE values (See Table 5.11.1). When the Minimum UTEs were applied, the 
indicators showed reductions of between 20 per cent and 24 per cent for licensed units 
and between 20 per cent and 25 per cent for unlicensed units. For the Maximum UTEs the 
licensed unit indicators increased by between 44 per cent and 78 per cent, whilst for 
unlicensed units they increased by between 38 per cent and 144 per cent The mix of 
products was the main cause for the variations. For example, the figure of 144 per cent 
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was somewhat skewed by the fact that the unit concerned was a large producer of 
minibag plus, the maximum value of which was 7 minutes compared to a mean of 1.5 
minutes. This range was proportionately the largest for any single product category. 
Otherwise the next largest increase was 88 per cent. 
There is a research question as to whether the mix of products influence how much time 
units are used for. However, a scatter diagram (Figure 5.13.1) linking the two relevant 
statistics clearly shows that this is not the case. 
Figure 5.13.1 Scattergram of AWTP and ADUHWC Values for Baseline Data 
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The expert panel concluded that the results demonstrated the value of both the data 
collected and the way it was analysed. The statistical indicators highlighted the diversity of 
how aseptic dispensing units are used across the North West. The derivation of the 
statistics was valid, and whilst there was inevitably a degree of statistical "noise" by the 
very nature of the Marker UTEs, the differences identified were too large to be attributable 
to this. 
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The expert panel advised that the indicators should be used to provide a profile of the 
workload for each unit, thereby enabling comparative performance to be benchmarked 
and interpreted locally to inform the development of capacity or workload. All required 
data is available from the baseline and quarterly surveys, and the Marker UTEs, with the 
number of cabinets readily obtained. 
The response from North West pharmacists, through the zonal networks and reported to 
the expert panel, was positive to the statistical indicators and their usage, illustrating that 
they were readily understood in the field. 
5.14 Modelling 
5.14.1 Capacity planning software 
The following was found in respect of the applicability of capacity planning software to 
NHS aseptic dispensing units: 
Overview 
" MRP2 system, in common with similar systems, is used In planning for the 
utilisation of labour, materials, equipment and facilities. 
" It leads to dynamic planning, applying finite capacity and forward scheduling. 
" It makes allowance for a "just-in-time" system of procurement and the smoothing 
of production cycles. 
" Such systems demand in-depth knowledge of which processes are both robust 
and routine. There was a need to remove variations during production, and for a 
critical mass to be processed that would make such systems financially viable 
(NHS Executive North West, 2001). 
Minimum requirements 
" Complex knowledge to build up product structures which must identify all 
components from start to finish. 
" There must be a definition of the maximum capacity of the equipment and the 
facilities available, including down time for maintenance and cleaning. 
" Staffing capacity must also be taken into account, with an 80 per cent capacity 
allowance generally made. 
" Allowance is made to ensure that external factors such as transport, quality control 
and suppliers' lead-time are included. 
" Any restrictions in the processes must be clearly identified (e. g. bottlenecks). The 
use of critical path analysis is helpful in most cases. 
200 
Constraints 
The systems also require: - 
Complex routine processes to have little variation from day to day. 
" Production processes to take place over relatively long timescales to enable pay 
back time for the planning processes. 
" Product ranges must normally be routine and limited, with minimal non-stock 
output. 
" Large-scale production. 
Evaluation 
The expert panel agreed that little or none of the constraints listed above fit the normal 
NHS hospital aseptic dispensing situation. This is because the planning of such services 
is not routine, there is a lot of variation, and plans cannot be made well in advance. In 
comparison to industry, batch sizes are relatively small, non uniform, and there are 
relatively short timescales involved due to the problems of product stability and storage 
(ibid). 
Given the above it was concluded that such computer models were not easily applicable 
to the NHS hospital aseptic dispensing situation. Therefore this type of approach to 
establishing capacity planning requirements was not really relevant to the research. 
5.14.2 Capacity Modelling 
The evaluation of the applicability of capacity modelling to NHS aseptic dispensing units 
found: 
" Capacity modelling is most easily applied where the main capacity issue is the use 
of (expensive) equipment and manpower is comparatively plentiful or low cost. 
Industry often has expensive equipment that needs to be used as intensively as 
possible, and relatively low cost staff - where the skills required can be acquired in 
a very short time. 
" NHS aseptic dispensing units have relatively low-cost equipment but scarce and 
expensive specialist/professional staff - it can take years to develop staff to fulfil all 
requirements, and when they leave it can have a very disruptive effect, unless 
there has been appropriate succession planning. 
" The wide range of products and specific drug regimens that can be required to be 
provided by a hospital aseptic dispensing unit means that the scope to produce a 
small number of very specific items in very large volumes does not exist. The skills 
have to be in place to accommodate the full range of patient requirements. 
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" Capacity planning for an aseptic unit is primarily a skills management issue, rather 
than one of (solely) process management. Therefore it is not best suited to 
capacity modelling techniques that require detailed statistical, process data. 
5.15 Acute Capacity Planning 
The emerging themes from the interviews (see Sections 11.46 - 11.49 for full details) and 
literature are: 
5.15.1 Chemotherapy Simulation Tool 
The web-based chemotherapy simulation tool enables Trusts and cancer networks to 
input local data and assumptions to understand current and future processes on a "what 
jr basis, down to individual sessions if necessary. Given the complexity - nursing 
requirements are included as well as pharmaceutical -a management consultancy was 
commissioned to construct it, and training is very important. Local data includes 52,000 
different combinations of regimens/cycles/tasks/resources. One aim is to benchmark data 
from the tool's application across the country to inform "best practice". By February 2007 it 
had been rolled-out to six cancer networks. 
5.15.2 Leeds Teaching Hospital 
Pharmacists developed Excel spreadsheets using the national capacity planning tool for 
chemotherapy (NHS Modernisation Agency, 2005), applying local timings. An iterative 
approach was applied to separate and self-contained work: 
"A Daily Planner; 
"A Clinical Trials Planner; 
"A Haematology Clinic Planner; and 
"A Chemotherapy Clinic Planner. 
The amount of data required is limited to a practical level, e. g. the Daily Planner only 
covers four product types, viz. TPN (Adult), TPN (Neonatal/Paediatric), Restricted Items 
(Cytotoxics) and "CIVAS". The latter therefore covers nine product types identified in the 
research, and each would need its own addition to the spreadsheet for it to be 
comprehensive. 
The spreadsheets require a lot of data, which is feasible and necessary for long- 
term/strategic capacity planning. However, far too much data is required to be used to 
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determine daily/weekly staffing and production, which would not be cost-effective. 
Therefore, a more qualitative approach is applied, using local knowledge, skills and 
experience to make practical judgements to balance available staff, and their grades, with 
the planned/anticipated workloads. This involves moving staff and work around to get a 
"best fit". This is far less scientific than using the spreadsheets, and involves more of a 
"feel". 
5.15.3 North Manchester General Hospital 
The local approach uses weekly schedules of each member of staffs daily commitments, 
divided into morning and afternoon, with their time availability for aseptic production on 
each day of the week calculated. The number of hours per week/day is then assigned set 
percentage factors for each person to reflect a combination of the available 'hands on' 
time and the person's competence. By multiplying these together a number of minutes 
availability is determined, before being divided by 4 to give a number of "Staff Time 
Equivalents" (STEs) availability for each person (local practice is that one STE equals 4 
minutes). The percentage factors for competencies for new staff are re-evaluated each 
week. 
The figures for individual personnel are then aggregated, with allowances for pre- 
registration, housekeeping and other duties, to provide a total number of available STEs 
for each day's production, to give a final figure against which production workload targets 
can be judged. 
Daily production projections are made weighting each product type for the number of 
STEs required to make it and then aggregated. A matching process between staff 
availability and production requirements then follows with a suitable reallocation of staff 
and/or workload between days to get an equitable balance. 
5.15.4 Conclusions 
Triangulating the above it is evident that to construct an Acute capacity planning model 
that will cover all product types and circumstances requires significant commitment in time 
and resources that is beyond any single hospital. It would involve a considerable amount 
of local data. In its absence, pharmacists develop practical local solutions where data 
requirements are manageable and the results meet their needs. 
Ideally a standard Acute capacity planning model should be developed, so that it is 
optimal and can enable benchmarking. Given variations in local approaches it would be 
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necessary to establish a consensus about the scope and detail first, before 
commissioning the work. The likelihood of this taking place in the foreseeable future is 
remote, and therefore this represents a boundary to the research. 
5.16 Transferability 
5.16.1 West Midlands Analysis 
Twenty-four Trusts from West Midlands submitted data to the survey. Only one was 
unable to do this, but as it involved a Radiopharmacy (which was not part of the survey), 
this represented a 100 per cent response. The one Trust that used aseptic products but 
did not have a local unit submitted data. Full details of the results are provided in Section 
11.50. 
The number of products produced and used in the West Midlands, by trust and by each 
type of product, during the financial year 2000/01 are shown in Tables 5.16.1 and 5,16.2 
respectively. 
The derived usage of the aseptic dispensing units in the West Midlands, applying the 
"Marker UTEs" is set out in Table 5.16.3. (This table also includes data on how long each 
unit was open, which was included in the consultancy specification, together with an 
indicator of how long each cabinet was in use as a percentage of the time the unit was 
open). 
At first sight the figures for Trust 222 may appear strange. This is because they relate to a 
specific Sterile Fluids Manufacturing Unit (SFMU) which is a specific facility on a major 
hospital site in Birmingham, but which operates as a business and only sells aseptic 
products. The recording of the data is therefore consistent with this situation and with the 
survey guidance. 
It can be seen that the "Aseptic Dispensing Unit Hours Per week Per Cabinet" varies 
considerably across the region. The figures range from 2.41 (Trust 213) to 38.88 (Trust 212). 
The latter unit is somewhat exceptional and is influenced by the large number of 
Neonatal/Paediatric TPNs produced. 
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Table 5.16.3 Derived Usage of Aseptic Dispensing Units in West Midlands (2000/01) 
Using (Mean) Marker Unit Time Equivalents 
Ca tegory 
I icensed 
Licensed 
Code 
71. E 
221 
h 
"= 
e 
s 
850 
il 
= oý 
xs 
4250 
cn x 
= i 
ä 
c 
= 
958 
- 
ö 
z 
-' 
v, 
! 1 
ä 
c 
c 
47'+ 
0 
1, 
ä 
1 
! 
t 
Licensed 222 8 00 4001-1 1 85 5 19 4-1191 -1 - 
Licensed 230 8 50 42 50 10,2 84 2 17 14 41-1 
Licensed 231 9 00 45.00 6073 81=18 
Licensed 232 753 3765 74 87 4 13'1' 
Licensed 233 8 50 42 50 49 64 2 _ 14 H 
Licensed 235 9 00 45.00 56.66 10 t35 '1. 
Unlicensed 211 7 50 37.50 9.34 2 4 67 1. ' 
Unlicensed 212 8 00 40.00 116.63 3 38 88 +. ' 
Unlicensed 213 8.00 40.00 4 81 2 241 
Unlicensed 215 8 25 41.25 5.76 2 288. 
Unlicensed 216 8 00 40 00 30 68 4 7 67 1' + 
Unlicensed 217 8 50 42.50 974 1 9 74 
Unlicensed 218 7 50 37 50 13 37 -' - 1 hi; 1;; 
Unlicensed 219 0 00 40 00 18 9 ' 9 40 
Unlicensed 220 25 41 25 45- 8 5 9 06 2 
Unlicensed 223 00 40 00 24.00 1 24 00 60 
Unlicensed 224 6 50 32 50 42 10 3 14 03 43 
Unlicensed 225 8 33 41 65 24 34 2 12 17 ,ý - 
Unlicensed 226 9LIO 45 00 34 28 4 8 57 I' l 
Unlicensed 227 8 00 41100 14 66 3 
- 
4 89 1 
Unlicensed 228 8 511 42 50 1 16 0i 4 - 
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II 
III I 
.1 
ir+, 
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1 
' The number of hours a Unit was open each day (on average) figures supplied by I rusts 
The number of hours a Unit was open each 5 day week 
This figure simply takes "Aseptic Dispensing Unit Hollis Per Week Per Cabinet" 
as a percentage of the number of hours a Unit was open, based on a5 day week. 
Robert Jones & Agnes Hunt Hospital Oswestry is not included because 
it does not have an aseptic dispensing emit. 
207 
5.16.2 West Midlands versus North West Comparisons 
The results that follow compare the two regions, and include several analyses that can be 
considered for the West Midlands alone. However, they are only shown here to avoid 
repetition. 
The total number of products produced in West Midlands units was 284,212 for 2000/01 - 
which was roughly 30 per cent of the North West baseline production. The sizes of the two 
regions were a little different - the West Midlands population is 81 per cent of that of the 
North West (5,335,598 and 6,595,330 respectively in 1999). Also, the in-patient workload 
for West Midlands was approximately two-thirds that of the North West (using both FCEs 
and Admissions). Calculating aseptic production as a rate against each of these 
parameters shows that there is clearly a different emphasis between the two regions (see 
Table 5.16.4). 
Table 5.16.4 Aseptic Production Rates in West Midlands and North West 
Aseptic Products Produced In 
Trust Units per Thousand: - 
West Midlands Region 
2000/01 
North West Region 
Baseline 
Resident Population 53 151 
Finished Consultant Episodes 216 506 
Admissions 235 562 
This situation is further illustrated by the sizes of the aseptic dispensing units in the two 
regions, in terms of production volumes (see Table 5.16.5). The size of production in 
individual units in the West Midlands is comparatively small. The North West analyses 
talked about units dealing with less than 15,000 products per annum as being "small". 
Only four West Midlands units would register amongst the "large" units of the North West, 
and the largest West Midlands unit with 46,452 units has eight North West units producing 
more products (two were more than double). 
Table 5.16.5 Number of products produced at individual Trusts in the West Midlands, 
compared with the North West 
Number of Products Number of Units producing 
that number of products In 
Trusts in the West 
Midlands 
Number of Units producing 
that number of products in 
Trusts In the North West 
More than 50,000 0 0% 7 21% 
25,000 - 49,999 4 17% 6 18% 
18,000 - 24,999 1 4% 6 18% 
9,000 - 17999 5 22% 0 0% 
Fewer than 9,000 13 57% 15 44% 
Total 23 100% 34 100% 
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The most significant result was that the product profiles in the two regions are totally 
different, as is illustrated in Figure 5.16.1. Key points to note are: - 
" Cytotoxics accounted for 57 per cent of all products in the West Midlands, with a total 
of 161,310. The total for the North West was about 111,000, which represented 11 per 
cent of all products. (However, the actual use of Cytotoxics was almost identical for 
the two Regions, because a substantial volume in the North West is acquired from a 
commercial source). 
" The product most produced in the North West was Minibag Plus (307,000), but the 
number produced in the West Midlands was zero. Clearly this reflected a difference in 
practice. 
" Minibag/Infusions and Prefilled Syringes each involved over 200,000 products In the 
North West, but the respective volumes in the West Midlands were 31,620 and 38,607 
respectively. 
" All other products in the West Midlands had volumes of less than 17,000 per annum, 
with no Cardioplegia Solutions at all. However, aggregating the three TPN categories 
together gives 30,497, which compares to 64,000 in the North West. 
The question of collaboration between Trusts in the West Midlands was explored by 
applying the collaboration diagram (see Section 5.9). The results are shown in Figure 
5.16.2, with the North West situation again shown in Figure 5.16.3 for comparative 
purposes. 
It can be seen that the situation is broadly similar for the two regions, although the SFMU 
situation throws up the clear "outlier" with 100 per cent "exports" and 0 per cent "imports". 
Many West Midlands Trusts largely deal with only their local situation. The majority of 
Trusts do not "export" products and five do not "import" any. Much of the collaboration 
seems to concentrate around the Birmingham area, but there are no clear geographical 
patterns. 
The annual total number of aseptically prepared products used in clinical areas per 
thousand acute admissions was calculated as (4.8 million products x 1000/1,774,000 
admissions =) 2,706 for the North West, using baseline data and data prepared for the 
C&CP (Beaumont, 1999). Therefore the 997,188 aseptic products prepared in pharmacies 
represented 21 per cent of the overall usage. 
Assuming that the same rate of usage applied in the West Midlands would mean a total 
annual usage of (2,706 x 1,209,000 admissions/1000 =) 3,271,251 aseptically prepared 
210 
products in clinical areas in the West Midlands. Therefore the 284,212 products prepared 
in pharmacies represents 9 per cent. 
Figure 5.16.2 Collaboration Diagram West Midlands (2000/01) 
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5.16.3 Overview 
The results and their acceptance by the chief pharmacists of the West Midlands 
demonstrated: 
" That the research and its methods was transferable to other parts of the NHS 
outside the North West; and 
" The power of the approach and the indicators to provide genuinely useful 
information, which could be used to establish differences between different parts of 
the country. 
5.17 Evaluation of Programme 
5.17.1 Coverage, consistency and presentation 
All 36 acute trust sites provided data, including those that did not have an aseptic 
dispensing unit. This represented full coverage of acute services in the North West. 
Figure 5.17.1 sets out the inter-relationship between the data collected on the single 
survey form used for this part of the research, and the previously data collected for the 
baseline and quarterly surveys (see Sections 5.3 & 5.5), and the West Midlands (see 
Section 5.16) which had been agreed by the expert panel. 
These relationships were used to aggregate the baseline data so that comparisons with 
the single survey data were valid. 
The presentation of the results use colour coding to delineate the type of unit(s) involved, 
for ease of reference, as follows: 
RED = Units that were Licensed for both the baseline and 2003/04 surveys, 
BLUE = Units that were Unlicensed for the baseline survey and Licensed for 
2003/04 survey; 
BLACK = Units that were Unlicensed for both the baseline and 2003/04 surveys; 
Full details of the results are provided in Section 11.52. 
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Figure 5.17.1 Inter-relationship between data collected for each Product Type within the 
single survey form (2003104) and the survey design agreed by the expert 
panel 
Single Survey Form (2003/04) Baseline, Quarterly & West Midlands Surveys 
Prepared within Pharmacy for Produced within Aseptic Preparation Unit for 
use within own Trust Individual Patients (Form one)* 
(Production); Produced within Aseptic Preparation Unit for Use 
as Ward Stock (Form one)* 
Outsourced from other Trusts Products used from Source: Other NHS Trust 
(Usage); Licensed Unit (Form two) 
Products used from Source: Other NHS Trust 
Unlicensed Unit (Form two) 
Acquired from Commercial Products used from Source: Commercial 
Sources (unlicensed products) Unlicensed Products (Form two) 
(Usage); Products used from Source: Other (Form two)" 
Prepared within Pharmacy for Produced within Aseptic Preparation Unit for Use 
other NHS Trusts and other users in Other NHS Trusts (Form one) 
(Production) Produced within Aseptic Preparation Unit for Use 
by Non-NHS Users (Form one) 
* Products used from Source: Within Trust (Form two) is the sum of these two 
pieces of data. 
** It should be noted that the number of such products in the baseline data was zero; 
its inclusion is to ensure that no unforeseen sources are inadvertently excluded. 
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5.17.2 Production and usage 
Table 5.17.1 compares the distribution of aseptic dispensing units in the North West by 
licensing type and production volume in the baseline and for 2003/04. There were eight 
more licensed units than there had been in the baseline, increasing the proportion of such 
units from 35 to 59 per cent. Licensed units accounted for 55 per cent of the products 
produced in the baseline and 84 per cent in 2003/04 (see Table 5.17.2). This 
demonstrates that the recommendations from the North West Chief Executives' and chief 
pharmacists' report (NHS Executive North West, 1997) for greater emphasis on licensed 
production were being progressed across the region, and not just focused on those units 
that received capital monies. 
Table 5.17.1 Comparison of Distribution of Aseptic Dispensing Units in the North West 
by Licensing Type and Production Volume: Baseline versus 2003/04 
Baseline 2003/04 
Total Products Produced 
No. of 
Licensed 
Units 
No. of 
Unlicensed 
Units 
No. of 
Licensed 
Units 
No. of 
Unlicensed 
Units 
55,000+ 5 3 9 1 
5,000 - 49,999 3 3 4 3 
18,000 - 24,999 1 4 3 0 
, 000 - 17,999 1 1 2 3 
9,000 1 9 1 6 
OTAL 11 20 19 13 
Table 5.17.2 shows the number of products produced and used by trusts in the North 
West. From the baseline to 2003/04, overall aseptic production in pharmacy facilities 
increased by 48 per cent and clinical use also increased by 45 per cent. At SHA level, 
production more than doubled in Lancashire, increased by two-thirds in Greater 
Manchester and increased by five percent in Cheshire and Merseyside. 
The number of products acquired from commercial sources increased by 89 per cent 
between the baseline and 2003/04, with such products accounting for 14 per cent of all 
products used in 2003/04. 
214 
Table 5.17.2 Changes in Production and Usage by Trust: Baseline to 2003/04 
I Total No. of Products Produced Within I 
Aseotic Preparation Unit Total No. of Products Used from All Sources 
Code Baseline 2003/04 Difference % Chan e Baseline 2003/04 Difference % Chan e 
111 20184 10972 -9212 -46% 21719 63719 42010 193% 
112 4901 10087 5186 106% 25085 15389 9696 -39% 
113 5304 11171 5867 111% 7009 23095 16086 230% 
114 46932 95260 48328 103% 40458 78132 :, i, /t 93% 
115 59941 87716 27775 , 46% 55206 97459 42253 771% 
116 0 0 0 - 12870 38290 25420 198% 
117 39575 62746 23171 59% 37395 59271 21876 58% 
118 18488 27137 8649 47% 21630 29837 8207 38% 
120 8389 86104 77715 926% 12881 36224 23343 181% 
121 3730 4670 940 25% 70130 . 74d70 tI1U 1% 
122 28173 3168 3995 14' ; ;: '(110 2I'11/ 10^, 
123 2561 2938 377 15% 5833 22300 16467 282% 
124 449 2305 1856 413% 2812 10597 7785 277% 
126 0 0 0 - 6415 2759 3656 57% 
127 3550 27202 23652 666% 11103 29015 , 11912 161% 
128 3437 6815 3378 98% 3437 35204 31767 924% 
129 27164 17688 -9476 -35% 41962 78204 36242 867 
131 0 39292 39292 - 2670 41396 38726 1450% 
132 40783 72387 31604 77'/. 40-162 74908 342.1; 85 
134 104093 210867 106774 103% i; 5 X77 86260 20683 : 32°1, 
135 0 0 0 - 392 1520 1128 288% 
136 71460 24712 -46748 -65% l c; i i4 x5931 71171 39^, 
137 98494 70389 . 28105 -29% 93858 66844 -27014 -29% 
138 33377 41241 7864 24% 55705 41441 -14264 -26% 
139 64814 38534 -26280 . 41% 77178 117028 39850 52% 
140 17077 21530 4453 261;, 0 1977 ')(i1! 
141 55101 63018 7917 14% 56577 62572 5995 11% 
143 12541 9579 -2962 -24% 36066 9547 -26519 -74% 
144 21888 36490 14602 67% 23136 36490 13354 58% 
145 L3279 183352 120073 190`; 6. -'920 1 11.152 2: 11.12 3! "., 
147 18903 5874 -13029 -69% 20096 27731 7635 38% 
148 2167 1645 522 -24% 3684 3216 -468 -13% 
149 0 0 0 - 395 764 369 93% 
150 2760 1304 -1456 -53% 11947 18196 6249 52% 
151 1=ýr_ýý 5206 29% 4861 21". 
152 40,102 41';, ...,. i, 4'01, 1G"". 
Total 983577 1454863 471286 48% 1101157 1597420 496263 45% 
Total No. of Products Produced Within 
Aseptic Preparation Unit Total No. of Products Used from All Sources 
Zonal Split Baseline 2003/04 Difference % Change. Baseline 2003104 Difference % Change 
Cheshire & Merseyside 387611 407183 19572 5% 407342 515765 108423 27% 
Greater Manchester 382737 617232 234495 61% 482658 709820 227 662 47% 
Lancashire 213229 430448 217219 102% 211157 371835 160678 76% 
Total 983577 1454863 471286 48% 1101157 1597420 496263, 45% 
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Table 5.17.3 shows changes in production and usage by product type, which were not 
uniform. In the baseline, the three product types with the largest production values were 
Minibag Plus (307k), Minibag/Infusion (241k) and Prefilled Syringes (220k), which 
collectively accounted for 78 per cent of North West production. They accounted for 80 
per cent of North West production in 2003/04: production of Minibag Plus more than 
doubled; Prefilled Syringes production was up by half; and Minibag/Infusions was down by 
almost a quarter. 
It is notable that Cytotoxics production was up by over half, presumably reflecting the 
implementation of the National Cancer Plan (DoH, 2000b). 
All the other product types increased in volumes produced, except TPN 
(Neonatal/Paediatric) and Irrigations, which reduced by 10 per cent & 85 per cent 
respectively. However, care should be exercise because of the comparatively small 
numbers that are involved for each. In terms of usage, the patterns were similar in terms 
of direction to those of production, although the percentages were usually different. It can 
be seen that usage went down for Eye Drops/Eye Irrigations, Injection Devices and TPN 
Adult (Compounded) despite (NHS) production increasing. The reverse was the case for 
TPN (Neonatal/Paediatric). 
A factor in this picture is the use of Commercial Sources (see Table 5.17.4), which went 
up from 123k products for the baseline to 232k in 2003/04 - an increase of 89 per cent. 
However, there were dramatic variations between the Product Types: numbers increased 
for six types and numbers decreased for six types. Although the numbers were often 
limited, the percentage swings were all quite large. Cytotoxics had accounted for 51 per 
cent of commercial products in the baseline, but now accounted for only 32 per cent, 
despite an increase of 19 per cent in their use. This was due to the main change, which 
was the acquisition of over 100k Minibag Plus from commercial sources - almost the same 
as the overall increase in itself. From none being acquired from commercial sources in the 
baseline, Minibag Plus was 44 per cent of all commercial products purchased. 
Table 5.17.5 summarises the aggregate increases in production for each product type, for 
the eight aseptic units that received monies from the capital programme, and compares 
them with the increases originally planned. The increased production in units that did not 
have such schemes was 239,000 products. Six of the eight units did not achieve their 
individual targets, with undershoots ranging from 1,000 to 165,000 for 2003/04. The other 
two units each exceeded their targets by 50,000 products. 
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Table 5.17.4 Changes in Usage of Commercial Sources: Baseline - 2003/04 
FlPröduct Category 
Baseline 2003104 Difference % Change 
C otoxics 62759 74389 11630 19% 
: Epidural Injections 3285 10740 7455 227% 
Ee Drops/Eye Irrigations 2502 1209 -1293 -52% 
Irrigations 21821 0 -21821 -100% 
! Miniba Pius 0 102978 102978 
Miniba ! Infusion 1863 33754 31891 1712% 
Injection Devices 3000 350 -2650 -88% 
Prefilled Syringe 24116 6555 -17561 -73% 
, TPN. Adult: Com ounded 
387 941 554 143% 
TPN, Adult: Sim le Additions 2703 21 -2682 -99% 
TPN-Neonatal! Paediatric 0 650 650 
! Other 317, 0 -317 -100% 
Total 122753 231587 108834 89% 
Table 5.17.5 Projected and Actual production levels for Aseptic Units at Trusts 
participating in the C&CP 
U 
N i ý FZ 
WI 
z 
ui O 
ý E Mö ; ü ° vz 
z U. ZI 
d z 
< z (A 
Pro duct Te ä WQ 
C otoxics 2547 4000 -1453 
TPN (All Types Combined) 1770 5750 3980 
Epidural Injections 4770 0 4770 
Eye drops/irrigations . 5138 100 . 5238 
Irrigations (ex 0 that 3313 200 -3513 
Miniba Pius 223820 155000 68820 
Miniba ! Infusion . 43753 129000 . 172753 
Injection devices* 795 0 795 
Prefilled syringes 56856 163000 -106144 
Other -6290 3000, 9290 
TOTAL 232064 460050 -227986 
5.17.3 Capacity issues 
Figure 5.17.2 shows the percentage change in the key indicators used for workload 
measurement for each category of aseptic unit from the baseline to 2003/04. The total 
number of cabinets (laminar flow cabinets and pharmaceutical isolators) at trusts in the 
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North West increased from 100 to 106. Eight licensed units installed new cabinets (12 
cabinets in total) and four units closed cabinets (six cabinets in total). 
All but five units had dedicated cabinets for preparing cytotoxic products. In 67 per cent of 
the units with dedicated facilities, the intensity of use of the general (i. e. non-cytotoxic) 
cabinets increased by between 4 and 97 per cent. In the other 33 per cent of units, the 
intensity of cabinet use decreased by between 1 and 49 per cent. Excluding a specialist 
TPN unit, all licensed units had average weighted time per product values below 8.0, and 
all unlicensed units had values above 8.0. 
5.17.4 Collaboration between trusts 
Figures 5.17.3 and 5.17.4 provide diagrammatic presentations of the collaboration 
indicators, setting out collaboration for individual product types in total for the baseline and 
2003/04. Overall collaboration between trusts increased over the period. The proportion of 
products exported (indicator II) increased from 12 per cent in the baseline to 27 per cent in 
2003/04. The proportion of products imported (indicator I, which includes commercially 
acquired products) increased from 21 per cent to 33 per cent over the same period. 
Regarding individual trusts, in 2003/04, five trusts exported more than 25 per cent of 
production, with one trust exporting nearly 60 per cent. 
Figures 5.17.5 and 5.17.6 apply the collaboration diagram for individual Trusts for the two 
periods respectively, showing changes in patterns, with Trusts generally moving away 
from the origin: five Trusts exported more than 30 per cent of products in 2003/04 (with 
three over 50 per cent), compared with two in the baseline; twelve Trusts imported over 
45 per cent of products used in 2003/04, compared with seven in the baseline. 
Table 5.17.6 and Figure 5.17.7 demonstrate the changes in the collaboration patterns 
when the focus is the three geographic (and operational) zones in the North West. 
Lancashire has become a significant nett exporter of products with big increases in both 
the percentage exported and imported. Greater Manchester is still a nett importer, despite 
major increases in the percentage products exported, and small increases in the 
percentage imported. By way of comparison, Cheshire & Merseyside is still a nett 
importer, and has more than doubled its percentage imported with a limited increase in its 
exports. The key factor in the situation in Cheshire & Merseyside is the significant 
increase in the acquisition of commercial products. 
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Figure 5.17.3 Collaboration by Product Type for Baseline 
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Figure 5.17.5 Collaboration by Trust for Baseline 
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Figure 5.17.6 Collaboration by Trust 2003/04 
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Figure 5.17.7 Collaboration by Geographical Zone: Baseline - 2003/04 
50% 
45% 
X 40% 
W 
C 
Co 35% 
30% 
To 
Ö 25% 
J 
20% 
15% 
N 
3 10% 
CL 5% 
0 
0% K 
0% 
Table 5.17.6 Analysis of Changes in Collaboration for each Zone in North West: 
Baseline - 2003/04 
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Period Zone A B C D E -(A x 100)/C -x 100)/E 
Baseline Cheshire & Merseyside 40165 347446 387611 59296 406742 10 4% 14 6% 
Baseline Greater Manchester 30643 352094 382737 130564 482658 80% 27 1% 
Baseline Lancashire 43353 169876 213229 41791 211667 20.3% 19.7% 
Baseline Total 114161 869416 983577 231651 1101067 116% 210% 
03/04 Cheshire & Merseyside 67725 339458 407183 176307 515765 16.6% 34.2% 
03i04 Greater Manchester 142869 474363 617232 235457 709820 231% 33 2% 
03/04 Lancashire 179039 251409 430448 120426 371835 41.6% 324% 
03104 Total 389633 1065230 1454863 532190 1597420 268% 333% 
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5.17.5 Scattergrams 
Figures 5.17.8 and 5.17.9 involve the scattergram showing the relationship between 
"Aseptic Dispensing Time per Cabinet per Week" and "Average Weighted Time per 
Product", which was aimed at clarifying whether the mix of products might be an influence 
on how much time units were used for. To allow for the license status of each unit, which 
was a key interest for the 2003/04 data, the baseline data was revisited to produce 
equivalent analyses (see Figure 5.13.1). This shows that whilst the values in total 
suggested that there was no such influence, when the license type is taken into account 
the values for the units that were licensed in both the baseline and 2003/04 are grouped 
together somewhat (except for the specialist TPN unit). 
When the same scattergram is constructed with 2003/04 data it can be seen that for each 
of the license types there has been something of a clustering occur. With the exception of 
a small number of units, the values for all units licensed in 2003/04 are grouped together, 
and these are separate from the values for units that remained unlicensed. The latter 
units, in turn, are seen to be in two distinct groups: those with "Aseptic Dispensing Time 
per Cabinet per Week" of less than 20 hours and those where the value is around 40 
hours - more than double. 
Figure 5.17.8 Scattergram of AWTP and ADUHWC Values by Type of Aseptic Unit - 
Baseline 
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Figure 5.17.9 Scattergram of AWTP and ADUHWC Values by Type of Aseptic Unit - 
2003/04 
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5.17.6 Moving preparation from clinical areas 
Table 5.17.7 sets out the results of applying the calculations developed for estimating the 
percentage of aseptic preparation in clinical areas in the West Midlands (see Section 
5.16), to the 2003/04 data, utilising Admissions, FCEs and Beddays. This was done for 
each of the three zones so as to establish any variations. 
Table 5.17.7 Estimation of Change in Aseptic Preparation Activity in Clinical Areas by 
Geographical Zone: Baseline - 2003/04 
Percentage of Total Demand that took place In 
Clinical Areas If Total Demand Changes pro rata to: 
Baseline FCEs Admissions Beddays 
one 2003/04 2003/04 
_ 2003/04 
Cheshire & Merseyside 72% 66% 64% 63% 
reater Manchester 80% 72% 70% 70% 
Lancashire 79% 69% 69% 66% 
Total 77% 70% 68% 67% 
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The percentage of aseptic preparation in clinical areas decreased from 77 per cent in for 
the baseline to around 67 per cent in 2003/04, when bed-days were used as proxy (the 
choice of the expert panel). If admissions or FCEs are used the 2003/04 figures are 68 
and 70. 
If unused capacity from the C&CP (see Table 5.17.5) were fully taken up and used within 
trusts in the North West, then the percentage of products prepared in clinical areas would 
have reduced to around 60 per cent (using beddays as the proxy). 
5.17.7 Trusts participating in C&CP 
Table 5.17.5 highlights that units included in the C&CP failed to meet their planned targets 
by 228k products, despite two of them significantly exceeding plans. Table 5.17.8 
provides details of the actual increases in production and how these compared with plans, 
for each Trust/unit. 
Detailed explanations for the failure to achieve targets were obtained from the relevant 
chief pharmacists. The details are provided in Section 11.53, and space does not permit 
their being fully quoted here. In summary, the main problem was one of timing and 
economics. When the whole programme was created Chief Executives of purchasing 
Trusts committed to (a minimum of) two years business for the additional production 
volumes. Unfortunately, the implementation of the schemes covered a 5-year period 
rather than the 18 months or so envisaged, which effectively negated the commitment to 
buy two years worth of products: 
" The purchasing Trusts concerned had to acquire the products from somewhere, to 
support the treatment of patients; 
" The climate of the NHS moved significantly more towards proper market conditions; 
" Those units that had increased their capacity in the early stages, and which had 
established transport and supply links, therefore had increased numbers of buyers 
who they could not reasonably refuse (the two units that produced 50k more products 
than originally projected both fell into this category); 
" Some purchasing Trusts were not necessarily realistic about what they should pay for 
products made in other NHS organisations. The producing Trusts were not going to 
produce more products without commitment: Boards will not approve the necessary 
investment in staff for increased production, unless there are guarantees. 
In addition, there were some specific local problems (see Section 11.53). 
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Table 5.17.8 Comparison of Actual & Planned Increases in Production for Trusts/Units 
that received Capital Funding (Anonymised) 
ACTUAL INCREASE Ulfierence D erween rinai masenne curve s 
uU nil A B C D E F G li Total 
C otoxics 2434 -675 -1152 964 0 196 416 364 2547 
E Idural Injections 0 0 0 0 0 0 0 4770 4U0 
Eye drops/Irrigations -425 371 -899 -3889 0 -30 -338 72 5138 
Irrigations (ex 0 that -215 0 0 -3098 0 0 0 0 J313 
Miniba Plus 0 0 113603 "40000 0 23420 109160 17637 223820 
Miniba ! Infusion -15318 4079 -7214 -16000 0 -11732 -12777 15209 43753 
'Injection devices' -483 569 -52 -8 0 53 0 716 795 
Prefilled syringes 3012 17871 5807 8730 0 -4309 22779 2+66 56856 
TPN - Compounded 216 460 34 -237 4107 329 -528 -381 4000 
TPN - Simple Additions -4 1059 -275 498 -1096 "387 756 -481 70 
TPN - Neonatal/Paediatric -122 -82 40 -2300 -194 223 605 "470 -2300 
TPN Total 90 1437 -201 -2039 2817 165 833 -1332 1770 
Other 1693 0 437 -8574 0 154 0 . 5576 
TOTAL -9212 23652 110329 43914 2817 7917 120073 40401 237064 
Pi A- Ji enmmhNA AL Merv 
st/ t A 0 C D E f G H Total 
C otoxics 0 0 0 2000 0 0 0 2000 1000 
Epidural Injections 0 0 0 0 0 0 0 0 0 
'Eye drops/irrigations 0 0 0 0 0 0 100 0 100 
Irrigations (ex 0 tha 0 0 0 0 0 0 200 0 200 
Mintba Plus 0 0 30000 0 0 5000 20000 100000 155000 
Minibs /infusion 0 0 30000 45000 0 15000 35000 4000 129000 
Injection devices' 0 0 0 0 0 0 0 0 0 
Prefilled syringes 20000 40000 0 55000 0 30000 15000 3000 163000 
'TPN - Compounded 0 
0 0 0 0 0 0 0 0 
TPN - Simple Additions 0 0 
0 0 0 0 0 0 0 
TPN - Neonatal/Paediatric 0 
0 0 0 0 0 0 0 0 
TPN Total 0 0 0 0 4250 1500 0 0 5750 
Other 0 0 0 0 0 0 0 310 3000 
TOTAL 20000 40000 60000 102000 4250 51500 70300 112000 460050 
ACTUAL INCREASED AC TIVITY L ESS PLAN NED ADDITIONAL ACTIVITY 
TEUjg Uni A 0 C 0 E F G H Total 
C otoxics 2434 -675 -1152 -1036 0 1% 416 -1636 . 1453 
Epidural In ections 0 0 0 0 0 0 0 4770 4710 
Eye dro rrl ations -425 371 -899 -3889 0 -30 -438 72 . 5238 
Irrigations (ex 0 tha -215 0 0 -3098 0 0 -200 0 . 3513 
Miniba Plus 0 0 83603 -40000 0 18420 89160 -82363 68820 
Miniba /Infusion -15318 4079 -37214 -61000 0 -26732 -47777 1120E . 111153 
Injection devices' -483 569 -52 -8 0 53 0 716 795 
Prefilled syringes -16988 -22129 5807 -46270 0 -34309 7779 -34 . 106144 
TPN - Compounded 216 460 34 -237 
4107 329 -528 -381 4000 
TPN - Simple Additions -4 
1059 -275 498 -1096 -387 756 -481 70 
TPN - Neonatal/Paediatric -122 -82 40 -2300 -194 
223 605 -470 -2300 
TPN Total 90 1437 -201 -2039 -1433 -1335 833 -1332 . 3980 
Other 1693 0 437 -8574 0 154 0 -3000 8576 
TOTAL -29212 -16348 503291 - . 
165914 . 1433 . 43583 49113 . 11598 . 221986 
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5.18 New Information Systems 
Triangulation of the five telephone interviews found that there was no new pharmacy 
(aseptic dispensing) information system, and in all cases the basic functionality and nature 
of the existing systems had not changed and no changes were anticipated. Therefore it is 
concluded that the situation described in the original audit still applied, and would still 
apply beyond the period of the research (see Section 11.57) 
The emerging themes for EPS were triangulated through the interviews and scrutiny of the 
EPS functional specification (CFH, 2007). Summary details from the interviews are 
provided in Section 11.55. 
The triangulated themes are that the planned EPS are output based and aimed at best 
use of medicines and risk reduction. They will not provide the data required by this 
research. For example, a prescription will state the required medicine but not how it is 
delivered (e. g. prefilled syringe, TPN, oral) or how the medicine originates (e. g. made up 
by pharmacy or by nurse on ward). The situation is basically the same as when the Data 
Audit exercise (see Section 5.2) took place, with aseptic preparation data insufficiently 
robust for the requirements of the research and analysing data not straightforward. Few 
hospitals have fully-fledged EPS in place, and rolling them out across all hospitals will 
take considerable time. 
The conclusion is that the new EPS will not generate the data identified by the research in 
the foreseeable future. This suggests that the research conclusions and recommendations 
will remain valid for some time. 
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Chapter 6 Discussion 
6.0 Aim and objectives and research process 
The primary aim of the research was to identify the types of data and ways of measuring 
aseptic preparation and production required to evaluate changes in activity and 
performance over time. The research addressed the following questions: - 
" How should activity relating to aseptic preparation in hospital pharmacies and 
clinical areas be counted, collated and analysed? 
" Can existing information systems readily provide such data? 
" What statistical indicators can be developed to support collaboration and capacity 
planning for (NHS) aseptic production, and to evaluate related initiatives? 
" How can such data and statistical indicators be best utilised? 
The objectives of the research were: - 
0 To establish sound, practical methods of collecting data which meet the needs of 
services; 
" To establish (proxy) statistical indicators that relate to the concepts of 
"collaboration", "capacity" and "workload"; 
" To provide analyses of the data collected to hospital trusts to support them with 
collaborative arrangements and capacity planning; 
" To evaluate the changes engendered by capital investment programmes. 
The practical boundaries of the research also needed to be established, i. e. what is the 
point beyond which the acquisition of data and use of statistical indicators ceases to be 
practical, acceptable and useful to professionals? 
The steps required to achieve these research goals have been outlined in Figure 1.2 in 
Section 1.20. 
6.1 Information Required and Data To Collect 
The first basic question was why professionals and managers require information and 
what data they require? The strength of a workshop approach (see Section 3.1) was that it 
could be structured to progress through linked processes to achieve desired outcomes, 
and enabled wide-ranging, relevant experience and expertise to come together and reach 
consensus: NHS & Industry; managers, pharmacists, nurses, doctors; different areas of 
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hospital care. Group work was carefully prepared to maintain professional balance whilst 
covering the full range of circumstances, with their independence meaning their results 
could be checked for consistency. Validation checks were integral to the structure and 
processes to assure quality outcomes. 
The evaluation of the Affinity analysis (Brassard, 1996) was that it was very successful: all 
participants made contributions; the vast majority could be described as significant. 
Compared with other Affinity Analysis exercises the total ideas generated (216) were at 
the high end of what could be expected, and underwrote the value of the outcome. 
The main outcome from the rest of the workshop was that key decisions were made that 
underpinned the whole of the research: 
" The data relevant to the research was established (See Section 5.1); 
" Data should be acquired by means of a survey; 
" The main data currency should be the Dose /Administration /Product (delivered to a 
patient), which should be assigned to Product Presentation/Type; 
" Product types were used differentially in different clinical areas; 
" The data should be robust across different clinical areas; 
" The importance of nomenclature issues was recognised; 
" The decision was reached that UTEs should be used to weight aseptic production 
rather than SMVs. 
The last point was of critical importance, and it is necessary to set out the reasoning: 
(a) UTEs allow for accurate comparison of total output, with analyses used for safety 
monitoring, long term business plans and strategic planning. Trend analyses use 
UTEs per cabinet, UTEs per person, UTEs per hour, etc. They are used irrespective 
of whether actual production (in any particular site) has the same time relationships. 
Therefore UTEs do not provide a quantitative measurement of efficiency. 
(b) The UTE approach was similar to that developed by Pharmacists in North West 
around costing and product assessment for the collaborative purposes (North West 
Aseptic Task Group, 1998). 
(c) SMVs consist of time studies, direct observations and interviews with aseptic 
personnel, and break down operations into their elements. They require the accurate 
breakdown and timing of all activities plus an understanding of complex formulae. 
Therefore, their calculation is a major exercise involving industrial engineers, and is 
normally only undertaken every five years or so, or when there is significant change. 
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The resources concerned can be considerable. SMVs will be different for each unit, 
and can therefore be used to calculate unit capacities and efficiencies. 
(d) Whilst in theory both approaches could be translated to the NHS, it was probably not 
feasible or practical to introduce SMVs throughout the NHS because of the amount of 
work (and consequent cost) involved. This conclusion was made because SMVs are 
different for each aseptic unit, and whilst Baxter's had four in the UK at the time there 
were over 40 in North West Trusts alone. Also, whereas Baxter's could focus on a 
comparatively limited range of products that are viable commercially (partly because 
of the comparatively large size of the facilities), the NHS has to deal with the full range 
of products and respond to prescriptions direct from clinical areas, often in small units. 
(e) The UTE approach allows the accurate comparison of total output between aseptic 
units and the monitoring of trends, once acceptable values had been determined. 
Their use involves little or no cost, which cannot be ignored within the NHS. 
(f) It was concluded that UTEs should be used as their use for comparing private sector 
aseptic units and monitoring trends is of direct relevance to the NHS and the 
research. 
The evaluation of the workshop by the expert panel (i. e. including the 'control' members) 
was that all aims and objectives had been met. This was a consensus (qualitative) view 
based on the results and outcomes papers, and the collective discussion. The out-turn 
questionnaires' results confirmed the workshop as a success (see Section 11.12). 
The chief impact was the multi-professional consensus about the data and time 
weightings to be collected to measure aseptic preparation and production activity. 
Although some individual aspects were not "new knowledge", linking them together and 
validating their potential for application was. 
6.2 Feasibility of Collecting Data 
Identifying the data required is of little use if it is not feasible to collect it and it is not 
robust. Different approaches were required for data from pharmacies and data from 
clinical areas (see Sections 3.2 and 3.7 respectively). 
The basic premise was that (pharmacy) data should be a by-product of operational 
systems (NHS Executive, 1998). Therefore it was necessary to confirm the pharmacy 
systems used, and then whether they could provide the data. The first step was to survey 
all hospitals' systems, with the second step being to scrutinise them for the identified data. 
The nature of a system is that it is (virtually) the same in whichever hospital it is installed, 
and so it was not necessary to investigate the situation in all hospitals: it was sufficient to 
231 
ensure all systems were investigated, across the spread of the types of hospitals, in case 
the different environments impact. There was little benefit from actually visiting a 
computer, and so a desktop approach analysing manuals, print-outs and similar, backed 
up by a questionnaire covering key issues, represented a robust use of resource. 
The results showed the required data could be acquired, sometimes with additional 
collation work. Data quality would be robust at product type level, but could not be 
guaranteed below this. Therefore, the research could continue. Also, as the systems 
examined were understood to cover practically the whole of the country, this pointed to 
the potential for research findings to be transferable. However, the systems did not hold 
data on aseptic preparation activity in clinical areas. 
To investigate data in clinical areas, the expert panel agreed the research methods should 
involve visits with structured interviews; to investigate ward stocks, prescribing and 
associated processes, existing documentation and recording methods. The number and 
range of clinical areas in all (acute) hospitals in the North West is huge, with the strong 
likelihood of varying practices, policies and documentation. It was impossible to visit all 
clinical areas in all hospitals, and therefore care was taken to visit each type of clinical 
area at least twice, with all different types of hospitals and each geographical zone also 
covered, to ensure that results were robust. This was reinforced by the interviews being 
undertaken by experienced senior nurses. 
It was found that within each NHS Trust, pharmaceutical management, i. e. stock control 
management issues, were managed according to the needs of the individual clinical area, 
within the constraints of budgeting, consultants' preferences, and available 
pharmaceutical resources. Documentation may be standard within a NHS Trust, but it was 
not standard throughout the North West. Whilst such standardisation is desirable, it would 
not be feasible. 
Information was readily available on all stock issued to a clinical area, but stock not 
obtained directly from pharmacy may or may not be recorded, given that it was usually 
required in emergency. Given the small numbers involved, it was noted, but ignored for 
data quality purposes. Aseptically prepared medicines fall into two categories: 
" Category one has a primarily one to one relationship (dose = product), a known 
currency of one single product dose. 
" Category two requires the combination of two or more ingredients and therefore 
has a1 to n relationship. 
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Should 'real-time' data be recorded the responsibility for data capture would fall to nursing 
staff. Historical data could be captured either by pharmacy or nursing staff. Concern was 
raised as to the consistency of data collated by nurses, where there was a heavy 
workload. Additional human resources may be necessary to undertake surveys in such 
circumstances. 
Given the number of administrations carried out in clinical areas, careful consideration 
should be given to what data is actually required. Prudent selection of only the minimum 
necessary should improve the consistency of data capture. Information extracted from 
pharmaceutical systems could be used to support any clinical area surveys. A sampling 
approach would best determine the levels of activity within clinical areas, as it would be 
unrealistic to carry out data collection in all areas 365 days a year. Collecting data on 
product and product dose, over a period of one month per year, or four individual weeks, 
every three months, should provide sufficient and representative data. Selectivity in which 
clinical areas to survey may be required, due to workloads and available resources. 
The importance of these findings is that they confirm the difficulty of acquiring standard, 
routine data for aseptic preparation in clinical areas. Although a negative result, it was 
positive in that it highlights a practical boundary for the research that might then be the 
subject of further work. The findings represent substantial new knowledge, as this Is an 
area not previously explored. The principle of having to rely on "snapshots" to collect 
pharmacy data in clinical areas was reaffirmed by Hardy and Mellor (2007). 
Having established the situation for both pharmacies and clinical areas, it was essential to 
validate the findings through a workshop, which included many professionals from the 
initial workshop for continuity. The results from the out-turn questionnaires confirmed the 
workshop as a success (see Section 11.22). 
6.3 Nomenclature Issues 
The initial workshop identified that there were nomenclature issues relating to aseptic 
preparation that could potentially influence data quality. Therefore it was essential to 
explore their extent and how they might impact on the research. As this was not 
anticipated when planning the research it was necessary to be pragmatic. As structured 
interviews would be required, primarily with nurses, the issues were included in the 
hospital visits, to explore local views and practices for comparison (see Section 3.8). 
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This was recognised as new ground from the outset, as was the need to keep focused on 
the needs of the research. Eight terms were key to the research which were known to 
have multiple interpretations, and which would require explicit definition to ensure their 
consistent use for the purposes of the research. Appropriate definitions were drafted and 
endorsed by the expert panel (which clearly understood the context) before being 
presented for validation to nurses interviewed. They could suggest amendments, which 
were considered by the expert panel to determine final definitions. 
Whilst such specifics were required, it was also desirable to establish how wide-ranging 
nomenclature issues might be. It was decided to try and identify all alternative terms used 
(however frequently) for nine selected words (four of which were included In the 
definitions). To make best use of time at visits, and illustrate what was being sought, the 
expert panel produced an initial list of alternative words, which professionals were asked 
to confirm that they had heard, and then invited to add others. The initial list had 93 words 
for the nine terms and had 37 added -a 40 per cent increase. 
The (interim) results were included in the Data Audit workshop for validation. There was 
debate about the sensitivity and objectivity of their use within and outside the scope of the 
research, and to the implications for the future. Examples of note were: 
1 There is a wide range of Routes of administration, with the most routinely used being: 
Intravenous, Intramuscular, Subcutaneous and Intradermal. Less common were: 
Intrathecal, Intrapleural, Intraperitoneal, Epidural, Intra-articular and Intraventricular. 
2 The term Parenteral was difficult to define explicitly, as it was used in several contexts 
by different professional groups. 
Dictionary definitions of "Parenteral" also differed. For example Mosby's Medical and 
Allied Health Dictionary states: "Not in or through the digestive system" (Glanze et al, 
1986) whilst On-line Medical Dictionary gives "Not through the alimentary canal but 
rather by injection through some other route, as subcutaneous, intramuscular, 
intraorbital, intracapsular, intraspinal, intrasternal, intravenous etc. " (On-line Medical 
Dictionary) 
Some definitions offered by expert panel and workshop members, for the purposes of 
the research, were: 
" The administration of medicines by any route other than the mouth or bowel; 
" The administration of medicines via the intravenous route; 
" Administration by injection which may occur via a number of routes; and 
" Administration by breach of the skin or mucous membrane. 
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Table 5.8.1 details the definition of "parenteral" finally agreed by the expert panel for 
use within the research. 
3 In addition, some nursing staff associated the term "parenteral" with TPN only. A quote 
from the hospital visits was: "We don't prepare TPN on the ward, so this research Is 
not relevant to our area. " 
4 Assembly had very different meanings for pharmacists and nurses. Pharmacists used 
the term when they assembled all of the materials and items together at the beginning 
of the aseptic preparation process in a pharmacy. Nurses used the term when they 
assembled the various components for administering a drug to a patient. 
5 Pharmacists strongly believed that Preparation should exclude licensed products that 
required no aseptic manipulation (unless further manipulation took place once 
received from the licensed unit). Nurses disagreed, emphasising that most products, 
whether licensed or not, require some level of aseptic preparation in the clinical area 
prior to administration. 
6 For pharmacists, the Aseptic Process began on receipt of a prescription. For nurses, 
the Aseptic Process began with hand washing prior to gathering together the items 
required for the preparation of the product in advance of administration. 
7 The definition of the act of actually administering the medicine parenterally was 
debated. A process familiar to every clinician, there was disagreement in choice of the 
word(s) to explicitly describe it. For use within this project, nurses preferred to use 
either Product Administration, or Product Dose. It should be borne in mind that the 
process of giving medicines to patients can mean a number of medicines being given 
during one procedure. One approach to a patient does not necessarily count as a 
single administration. 
8 The term Dose was often colloquially used as a generic term to cover several other 
specific terms. For example, it could be applied to each of the ingredients being 
combined in the (nurses') aseptic process, to the resulting combination, and to the 
actual administration itself. Also, for Patient Controlled Analgesia (PCA) devices, is a 
dose counted as the full content of the delivery vehicle, or one boost administered by 
the patient? Clearly, this term is ripe for confusion. 
9 There are differences uses of nomenclature across countries. The use of some specific 
terminology is different in the US compared to the UK (see Section 11.2 Reference 4) 
sometimes leading to confusion when people communicate across the Atlantic. 
Examples include: batch production; central intravenous additives service (CIVAS); 
dispensing; multidose therapy; and patient specific. 
There is no statistical validity in comparing the number of additional words suggested by 
local staff with the numbers on the initial list, as shown in Table 5.8.2 because the initial 
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list simply reflected the efforts of the expert panel. Nevertheless, despite an extensive 
initial list of 93 words being prepared, local staff still suggested 37 additional words -a 40 
per cent increase. The key issue is the total number and variety of words - 130 words 
were identified as being used in relation to nine main terms: an average of over 14 words 
per term, with a range from 8 (Acquisition and Custody) to 21 (Route). 
Clearly it would be impossible to try and get all staff in all hospitals in the North West (let 
alone the UK) to use just a single set of terms and definitions, which in theory would be 
one way to resolve the issue. The only practical way to address the issues for the 
research was to ensure that there was an explicit set of definitions for key terms, which 
might impact of data quality, for use and reference within the research itself, so as to 
ensure consistency within the research. The work demonstrated new knowledge (Gandy 
et al, 2002). 
6.4 Feasibility of Collecting Data and Creation of Baseline 
Having determined the research data required and ascertained that in principle it should 
be collectable it was necessary to test this in practice, and thereby create a baseline for 
the research. A survey had been agreed as the most practical means, and the structure 
and content agreed following pilot work (see Section 3.3). Validation checks were inbuilt 
which aided data quality. 
Some data in the original survey (Gandy et al, 1998a) was not relevant to the research 
and excluded, or covered in other ways: expiry periods for "tracer" products; whether there 
is scope for increasing the capacity of a unit; whether "on-call" arrangements existed; and, 
times a unit was open. The workshops and expert panel considered these latter times of 
questionable use; given they did not fully reflect local circumstances and their use could 
be misleading. "Time" would be covered by the use of UTEs. Cross-reference to the 
original survey (ibid) enabled confirmation of (non-acute) organisations that were not 
relevant and could be excluded. Anonymous codes were used to encourage responses, 
with the outcome of a 100 per cent response from the 37 Trusts. 
Form Three had been introduced comparatively late in the process to address the fact that 
some licensed aseptic products were being bought commercially and distributed directly 
to clinical areas without further manipulation in a pharmacy aseptic unit prior to 
administration to patients. TPNs were often used in this manner. The concern was that if 
Trusts show an increase in the production and usage of such a product over time, based 
on the analysis of data from Forms One & Two, it is not possible to establish whether this 
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represents a real increase or simply a switch in the use of such commercial products from 
the clinical areas. The list of products from the first two forms was used. 
The overall size of baseline production and usage was in line with the original survey (ibid) 
but there was much greater detail. Details at organisation and product type level are 
shown in Section 5.3. The number of products produced varied considerably between 
aseptic units. Production was generally dictated by whether or not the unit held a "specials 
licence" from the Medicines Control Agency. 
The success of the survey meant there was a robust baseline for the research, and useful 
analyses for immediate local, zonal and regionwide consideration, in the development of 
plans. Whilst the survey repeated some elements of the original survey (ibid) the greater 
detail and robustness of data represented new knowledge. 
6.5 Baseline Survey Evaluation 
However successful the baseline survey might be, it could not be assumed that no 
improvements could be identified. A thorough evaluation process was planned from the 
beginning, and included: interviews with lead pharmacists and managers, canvassing 
views at group meetings, and the opportunity to raise queries and comments, which were 
logged (see Section 3.5). 
These were all summarised for the expert panel's consideration (see Section 5.4), which 
took the view that queries and issues were inevitable because of the nature of the survey 
and the complexity of the subject matter. The main changes agreed were: 
1. Radiopharmaceuticals were excluded from the research, following representations 
from the Regional Radiopharmaceutical Group, because of their special 
characteristics: there are (at least) two separate stages, where staff leave the facility 
and undertake other work in between, which is totally unlike general aseptic 
dispensing unit processes. A complication is that only a limited number of Trusts are 
involved and the departments are not always managed by Pharmacy - Medical 
Physics can have responsibility. 
2. The distinction of whether a cytotoxic was an infusion, syringe or device was removed. 
Data available from pharmacy computer systems did not necessarily provide this level 
of detail, and so pharmacists estimated the split. The split had been proposed 
because pharmacists considered the amount of work involved varied between the 
categories, and allowance should be made. The data had to be robust, otherwise the 
benefits of subdividing the category are spurious. (If anything, the expert panel had 
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been guilty of trying to increase the amount of detail included in the survey beyond 
that dealt with by the data audit exercise (see Section 3.2) because it 
recognised/anticipated differentials in time and resource within certain product types, 
e. g. cytotoxics and TPN, which could be important in workload evaluation. The fact 
that such data could not always be acquired meant the survey had empirically tested 
the boundaries of feasibility). 
3. The amount of work required to collect Form Three data was found to be prohibitive 
(and in some cases impossible). It was not possible to establish a clear definition of 
the commercially-acquired licensed products for which data was requested, and so the 
data received was inconsistent. The forms returned indicated that the number of these 
products used in the trusts was relatively small. Therefore it was agreed that Form 
Three be discontinued. 
4. The question was asked whether terminally sterilised products should be included, but 
they were excluded because they do not really relate to the purpose of the research. 
This was relayed to Trusts to ensure that they had not included such products, with 
the opportunity for any data to be amended accordingly. (No Trusts submitted revised 
data as a result; however, when the final survey was undertaken (see Section 5.17) it 
transpired that one Trust had inadvertently included small numbers; the baseline data 
was retrospectively amended accordingly, but this is not reflected in the results in this 
section). 
5. Other specific data issues and qualifications are summarised below, with the response 
indicated in brackets: 
" There was no scope to highlight which products were produced on site under a 
"specials" licence. (Noted) 
" On Form Two, where commercial compounded TPNs were purchased and 
subsequently used for simple additions then they appeared twice. Similar 
circumstances applied to cytotoxics syringes. (This was deemed acceptable because 
two separate processes were involved) 
" Oral products were not part of the survey or project and were therefore excluded. This 
was because they were not aseptic products. 
" Statements clarifying that a neonatal TPN might involve one compounded TPN plus a 
prefilled syringe were accepted. 
" BCGs should be classed under "Other" rather than be included in another category. 
" Cytotoxics eye drops should be included in "Cytotoxics" and not "Eye Drops". 
" Bladder installations should be classed as "Irrigations" and not "Prefilled Syringes". 
Taking the above into account, and the quality of the data received, the expert panel 
deemed the survey had been a significant success, and should act as baseline for the 
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research. It had established that the basic currency for measuring activity is the number of 
products produced and used by product type. There was complete confidence that the 
amendments to the survey design and guidelines, agreed as a result of the evaluation, 
meant that future data collected would be totally robust. 
This represented a major breakthrough and new knowledge, because for the first time 
there was clarity about data to be collected in respect of aseptic production and usage, 
together with comprehensive guidelines and definitions. 
6.6 Quarterly Surveys 
The five quarterly surveys were designed to collect the data necessary to evaluate the 
overall C&CP, and identify any short-term changes associated with capital schemes. The 
method of collecting data was developed so that pharmacists could record data with a 
frequency that suited them, before collating it and emailing it to the main database. (see 
Section 4.6). 
In the event, ten of the 37 trusts did not submit any quarterly data or there were significant 
shortfalls in the data submitted. They included one trust that had received capital monies 
as part of the C&CP. Some "non-responding" trusts had closed their units, and trusts that 
did not have aseptic units generally did not respond. These trusts were excluded from the 
analysis. The trusts fully included in the quarterly surveys accounted for 71 per cent of all 
aseptic dispensing units and 63 per cent of the aseptic dispensing unit production activity 
across the region according to the baseline survey. They also accounted for 57 per cent of 
the total product usage. 
Longstanding relationships existed between trusts that did and did not participate in the 
surveys, and based on local knowledge, senior pharmacists did not feel that the response 
was skewed, given the regionwide move for greater collaboration. 
Activity and trends in the numbers of products produced at participating trusts throughout 
the survey period are shown in Section 5.5. Overall there was a 25 per cent increase In 
the number of products up until the end of quarter 3, followed by a dip. The fall in the last 
two quarters was largely due to production at one (major) trust being reduced as its 
aseptic unit was replaced with a new unit. If production in that aseptic unit were to return 
to its quarter 3 level when the new unit opened, the overall increase in production across 
the trusts would have been around 32 per cent. Such patterns highlight the important point 
that aseptic units may have to close (albeit temporarily) when changes, developments and 
problems occur. 
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Data from individual trusts fluctuated dramatically between quarters. A small number 
showed reductions in production (other than those being upgraded), but otherwise there 
were notable increases. This perhaps points to better use being made of the units, for 
example, by some moving of activity from clinical areas (Gandy and Beaumont, 2003a). 
The capital schemes did not progress to the planned timetable, which complicated 
monitoring. Only two were completed during the period covered by the quarterly surveys, 
and one of these was right at the end. This meant that the overall impact of the C&CP 
could not be determined. 
The evaluation by the expert panel confirmed the efficacy of the quarterly survey design, 
concluding that the data collection problems (which were outside the researcher's control) 
did not invalidate the research in any way. The analyses of the data over the five quarters 
demonstrated the key objective of establishing how changes/trends could be measured 
and monitored, had been achieved. Although circumstances had conspired against 
measuring the impact of the completed C&CP, the evaluation confirmed that the identified 
research data and how it could be analysed was fit for this purpose. 
The response from the pharmacist community to this component of the research (ibid) 
reaffirmed new knowledge. 
6.7 Collaboration 
When the agreed collaboration model (see Section 3.9) was applied to the baseline data, 
the results (see Section 11.25) showed that the average import figure across trusts (i. e. 
indicator I) was 21 per cent, whilst the average export figure across trusts (i. e. indicator II) 
was 12 per cent. (Products acquired from commercial sources are deemed "imports", 
which means that indicator I will probably always be greater than indicator II). Trusts were 
described as nett importers or nett exporters according to whether the value of Indicator II 
was lower/higher than that of indicator I respectively. 
The majority of trusts did not produce many or any products for other trusts (i. e. indicator 
II was less than 10 per cent). Four of the trusts exported more than 15 per cent of their 
products (indicator II ranged 16 to 37), and were described as "high exporting units". 
These trusts would naturally produce the majority of products for local usage as well. 
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(Trusts without a local aseptic dispensing unit were excluded from collaboration diagrams 
as they necessarily import all products). 
Figure 5.9.3 shows how the collaboration diagram demonstrates changing patterns over 
time: 4/5 units significantly increased their percentage exports over the period; the other 
Trusts are well distributed in their percentage imports, with a cluster of Trusts being 
largely self-sufficient (those grouped around the origin). 
Table 5.9.1 and Figure 5.9.4 summarise the overall picture. The latter shows the way in 
which the percentage of exports has substantially increased whilst the percentage Imports 
originally increased before falling back a little. 
However, if the unit that had closed for capital work had continued at even its Quarter 3 
level (i. e. ignoring any planned increases associated with the scheme), the total number of 
exported products at the end of Quarter 5 would have been 71,421, with a total production 
of 207,131. This would mean that the value of indicator II would have been 34 per cent. 
This suggests that collaboration generally increased throughout the research period. It Is 
inferred that this was the result of both the capital (and other) initiatives - one trust unit 
reopened as a licensed unit during Quarter 3- and a consensus between trusts that 
collaboration should increase. 
As the C&CP did not proceed according to plan, it was impossible to establish its full 
effect on collaboration, as intended. Nevertheless, the results clearly demonstrated how 
the indicators and diagrams could be used to measure/demonstrate "collaboration" both at 
a given point and over time. 
The response from the pharmacist community and the expert panel was positive because, 
for the first time, they had clear and understandable means of describing "collaboration" 
for aseptic production and usage. The conceptual interpretation of "collaboration" In terms 
of "imports" and "exports" was consistent with the fact that hospitals trade with one 
another, and the statistical indicators were simple and used the research data. As a result 
"collaboration" was now measurable. This component of the research clearly represented 
new knowledge (Gandy and Beaumont, 2003b). 
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6.8 Time Weightings 
A central objective of the research was to establish time weightings that could be applied 
to aseptic production activity figures, so that production time could be quantified and 
analysed. As seen in Section 6.1, UTEs would be the means of doing this. The expert 
panel decided that they should relate specifically to the production process: the period 
from the receipt of a request/prescription/order to the approval of the finished product by 
the supervising pharmacist. The question was how to determine their values? 
The first methodological choice was for empirical observation, applying work-study 
techniques. This yielded some valuable results (see Section 5.10) but did not achieve full 
UTE values because of problems, mainly about the work-study professional being present 
in a unit when aseptic preparation was taking place. For example, in order to maintain an 
aseptic environment, the professional could not sit next to the pharmacist or technician 
preparing the products, and to be in the unit at all, the professional needed to "gown up" 
and appropriately cover his monitoring equipment (for example, stopwatch, clipboard, 
paper). In the few units where CCTV existed, the whole of the cabinet was not in view, 
and so UTEs could not reliably be obtained from reviewing the footage. (That the whole of 
the cabinet is not covered by CCTV is not a problem during normal use because 
operators are trained to hold objects up to the camera, for example, for checking). 
Notwithstanding these problems, the work-study professional did identify wide variations 
in the time taken to make up items in a particular product category both between units 
(often depending on the method of work) and within units. For example, one unit visited 
prepared 37 different types of prefilled syringes, with the number of ampoules required to 
make one syringe varying considerably up to a maximum of 25. The process time involved 
in making similar products also varied depending on the speed with which solutions mix. It 
was clear that unless each item in each category was individually times and unless each 
product category in each unit was given its own unique time, establishing UTEs by this 
method was not possible. Undertaking this work was not practical within the scope of the 
research. 
Given this situation an alternative approach was essential, with an iterative process using 
statistical techniques of "multiple perspectives" and "Delphi" (Linstone and Turoff, 1975; 
Linstone, 1984; Surowiecki, 2004) with as much cross-checking as possible (see Section 
3.11). The basis of the approach had been successfully used by pharmacists in the past 
and in industry (see Section 11.2 References 3 and 8). 
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Surowiecki (2004) describes how a crowd's views can be better than those of a small 
group of experts when there is: diversity of opinion; independence of members from one 
another; decentralisation; and a good method for aggregating opinions. The methods of 
validating expert opinion used the North West pharmacists as the "crowd", with these 
conditions applying as they work independently, are geographically separated and freely 
expressed their opinions at all stages of the research. The forms which invited 
confirmation of, or alternatives to experts' proposed LITE values were robust and enabled 
opinions to be aggregated. The adjustment to create UTEs for licensed and unlicensed 
products was effective. 
There was considerable variation in UTE values between the different product categories 
(see Section 5.11). The products produced in high numbers (minibag plus, 
minibag/infusion and pre-filled syringes) all have low UTE values. 
Yet the expert panel saw that the different circumstances and practices of units might 
mean aseptic managers not accepting the UTEs applicability to their local situation. 
Consequently how UTEs were to be used was important. As the emphasis for developing 
capacity plans lay with local Trusts, informed by benchmarking data, it was essential for 
local pharmacists and managers to feel comfortable and confident in such data for them to 
use it. If the UTEs were presented as reasonable mean times which local units could 
compare with what was achieved locally then their threat would be minimised. Such units 
could then analyse what local circumstances or practices might account for any variation 
and act accordingly. However, if the UTEs were presented as fixed (performance) targets, 
say, then they would be viewed and used very differently. Consequently the expert panel 
proposed that the mean UTEs used in the benchmarking analyses should be described as 
"Marker UTEs". 
It was important to appreciate that there will be dynamics in aseptic production which will 
mean that any UTE values will change over time, presumably to reduce. By adopting a 
professional judgement approach to setting Marker UTEs, backed up by empirical 
evidence wherever possible, it is easier to maintain and update a benchmarking database. 
The Marker UTE values represent a major breakthrough because they mean that for the 
first time NHS aseptic production activity can be robustly weighted to reflect the actual 
time involved, which is central to measuring capacity and workload. The confidence 
intervals enable sensitivity analyses to review local performance (Gandy and Beaumont, 
2003b). 
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6.9 Quantifying the Concepts of Capacity and Workload 
As described in Section 3.12 "capacity" and "workload" are essentially concepts that do 
not have a single, measurable meaning. Therefore it was necessary to determine what 
they mean in the context of aseptic production, in a way that can be measured. 
Section 3.12 sets out the reasons for, and the design of an initial workshop to explore this. 
Section 5.12 gives the main results. The Affinity analysis resulted in 91 post-its presented 
by the group (albeit with a small number of duplicates), which were arranged into ten 
Affinity groups. The average number of post-its was approximately 8 per person, above 
average for such exercises; reflecting well on the interest and commitment of the 
participants. The results underwrote the value of the outcomes. 
Independently of one another, the syndicate groups explored very different approaches to 
defining and measuring capacity and workload, but the outcome was that no consensus 
could be reached about their definition. Neither of the models pursued was entirely 
satisfactory, and the lack of consistency in aseptic unit design was a major constraint. 
Capacity was generally viewed as a measure of a unit's ability to maximise its workload. 
Considerably more information would need to be collected than was collected in the 
baseline survey to take full account of the numerous factors (especially on staffing and 
staff mix) that influence capacity. Collecting this large amount of information for all trusts 
would be difficult in terms of ensuring data quality and consistency. Also, even if the data 
could be collected, there would still be issues about how it should be used. Clarity about 
the benefits and use of additional data is essential to be able to justify requests for data 
from pharmacists. 
In light of the above, it was decided that the appropriate way forward was for each unit or 
trust to develop its own capacity plan. The model developed by the NHS pharmaceutical 
production committee was a good example (Lillywhite, 2000). The plan should make 
explicit, for example, a trust's assumptions, resources and constraints. Although capacity 
plans should be developed locally, they should be open to external scrutiny, particularly 
where collaborative arrangements are in place. 
The data collected in the research provide a basis for constructing such capacity plans 
through a benchmarking approach. It enables relativities between trusts to be highlighted, 
and can be used by trusts to inform and justify local capacity plans, taking local factors 
into account. 
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The only additional data specified was the number of cabinets (i. e. laminar air flow 
cabinets and pharmaceutical isolators) because the greater the number the greater the 
potential production. The number of cabinets is required rather than the number of 
associated workstations because, in practice, in NHS aseptic units, only one operator 
carries out aseptic manipulation in multiple-workstation cabinets at a time. 
The workshop was a success in how it was organised, but the mixed responses about 
whether the workshop and syndicate groups achieved their objectives arguably reflected 
the complexity and nature of the subject (see Section 11.36). 
There can be no doubt that this workshop dealt with the most difficult issues of the 
research to date. There were different approaches and viewpoints, generating 
considerable (healthy) debate, with no obvious solutions apparent. Yet such a negative 
outcome was actually positive because, for the first time, the whole issue had been 
formally investigated and any notions that there are straightforward definitions that can be 
readily measured were completely dispelled. This is critically important for pharmacists 
and managers to know so that they do not waste time. 
Identifying that a specific statistical definition of capacity is not feasible and that Individual 
capacity plans should be developed for trusts using a benchmarking approach was an 
important conclusion (Gandy and Beaumont, 2003b), which was triangulated at the Audit 
Training Course in Birmingham (NHS Executive North West, 2001). 
6.10 Statistical Indicators 
Without a single all-encompassing statistical indicator to describe capacity or workload a 
range of statistical indicators are required, which only use the identified data, from which 
(relative) performance can be inferred to inform capacity planning. The iterative process 
for doing this is described in Section 3.13, with the main results of applying them to the 
baseline data shown in Sections 11.40 and 11.52. 
The baseline results showed there was wide variation in the use made of aseptic 
dispensing unit facilities. For example, ADUHW ranged from 7-114 hours for licensed 
units and from 2-348 hours for unlicensed units. The number of cabinets was a clear 
factor, and when this was taken into account (i. e. by using ADUHWC) there was greater 
consistency, although the variations were still marked (7-38 hours for licensed units and 
from 1-69 hours for unlicensed units). The highest ADUHWC figure was for a licensed 
unit that only produced TPNs (which have high marker UTEs). The highest ADUHWC 
figures for unlicensed units were for high volume units. This was not surprising because 
245 
producing a large number of products enables efficiencies in processes to be effected, 
and these efficiencies are not accounted for in the UTE values for unlicensed units. It may 
therefore be appropriate for high volume unlicensed units to use the marker UTEs for 
licensed units, but this is something for the units themselves to consider when assessing 
their performance. 
When considering the time spent using the cabinets, only seven units seemed to use each 
of their cabinets for more than two hours per day. Even if the figure of 40 per cent (the top 
of the range of cabinet time observed by the work-study professional) was used to 
calculate CHWC, only one additional unit would meet this level of usage. It should be 
appreciated that the CHWC figure is by definition an average over a week and that there 
are necessarily variations in the workload, with Thursdays and Fridays generally having 
the highest workloads in preparation for the weekend. This points to cabinets being used 
sparingly at other times. It is arguably unrealistic for some smaller units to increase their 
workload significantly, because they essentially perform an "insurance" role - in other 
words, they are there to provide an essential but irregularly used aseptic facility and must 
be maintained in an operational state in case patient need arises. 
It was reasonable to anticipate that the mix of products would influence how much time 
units were used for. However, a scatter diagram (Figure 5.13.1) linking the two relevant 
statistics clearly shows that this is not the case, as the R2 value was 0.0002. (The R2 
value shows how good one term is at predicting another; if it is 1.0 then given the value of 
one term, the value of another term can be perfectly predicted, but if it is 0.0 then knowing 
one term does not help the prediction of another term at all). 
The numbers of cabinets were "at a point in time" - rather than the average availability 
over a given period. Chief pharmacists on the expert panel advised that the latter would 
be too difficult to collect accurately. Nevertheless, in principle, where there have been 
changes (through expansion or rationalisation) the average available number of cabinets 
could be calculated for a period, and the related indicators would remain valid. 
The results demonstrate the value of both the data collected and the way it has been 
analysed. The statistics highlighted the diversity of what happened in aseptic dispensing 
units across the North West. The derivation of the statistics is valid, and whilst there will 
inevitably be a degree of statistical "noise" by the very nature of the Marker UTEs, the 
differences identified are too large to be attributable to this. The view of the expert panel 
was that there can be no doubt that the statistics are genuinely capable of generating and 
informing local debate about the use and performance of the aseptic dispensing units. 
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The development of the statistical indicators and their application to the baseline (and 
subsequent) data was significant new knowledge that enabled aseptic production 
performance to be evaluated in detail (Gandy and Beaumont, 2003b). 
6.11 Use of Data and Statistical Indicators to Evaluate Change 
A primary purpose of the research was to identify data and means of measuring aseptic 
preparation and production to evaluate the outcome of the C&CP, i. e. to evaluate changes 
in activity and performance over time. The statistical indicators had been successfully 
applied to the baseline data, together with analyses of activity trends over the five 
subsequent quarters. The use of arrows had successfully been used to this end on 
collaboration diagrams. 
The real test of the research findings' efficacy was therefore when survey data was 
available for all North West trusts following the last capital scheme's completion. Section 
4.17 describes the methods, the allowances for organisational changes and the 
requirements of pharmacists relating to data collection. 
Comparing the results from the baseline and final surveys raised many points. There were 
clearly major increases in aseptic production in the North West, with the three main 
objectives of the C&CP achieved: 
" Aseptic production and production capacity significantly increased; 
" Collaboration very much increased between Trusts; and 
9 The balance of aseptic preparation moved towards pharmaceutical units. 
Chief pharmacists across the North West appear to have reviewed local practice and 
assessed risks, and worked collectively to make best use of available resources. More of 
the time-intensive products (which possibly involve most risk) were prepared in-house in 
the aseptic dispensing units. 
The major increase in the number of licensed units reflected regional recommendations 
(NHS Executive North West, 1997), and available facilities (in terms of cabinets) were 
used more intensively. There appeared to be greater consistency in the relationship 
between how intensively cabinets are used and the mix of the products, in line with 
whether a unit is licensed or not. 
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There were major changes in (some of) the export/import patterns for different product 
types, with collaboration increasing, although the individual zones developed different 
emphases. Greater use was made of commercial sources, where appropriate. 
There are clearly differentials between the zones, with Lancashire arguably moving ahead 
further than the others. Interestingly, Lancashire has almost had to "run to stand still", 
given that patient activity greatly increased, and with it (it is inferred) the demand for 
aseptic products. 
Reducing the aseptic preparation taking place in clinical areas to 67 per cent (with 
potential to further reduce it to around 60 per cent) represents a major achievement; the 
figure estimated for West Midlands Region was 91 percent (see Section 5.16). 
Nevertheless, the fact that most of the units having capital schemes did not achieve their 
projected targets was a source of concern. Their chief pharmacists each gave reasons for 
this (see Section 11.53). They were not all the same, and included problems where an 
aseptic unit staff member suffered from repetitive strain injury and the local Occupational 
Health advice placed considerable constraints on how much work could be done. 
Production consequently fell below previous workload levels, although the situation 
subsequently improved. 
The main problem appeared to be one of timing and economics. When the C&CP was 
created Chief Executives were required to sign up for two years business for the 
additional production volumes. Unfortunately, the implementation of the schemes covered 
a 5-year period rather than the 18 months envisaged. The reasons for the delays are not 
relevant to the debate, but such an extended period of implementation effectively negated 
the commitment to buy two years worth of products: purchasing Trusts had to acquire 
products from somewhere, to support patient treatment, and those units that had 
increased capacity in the early stages (which had established transport and supply links) 
therefore had increased numbers of buyers who they could not reasonably refuse. The 
two units that produced 50,000 more products than originally projected both fell into this 
category. 
In addition, the NHS climate moved significantly more towards proper market conditions. 
The view was expressed that some/many of the 'purchasing' Trusts are not necessarily 
realistic about the price for products from other NHS organisations, and this is possibly a 
major hurdle. 'Producing' Trusts will not produce more products unless there is the 
business/commitment. Certainly, chief pharmacists will not get Board approval for the 
necessary investment in staff for increased production, unless there are guarantees. 
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If all the unused capacity from the C&CP were fully taken up and used within trusts in the 
North West, then a further 328,000 products would be made, and aseptic production 
would increase by 81 per cent instead of 48 per cent, with aseptic use increasing by 75 
per cent instead of 45 per cent. 
An evaluation of the individual capital schemes associated with the C&CP is in Section 
11.53. The overall conclusions in respect of the C&CP are: 
1. In the main it was a success, with two Trusts/units far exceeding projected 
volumes and another four significantly increasing production; 
2. Local problems and issues affected the situation at the remaining two Trusts/units, 
but both look forward to increasing activity in the future; 
3. The failure of the internal market arrangements, as originally agreed, impacted on 
several Trusts/units; 
4. Practices at two Trusts in respect of the use of minibag plus need to be noted and 
included in any debate. 
The issue referred to in (4) relates to where, following risk assessment, the view was 
taken that issuing minibag plus, without a vial attached, is a lower risk item for aseptic 
manipulation in clinical areas. Given the predicament at both the Trusts concerned - 
aseptic production was severely constrained at particular points in time - it made sense to 
acquire minibag plus commercially and then issue to a ward for subsequent addition of the 
vial. This led to both Trusts not manufacturing minibag plus themselves at the scale 
originally planned. These two Trusts were responsible for almost all the acquisition and 
supply of undocked minibag plus across the North West. 
It is concluded that the overall Collaborative and Capital programme was a significant 
success. There were instances where ambitions have not been (fully) realised, primarily In 
respect of some of the capital schemes, but this did not detract from the major increases 
in aseptic production, usage and collaboration, and the reduction in aseptic preparation 
taking place in clinical areas. 
The analytical methods developed within the research proved their worth, by enabling the 
analysis of change over time, when quite complex issues were at play. They were 
sufficiently flexible and robust to deal with the various organisational changes that had 
taken place. 
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This was the first complete evaluation of an aseptic dispensing initiative of this size and it 
demonstrated its worth by the lessons and impacts revealed. This provided a practical 
template for the monitoring and evaluation of such programmes as well as local 
performance. 
6.12 Transferability 
It was essential to demonstrate the research data and methods could be used outside the 
North West, to confirm their general applicability. The opportunity arose in respect of the 
West Midlands. In essence the methods involved simply applying the research survey 
methods to the region and then analysing the data (see Section 4.16 and Section 11.50). 
The survey in the West Midlands was a success and provided useful data for local 
purposes. The main value was in how the results showed the very different profiles for 
aseptic preparation in the two regions. For example, it was inferred that many more 
products were prepared on the wards in the West Midlands: extrapolating North West 
figures, using admission data, suggested that circa. 3.2 million products were used by 
trusts in the West Midlands with only 9 per cent prepared under pharmacy control. Nearly 
13,000 products were acquired from commercial sources in the West Midlands, 
accounting for just over 4 per cent of products used, which was much less than the North 
West. The most significant result was that the product profiles in the two Regions were 
totally different (see Figure 5.16.1). 
There was limited collaboration in producing products between West Midlands trusts. The 
average export figure (indicator II) across the 23 trusts that produced aseptic products 
was 13 per cent, with the average import figure (indicator I) being 16 per cent. (These 
compare to 12 and 21 respectively for the North West baseline). It appeared that many 
West Midlands Trusts largely dealt with only their local situation. The majority of Trusts did 
not "export" products and five did not "import" any. Much of the collaboration seems to 
concentrate around the Birmingham area, but there were no clear geographical patterns. 
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Having confirmed the transferability of the research, it is worth noting that it has been 
successfully applied across two regions in the UK, the combined population of which is 
circa. 12 million (Gandy et al, 2003). To put this in perspective, this population is greater 
than that of the majority of countries in Europe. Only seven have a larger population, viz. 
France, Germany, Holland, Italy, Poland, Romania and Spain (United Nations Economic 
Commission for Europe, 2007). This suggests the methods could be applied outside the 
UK, in terms of time and effort, if aseptic preparation and pharmacy arrangements share 
relevant similarities. 
The exercise represented new knowledge and pointed to the prospect that the profiles of 
aseptic preparation and production could be different throughout the UK. 
6.13 Modelling 
A natural step after identifying data and statistical indicators to enable activity and 
performance evaluation of aseptic production is to examine whether they can underpin 
modelling techniques. If this is possible and such techniques can be computerised then 
there would be the opportunity to optimise various projections. 
It was shown that capacity planning software was not easily applicable to the NHS 
hospital aseptic dispensing situation (see section 5.13). A critical review of capacity 
modelling in relation to NHS aseptic dispensing units indicated (see Section 11.41): it Is 
applicable where (expensive) equipment is used and manpower is comparatively plentiful 
or low cost - industry configures a factory/unit to produce very large numbers of a limited 
range of products, and equipment operators are semi-skilled or skilled as opposed to 
professional/specialist; the wide range of products and specific drug regimens provided In 
the NHS means the scope to produce a small number of very specific items in very large 
volumes does not exist - skills have to be in place to accommodate the full range of 
patient requirements; smaller aseptic dispensing units serve an "insurance" role; In effect, 
NHS aseptic units have relatively low-cost equipment but scarce and expensive 
specialist/professional staff, where their absence can have a potentially disruptive effect. 
In terms of Schmenner's Service Classifications, described by Dotchin and Oakland 
(1993), this analysis arguably places (unlicensed) NHS aseptic units as a "Professional 
service", because of the high interaction and customisation and high labour intensity, 
where the latter is defined as a ratio of labour costs to capital equipment costs. By 
comparison, licensed production has low interaction and customisation whilst maintaining 
high labour intensity, which would place it as a "Mass service" (ibkf). 
251 
It is concluded that capacity planning for an aseptic unit is primarily a skills management 
issue, rather than one of (solely) process management. Therefore it is not suited to 
capacity modelling techniques that require detailed statistical, process data. 
NHS initiatives in respect of skill mix and competencies do not appear to be strongly 
linked with what might be required to support improvements in capacity planning 
methodologies, which could in turn benefit from a skills-based quality management 
approach. This connection must be made if capacity planning for aseptic preparation Is to 
go on to the next level, which is necessary if preparation is to be appropriately and 
economically maximised, so that related risks are best managed and minimised (Gandy et 
al, 2006). 
This establishes a clear boundary to the research beyond which it is not feasible for the 
researcher to proceed. 
6.14 Acute versus Medium/Long-term Capacity Planning 
The research data was collected for a quarter and a year. Therefore its efficacy, and that 
of the methods, has only been established for these, or longer periods. However, aseptic 
dispensing unit workload varies over a week for several reasons, often with peaks on 
Thursdays and Fridays to cover week-end requirements (see Section 5.10). Therefore it is 
important to determine whether the research can apply for acute capacity planning, i. e. 
daily/weekly. 
The evaluation included a literature review and contacts with lead pharmacy personnel in 
respect of local approaches, followed by a critical review of the information (some is work 
in progress) (see Section 4.14). 
The national chemotherapy simulation tool (Concentra, 2006) addresses acute capacity 
planning but required considerable resource to develop, great amounts of data (over 
52,000 different regimens/cycles/tasks/resources combinations) and significant training. 
This suggests that acute capacity planning is more complicated than the use of the 
research data and statistical indicators. Yet there are similarities in that the emphasis is on 
local interpretation and data and there is the intention to benchmark data. 
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The tool utilises the approach from Shield (2004) for unlicensed situations. There is no 
batch processing/licensed model available. Inevitably some networks and Trusts will have 
licensed facilities, which will incorporate (some) batch production. Indeed, commercial 
organisations such as Baxter's use batch processes considerably and provide 
chemotherapy for major centres such as Christies in Manchester. 
The complexity is also reflected by hospitals having to develop local means of projecting 
daily/weekly production requirements and matching them to staff (and skill) availability. 
The suggestion that the Excel spreadsheets developed at Leeds act as a basis for 
publication, despite limited coverage, highlights the lack of sophisticated, comprehensive 
models for acute capacity planning (see Sections 11.48 and 11.49). 
Local developments mean the aseptic production process may be broken down differently 
by different hospitals in their models, and innovations can apply, such as "Staff Time 
Equivalents" to allow for competencies (see Section 11.49). Approaches are pragmatic 
and been successfully applied to local circumstances. The technical efficacy of some 
might be questioned. 
Such approaches use projected/planned workloads, which are prospective in nature, and 
which can be fairly readily set. To try and optimise production on a daily/weekly basis 
could be difficult because assumptions would need to be built in about what ad hoc 
requests might arise daily. Such demand would mean statistically analysing historic daily 
data and calculating means and ranges. 
No doubt the research methods and Marker UTEs can be applied to retrospective and 
prospective daily and weekly data, if so desired. However, as the time covered by the 
UTEs does not cover all tasks and requirements, the resultant analyses would be of 
questionable value. To develop a sophisticated, comprehensive computer-based model 
that can automatically project the demand for aseptic production for each day of the next 
week, and match the necessary staff and other resources, whilst allowing for holidays, 
training, etc. in both licensed and unlicensed facilities, would require time and investment 
beyond the researcher. That there is a need for such a model for acute capacity planning 
is clear, but like some of the other issues raised, it is effectively a practical boundary to the 
research covered by this thesis. 
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6.15 Impact of New Information Systems 
As information systems develop, they might include data previously unavailable. Section 
5.2 indicates that pharmacy systems provide data for aseptic production, albeit sometimes 
with additional collation. The check in November 2005 confirmed that this situation is 
unlikely to change (see Section 5.18). 
The acquisition of data relating to aseptic preparation in clinical areas requires surveys 
(see Section 5.7). The priority placed on introducing EPS throughout hospitals (NHS 
Executive, 1998) offers the potential for such data to be collected, in which case 
professionals could have the information they require to support clinical governance In this 
regard. It is therefore important to clarify the likelihood that current EPS plans will Include 
a requirement for related data. 
Section 4.18 describes how information about the new EPS was triangulated, confirming 
that they are required to interface with pharmacy stock control systems, for the 
foreseeable future they will not provide data for aseptic preparation in clinical areas 
relevant to this research. Therefore quantifying such activity will require surveys or other 
estimates. This is important new knowledge that sets a practical boundary for the 
research. 
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6.16 Use of Research Data and Statistical Indicators 
It bears summary that the research has confirmed what data is required in respect of 
aseptic preparation and production, and has provided methods of collecting the latter. 
Applying the Marker UTEs to the activity data provides important analyses to support 
capacity planning. Because no two aseptic units are the same (NHS Executive North 
West, 2001) and because the research statistical indicators reflect, or are proxies for 
concepts such as "capacity", "workload" and "collaboration", the data and indicators 
should be used on a benchmarking basis. 
Nevertheless, information can be a double-edged sword, and whilst some pharmacists are 
keen to obtain data and use it to explore issues and influence their plans, there can be no 
doubt that some will see making their local performance transparent as a threat. Therefore 
perverse incentives can apply (Gandy, 2004), which may reflect local politics and 
agendas, and the prevailing style of management. 
Ideally there would be a nationwide benchmarking database using the research methods 
and findings, in order that consistent data can be collected across Trusts and pharmacies, 
with organisations set into appropriate categories so that like can be compared with like. 
This would enable objective comparisons to help inform capacity planning and clinical 
governance, and the evaluation of specific initiatives. The researcher did try to create a 
benchmarking club to this end (Aseptic Benchmarking Club©, 2002), but found that 
Trusts/pharmacies were not prepared to pay the economic cost (£395 + VAT In 2002) to 
participate. Therefore it is inferred that a database should be web-based to maximise 
accessibility and be free to users, i. e. governmental funds and/or advertising revenue 
would be required. Such a website should have a facility to enable the values of the 
Marker UTEs to be updated. 
There could be no compulsion for Trusts to use the database, given the trend for them to 
operate in a competitive healthcare environment (Secretary of State for Health, 2005) but 
equally there are advantages in their collaborating with one another for aseptic dispensing 
and usage purposes. A national web-based database therefore would offer a practical 
third-party means of moving forward, with it anticipated that the major Trusts which see 
aseptic preparation as a key issue readily participating. Peer pressure would undoubtedly 
draw in other Trusts. 
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Chapter 7 Further Work 
7.1 Connecting with Hospital Service Activity and Plans 
Pharmacy is a critical support service within a hospital, with aseptic dispensing units a key 
component. The research identified how aseptic preparation should be counted, quantified 
and analysed for both production and usage, to support the capacity planning and 
evaluation of these services. But it must be emphasised that it is a support service and 
that the amount of aseptic preparation required in the future will be dictated by the size 
and nature of patient activity undertaken in hospitals at the time and will reflect clinical 
trends and related guidance, such as the publication of national advice on injectable 
medicines in late 2007 (Hardy and Mellor 2007). Therefore a priority area for further work 
is to make the connection between aseptic preparation and the different services provided 
by hospitals. 
If hospital information systems will not provide data on the number of aseptic preparations 
then it is important to create some means of estimating this. One way is to undertake 
regular surveys to directly collect data on such activity, from which extrapolations can be 
made for set periods. The alternative is to determine the relationships between the use of 
aseptic products and particular hospital services and (types of) specialties, so that they 
can be used as proxy measures to translate stock issue data into reasonable estimates of 
the total number of aseptic preparations undertaken in clinical areas. (Section 11.23 
describes supplementary projects for this purpose). By then identifying the number of 
pharmaceutically prepared products that have been used in the hospital, it would be 
possible to calculate, and therefore monitor for clinical governance purposes, the 
percentage of aseptic preparation undertaken in clinical areas and in pharmacies. 
Hospital Trusts and Primary Care Trusts are required to have capacity plans for their 
patient services, so that any capacity gaps can be addressed to ensure that key targets 
such as the 18-week patient pathway are achieved (DoH, 2006). Details include the 
numbers of different types of cases (non-elective inpatients, elective Inpatients and 
outpatients) for each specialty on an annual basis for future years (see Section 11.2 
Reference 13). It would be desirable to match the capacity plans for aseptic preparation 
with Trusts' service capacity plans to ensure that they are as consistent. This would need 
to involve specialty and type of case-specific rates of aseptic preparation, given that the 
use of aseptic preparations varies between them. Set out below is an outline of the type of 
approach and further work that would be required: 
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(a) Determine the number of aseptic preparations in relation to each specialty for 
each type of case (any sub-categorisation of specialties and types of case would 
need to be agreed); 
(b) Calculate rates by dividing the resultant figures by relevant currencies (e. g. 
number of aseptic preparations per 100 Non-Elective General Medicine 
Admissions or number of aseptic preparations per 100 Non-Elective General 
Medicine beddays); 
(c) Apply such rates to the (Trust) service capacity plans to calculate projections for 
the number of aseptic preparations, and determine the likely change over the 
period; make allowance for any anticipated changes in lengths of stay, for rates 
relating to beddays; 
(d) Agree a target percentage for aseptic preparation to be pharmacy based, taking 
into account local clinical governance and risk policies, and apply this to the 
projections to give the planned number of pharmaceutically prepared products 
each year; the corollary is that such policies will need to be clear about where and 
in what circumstances continued aseptic preparation in clinical areas Is 
acceptable; some phasing might be allowed; 
(e) Compare the resultant planned number with the existing local usage of 
pharmaceutically prepared products to give the difference between the current 
and projected usage of pharmaceutically prepared products; meeting any 
(significant) shortfall would then be the focus of capacity planning for aseptic 
dispensing units, including the potential contribution of outside sources; 
(f) A given drug can be delivered through different product types, and the research 
has demonstrated that the choice of product type can vary; therefore the projected 
usage of pharmaceutically prepared products needs to be translated Into specific 
targets for each product type; this may be the subject of informed professional 
judgement apportioning the overall target number between the different product 
types, or it might involve the collection of data to establish any relationships that 
can then be applied. 
(g) Suitable adjustments to the projections in (c) & (d) would be necessary if there are 
moves to reduce demand by using alternative routes of administration, such as 
switching from intravenous to oral antibiotics (Hardy and Mellor, 2007). 
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The subsequent process(es) would be the subject of collaboration between Trusts, and 
possibly the commercial sector, to develop and appraise available options to meet 
aggregate requirements. This would take into account a wide range of factors, such as: 
the potential impact and acceptability of dose banding; the scope for individual aseptic 
dispensing units to expand production, and the implications of delivery; the condition of 
the existing estate and equipment; the need to retain a local aseptic dispensing capability; 
finances; skill-mix and workforce planning; transport links; etc. A key factor is the fact that 
Foundation Trusts (and the commercial sector) will be governed by legally enforceable 
contracts. This means that any plans for aseptic production and provision need to be as 
robust and accurate as possible, for business purposes, which serves to highlight the 
importance of the above. 
It will be seen that steps (a) and (b), and the last element of (f) all involve further research 
work, probably involving surveys and Delphi techniques, or a combination. 
From the above it will be seen that whilst the two areas of work have some similarities, 
they are complementary with one another: the first seeks to translate data on stock issued 
so that it can be used to monitor activity on an ongoing basis, whilst the second is 
strategic in scope. 
A refinement of the above would be to aim for specific recommended targets for the 
percentage of aseptic preparation in pharmacies for each specialty and type of case 
combination, reflecting their relative risks. Applying these to projected activity and 
aggregating the results would produce hospital-specific targets for pharmaceutical 
preparation that reflect local casemix. The likely amount of detail required makes this 
more long term. 
7.2 Acute Capacity Planning 
The principles of Acute capacity planning are established. The problem appears to be one 
of time and resource to deal with the complexities, and produce a sufficiently sophisticated 
(computer) model that pharmacies can readily utilise and tailor to local needs, including 
recording local times. Given that most pharmacies work under pressure, it is unlikely that 
individual pharmacies will have an opportunity to achieve such a goal. The danger is that 
if different pharmacies produce local computer models, they will inevitably be different 
from one another. Therefore useful further work would be to develop a (standard) 
computer model. 
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7.3 Linking Research in Skill Mix and Competencies to Support Capacity 
Planning Methodologies 
Section 6.13 identified that whilst progress is being made on a range of fronts within the 
hospital pharmacy sector of the NHS in respect of skill mix and competencies, these did 
not appear to be strongly linked with what might be required to support improvements in 
capacity planning methodologies, which in turn could benefit from a skills-based quality 
management approach. This connection must be made if capacity planning for aseptic 
preparation is to go on to the next level. 
7.4 Refinements of Research Data and Approach 
If local pharmacy information systems can be enhanced so that analyses can be readily 
undertaken to distinguish between production that is licensed and unlicensed (in licensed 
units) then the respective Marker UTEs could be applied to ensure more appropriate 
values for the statistical indicators produced by this research. (This would impact on the 
design of the data input). 
7.5 Benchmarking Website 
There should be a facility that enables hospitals to benchmark aseptic activity, using the 
research findings, to inform capacity planning and clinical governance. There could be no 
compulsion for Trusts to participate in such a facility, and therefore it would need to be 
made so easy and attractive to use that they would want to do this. 
The proposed model would be to develop a benchmarking database which can be 
accessed via a website, and which would provide downloadable analyses and diagrams. 
There would need to be agreed processes and protocols to ensure the quality and 
timeliness of data. 
The database should also have a facility for pharmacists to record local values of Marker 
UTEs, so that consideration can be given to whether they should be revised. 
The benefit would be the accessibility to all Trusts across the country, thereby offering 
opportunities for (anonymised) regional, and other, comparisons that could inform national 
plans and policy. 
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Chapter 8 Recommendations 
The research involves many recommendations: 
Capacity 
It was determined that a specific, single statistical definition of "Capacity" is not feasible. 
"Capacity" is related to available skill mix and therefore research should take place to link 
capacity planning with a skills-based quality management approach. Aseptic dispensing 
units should have locally developed capacity plans detailing their strategy, which are open 
to external scrutiny, particularly where collaborative arrangements are in place. 
Benchmarking should enable relativities between Trusts to be highlighted. This should be 
used by Trusts to inform and justify their local capacity plans. The research data and the 
associated statistical indicators are viable and appropriate to be used to inform the 
development and maintenance of such plans. The survey methods and documentation 
are appropriate and sufficient to collect the required data, so that benchmarking can be 
developed. 
Existing software packages for capacity 
dispensing units in the NHS. 
planning are not appropriate for aseptic 
Nomenclature 
Nomenclature is of fundamental importance to the research. Different terms are used or 
interpreted in different ways by different people, largely reflecting professional 
background. Therefore it was necessary to adopt a set of terms and definitions for 
consistent use for the purposes of the research, with definitions agreed for: 
"Administration"; (when) "Administration begins"; (when) "Administration ends"; 
"Assembly"; "Ingredients"; 'Parenteral ; "Preparation"; and "Product". These definitions 
should continue to be used in any future surveys based on the research. 
Measuring Workload 
The data required to make workload calculations are: the period of time covered; the 
number of products produced during this period for each product type; standard times for 
the production of each product type; and, the number of cabinets (i. e. isolators and 
laminar flow cabinets) available for use. 
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Unit time equivalents represent the most appropriate form of standard time, and they are 
suitable for benchmarking. It is important that these should be acceptable to pharmacists 
and managers. Given variations in local circumstances or practices, these times should be 
described as "Marker UTEs" and not used as specific targets to be achieved. This Is 
consistent with a benchmarking approach. It is desirable to ensure the values of Marker 
UTEs are kept up-to-date. The statistical indicators devised to enable workloads to be 
benchmarked utilising survey data and Marker UTEs are: 
" "Aseptic Dispensing Unit Hours per Week" (which can be compared locally with the 
amount of time a unit is normally open); 
" "Aseptic Dispensing Unit Hours per Week per Cabinet"; 
" "Cabinet Hours per Week per Cabinet"; and 
" "The Average Weighted Time per Product" (which reflects the relative mix of 
products). 
Pharmacists should separate out cytotoxics activity from the overall aseptic dispensing 
unit's activity where there are specialist cabinets that are used only for cytotoxics and for 
all cytotoxics. This is to avoid skewing the statistical indicator values for the other 
products. (The same applies to any situation where there is a cabinet used specifically for 
a given type of product). 
In aggregate, cabinet time (i. e. that part of the process directly involving an isolator or 
laminar flow cabinet) accounts for approximately one third of total aggregate activity time, 
varying between 25 per cent and 40 per cent for observed products. 
Variations in "performance" point to it being unrealistic for some smaller units to increase 
their workload significantly, as they essentially fulfil an "insurance" role. Whether this 
situation applies for an aseptic dispensing unit should be made clear, so as to support the 
development of capacity plans. 
Collaboration 
The definition of "Collaboration" within the research is appropriate and consistent with its 
goals. The results support collaboration between Trusts because they set out the 
respective levels of aseptic activity, relative performance and the degree of interaction. 
The collaboration diagrams can demonstrate trends over time by the use of arrows. 
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Ensuring Consistency of Data 
Allowance needs to be made when comparing units' performance over time for any 
changes in license status. (A simple method of categorising units according to past and 
current status, using different colours, should be sufficient (see Section 5.17)). 
Comparisons over time require allowance for any organisational change. For example, 
where two hospitals merge, was there significant traffic between them previously in 
respect of aseptic products? A transparent decision should be taken about how to deal 
with this, giving reasons if necessary. The research is sufficiently flexible and robust to 
deal with this. 
EPS 
Future developments of specifications for EPS should take on board the findings of this 
research, with a view to the number of aseptic preparations taking place in clinical areas 
being readily identifiable from routine data. 
Estimation of Aseptic Preparation in Clinical Areas 
In the absence of readily available routine data from EPS, proxy measures/rates should 
be developed for aseptic preparation in clinical areas so that: 
(a) The actual number of aseptic preparations can be inferred from stock issue data; 
and 
(b) The projections can be made of to reflect the future likely demand associated with 
a Trust's capacity plan for its patient services. 
Until (b) comes to fruition, the number of aseptic preparations per admission and per 
bedday calculated for the North West can be used as reasonable proxies for extrapolating 
overall activity. 
Other Recommendations: 
"A standard computer model for Acute capacity planning in aseptic dispensing units 
should be developed. 
"A web-based nationwide benchmarking database should be developed, based on the 
research methods and findings, to enable Trusts to evaluate their performance. This 
should be free to Trusts and enable Marker LITE values to be updated. 
" Every opportunity should be taken to undertake greater dissemination of the research 
findings. 
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Chapter 9 Conclusions 
Section 1.18 states that the aim of the research is to identify the types of data and ways of 
measuring aseptic preparation and production required to evaluate changes in activity and 
performance over time, and that it will address the following questions: 
" How should activity relating to aseptic preparation in hospital pharmacies and 
clinical areas be counted, collated and analysed? 
" Can existing information systems readily provide such data? 
" What statistical indicators can be developed to support collaboration and capacity 
planning for (NHS) aseptic production, and to evaluate related initiatives? 
" How can such data and statistical indicators be best utilised? 
The research achieved all of this aim: it identified how activity relating to aseptic 
preparation in pharmacies and clinical areas should be counted, collated and analysed. It 
determined what relevant data existing pharmacy information systems can provide and 
that these systems are unlikely to change soon. The main constraint is the current lack of 
systems to enable data on the activity in clinical areas to be collected, and the fact that no 
such systems are likely to be introduced in the foreseeable future. 
This means that in order to establish the balance of aseptic preparation between 
pharmacies and clinical areas -a key issue highlighted by Breckenridge (1976) and 
subsequent reports (Farwell, 1995; NHS Executive North West, 2001; Audit Commission, 
2001) - it will be necessary to apply proxy calculations for total aseptic preparation that 
use admissions and beddays figures (as the only relevant published currencies), 
Subtracting the number of products used that were pharmaceutically prepared then gives 
the number prepared in clinical areas. 
The research has shown how such proxy calculations are undertaken, and demonstrated 
the usefulness of the results, both to compare different regions and to evaluate changes 
over time. These calculations implicitly took the total level of aseptic preparation in the 
North West per admission and bedday as being fixed at the point when the data and 
business cases were made for the C&CP (Beaumont, 1999; NHS Executive North West, 
2001). Further work would be required to update such data and determine whether the 
total level has changed, with the opportunity taken to establish the degree of preparation 
involved in different clinical areas (see Section 7.1). 
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However, the overall balance is still very much towards aseptic preparation in clinical 
areas with considerable effort and investment required to effect further significant shifts 
towards pharmacies, as illustrated by the evaluation of the impact of the C&CP. It is 
therefore arguably sufficient, for the foreseeable future, to use the North West's total 
aseptic preparation rates for proxy calculations to estimate the percentage of preparation 
in clinical areas, as this figure is likely to remain high for some time (i. e. well over 50 per 
cent): it will be clinical governance and risk management issues and requirements that 
drive local decision-making processes. The proxy calculations will inform and support 
such decisions, and knowing the magnitude of the balance should be enough for these 
purposes, i. e. is aseptic preparation in clinical areas 60 per cent or 90 per cent? Whilst 
increased accuracy is always desirable, being able to say that the figure should be 62 per 
cent instead of 65 per cent will not influence a Trust's decision as to whether to make 
plans and investment available to shift the balance. 
The research determined that the main level of data to be collected is that of product type. 
It is the product type that largely determines the amount of production time involved within 
an aseptic dispensing unit. The list recommended by the research covers all main product 
types. 
Two different types of data are then required: production activity and usage activity. For 
production, data needs to show where products went (Individual Patients, Use as Ward 
Stock, Use in Other NHS Trusts, and Use by Non-NHS Users are the recommended 
categories). For usage, data needs to show from where products were sourced (Within 
Trust, Other NHS Trust Licensed Unit, Other NHS Trust Unlicensed Unit, Commercial 
Unlicensed Products, and Other are the recommended categories). In both cases the 
categories can be amended, as long as they are mutually exclusive and cover the full 
range (see Section 4.17). 
The research provided a set of guidelines that supported the consistent recording and 
quality of data. These took on board real issues in pharmacies and dealt with them 
practically and clearly. In some cases the research forced the creation of definitions that 
reflected professional practice, e. g. making a distinction between "TPN - Compounded" 
and "TPN - Simple Additions". 
The data identified by the research can be submitted in either paper or electronic format, 
with the latter being more efficient, and a precursor for any development of a web-based 
solution. The fact that the final survey used a modified and abbreviated version of the data 
agreed for collection for the quarterly surveys, which was endorsed by the expert group as 
the data required to be collected, shows that the data is robust and flexible. Pharmacists 
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and managers should decide what is most practical for their requirements, if they look to 
undertake such a survey. 
The research determined weightings (viz. Marker UTEs) that can be applied to production 
activity (from the assembly of components/documentation to product approval) In aseptic 
dispensing units, whether they are licensed or unlicensed, so that production time can be 
aggregated and analysed. Their robustness was confirmed by a series of sensitivity 
analyses and other calculations. The Delphi methods applied in their derivation helped 
ensure their acceptability to pharmacists; without such acceptance the research would be 
of very limited value. Similarly, clarifying that the Marker UTEs were to be viewed as 
reasonable mean production times to be used for comparative purposes and local 
interpretation, rather than fixed performance targets, increased their acceptability. 
The failure of the work-study exercise to deliver production time weightings demonstrated 
that genuine problems cannot always be overcome. The aseptic environment by its very 
nature militates against this type of empirical observation. In retrospect it may also have 
been more difficult to ensure the acceptability of any production times resulting from the 
exercise, given that work-study by its very nature can be, and often is used to set targets. 
By applying Marker UTEs, the research created a series of statistical indicators that 
aggregated the activity data in a meaningful way for pharmacists. They were 
straightforward and were reasonably simple conceptually. Pharmacists found the results 
useful and informative, in that they showed variations between different units. The 
research also showed the impact on the indicators of separating out specific, identifiable 
subcomponents of units' production, i. e. cytotoxics. 
There were two limitations to the statistical indicators. The first was that all production In a 
licensed aseptic unit was assigned the licensed Marker UTEs, although some production 
will inevitably take place on an unlicensed basis. This is because to try and distinguish 
licensed and unlicensed production from existing pharmacy information systems was 
considered impractical by pharmacists, and to do so would raise the prospect of 
significantly increasing the amount of data to be collected: it would be likely that the 
existing research data collection forms would need to have both a "licensed" and 
"unlicensed" version completed. Yet the fact that licensed work usually involves batch 
processing means that the weight of activity in licensed units will be for this type of 
product. Therefore it is inferred that the impact of collecting such detail and applying 
differential Marker UTEs would have a comparatively marginal effect on the overall values 
for the statistical indicators for the units concerned. (This research question needs testing 
if such data becomes available). 
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The second limitation was that certain units effectively operated as licensed units, but 
retained an unlicensed status. As a result of applying unlicensed Marker UTEs, it would 
appear that a unit was operating for far more hours in a week than could reasonably be 
expected: Trust 137 was the prime example in the baseline survey with production 
apparently involving 50 aseptic dispensing units hours per week per cabinet. It is 
reasonable in such circumstances to infer that their actual production times would be 
towards the minimum of the range for unlicensed Marker UTEs, because they are likely to 
function as a quasi-licensed unit with associated efficiencies in processes. The simple 
way to deal with this is either to apply minimum Marker unlicensed LITE values, or apply 
licensed Marker UTES to illustrate the potential impact of such units becoming licensed. 
Notwithstanding the above, the robustness of the statistical indicators was demonstrated 
by the way that they were used to show differences between regions, and trends over 
time within the North West, and be meaningful -to the pharmaceutical and managerial 
audiences. 
However, all data collected was for either a three-month or one-year period, and was 
retrospective. As confirmed by the work-study exercise, daily production varies In 
hospitals, often with increased production towards the end of the week to cover week-end 
requirements. The focus of such acute capacity planning is prospective - to balance the 
availability of staff and other resources with production demands. To do this properly, 
pharmacy managers have to take into account all (local) factors, which will include those 
outside what is covered by the Marker UTEs: cleaning, packaging, delivery, training, 
holidays, staff skill mix, and opening and closing times for the unit. Therefore, whilst the 
research methodology and the Marker UTEs can clearly be applied to daily data, it Is 
questionable as to the worth of doing so, unless it is to undertake a retrospective audit 
and identify patterns that might be informative. 
A related, critical point that shaped the scope and reach of the research is the fact that no 
two aseptic dispensing units are the same in their design and resources. This is generally 
recognised and accepted, and was highlighted in Section 5.12. Therefore the question 
arises as to the degree to which the research can and should try to cover all aspects of 
aseptic dispensing? 
Given the uniqueness of aseptic dispensing units, it follows that the amount of data and 
other information required to fully evaluate their performance is considerable - for 
example, the times and resources associated with all the tasks and factors listed above 
that are outside what is covered by the Marker UTEs - and requires detailed local 
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knowledge for interpretation. Therefore, the only practical approach is to develop robust 
and transparent benchmarking information, that enables local pharmacists and managers 
to benchmark their activity and performance, and then use this to inform where there Is 
the potential for improvements and/or increased production, taking into account local 
circumstances and knowledge. This can then form the basis for their local capacity plans. 
Therefore it was essential to confirm that the research has gone as far as it reasonably 
could, by determining its realistic boundaries. These were as follows: 
" The lack of robust sources of data for aseptic preparation activity in clinical areas 
meant that whilst the research could identify key points and suggest further work 
and opportunities, it could not fully encompass this area in detail (Sections 3.7,4.7 
& 5.7). 
" Issues surrounding Nomenclature become more complicated if data goes to a 
more detailed level than that proposed by the research, with data quality being 
potentially compromised (Sections 3.8,4.8 & 5.8). 
" The prospect of developing the research to make firm proposals for specific 
capacity calculations was nullified by the identification that mainstream capacity 
planning software does not lend itself to aseptic dispensing in NHS hospitals, and 
that many "capacity planning" initiatives are actually aimed at workload and/or 
staffing. Accordingly capacity planning for an aseptic unit is primarily a skills 
management issue, rather than solely one of process management, and it is not 
best suited to capacity modelling techniques that require detailed statistical data. 
To pursue research into the skills management dimension would have moved well 
beyond the central focus of the research, and would involve a great amount of time 
and effort. (Sections 3.14,4.14 & 5.14). 
"A major point for Acute capacity planning is that the amount of data required Is far 
greater than that identified by the research, involving factors outside the actual 
aseptic dispensing process. Given variations between hospitals' aseptic 
dispensing units and associated resources, it would be difficult to determine and 
get agreement on standard data to be collected, and how this might be analysed. 
The requirement is for a sufficiently sophisticated (computer) model that 
pharmacies can readily utilise and tailor to local needs. The requirements for 
developing such a model would be beyond the scope of this research. (Sections 
3.15,4.15&5.15). 
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Capacity plans are required of hospitals, but the nature of how services currently work and 
how they are likely to evolve, is that capacity plans should be for groups of hospitals 
collaborating with one another (and possibly with the commercial sector). Therefore, the 
capacity of a given group of hospitals will not necessarily be the aggregate total of the 
activity specified in their respective capacity plans, if developed independently of one 
another. It would be expected that collaboration should enable further performance 
improvements. This serves to emphasise the need to measure collaboration. The 
research has identified how "collaboration" can be defined, in such a way that it can be 
measured and monitored in respect of time and area (with allowance for the commercial 
sector), utilising the research data (Sections 3.9,4.9 & 5.9). 
Nevertheless, the value of the research would be restricted if its only achievement was to 
provide a high-level descriptive comparison of Trusts in the North West of England. Its 
strength has been demonstrated by its transferability to other parts of the UK (Sections 
3.16,4.16 & 5.16), and that they can provide detailed, objective evaluation of a major 
change programme (Sections 3.1,4.17 & 5.17): 
" The research survey methods were successfully transferred for the West Midlands 
without difficulty, producing results useful to local pharmacists. The significant 
variation of the results from those in the North West, showed that practices vary In 
different regions, and these need to be identified and understood, so as to Inform 
both capacity planning and clinical practice. It was inferred that there was no 
reason why this should not apply equally to other parts of the UK. The combined 
size of the two regions would suggest that, in principle, the methods could also be 
applied in other countries, where aseptic preparation and pharmacy arrangements 
share relevant similarities to those in the UK. 
" The research survey methods were successfully applied to evaluate the North 
West C&CP (Beaumont, 1999; NHS Executive North West, 2001) Identifying: 
changes in production and usage for each unit/Trust; whether or not units/Trusts 
receiving capital funds had achieved their business plans; the contribution of other 
units/Trusts to the overall changes; the relative situation in each zone; and the 
degree to which trends in hospital service activity were reflected. 
The research methods are now considered a standardised approach contributing to the 
development of capacity plans for aseptic dispensing (Beaney, 2006). 
The logical way that the NHS could build on the research would be to create/sponsor a 
nationwide benchmarking database that uses its methods and findings: 
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" This could enable consistent data to be collected across Trusts and pharmacies, with 
organisations set into appropriate categories, as to size and type, so that like can be 
compared with like. 
" Such objective comparisons would inform capacity planning and clinical governance, 
and the evaluation of specific initiatives. 
" The database should be web-based to maximise accessibility and be free to users, i. e. 
governmental funds and/or advertising revenue would be required. 
" Such a website should have a facility to enable the values of the Marker UTEs to be 
updated. 
(For other potential further work see Chapter 7) 
The research necessarily involved an iterative and complementary application of both 
qualitative and quantitative methodologies and methods. Effectively it looked at how the 
evaluation of plans, practices and performance in the area of aseptic preparation, should 
itself be evaluated. A mixed methodological approach was required, with both quantitative 
and qualitative methods used on an iterative basis. The basic cycle of: develop concepts - 
produce (measurable) proposals - test/evaluate proposals - further develop concepts; 
reflected the fact that the research primarily involved the creation of data and the 
development of related quantitative indicators and analyses which had to be qualitatively 
assessed by the audience professionals in order to validate whether they represented 
suitable and appropriate interpretations of key concepts, such as collaboration and 
capacity, and whether their current and future needs were being met. A series of 
cumulative and sequential steps were involved, and validation was required at each and 
every stage, not least to ensure continuing support. The methods applied were sufficient 
and appropriate in each case. 
There can be relatively few similar opportunities where there are important, established 
(health) services which are the subject of significant change and development, but where 
there is no (central) requirement for data to be collected and no standardised approach to 
measuring activity and performance. Consequently, it can be stated that the research and 
its findings represent new knowledge of what data is required in respect of aseptic 
preparation, and how this can be analysed for the purposes of planning, performance, 
monitoring, and evaluation. The research is substantial and robust, and acts as a platform 
for further work. 
The value of the research is that it is readily usable and transferable, and has been 
actively used to support pharmacists and managers in their planning and evaluation of 
aseptic dispensing services. 
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